{"PMC6868266": [["IntroductionMiddle East respiratory syndrome coronavirus (MERS-CoV) is a newly emerging human coronavirus that was discovered in 2012 in a 60-year-old Saudi Arabian man [1].", [["Middle East respiratory syndrome coronavirus", "DISEASE", 12, 56], ["coronavirus", "DISEASE", 94, 105], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 12, 56], ["MERS-CoV", "ORGANISM", 58, 66], ["human", "ORGANISM", 88, 93], ["man", "ORGANISM", 165, 168], ["MERS-CoV", "SPECIES", 58, 66], ["human", "SPECIES", 88, 93], ["coronavirus", "SPECIES", 94, 105], ["man", "SPECIES", 165, 168], ["Middle East respiratory syndrome coronavirus", "SPECIES", 12, 56], ["MERS-CoV", "SPECIES", 58, 66], ["human coronavirus", "SPECIES", 88, 105], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 12, 56], ["a newly emerging human coronavirus", "PROBLEM", 71, 105], ["Middle", "ANATOMY_MODIFIER", 12, 18], ["respiratory syndrome", "OBSERVATION", 24, 44]]], ["Following its discovery, many cases were identified in different regions of the Arabian Peninsula and worldwide thereafter [2,3].", [["Arabian Peninsula", "ANATOMY", 80, 97]]], ["The most recent outbreak occurred in June 2015 in South Korea and was linked to a South Korean man who had recently traveled to the Middle East [3].", [["man", "ORGANISM", 95, 98], ["man", "SPECIES", 95, 98]]], ["The infection then rapidly spread to 26 persons through close contact in a hospital.", [["infection", "DISEASE", 4, 13], ["persons", "ORGANISM", 40, 47], ["persons", "SPECIES", 40, 47], ["The infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13]]], ["Within a few months, many cases (n=186) were reported in hospitalized and non-hospitalized persons in South Korea [3].", [["persons", "ORGANISM", 91, 98], ["persons", "SPECIES", 91, 98]]], ["The disease showed a high mortality rate that reached up to 40%, which was higher than that of the severe acute respiratory syndrome coronavirus (SARS-CoV) outbreak in 2002-2003 (10%) [4].IntroductionCoronaviruses belong to the subfamily Coronavirinae within the family Coronaviridae of the order Nidovirales [5].", [["acute respiratory syndrome coronavirus", "DISEASE", 106, 144], ["SARS-CoV)", "DISEASE", 146, 155], ["SARS-CoV", "ORGANISM", 146, 154], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 200, 213], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 238, 251], ["Coronaviruses", "PROTEIN", 200, 213], ["severe acute respiratory syndrome coronavirus", "SPECIES", 99, 144], ["SARS-CoV", "SPECIES", 146, 154], ["The disease", "PROBLEM", 0, 11], ["a high mortality rate", "PROBLEM", 19, 40], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 95, 144], ["disease", "OBSERVATION", 4, 11], ["high", "OBSERVATION_MODIFIER", 21, 25], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["respiratory syndrome coronavirus", "OBSERVATION", 112, 144]]], ["Five human coronaviruses were identified (229E, OC43, NL63, HKU1, and SARS-CoV) before MERS-CoV.", [["human", "ORGANISM", 5, 10], ["coronaviruses", "ORGANISM", 11, 24], ["NL63", "GENE_OR_GENE_PRODUCT", 54, 58], ["HKU1", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["MERS-CoV", "ORGANISM", 87, 95], ["human", "SPECIES", 5, 10], ["human coronaviruses", "SPECIES", 5, 24], ["SARS-CoV", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 87, 95], ["Five human coronaviruses", "TEST", 0, 24], ["OC43", "TEST", 48, 52], ["NL63", "TEST", 54, 58], ["HKU1", "TEST", 60, 64], ["SARS", "TEST", 70, 74], ["coronaviruses", "OBSERVATION", 11, 24]]], ["Lineage C of betacoronaviruses includes bat coronaviruses, which give a primitive impression regarding the origin of the virus [6].", [["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 13, 30], ["bat coronaviruses", "ORGANISM", 40, 57], ["bat coronaviruses", "SPECIES", 40, 57], ["bat coronaviruses", "SPECIES", 40, 57], ["Lineage C of betacoronaviruses", "PROBLEM", 0, 30], ["bat coronaviruses", "PROBLEM", 40, 57], ["the virus", "PROBLEM", 117, 126]]], ["The detection of MERS-CoV and its neutralizing antibodies in the sera of dromedary camels has shed light on the role of the camel as a possible animal reservoir, which may transmit the virus to humans [7-10].", [["sera", "ANATOMY", 65, 69], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["sera", "ORGANISM_SUBSTANCE", 65, 69], ["camel", "ORGANISM", 124, 129], ["humans", "ORGANISM", 194, 200], ["MERS-CoV", "PROTEIN", 17, 25], ["neutralizing antibodies", "PROTEIN", 34, 57], ["humans", "SPECIES", 194, 200], ["MERS-CoV", "SPECIES", 17, 25], ["camel", "SPECIES", 124, 129], ["humans", "SPECIES", 194, 200], ["The detection", "TEST", 0, 13], ["MERS", "PROBLEM", 17, 21], ["CoV", "PROBLEM", 22, 25], ["its neutralizing antibodies", "TEST", 30, 57], ["animal reservoir", "TREATMENT", 144, 160]]], ["Indeed, researchers isolated the same MERS-CoV strain from both a camel \u201cin a barn\u201d and its infected owner in Saudi Arabia, thus providing further evidence of the potential airborne and direct contact transmission of the virus between camels and humans [11].IntroductionThere have been several attempts to develop a protective vaccine against MERS-CoV [12-23].", [["MERS-CoV", "ORGANISM", 38, 46], ["camel", "ORGANISM", 66, 71], ["camels", "ORGANISM", 235, 241], ["humans", "ORGANISM", 246, 252], ["MERS-CoV", "ORGANISM", 343, 351], ["camel", "SPECIES", 66, 71], ["humans", "SPECIES", 246, 252], ["MERS-CoV", "SPECIES", 38, 46], ["camel", "SPECIES", 66, 71], ["humans", "SPECIES", 246, 252], ["MERS-CoV", "SPECIES", 343, 351], ["CoV strain", "PROBLEM", 43, 53], ["the potential airborne", "PROBLEM", 159, 181], ["a protective vaccine", "TREATMENT", 314, 334], ["CoV", "TEST", 348, 351], ["infected", "OBSERVATION_MODIFIER", 92, 100]]], ["Researchers around the world are focused on the spike protein as the main target for vaccine development against MERS-CoV.", [["MERS-CoV", "ORGANISM", 113, 121], ["spike protein", "PROTEIN", 48, 61], ["MERS-CoV", "SPECIES", 113, 121], ["vaccine", "TREATMENT", 85, 92]]], ["The spike protein of MERS-CoV attaches to the host dipeptidyl peptidase-4 (DPP4) receptor, which is expressed on several types of human cells [24].", [["cells", "ANATOMY", 136, 141], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 21, 29], ["dipeptidyl peptidase-4", "GENE_OR_GENE_PRODUCT", 51, 73], ["DPP4", "GENE_OR_GENE_PRODUCT", 75, 79], ["human", "ORGANISM", 130, 135], ["cells", "CELL", 136, 141], ["spike protein", "PROTEIN", 4, 17], ["MERS", "PROTEIN", 21, 25], ["CoV", "PROTEIN", 26, 29], ["dipeptidyl peptidase-4 (DPP4) receptor", "PROTEIN", 51, 89], ["human cells", "CELL_TYPE", 130, 141], ["human", "SPECIES", 130, 135], ["MERS-CoV", "SPECIES", 21, 29], ["human", "SPECIES", 130, 135], ["The spike protein", "TEST", 0, 17], ["MERS", "PROBLEM", 21, 25], ["the host dipeptidyl peptidase-4 (DPP4) receptor", "TREATMENT", 42, 89], ["human cells", "TREATMENT", 130, 141]]], ["Many studies published since 2012 suggesting vaccine models were constructed based on the spike protein and its receptor-binding domain (RBD) region to elicit a strong and protective immune response in vitro and in vivo [25].", [["spike protein", "PROTEIN", 90, 103], ["receptor-binding domain (RBD) region", "PROTEIN", 112, 148], ["Many studies", "TEST", 0, 12], ["vaccine models", "TREATMENT", 45, 59], ["the spike protein", "TEST", 86, 103]]], ["Recombinant adenoviral vector vaccines are one of the most effective vaccines and showed interesting results during SARS-CoV outbreaks [12,26,27].", [["SARS-CoV outbreaks", "DISEASE", 116, 134], ["adenoviral", "ORGANISM", 12, 22], ["SARS-CoV", "ORGANISM", 116, 124], ["adenoviral", "SPECIES", 12, 22], ["SARS-CoV", "SPECIES", 116, 124], ["Recombinant adenoviral vector vaccines", "TREATMENT", 0, 38]]], ["Since 2013, several studies were published, in which different viral vectors (e.g., adenoviruses and vaccinia virus) were used to develop recombinant vaccine candidates based on full spike gene or part of it and tested their ability to produce protective immunity against MERS-CoV infection [13-23].", [["MERS-CoV infection", "DISEASE", 272, 290], ["adenoviruses", "ORGANISM", 84, 96], ["vaccinia virus", "ORGANISM", 101, 115], ["MERS-CoV", "ORGANISM", 272, 280], ["spike gene", "DNA", 183, 193], ["vaccinia virus", "SPECIES", 101, 115], ["vaccinia virus", "SPECIES", 101, 115], ["MERS-CoV", "SPECIES", 272, 280], ["several studies", "TEST", 12, 27], ["different viral vectors", "PROBLEM", 53, 76], ["adenoviruses", "PROBLEM", 84, 96], ["vaccinia virus", "TREATMENT", 101, 115], ["recombinant vaccine candidates", "TREATMENT", 138, 168], ["MERS", "PROBLEM", 272, 276], ["CoV infection", "PROBLEM", 277, 290], ["viral vectors", "OBSERVATION", 63, 76]]], ["However, further investigations are needed on these suggested vaccines including testing their ability to elicit neutralizing antibodies in different animal models, stimulation of both innate and adaptive immune responses and their corresponding cytokine and chemokine profiles, distribution within the host, and their safety and duration profiles.IntroductionIn this study, a recombinant adenoviral-based vaccine encoding the spike 1 (S1) subunit of the MERS-CoV genome was constructed, and its humoral, and cellular immune responses were evaluated in mice.Ethical approval ::: Materials and MethodsAll procedures performed in this study were approved by the Jordan University of Science and Technology Animal Use and Care Committee.Construction of the recombinant vaccine ::: Materials and MethodsThe recombinant human adenovirus type 5 (dE1/E3) vaccine was designed to express the S1 domain of the spike protein of MERS-CoV isolate Hu/Jordan-20140010168/2014 (GenBank accession number KT861627) under the control of the cytomegalovirus (CMV) promoter.", [["cellular", "ANATOMY", 509, 517], ["adenoviral", "ORGANISM", 389, 399], ["spike 1", "GENE_OR_GENE_PRODUCT", 427, 434], ["S1", "GENE_OR_GENE_PRODUCT", 436, 438], ["MERS-CoV", "ORGANISM", 455, 463], ["cellular", "CELL", 509, 517], ["mice", "ORGANISM", 553, 557], ["human", "ORGANISM", 815, 820], ["adenovirus type 5", "ORGANISM", 821, 838], ["dE1", "ORGANISM", 840, 843], ["E3", "GENE_OR_GENE_PRODUCT", 844, 846], ["MERS-CoV", "ORGANISM", 918, 926], ["cytomegalovirus", "ORGANISM", 1023, 1038], ["CMV", "ORGANISM", 1040, 1043], ["neutralizing antibodies", "PROTEIN", 113, 136], ["cytokine", "PROTEIN", 246, 254], ["chemokine", "PROTEIN", 259, 268], ["spike 1 (S1) subunit", "PROTEIN", 427, 447], ["MERS-CoV genome", "DNA", 455, 470], ["E3", "PROTEIN", 844, 846], ["S1 domain", "PROTEIN", 884, 893], ["spike protein", "PROTEIN", 901, 914], ["cytomegalovirus (CMV) promoter", "DNA", 1023, 1053], ["mice", "SPECIES", 553, 557], ["human", "SPECIES", 815, 820], ["MERS-CoV", "SPECIES", 455, 463], ["mice", "SPECIES", 553, 557], ["human adenovirus type 5", "SPECIES", 815, 838], ["MERS-CoV isolate Hu/Jordan-20140010168/2014", "SPECIES", 918, 961], ["CMV", "SPECIES", 1040, 1043], ["further investigations", "TEST", 9, 31], ["vaccines", "TREATMENT", 62, 70], ["testing", "TEST", 81, 88], ["neutralizing antibodies", "PROBLEM", 113, 136], ["chemokine profiles", "TEST", 259, 277], ["this study", "TEST", 363, 373], ["a recombinant adenoviral-based vaccine", "TREATMENT", 375, 413], ["All procedures", "TEST", 600, 614], ["this study", "TEST", 628, 638], ["Materials", "TREATMENT", 778, 787], ["Methods", "TREATMENT", 792, 799], ["The recombinant human adenovirus type 5 (dE1/E3) vaccine", "TREATMENT", 799, 855], ["the cytomegalovirus (CMV) promoter", "TREATMENT", 1019, 1053]]], ["This vaccine was constructed in the Laboratories of Vector Biolabs (The Gene Delivery Company, PA, USA) [28].Experimental design ::: Materials and MethodsSix to eight week-old male BALB/c mice (n=168) were purchased from Animal House at Jordan University of Science and Technology (Irbid-Jordan) and distributed into three groups in a replicate manner (56 each).", [["BALB/c mice", "ORGANISM", 181, 192], ["mice", "SPECIES", 188, 192], ["mice", "SPECIES", 188, 192], ["This vaccine", "TREATMENT", 0, 12]]], ["Animals in the first group were immunized with the Ad-CMV-MERS-CoV-Spike1 \u201cAd-MERS-S1.\u201d", [["Animals", "ORGANISM", 0, 7], ["Spike1", "PROTEIN", 67, 73], ["S1", "ANATOMY", 83, 85]]], ["Animals in the second group received the vector-only \u201cAd-CMV,\u201d and animals in the last group served as a control and received 1\u00d7 phosphate-buffered saline (PBS).", [["phosphate", "CHEMICAL", 129, 138], ["phosphate", "CHEMICAL", 129, 138], ["Animals", "ORGANISM", 0, 7], ["CMV", "ORGANISM", 57, 60], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 129, 154], ["the vector", "TEST", 37, 47], ["1\u00d7 phosphate", "TREATMENT", 126, 138], ["buffered saline (PBS", "TREATMENT", 139, 159], ["CMV", "OBSERVATION", 57, 60]]], ["For the first immunization, the Ad-MERS-S1 vaccine was injected intramuscularly at a dose of 0.1 ml containing 1\u00d7107 PFU/dose/mouse.", [["intramuscularly", "ANATOMY", 64, 79], ["Ad-MERS-S1", "CHEMICAL", 32, 42], ["Ad", "ORGANISM", 32, 34], ["MERS-S1", "ORGANISM", 35, 42], ["mouse", "ORGANISM", 126, 131], ["mouse", "SPECIES", 126, 131], ["mouse", "SPECIES", 126, 131], ["the first immunization", "TREATMENT", 4, 26], ["the Ad-MERS-S1 vaccine", "TREATMENT", 28, 50]]], ["The same volume of Ad-CMV or PBS was used for the other two groups.", [["Ad", "ORGANISM", 19, 21], ["CMV", "ORGANISM", 22, 25], ["Ad-CMV or PBS", "TREATMENT", 19, 32], ["volume", "OBSERVATION_MODIFIER", 9, 15]]], ["The booster dose was carried out 3 weeks later by intranasal route at a dose of 0.1 ml containing 1\u00d7107 PFU/dose/mouse.", [["mouse", "ORGANISM", 113, 118], ["mouse", "SPECIES", 113, 118], ["mouse", "SPECIES", 113, 118], ["The booster dose", "TREATMENT", 0, 16]]], ["All experimental procedures used in this study were approved by the Animal Care and Use Committee at the Faculty of Veterinary Medicine (Irbid-Jordan).Sample collection and processing ::: Materials and MethodsLung, kidney, and spleen tissue samples were harvested from each mouse in all groups after 3, 4, 5, and 6 weeks from the first immunization.", [["kidney", "ANATOMY", 215, 221], ["spleen tissue samples", "ANATOMY", 227, 248], ["kidney", "ORGAN", 215, 221], ["spleen tissue samples", "TISSUE", 227, 248], ["mouse", "ORGANISM", 274, 279], ["mouse", "SPECIES", 274, 279], ["mouse", "SPECIES", 274, 279], ["All experimental procedures", "TREATMENT", 0, 27], ["this study", "TEST", 36, 46], ["Sample collection", "TEST", 151, 168], ["MethodsLung", "TREATMENT", 202, 213], ["the first immunization", "TREATMENT", 326, 348], ["kidney", "ANATOMY", 215, 221], ["spleen", "ANATOMY", 227, 233]]], ["Parts of lung and kidneys were preserved in 10% formalin solution for 24-h, then embedded in paraffin blocks for immunohistochemical analysis, while the other parts were stored at \u221280\u00b0C for polymerase chain reaction (PCR) analysis.", [["lung", "ANATOMY", 9, 13], ["kidneys", "ANATOMY", 18, 25], ["formalin", "CHEMICAL", 48, 56], ["formalin", "CHEMICAL", 48, 56], ["lung", "ORGAN", 9, 13], ["kidneys", "ORGAN", 18, 25], ["10% formalin solution", "TREATMENT", 44, 65], ["immunohistochemical analysis", "TEST", 113, 141], ["polymerase chain reaction", "TEST", 190, 215], ["PCR) analysis", "TEST", 217, 230], ["lung", "ANATOMY", 9, 13], ["kidneys", "ANATOMY", 18, 25], ["preserved", "OBSERVATION", 31, 40]]], ["Spleen tissues were harvested and stored at \u221280\u00b0C for cell culture analysis.", [["Spleen tissues", "ANATOMY", 0, 14], ["cell", "ANATOMY", 54, 58], ["Spleen tissues", "TISSUE", 0, 14], ["cell", "CELL", 54, 58], ["cell culture analysis", "TEST", 54, 75], ["tissues", "ANATOMY", 7, 14], ["harvested", "OBSERVATION", 20, 29]]], ["Blood samples were drawn through facial vein route, left 30 min at room temperature, and centrifuged at 2000 rpm for 20 min.", [["Blood samples", "ANATOMY", 0, 13], ["facial vein", "ANATOMY", 33, 44], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["facial vein", "MULTI-TISSUE_STRUCTURE", 33, 44], ["Blood samples", "TEST", 0, 13], ["facial vein", "ANATOMY", 33, 44]]], ["Collected sera were stored at \u221220\u00b0C for subsequent analysis.Detection of S1 gene expression by heminested PCR ::: Materials and MethodsTo study the distribution of the recombinant vaccine, total of 50-100 mg of lung and kidney tissues at weeks 3 and 5 post-prime immunization was cut and homogenized in 1 ml of diethyl pyrocarbonate-treated water.", [["sera", "ANATOMY", 10, 14], ["lung", "ANATOMY", 211, 215], ["kidney tissues", "ANATOMY", 220, 234], ["diethyl pyrocarbonate", "CHEMICAL", 311, 332], ["diethyl pyrocarbonate", "CHEMICAL", 311, 332], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["C", "GENE_OR_GENE_PRODUCT", 34, 35], ["S1", "GENE_OR_GENE_PRODUCT", 73, 75], ["lung", "ORGAN", 211, 215], ["kidney tissues", "TISSUE", 220, 234], ["diethyl", "SIMPLE_CHEMICAL", 311, 318], ["pyrocarbonate", "SIMPLE_CHEMICAL", 319, 332], ["S1 gene", "DNA", 73, 80], ["Collected sera", "TEST", 0, 14], ["subsequent analysis", "TEST", 40, 59], ["the recombinant vaccine", "TREATMENT", 164, 187], ["-prime immunization", "TREATMENT", 256, 275], ["diethyl pyrocarbonate", "TREATMENT", 311, 332], ["lung", "ANATOMY", 211, 215], ["kidney tissues", "ANATOMY", 220, 234]]], ["Homogenized samples were then centrifuged at 800 rpm for 5 min, and 150 \u00b5l of the supernatant was used for the extraction.", [["samples", "ANATOMY", 12, 19], ["supernatant", "ANATOMY", 82, 93], ["Homogenized samples", "TEST", 0, 19], ["the supernatant", "TREATMENT", 78, 93], ["the extraction", "TREATMENT", 107, 121]]], ["The extraction was performed using the Viral Gene-Spin RNA Extraction Kit (Intron Biotechnology, Korea) according to the manufacturer\u2019s instructions.", [["Viral Gene", "DNA", 39, 49], ["The extraction", "TREATMENT", 0, 14], ["the Viral Gene", "TREATMENT", 35, 49]]], ["The extracted RNA was used for cDNA synthesis through a reverse transcription system (Promega, Madison, WI, USA) according to the manufacturer\u2019s instructions.", [["The extracted RNA", "TREATMENT", 0, 17], ["cDNA synthesis", "TREATMENT", 31, 45], ["a reverse transcription system", "TREATMENT", 54, 84]]], ["The cDNA was kept at \u221220\u00b0C until PCR analysis.", [["C", "GENE_OR_GENE_PRODUCT", 25, 26], ["cDNA", "DNA", 4, 8], ["The cDNA", "TEST", 0, 8], ["PCR analysis", "TEST", 33, 45]]], ["The DNA template of the constructed vaccine was also purified and used as a positive control in this experiment.Detection of S1 gene expression by heminested PCR ::: Materials and MethodsHeminested PCR was carried out using specific primers targeting specific sequences within the S1 region, as shown in Table-1 [29].", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["S1", "GENE_OR_GENE_PRODUCT", 125, 127], ["S1 gene", "DNA", 125, 132], ["S1 region", "DNA", 281, 290], ["the constructed vaccine", "TREATMENT", 20, 43], ["a positive control", "TREATMENT", 74, 92], ["MethodsHeminested PCR", "TEST", 180, 201], ["specific primers", "TEST", 224, 240], ["S1", "ANATOMY", 281, 283], ["region", "ANATOMY_MODIFIER", 284, 290]]], ["The first PCR targeted a 1172 bp sequence.", [["1172 bp sequence", "DNA", 25, 41], ["The first PCR", "TEST", 0, 13], ["a 1172 bp sequence", "TEST", 23, 41]]], ["PCR mixture contained 0.4 \u00b5M of each primer and using 3 \u00b5l of the cDNA template.", [["cDNA template", "DNA", 66, 79], ["PCR mixture", "TEST", 0, 11], ["the cDNA template", "TREATMENT", 62, 79]]], ["Touchdown PCR assay was programmed on the MyCycler thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA) as the following conditions: 95\u00b0C for 10 min, followed by 10 cycles of 95\u00b0C for 35 s, 63-54\u00b0C for 40 s, and 72\u00b0C for 1 min and 15 s, then 35 cycles of 95\u00b0C for 40 s, 56\u00b0C for 40 s, 72\u00b0C for 1 min and 15 s, and a final extension step at 72\u00b0C for 5 min.", [["Touchdown PCR assay", "TEST", 0, 19], ["the MyCycler thermal cycler", "TREATMENT", 38, 65]]], ["Two microliters from the first PCR product were used as a template for the second (heminested) PCR to amplify the 1142 bp product following the first PCR conditions.", [["1142 bp product", "PROTEIN", 114, 129], ["Two microliters", "TREATMENT", 0, 15], ["the first PCR product", "TREATMENT", 21, 42], ["a template for the second (heminested) PCR", "TREATMENT", 56, 98], ["the first PCR conditions", "TEST", 140, 164]]], ["The bands were visualized in 1.5% agarose gels using an ultra-violet transilluminator.Immunohistochemistry (IHC) ::: Materials and MethodsLocalization of S1 protein expression was investigated in both kidney and lung tissues from all groups at week 6 after the first vaccination.", [["kidney", "ANATOMY", 201, 207], ["lung tissues", "ANATOMY", 212, 224], ["S1", "GENE_OR_GENE_PRODUCT", 154, 156], ["kidney", "ORGAN", 201, 207], ["lung tissues", "TISSUE", 212, 224], ["S1", "PROTEIN", 154, 156], ["The bands", "TREATMENT", 0, 9], ["1.5% agarose gels", "TREATMENT", 29, 46], ["an ultra-violet transilluminator", "TREATMENT", 53, 85], ["Immunohistochemistry", "TEST", 86, 106], ["S1 protein expression", "PROBLEM", 154, 175], ["the first vaccination", "TREATMENT", 257, 278], ["both", "ANATOMY_MODIFIER", 196, 200], ["kidney", "ANATOMY", 201, 207], ["lung", "ANATOMY", 212, 216], ["tissues", "ANATOMY_MODIFIER", 217, 224]]], ["IHC using rabbit-specific HRP/DAB (ABC) detection IHC kit (Abcam, Cambridge, UK) was adapted, with using antinovel coronavirus spike protein S1 polyclonal antibodies (1:1000; Sino-Biological, PA, USA).", [["rabbit", "ORGANISM", 10, 16], ["HRP", "GENE_OR_GENE_PRODUCT", 26, 29], ["DAB", "GENE_OR_GENE_PRODUCT", 30, 33], ["ABC", "GENE_OR_GENE_PRODUCT", 35, 38], ["HRP", "PROTEIN", 26, 29], ["DAB (ABC) detection IHC kit", "PROTEIN", 30, 57], ["Abcam", "PROTEIN", 59, 64], ["antinovel coronavirus spike protein S1 polyclonal antibodies", "PROTEIN", 105, 165], ["rabbit", "SPECIES", 10, 16], ["rabbit", "SPECIES", 10, 16], ["antinovel coronavirus", "SPECIES", 105, 126], ["IHC", "TEST", 0, 3], ["rabbit", "TEST", 10, 16], ["specific HRP", "TEST", 17, 29], ["IHC kit", "TEST", 50, 57], ["Abcam", "TEST", 59, 64], ["antinovel coronavirus spike protein S1 polyclonal antibodies", "TEST", 105, 165]]], ["A 5-\u00b5m thick section of formalin was fixed, and paraffin-embedded tissues were cut and loaded on specially coated slides.", [["tissues", "ANATOMY", 66, 73], ["formalin", "CHEMICAL", 24, 32], ["formalin", "CHEMICAL", 24, 32], ["paraffin", "CHEMICAL", 48, 56], ["formalin", "SIMPLE_CHEMICAL", 24, 32], ["tissues", "TISSUE", 66, 73], ["A 5-\u00b5m thick section of formalin", "TREATMENT", 0, 32], ["paraffin-embedded tissues", "TREATMENT", 48, 73]]], ["The prepared slides were put in an oven at 70\u00b0C for 30 min followed by 15 min in a xylene solution for deparaffinization.", [["xylene", "CHEMICAL", 83, 89], ["xylene", "SIMPLE_CHEMICAL", 83, 89], ["a xylene solution", "TREATMENT", 81, 98], ["deparaffinization", "TREATMENT", 103, 120]]], ["The sections were dried and surrounded by liquid blocker (Dako pen).", [["sections", "ANATOMY", 4, 12], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["liquid blocker", "TREATMENT", 42, 56]]], ["The antigen retrieval (pretreatment) step was executed by immersing the sections in 1\u00d7 reveal Decloaker reagent (Biocare Medical, Pacheco, CA, USA) and heating in a microwave several times for 30 min then cool at room temperature for 15-20 min.", [["sections", "ANATOMY", 72, 80], ["The antigen retrieval", "TREATMENT", 0, 21], ["Decloaker reagent", "TREATMENT", 94, 111], ["heating in a microwave", "TREATMENT", 152, 174]]], ["After that, staining procedure was carried out by following the manufacturer\u2019s instructions of the ABC kit.", [["ABC", "GENE_OR_GENE_PRODUCT", 99, 102], ["staining procedure", "TREATMENT", 12, 30], ["the ABC kit", "TEST", 95, 106]]], ["To eliminate the effect of internal renal biotin, 0.05% avidin was applied (Sigma-Aldrich, St. Louis, MO, USA) only on kidney sections for 15 min at room temperature [30,31].", [["renal", "ANATOMY", 36, 41], ["kidney sections", "ANATOMY", 119, 134], ["biotin", "CHEMICAL", 42, 48], ["biotin", "CHEMICAL", 42, 48], ["renal", "ORGAN", 36, 41], ["biotin", "SIMPLE_CHEMICAL", 42, 48], ["avidin", "SIMPLE_CHEMICAL", 56, 62], ["St. Louis", "ORGANISM", 91, 100], ["kidney sections", "MULTI-TISSUE_STRUCTURE", 119, 134], ["internal renal biotin", "TREATMENT", 27, 48], ["0.05% avidin", "TREATMENT", 50, 62], ["kidney sections", "TREATMENT", 119, 134], ["renal", "ANATOMY", 36, 41], ["kidney", "ANATOMY", 119, 125]]], ["The immunoreactivity of the expressed S1 protein was visualized using a light microscope at different magnifications.Lymphocyte cell culture ::: Materials and MethodsSpleen tissues from each group were collected, pooled, and homogenized to obtain single-cell suspensions.", [["Lymphocyte cell", "ANATOMY", 117, 132], ["MethodsSpleen tissues", "ANATOMY", 159, 180], ["cell", "ANATOMY", 254, 258], ["S1", "GENE_OR_GENE_PRODUCT", 38, 40], ["Lymphocyte cell", "CELL", 117, 132], ["MethodsSpleen tissues", "TISSUE", 159, 180], ["cell", "CELL", 254, 258], ["S1 protein", "PROTEIN", 38, 48], ["Lymphocyte cell culture", "CELL_LINE", 117, 140], ["a light microscope", "TEST", 70, 88], ["Lymphocyte cell culture", "TEST", 117, 140], ["MethodsSpleen tissues", "PROBLEM", 159, 180], ["single-cell suspensions", "TREATMENT", 247, 270]]], ["The cells were centrifuged for 10 min at 800 rpm, and the pellet was re-suspended in Roswell Park Memorial Institute Medium (RPMI) (Gibco, Grand Island, NY, USA), supplemented with 10% fetal calf serum, 20 mM HEPES, 10 \u00b5g/ml penicillin/streptomycin, 2 mM L-glutamine, 50 \u00b5M 2-mercaptoethanol, and 500 ng/ml Amphiostat B (complete RPMI) [32].", [["cells", "ANATOMY", 4, 9], ["fetal calf serum", "ANATOMY", 185, 201], ["penicillin", "CHEMICAL", 225, 235], ["streptomycin", "CHEMICAL", 236, 248], ["L-glutamine", "CHEMICAL", 255, 266], ["2-mercaptoethanol", "CHEMICAL", 274, 291], ["Amphiostat B", "CHEMICAL", 307, 319], ["HEPES", "CHEMICAL", 209, 214], ["penicillin", "CHEMICAL", 225, 235], ["streptomycin", "CHEMICAL", 236, 248], ["L-glutamine", "CHEMICAL", 255, 266], ["2-mercaptoethanol", "CHEMICAL", 274, 291], ["Amphiostat B", "CHEMICAL", 307, 319], ["cells", "CELL", 4, 9], ["calf", "ORGANISM", 191, 195], ["serum", "ORGANISM_SUBSTANCE", 196, 201], ["penicillin", "SIMPLE_CHEMICAL", 225, 235], ["streptomycin", "SIMPLE_CHEMICAL", 236, 248], ["L-glutamine", "SIMPLE_CHEMICAL", 255, 266], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 274, 291], ["calf", "SPECIES", 191, 195], ["fetal calf serum", "TEST", 185, 201], ["20 mM HEPES", "TREATMENT", 203, 214], ["penicillin", "TREATMENT", 225, 235], ["streptomycin", "TREATMENT", 236, 248], ["2 mM L-glutamine", "TREATMENT", 250, 266], ["mercaptoethanol", "TREATMENT", 276, 291]]], ["The cell suspension was washed again by centrifugation as described earlier.", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["The cell suspension", "TREATMENT", 0, 19], ["cell suspension", "OBSERVATION", 4, 19]]], ["Spleen cells were re-suspended in red blood cell lysis buffer (Tris-buffered NH4CL) to remove erythrocytes.", [["Spleen cells", "ANATOMY", 0, 12], ["red blood cell", "ANATOMY", 34, 48], ["erythrocytes", "ANATOMY", 94, 106], ["NH4CL", "CHEMICAL", 77, 82], ["Spleen cells", "CELL", 0, 12], ["red blood cell", "CELL", 34, 48], ["Tris-buffered NH4CL", "SIMPLE_CHEMICAL", 63, 82], ["erythrocytes", "CELL", 94, 106], ["Spleen cells", "CELL_TYPE", 0, 12], ["erythrocytes", "CELL_TYPE", 94, 106], ["Spleen cells", "TEST", 0, 12], ["red blood cell lysis buffer", "TREATMENT", 34, 61], ["Tris-buffered NH4CL", "TREATMENT", 63, 82], ["erythrocytes", "PROBLEM", 94, 106], ["blood cell lysis", "OBSERVATION", 38, 54]]], ["Cells from each group (1\u00d7105) were re-suspended in 1 ml of complete RPMI and plated in 24-well plates in triplicate in parallel, adjacent wells.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["complete RPMI", "TEST", 59, 72]]], ["The first set of samples was stimulated with 10 \u00b5g of specific peptide \u201cepitope\u201d CYSSLILDY per well.", [["samples", "ANATOMY", 17, 24], ["samples", "CANCER", 17, 24], ["specific peptide \u201cepitope", "TREATMENT", 54, 79]]], ["This antigen was defined as the highest potential T-cell epitope from a total of eight potential epitopes within the RBD region of the S1 subunit of the spike protein of MERS-CoV genome and was expected to display interactions with the maximum number of major histocompatibility complex (MHC) Class I molecules, and to show the highest peak in the B-cell antigenicity plot [33].", [["T-cell", "ANATOMY", 50, 56], ["B-cell", "ANATOMY", 348, 354], ["T-cell", "CELL", 50, 56], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 170, 178], ["B-cell", "CELL", 348, 354], ["T-cell epitope", "PROTEIN", 50, 64], ["RBD region", "PROTEIN", 117, 127], ["S1 subunit", "PROTEIN", 135, 145], ["spike protein", "PROTEIN", 153, 166], ["MERS-CoV genome", "DNA", 170, 185], ["major histocompatibility complex (MHC) Class I molecules", "PROTEIN", 254, 310], ["MERS-CoV", "SPECIES", 170, 178], ["This antigen", "TEST", 0, 12], ["cell epitope", "OBSERVATION", 52, 64], ["RBD", "ANATOMY", 117, 120], ["region", "ANATOMY_MODIFIER", 121, 127], ["S1", "ANATOMY_MODIFIER", 135, 137], ["spike", "OBSERVATION_MODIFIER", 153, 158], ["highest", "OBSERVATION_MODIFIER", 328, 335], ["peak", "OBSERVATION_MODIFIER", 336, 340]]], ["The second set of samples was stimulated with 50 \u00b5g of non-specific stimulant phytohemagglutinin to confirm the viability and productivity of the cultured cells.", [["samples", "ANATOMY", 18, 25], ["cells", "ANATOMY", 155, 160], ["samples", "CANCER", 18, 25], ["phytohemagglutinin", "SIMPLE_CHEMICAL", 78, 96], ["cells", "CELL", 155, 160], ["phytohemagglutinin", "PROTEIN", 78, 96], ["cultured cells", "CELL_LINE", 146, 160], ["non-specific stimulant phytohemagglutinin", "TREATMENT", 55, 96], ["the viability", "PROBLEM", 108, 121], ["the cultured cells", "TEST", 142, 160]]], ["The third set of samples was not stimulated as a control set.", [["samples", "ANATOMY", 17, 24], ["samples", "CANCER", 17, 24]]], ["Cells were incubated in round-bottom 24-well microtiter plates at 37\u00b0C in 5% CO2.", [["Cells", "ANATOMY", 0, 5], ["CO2", "CHEMICAL", 77, 80], ["CO2", "CHEMICAL", 77, 80], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 77, 80], ["Cells", "TEST", 0, 5], ["microtiter plates", "TEST", 45, 62]]], ["The cultured media were collected after 96 h, and the samples were centrifuged for 20 min at 2000 rpm.", [["samples", "ANATOMY", 54, 61], ["The cultured media", "TEST", 0, 18]]], ["The supernatants were stored at \u221220\u00b0C before cytokine analysis, while the pellets were stored at \u221280\u00b0C until real-time (RT)-PCR analysis.Humoral MERS-S1 immunoglobulin G (IgG) response in mice sera ::: Materials and MethodsDetection and measurement of specific MERS-S1 IgG were achieved using a semi-quantitative anti-MERS-CoV ELISA (IgG) (EUROIMMUN AG, Luebeck, Germany) with a slight modification using universal enzyme conjugate, anti-mouse IgG-conjugated HRP, to be able to detect mouse IgG antibodies instead of human IgG antibodies.", [["supernatants", "ANATOMY", 4, 16], ["sera", "ANATOMY", 193, 197], ["C", "GENE_OR_GENE_PRODUCT", 36, 37], ["MERS-S1", "GENE_OR_GENE_PRODUCT", 145, 152], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 153, 169], ["IgG", "GENE_OR_GENE_PRODUCT", 171, 174], ["mice", "ORGANISM", 188, 192], ["sera", "ORGANISM_SUBSTANCE", 193, 197], ["MERS-S1 IgG", "GENE_OR_GENE_PRODUCT", 261, 272], ["HRP", "SIMPLE_CHEMICAL", 459, 462], ["mouse", "ORGANISM", 485, 490], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 491, 505], ["human", "ORGANISM", 517, 522], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 523, 537], ["cytokine", "PROTEIN", 45, 53], ["immunoglobulin G", "PROTEIN", 153, 169], ["IgG", "PROTEIN", 171, 174], ["MERS-S1 IgG", "PROTEIN", 261, 272], ["anti-MERS", "PROTEIN", 313, 322], ["IgG", "PROTEIN", 334, 337], ["universal enzyme conjugate", "PROTEIN", 405, 431], ["anti-mouse IgG", "PROTEIN", 433, 447], ["conjugated HRP", "PROTEIN", 448, 462], ["mouse IgG antibodies", "PROTEIN", 485, 505], ["human IgG antibodies", "PROTEIN", 517, 537], ["mice", "SPECIES", 188, 192], ["anti-mouse", "SPECIES", 433, 443], ["mouse", "SPECIES", 485, 490], ["human", "SPECIES", 517, 522], ["mice", "SPECIES", 188, 192], ["mouse", "SPECIES", 485, 490], ["human", "SPECIES", 517, 522], ["cytokine analysis", "TEST", 45, 62], ["RT)-PCR analysis", "TEST", 120, 136], ["Humoral MERS", "TEST", 137, 149], ["MethodsDetection", "TEST", 216, 232], ["specific MERS", "TEST", 252, 265], ["S1 IgG", "TEST", 266, 272], ["CoV ELISA", "TEST", 323, 332], ["a slight modification", "TREATMENT", 377, 398], ["universal enzyme conjugate", "TREATMENT", 405, 431], ["anti-mouse IgG", "TEST", 433, 447], ["conjugated HRP", "PROBLEM", 448, 462], ["mouse IgG antibodies", "TEST", 485, 505], ["human IgG antibodies", "TEST", 517, 537]]], ["Microtiter plates were pre-coated with purified S1 antigen of MERS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["purified S1 antigen", "PROTEIN", 39, 58], ["MERS-CoV", "SPECIES", 62, 70], ["Microtiter plates", "TEST", 0, 17]]], ["Mouse diluted serum samples (1:100) were incubated in each well from the three experimental groups (Ad-MERS-S1, Ad-CMV, and PBS) for 30 min at room temperature by following the manufacturer\u2019s instructions.", [["serum samples", "ANATOMY", 14, 27], ["Mouse", "ORGANISM", 0, 5], ["serum samples", "ORGANISM_SUBSTANCE", 14, 27], ["Ad", "ORGANISM", 112, 114], ["CMV", "ORGANISM", 115, 118], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse diluted serum samples", "TEST", 0, 27], ["Ad-CMV", "TREATMENT", 112, 118], ["PBS", "TREATMENT", 124, 127]]], ["The color intensity was measured using an ELISA plate reader (BioTek, Winooski, VT, USA).Detection of mouse cytokines (interferon-\u03b3 [IFN-\u03b3], interleukin [IL]-12, and IL-4) in cell culture supernatant ::: Materials and MethodsCell culture supernatants from stimulated and corresponding non-stimulated samples of the three groups were tested for the level of mouse cytokines at weeks 4 and 6 post-prime using a quantitative sandwich enzyme immunoassay technique (Quantikine ELISA Mouse Cytokines Immunoassay, Minneapolis, MN, USA) according to the manufacturer\u2019s instructions.Gene expression of mouse cytokines (IFN-\u03b3 and IL-4) in the cell culture pellet ::: Materials and MethodsRelative quantification of mouse IFN-\u03b3 and IL-4 was normalized to the housekeeping gene \u03b2-actin in the cell culture yield of stimulated groups.", [["cell", "ANATOMY", 175, 179], ["Cell", "ANATOMY", 225, 229], ["supernatants", "ANATOMY", 238, 250], ["samples", "ANATOMY", 300, 307], ["cell culture", "ANATOMY", 633, 645], ["cell", "ANATOMY", 781, 785], ["mouse", "ORGANISM", 102, 107], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 119, 131], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 133, 138], ["interleukin [IL]-12", "GENE_OR_GENE_PRODUCT", 141, 160], ["IL-4", "GENE_OR_GENE_PRODUCT", 166, 170], ["cell", "CELL", 175, 179], ["Cell", "CELL", 225, 229], ["mouse", "ORGANISM", 357, 362], ["mouse", "ORGANISM", 593, 598], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 610, 615], ["IL-4", "GENE_OR_GENE_PRODUCT", 620, 624], ["cell", "CELL", 633, 637], ["mouse", "ORGANISM", 705, 710], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 711, 716], ["IL-4", "GENE_OR_GENE_PRODUCT", 721, 725], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 766, 773], ["cell", "CELL", 781, 785], ["mouse cytokines", "PROTEIN", 102, 117], ["interferon-\u03b3 [IFN-\u03b3", "PROTEIN", 119, 138], ["interleukin [IL]-12", "PROTEIN", 141, 160], ["IL", "PROTEIN", 166, 168], ["mouse cytokines", "PROTEIN", 357, 372], ["mouse cytokines", "PROTEIN", 593, 608], ["IFN-\u03b3 and IL-4", "PROTEIN", 610, 624], ["IFN", "PROTEIN", 711, 714], ["IL-4", "PROTEIN", 721, 725], ["housekeeping gene \u03b2-actin", "DNA", 748, 773], ["mouse", "SPECIES", 102, 107], ["mouse", "SPECIES", 357, 362], ["Mouse", "SPECIES", 478, 483], ["mouse", "SPECIES", 593, 598], ["mouse", "SPECIES", 705, 710], ["mouse", "SPECIES", 102, 107], ["mouse", "SPECIES", 357, 362], ["Mouse", "SPECIES", 478, 483], ["mouse", "SPECIES", 593, 598], ["mouse", "SPECIES", 705, 710], ["an ELISA plate reader", "TREATMENT", 39, 60], ["mouse cytokines", "TEST", 102, 117], ["interferon", "TEST", 119, 129], ["IFN", "TEST", 133, 136], ["interleukin [IL]", "TREATMENT", 141, 157], ["IL", "TREATMENT", 166, 168], ["MethodsCell culture supernatants", "TEST", 218, 250], ["a quantitative sandwich enzyme immunoassay technique", "TEST", 407, 459], ["Immunoassay", "TEST", 494, 505], ["mouse cytokines", "TEST", 593, 608], ["IFN", "TEST", 610, 613], ["mouse IFN", "TEST", 705, 714], ["IL", "TEST", 721, 723], ["color", "OBSERVATION_MODIFIER", 4, 9], ["intensity", "OBSERVATION_MODIFIER", 10, 19]]], ["The collected pellets from cell culture were used to extract total RNA using the SV Total RNA Isolation System (Promega) according to the manufacturer\u2019s instructions; this extraction kit has a DNase incubation step to eliminate any DNA in the sample.", [["cell", "ANATOMY", 27, 31], ["sample", "ANATOMY", 243, 249], ["cell culture", "CELL", 27, 39], ["DNase", "GENE_OR_GENE_PRODUCT", 193, 198], ["DNA", "CELLULAR_COMPONENT", 232, 235], ["total RNA", "RNA", 61, 70], ["DNase", "PROTEIN", 193, 198], ["cell culture", "TEST", 27, 39], ["total RNA", "TREATMENT", 61, 70], ["the SV Total RNA Isolation System (Promega)", "TREATMENT", 77, 120], ["this extraction", "TREATMENT", 167, 182], ["a DNase incubation step", "TREATMENT", 191, 214], ["any DNA in the sample", "PROBLEM", 228, 249]]], ["Isolated RNA (40 \u00b5l) was stored at \u221280\u00b0C before RT-PCR analysis.", [["C", "GENE_OR_GENE_PRODUCT", 39, 40], ["Isolated RNA", "PROBLEM", 0, 12], ["RT-PCR analysis", "TEST", 48, 63], ["RNA", "OBSERVATION_MODIFIER", 9, 12]]], ["RNA concentration was adjusted to 10 ng/\u00b5l using TE buffer.", [["RNA concentration", "TREATMENT", 0, 17], ["TE buffer", "TREATMENT", 49, 58]]], ["Purified RNA (10 \u00b5l) was used as a template to produce 20 \u00b5l of cDNA using the reverse transcription system (Promega) kit.", [["Purified RNA", "RNA", 0, 12], ["cDNA", "DNA", 64, 68], ["the reverse transcription system", "TREATMENT", 75, 107]]], ["Relative RT-PCR assay was performed to determine the mRNA expression levels of mouse IFN-\u03b3 and IL-4 in the cell culture.", [["cell culture", "ANATOMY", 107, 119], ["mouse", "ORGANISM", 79, 84], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 85, 90], ["IL-4", "GENE_OR_GENE_PRODUCT", 95, 99], ["cell culture", "CELL", 107, 119], ["mouse IFN-\u03b3 and IL-4", "PROTEIN", 79, 99], ["mouse", "SPECIES", 79, 84], ["mouse", "SPECIES", 79, 84], ["Relative RT-PCR assay", "TEST", 0, 21], ["mouse IFN", "TEST", 79, 88], ["IL", "TEST", 95, 97], ["the cell culture", "TEST", 103, 119]]], ["The fold changes were calculated using the 2\u2212\u0394\u0394CT method normalized to \u03b2-actin [34].", [["The fold changes", "PROBLEM", 0, 16], ["the 2\u2212\u0394\u0394CT method", "TREATMENT", 39, 56]]], ["Specific primer sets were used, as shown in Table-2 [35].", [["primer sets", "DNA", 9, 20], ["Specific primer sets", "TEST", 0, 20]]], ["Extracted RNA (2 \u00b5l) was used as a template in the PCR reaction mixture (20 \u00b5l), which was composed of 0.5 \u00b5M each of the forward and reverse primers, 10 \u00b5l of PowerUp SYPR Green Master Mix (Applied Biosystems, Foster City, CA, USA), and 6 \u00b5l of nuclease-free water.", [["nuclease", "PROTEIN", 246, 254], ["Extracted RNA", "PROBLEM", 0, 13], ["a template in the PCR reaction mixture", "TREATMENT", 33, 71], ["reverse primers", "TREATMENT", 134, 149], ["PowerUp SYPR Green Master Mix", "TREATMENT", 160, 189], ["nuclease", "TREATMENT", 246, 254]]], ["RT-PCR conditions were programmed in Rotor Gene-Q (Qiagen, Hilden, Germany) as follows: 50\u00b0C for 2 min, 95\u00b0C for 10 min, followed by 40 cycles of 95\u00b0C s, 60\u00b0C for 1 min, and a melting step at 55-99\u00b0C for 30 s.Statistical analysis ::: Materials and MethodsData for ELISA and fold changes were expressed at mean \u00b1 standard deviation.", [["RT-PCR conditions", "TEST", 0, 17], ["a melting step", "TEST", 174, 188], ["MethodsData", "TREATMENT", 248, 259], ["ELISA and fold changes", "PROBLEM", 264, 286]]], ["One-way ANOVA and t-test were used to compare different values in all groups using OpenEpi software (Emory University, USA).", [["t-test", "TEST", 18, 24]]], ["Parameter differences were indicated by small letters labeled within each group; different letters indicated significant differences at p<0.05.Biodistribution and localization of S1 protein in mice tissues ::: ResultsDistribution and expression of the S1 subunit of the MERS-CoV spike protein in mice tissues were detected at weeks 3 and 5 post first immunization in the kidneys and lungs of the vaccinated group but not in control groups using conventional PCR (Figure-1).", [["tissues", "ANATOMY", 198, 205], ["tissues", "ANATOMY", 301, 308], ["kidneys", "ANATOMY", 371, 378], ["lungs", "ANATOMY", 383, 388], ["S1", "GENE_OR_GENE_PRODUCT", 179, 181], ["mice", "ORGANISM", 193, 197], ["tissues", "TISSUE", 198, 205], ["S1", "GENE_OR_GENE_PRODUCT", 252, 254], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 270, 278], ["mice", "ORGANISM", 296, 300], ["tissues", "TISSUE", 301, 308], ["kidneys", "ORGAN", 371, 378], ["lungs", "ORGAN", 383, 388], ["S1 protein", "PROTEIN", 179, 189], ["S1 subunit", "PROTEIN", 252, 262], ["MERS-CoV spike protein", "PROTEIN", 270, 292], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 296, 300], ["mice", "SPECIES", 193, 197], ["MERS-CoV", "SPECIES", 270, 278], ["mice", "SPECIES", 296, 300], ["the MERS", "TEST", 266, 274], ["CoV spike protein in mice tissues", "PROBLEM", 275, 308], ["conventional PCR", "TEST", 445, 461], ["small", "OBSERVATION_MODIFIER", 40, 45], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["S1", "ANATOMY", 179, 181], ["S1", "ANATOMY", 252, 254], ["MERS", "OBSERVATION", 270, 274], ["mice tissues", "ANATOMY", 296, 308], ["kidneys", "ANATOMY", 371, 378], ["lungs", "ANATOMY", 383, 388]]], ["Using IHC, S1 protein expression was detected in the cytoplasm of proximal tubule epithelium in the vaccinated mice at week 6 post first immunization but not in the control groups (Figure-2).", [["cytoplasm", "ANATOMY", 53, 62], ["proximal tubule epithelium", "ANATOMY", 66, 92], ["S1", "GENE_OR_GENE_PRODUCT", 11, 13], ["cytoplasm", "ORGANISM_SUBSTANCE", 53, 62], ["proximal tubule epithelium", "TISSUE", 66, 92], ["mice", "ORGANISM", 111, 115], ["S1", "PROTEIN", 11, 13], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["IHC", "TEST", 6, 9], ["S1 protein expression", "TEST", 11, 32], ["first immunization", "TREATMENT", 131, 149], ["proximal", "ANATOMY_MODIFIER", 66, 74], ["tubule", "ANATOMY_MODIFIER", 75, 81], ["epithelium", "ANATOMY_MODIFIER", 82, 92]]], ["S1 expression was not detected in lung tissues in either the vaccinated or the control groups (Figure-2).Detection of specific MERS-S1-IgG in mice sera ::: ResultsThere was a significant level (p<0.05) of MERS-S1 specific IgG antibodies detected in the mice sera of the vaccinated group at weeks 4 and 6 post-prime.", [["lung tissues", "ANATOMY", 34, 46], ["sera", "ANATOMY", 147, 151], ["sera", "ANATOMY", 258, 262], ["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["lung tissues", "TISSUE", 34, 46], ["MERS-S1", "GENE_OR_GENE_PRODUCT", 127, 134], ["IgG", "GENE_OR_GENE_PRODUCT", 135, 138], ["mice", "ORGANISM", 142, 146], ["sera", "ORGANISM_SUBSTANCE", 147, 151], ["MERS-S1", "GENE_OR_GENE_PRODUCT", 205, 212], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 222, 236], ["mice", "ORGANISM", 253, 257], ["sera", "ORGANISM_SUBSTANCE", 258, 262], ["S1", "PROTEIN", 0, 2], ["MERS", "PROTEIN", 127, 131], ["S1", "PROTEIN", 132, 134], ["IgG", "PROTEIN", 135, 138], ["MERS-S1 specific IgG antibodies", "PROTEIN", 205, 236], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 253, 257], ["specific MERS", "TEST", 118, 131], ["MERS", "TEST", 205, 209], ["S1 specific IgG antibodies", "TEST", 210, 236], ["not detected", "UNCERTAINTY", 18, 30], ["lung", "ANATOMY", 34, 38]]], ["The combined results of weeks 4 and 6 revealed that the IgG antibody response was significantly higher (p<0.05) in the vaccinated group than in the control groups (Figure-3).Effect of vaccination and antigen-specific stimulation on the production level of mouse cytokines in vitro ::: ResultsThe level of mouse cytokines at weeks 4 and 6 after the first vaccination in the cell culture supernatants of stimulated and corresponding non-stimulated samples of the three groups was tested by sandwich ELISA assay.", [["cell", "ANATOMY", 373, 377], ["supernatants", "ANATOMY", 386, 398], ["samples", "ANATOMY", 446, 453], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 56, 68], ["antigen", "GENE_OR_GENE_PRODUCT", 200, 207], ["mouse", "ORGANISM", 256, 261], ["mouse", "ORGANISM", 305, 310], ["cell", "CELL", 373, 377], ["IgG antibody", "PROTEIN", 56, 68], ["mouse cytokines", "PROTEIN", 256, 271], ["mouse cytokines", "PROTEIN", 305, 320], ["mouse", "SPECIES", 256, 261], ["mouse", "SPECIES", 305, 310], ["mouse", "SPECIES", 256, 261], ["mouse", "SPECIES", 305, 310], ["the IgG antibody response", "TEST", 52, 77], ["vaccination", "TREATMENT", 184, 195], ["antigen", "TEST", 200, 207], ["the first vaccination", "TREATMENT", 344, 365], ["the cell culture", "TEST", 369, 385], ["sandwich ELISA assay", "TEST", 488, 508], ["higher", "OBSERVATION_MODIFIER", 96, 102]]], ["Mice cytokines (IFN-\u03b3, IL-12, and IL-4) production in the Ad-CMV and PBS groups were combined and expressed collectively as one group (control groups) due to the non-significant differences shown across these time points between these two groups (Figure-4).", [["Mice", "ORGANISM", 0, 4], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 16, 21], ["IL-12", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-4", "GENE_OR_GENE_PRODUCT", 34, 38], ["Ad", "ORGANISM", 58, 60], ["CMV", "ORGANISM", 61, 64], ["cytokines", "PROTEIN", 5, 14], ["IFN", "PROTEIN", 16, 19], ["Mice", "SPECIES", 0, 4], ["Mice cytokines", "TEST", 0, 14], ["IFN", "TEST", 16, 19], ["IL", "TEST", 23, 25], ["IL", "TEST", 34, 36], ["the non-significant differences", "PROBLEM", 158, 189]]], ["Therefore, the levels of each cytokine at the two tested time points (weeks 4 and 6 after the first vaccination) were also combined and expressed as one unit.Effect of vaccination and antigen-specific stimulation on the production level of mouse cytokines in vitro ::: ResultsRegardless of in vitro stimulation, production of IFN-\u03b3 was significantly (p<0.05) higher in the vaccinated group compared with the control groups (Ad-CMV and PBS) at all tested time points (Figure-4).Effect of vaccination and antigen-specific stimulation on the production level of mouse cytokines in vitro ::: ResultsIn terms of IL-12 production, in vitro stimulation with the MERS-specific peptide \u201cCYSSLILDY\u201d resulted in a significant (p<0.05) upregulation in production when compared with the antigen-stimulated and non-stimulated cell culture in the vaccinated group only (Figure-4).Effect of vaccination and antigen-specific stimulation on the production level of mouse cytokines in vitro ::: ResultsAlthough there was no significant difference in IL-4 production between the control groups and the vaccinated group in non-stimulated cell culture, antigen-specific stimulation clearly revealed a higher production of this cytokine in the control groups above the vaccinated group level of production (p<0.05).", [["cell", "ANATOMY", 812, 816], ["cell", "ANATOMY", 1117, 1121], ["antigen", "GENE_OR_GENE_PRODUCT", 184, 191], ["mouse", "ORGANISM", 240, 245], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 326, 331], ["Ad", "ORGANISM", 424, 426], ["CMV", "ORGANISM", 427, 430], ["antigen", "GENE_OR_GENE_PRODUCT", 503, 510], ["mouse", "ORGANISM", 559, 564], ["IL-12", "GENE_OR_GENE_PRODUCT", 607, 612], ["CYSSLILDY", "SIMPLE_CHEMICAL", 678, 687], ["cell", "CELL", 812, 816], ["antigen", "GENE_OR_GENE_PRODUCT", 891, 898], ["mouse", "ORGANISM", 947, 952], ["IL-4", "GENE_OR_GENE_PRODUCT", 1031, 1035], ["cell", "CELL", 1117, 1121], ["antigen", "GENE_OR_GENE_PRODUCT", 1131, 1138], ["cytokine", "PROTEIN", 30, 38], ["mouse cytokines", "PROTEIN", 240, 255], ["IFN", "PROTEIN", 326, 329], ["mouse cytokines", "PROTEIN", 559, 574], ["IL", "PROTEIN", 607, 609], ["non-stimulated cell culture", "CELL_LINE", 797, 824], ["mouse cytokines", "PROTEIN", 947, 962], ["IL-4", "PROTEIN", 1031, 1035], ["non-stimulated cell culture", "CELL_LINE", 1102, 1129], ["cytokine", "PROTEIN", 1205, 1213], ["mouse", "SPECIES", 240, 245], ["mouse", "SPECIES", 559, 564], ["mouse", "SPECIES", 947, 952], ["mouse", "SPECIES", 240, 245], ["mouse", "SPECIES", 559, 564], ["mouse", "SPECIES", 947, 952], ["the first vaccination", "TREATMENT", 90, 111], ["vaccination", "TREATMENT", 168, 179], ["antigen", "TEST", 184, 191], ["vitro stimulation", "TREATMENT", 293, 310], ["IFN", "TEST", 326, 329], ["Ad-CMV and PBS", "TREATMENT", 424, 438], ["Figure", "TEST", 467, 473], ["vaccination", "TREATMENT", 487, 498], ["antigen", "TEST", 503, 510], ["IL", "TEST", 607, 609], ["vitro stimulation", "TREATMENT", 628, 645], ["a significant (p<0.05) upregulation in production", "PROBLEM", 701, 750], ["the antigen", "TEST", 770, 781], ["non-stimulated cell culture", "TEST", 797, 824], ["Figure", "TEST", 855, 861], ["vaccination", "TREATMENT", 875, 886], ["antigen", "TEST", 891, 898], ["IL", "TEST", 1031, 1033], ["non-stimulated cell culture", "TEST", 1102, 1129], ["antigen", "TEST", 1131, 1138], ["significant", "OBSERVATION_MODIFIER", 703, 714], ["no", "UNCERTAINTY", 1002, 1004], ["significant", "OBSERVATION_MODIFIER", 1005, 1016], ["difference", "OBSERVATION_MODIFIER", 1017, 1027]]], ["In addition, in vitro stimulation with the MERS specific peptide \u201cCYSSLILDY\u201d resulted in a significant upregulation in this production of this cytokine in the control groups while the same antigen stimulation resulted in a significant decrease in IL-4 production in the vaccinated group (p<0.05) (Figure-4).Gene expression of mouse cytokines in the cell culture pellet ::: ResultsAt week 4 post first immunization, the fold change in IFN-\u03b3 gene expression was significantly higher than that in the control groups (Ad-CMV and PBS) (p<0.05).", [["cell culture", "ANATOMY", 349, 361], ["IL-4", "GENE_OR_GENE_PRODUCT", 247, 251], ["mouse", "ORGANISM", 326, 331], ["cell", "CELL", 349, 353], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 434, 439], ["Ad", "ORGANISM", 514, 516], ["CMV", "ORGANISM", 517, 520], ["cytokine", "PROTEIN", 143, 151], ["IL-4", "PROTEIN", 247, 251], ["mouse cytokines", "PROTEIN", 326, 341], ["IFN", "PROTEIN", 434, 437], ["mouse", "SPECIES", 326, 331], ["mouse", "SPECIES", 326, 331], ["vitro stimulation", "TREATMENT", 16, 33], ["a significant upregulation", "PROBLEM", 89, 115], ["this cytokine in the control groups", "TREATMENT", 138, 173], ["a significant decrease in IL", "PROBLEM", 221, 249], ["mouse cytokines", "PROBLEM", 326, 341], ["first immunization", "TREATMENT", 395, 413], ["the fold change", "PROBLEM", 415, 430], ["IFN", "TEST", 434, 437], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["upregulation", "OBSERVATION", 103, 115], ["significant", "OBSERVATION_MODIFIER", 223, 234], ["decrease", "OBSERVATION_MODIFIER", 235, 243], ["IL", "OBSERVATION_MODIFIER", 247, 249], ["mouse cytokines", "OBSERVATION", 326, 341]]], ["However, there was a prominent increase in IFN-\u03b3 gene expression at week 6 post-prime in both the vaccinated and Ad-CMV groups compared to that in week 4 (p<0.05).", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 43, 48], ["Ad-CMV", "ORGANISM", 113, 119], ["IFN", "PROTEIN", 43, 46], ["Ad-CMV", "SPECIES", 113, 119], ["a prominent increase in IFN", "PROBLEM", 19, 46], ["prominent", "OBSERVATION_MODIFIER", 21, 30], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["The expression of IFN-\u03b3 was slightly higher but not statistically significant in the vaccinated group compared to that in the Ad-CMV group at week 6 (p>0.05) (Figure-5).Gene expression of mouse cytokines in the cell culture pellet ::: ResultsThe only significant change (p<0.05) in IL-4 gene expression was observed in the Ad-CMV group at week 6 (Figure-5) while no significant changes were observed in the vaccinated group at any time point.DiscussionIn this study, potentially protective humoral and cellular immune responses were elicited in mice by immunization using a recombinant adenoviral-based vaccine encoding the S1 subunit of the MERS-CoV spike gene.", [["cell culture", "ANATOMY", 211, 223], ["cellular", "ANATOMY", 502, 510], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 18, 23], ["Ad-CMV", "ORGANISM", 126, 132], ["mouse", "ORGANISM", 188, 193], ["cell", "CELL", 211, 215], ["IL-4", "GENE_OR_GENE_PRODUCT", 282, 286], ["Ad-CMV", "ORGANISM", 323, 329], ["cellular", "CELL", 502, 510], ["mice", "ORGANISM", 545, 549], ["adenoviral", "ORGANISM", 586, 596], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 642, 650], ["IFN", "PROTEIN", 18, 21], ["\u03b3", "PROTEIN", 22, 23], ["mouse cytokines", "PROTEIN", 188, 203], ["IL-4 gene", "DNA", 282, 291], ["S1 subunit", "PROTEIN", 624, 634], ["MERS-CoV spike gene", "DNA", 642, 661], ["mouse", "SPECIES", 188, 193], ["mice", "SPECIES", 545, 549], ["mouse", "SPECIES", 188, 193], ["mice", "SPECIES", 545, 549], ["MERS-CoV", "SPECIES", 642, 650], ["IFN", "TEST", 18, 21], ["mouse cytokines", "PROBLEM", 188, 203], ["significant change", "PROBLEM", 251, 269], ["Figure", "TEST", 347, 353], ["significant changes", "PROBLEM", 366, 385], ["this study", "TEST", 455, 465], ["immunization", "TREATMENT", 553, 565], ["a recombinant adenoviral-based vaccine", "TREATMENT", 572, 610], ["mouse cytokines", "OBSERVATION", 188, 203], ["significant", "OBSERVATION_MODIFIER", 251, 262], ["change", "OBSERVATION_MODIFIER", 263, 269], ["CoV spike", "OBSERVATION", 647, 656]]], ["Several studies have been published that constructed similar vaccines against MERS-CoV and tested their ability to induce production of neutralizing antibodies and other immune system components [13,14,17,19-23].", [["MERS-CoV", "ORGANISM", 78, 86], ["neutralizing antibodies", "PROTEIN", 136, 159], ["MERS-CoV", "SPECIES", 78, 86], ["Several studies", "TEST", 0, 15], ["neutralizing antibodies", "PROBLEM", 136, 159]]], ["The results of these studies were encouraging and showed that such vaccines may be promising to prevent the global threat of MERS-CoV infection [13,14,17,19-23].", [["MERS-CoV infection", "DISEASE", 125, 143], ["MERS-CoV", "ORGANISM", 125, 133], ["MERS-CoV", "SPECIES", 125, 133], ["these studies", "TEST", 15, 28], ["such vaccines", "TREATMENT", 62, 75], ["CoV infection", "PROBLEM", 130, 143]]], ["However, the safety and efficacy of these vaccines still to be confirmed.", [["these vaccines", "TREATMENT", 36, 50]]], ["It was confirmed that the S protein is responsible for the production of neutralizing antibodies [22,31].", [["S protein", "PROTEIN", 26, 35], ["neutralizing antibodies", "PROTEIN", 73, 96], ["the S protein", "TEST", 22, 35], ["the production of neutralizing antibodies", "PROBLEM", 55, 96]]], ["The S1 subunit contains the RBD, which binds to its host receptor DPP4 (also known as CD26) and induces production of specific neutralizing antibodies.", [["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["RBD", "GENE_OR_GENE_PRODUCT", 28, 31], ["DPP4", "GENE_OR_GENE_PRODUCT", 66, 70], ["CD26", "GENE_OR_GENE_PRODUCT", 86, 90], ["S1 subunit", "PROTEIN", 4, 14], ["RBD", "PROTEIN", 28, 31], ["DPP4", "PROTEIN", 66, 70], ["CD26", "PROTEIN", 86, 90], ["neutralizing antibodies", "PROTEIN", 127, 150], ["the RBD", "PROBLEM", 24, 31], ["DPP4", "TEST", 66, 70], ["CD26", "TEST", 86, 90], ["specific neutralizing antibodies", "PROBLEM", 118, 150], ["S1", "ANATOMY_MODIFIER", 4, 6], ["RBD", "OBSERVATION", 28, 31], ["neutralizing antibodies", "OBSERVATION", 127, 150]]], ["Several studies have supported the role of this domain to elicit protective immunity against MERS-CoV challenge [25,36,37].DiscussionIn this study, we were able to demonstrate the distribution and expression of the S1 protein in the vaccinated group but not in the control groups (Ad-CMV and PBS) by detection of the truncated protein-encoding segment in kidney and lung tissues following vaccination using conventional PCR and IHC.", [["kidney", "ANATOMY", 355, 361], ["lung tissues", "ANATOMY", 366, 378], ["MERS-CoV", "ORGANISM", 93, 101], ["S1", "GENE_OR_GENE_PRODUCT", 215, 217], ["Ad-CMV", "ORGANISM", 281, 287], ["kidney", "ORGAN", 355, 361], ["lung tissues", "TISSUE", 366, 378], ["S1 protein", "PROTEIN", 215, 225], ["truncated protein", "PROTEIN", 317, 334], ["MERS-CoV", "SPECIES", 93, 101], ["Several studies", "TEST", 0, 15], ["this study", "TEST", 136, 146], ["the S1 protein", "PROBLEM", 211, 225], ["the truncated protein-encoding segment in kidney and lung tissues", "PROBLEM", 313, 378], ["vaccination", "TREATMENT", 389, 400], ["conventional PCR", "TEST", 407, 423], ["IHC", "TEST", 428, 431], ["truncated protein", "OBSERVATION", 317, 334], ["segment", "ANATOMY_MODIFIER", 344, 351], ["kidney", "ANATOMY", 355, 361], ["lung tissues", "ANATOMY", 366, 378]]], ["These findings support the ability of this vaccine candidate to distribute effectively within host tissues and express the target protein.", [["tissues", "ANATOMY", 99, 106], ["tissues", "TISSUE", 99, 106], ["target protein", "PROTEIN", 123, 137], ["this vaccine", "TREATMENT", 38, 50]]], ["It has been established that DPP4 is expressed on multiple cell types in the human body including cells in the kidneys and lungs [24].", [["cell", "ANATOMY", 59, 63], ["body", "ANATOMY", 83, 87], ["cells", "ANATOMY", 98, 103], ["kidneys", "ANATOMY", 111, 118], ["lungs", "ANATOMY", 123, 128], ["DPP4", "GENE_OR_GENE_PRODUCT", 29, 33], ["cell", "CELL", 59, 63], ["human", "ORGANISM", 77, 82], ["body", "DEVELOPING_ANATOMICAL_STRUCTURE", 83, 87], ["cells", "CELL", 98, 103], ["kidneys", "ORGAN", 111, 118], ["lungs", "ORGAN", 123, 128], ["DPP4", "PROTEIN", 29, 33], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["multiple", "OBSERVATION_MODIFIER", 50, 58], ["cell types", "OBSERVATION", 59, 69], ["human body", "ANATOMY_MODIFIER", 77, 87], ["kidneys", "ANATOMY", 111, 118], ["lungs", "ANATOMY", 123, 128]]], ["However, the N glycoprotein, but not the S glycoprotein, of MERS was the target of investigation of MERS-CoV localization using IHC [38].", [["N glycoprotein", "GENE_OR_GENE_PRODUCT", 13, 27], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 41, 55], ["MERS", "GENE_OR_GENE_PRODUCT", 60, 64], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["N glycoprotein", "PROTEIN", 13, 27], ["S glycoprotein", "PROTEIN", 41, 55], ["MERS", "PROTEIN", 60, 64], ["MERS-CoV", "SPECIES", 100, 108], ["the N glycoprotein", "TREATMENT", 9, 27], ["IHC", "TEST", 128, 131]]], ["The N glycoprotein was clearly present in lung tissues following MERS exposure.", [["lung tissues", "ANATOMY", 42, 54], ["MERS", "CHEMICAL", 65, 69], ["N glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 18], ["lung tissues", "TISSUE", 42, 54], ["MERS", "SIMPLE_CHEMICAL", 65, 69], ["N glycoprotein", "PROTEIN", 4, 18], ["The N glycoprotein", "TREATMENT", 0, 18], ["lung tissues", "ANATOMY", 42, 54]]], ["In fact, the current study can be considered pioneering given the use of the S1 glycoprotein to express viral distribution in tissues.", [["tissues", "ANATOMY", 126, 133], ["S1 glycoprotein", "GENE_OR_GENE_PRODUCT", 77, 92], ["tissues", "TISSUE", 126, 133], ["S1 glycoprotein", "PROTEIN", 77, 92], ["the current study", "TEST", 9, 26], ["the S1 glycoprotein", "TREATMENT", 73, 92], ["viral distribution in tissues", "PROBLEM", 104, 133], ["viral distribution", "OBSERVATION", 104, 122]]], ["Therefore, the expression of S1 protein in kidney tissues and not in lung might be used to explain previous in vitro experiments, which found a cytopathic effect of the MERS-CoV infection inside primary human kidney cells but not in primary human bronchial epithelial cells [39].", [["kidney tissues", "ANATOMY", 43, 57], ["lung", "ANATOMY", 69, 73], ["kidney cells", "ANATOMY", 209, 221], ["bronchial epithelial cells", "ANATOMY", 247, 273], ["infection", "DISEASE", 178, 187], ["S1", "GENE_OR_GENE_PRODUCT", 29, 31], ["kidney tissues", "TISSUE", 43, 57], ["lung", "ORGAN", 69, 73], ["MERS-CoV", "ORGANISM", 169, 177], ["human", "ORGANISM", 203, 208], ["kidney cells", "CELL", 209, 221], ["human", "ORGANISM", 241, 246], ["bronchial epithelial cells", "CELL", 247, 273], ["S1 protein", "PROTEIN", 29, 39], ["primary human kidney cells", "CELL_TYPE", 195, 221], ["primary human bronchial epithelial cells", "CELL_TYPE", 233, 273], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 241, 246], ["MERS-CoV", "SPECIES", 169, 177], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 241, 246], ["S1 protein in kidney tissues", "PROBLEM", 29, 57], ["a cytopathic effect", "PROBLEM", 142, 161], ["the MERS", "PROBLEM", 165, 173], ["CoV infection", "PROBLEM", 174, 187], ["primary human kidney cells", "PROBLEM", 195, 221], ["kidney tissues", "ANATOMY", 43, 57], ["lung", "ANATOMY", 69, 73], ["cytopathic", "OBSERVATION_MODIFIER", 144, 154], ["kidney", "ANATOMY", 209, 215], ["bronchial", "ANATOMY", 247, 256], ["epithelial cells", "OBSERVATION", 257, 273]]], ["In a recent study, the adenoviral vector with enhanced green fluorescent protein but not the adenoviral vector with MERS in a hDPP4 mice experiment after intramuscular or intranasal injection [21].", [["intramuscular", "ANATOMY", 154, 167], ["adenoviral", "ORGANISM", 23, 33], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 55, 80], ["adenoviral", "ORGANISM", 93, 103], ["mice", "ORGANISM", 132, 136], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 154, 167], ["green fluorescent protein", "PROTEIN", 55, 80], ["MERS", "PROTEIN", 116, 120], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 132, 136], ["a recent study", "TEST", 3, 17], ["the adenoviral vector", "TREATMENT", 19, 40], ["enhanced green fluorescent protein", "PROBLEM", 46, 80], ["the adenoviral vector", "TREATMENT", 89, 110], ["a hDPP4 mice experiment", "TREATMENT", 124, 147], ["intramuscular or intranasal injection", "TREATMENT", 154, 191]]], ["This supporting our finding that this construct was able to reach the lung tissues, but the S1 protein was not expressed in lung tissues.", [["lung tissues", "ANATOMY", 70, 82], ["lung tissues", "ANATOMY", 124, 136], ["lung tissues", "TISSUE", 70, 82], ["S1", "GENE_OR_GENE_PRODUCT", 92, 94], ["lung tissues", "TISSUE", 124, 136], ["S1 protein", "PROTEIN", 92, 102], ["the S1 protein", "TEST", 88, 102], ["lung tissues", "ANATOMY", 70, 82], ["lung", "ANATOMY", 124, 128], ["tissues", "OBSERVATION", 129, 136]]], ["However, S1 gene detection in lung tissues by conventional PCR and not by IHC indicates further investigation is necessary regarding the level and intensity of S1 expression in this tissue.", [["lung tissues", "ANATOMY", 30, 42], ["tissue", "ANATOMY", 182, 188], ["S1", "GENE_OR_GENE_PRODUCT", 9, 11], ["lung tissues", "TISSUE", 30, 42], ["S1", "GENE_OR_GENE_PRODUCT", 160, 162], ["tissue", "TISSUE", 182, 188], ["S1 gene", "DNA", 9, 16], ["S1", "PROTEIN", 160, 162], ["S1 gene detection in lung tissues", "PROBLEM", 9, 42], ["conventional PCR", "TEST", 46, 62], ["IHC", "TEST", 74, 77], ["further investigation", "TEST", 88, 109], ["S1 expression in this tissue", "PROBLEM", 160, 188], ["lung", "ANATOMY", 30, 34], ["S1 expression", "OBSERVATION", 160, 173]]], ["Additional studies are also needed to explore S1 protein expression in other tissues such as the liver and intestine given the expression of DPP4 in these tissues [40].DiscussionIn this study, there was a significant serum level of the S1-specific IgG antibody in the vaccinated group but not in the control groups (Ad-CMV and PBS).", [["tissues", "ANATOMY", 77, 84], ["liver", "ANATOMY", 97, 102], ["intestine", "ANATOMY", 107, 116], ["tissues", "ANATOMY", 155, 162], ["serum", "ANATOMY", 217, 222], ["S1", "GENE_OR_GENE_PRODUCT", 46, 48], ["tissues", "TISSUE", 77, 84], ["liver", "ORGAN", 97, 102], ["intestine", "ORGAN", 107, 116], ["DPP4", "GENE_OR_GENE_PRODUCT", 141, 145], ["tissues", "TISSUE", 155, 162], ["serum", "ORGANISM_SUBSTANCE", 217, 222], ["S1", "GENE_OR_GENE_PRODUCT", 236, 238], ["IgG", "GENE_OR_GENE_PRODUCT", 248, 251], ["Ad-CMV", "ORGANISM", 316, 322], ["S1", "PROTEIN", 46, 48], ["DPP4", "PROTEIN", 141, 145], ["S1", "PROTEIN", 236, 238], ["IgG antibody", "PROTEIN", 248, 260], ["Additional studies", "TEST", 0, 18], ["S1 protein expression in other tissues", "PROBLEM", 46, 84], ["DPP4 in these tissues", "PROBLEM", 141, 162], ["this study", "TEST", 181, 191], ["a significant serum level", "PROBLEM", 203, 228], ["specific IgG antibody", "TEST", 239, 260], ["liver", "ANATOMY", 97, 102], ["intestine", "ANATOMY", 107, 116]]], ["Similar results have been shown previously: The SARS-CoV vaccine had a strong ability to elicit the S1-specific IgG antibody response [26].", [["SARS-CoV", "ORGANISM", 48, 56], ["S1", "GENE_OR_GENE_PRODUCT", 100, 102], ["IgG", "GENE_OR_GENE_PRODUCT", 112, 115], ["S1", "PROTEIN", 100, 102], ["IgG antibody", "PROTEIN", 112, 124], ["SARS-CoV", "SPECIES", 48, 56], ["The SARS-CoV vaccine", "TREATMENT", 44, 64]]], ["The results presented in this study also supported the findings of recent publications applying a similar vector vaccine construction [13,14,17,19-23].DiscussionThe T helper 1 immune response is known as the dominant immune response in the case of intracellular pathogens, such as viruses and bacteria, while the T helper 2 immune response is the dominant immune response in cases of extracellular pathogens and allergic reactions [41].", [["intracellular", "ANATOMY", 248, 261], ["extracellular", "ANATOMY", 384, 397], ["allergic reactions", "DISEASE", 412, 430], ["T helper 1", "GENE_OR_GENE_PRODUCT", 165, 175], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 248, 261], ["T helper 2", "GENE_OR_GENE_PRODUCT", 313, 323], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 384, 397], ["this study", "TEST", 25, 35], ["recent publications", "PROBLEM", 67, 86], ["a similar vector vaccine construction", "TREATMENT", 96, 133], ["intracellular pathogens", "PROBLEM", 248, 271], ["viruses", "PROBLEM", 281, 288], ["bacteria", "PROBLEM", 293, 301], ["extracellular pathogens", "PROBLEM", 384, 407], ["allergic reactions", "PROBLEM", 412, 430], ["intracellular pathogens", "OBSERVATION", 248, 271], ["immune response", "OBSERVATION", 356, 371], ["extracellular pathogens", "OBSERVATION", 384, 407]]], ["Many pathogens, especially viruses, shift the host immune response toward Th2 dominance over the Th1 response to evade cellular immunity.", [["cellular", "ANATOMY", 119, 127], ["cellular", "CELL", 119, 127], ["Many pathogens", "PROBLEM", 0, 14], ["viruses", "PROBLEM", 27, 34], ["Th2 dominance", "PROBLEM", 74, 87], ["pathogens", "OBSERVATION", 5, 14], ["cellular immunity", "OBSERVATION", 119, 136]]], ["In this study, Ad-MERS-S1 was able to provoke pro-inflammatory but not anti-inflammatory cytokine release.", [["MERS-S1", "GENE_OR_GENE_PRODUCT", 18, 25], ["MERS", "PROTEIN", 18, 22], ["cytokine", "PROTEIN", 89, 97], ["this study", "TEST", 3, 13], ["anti-inflammatory cytokine release", "TREATMENT", 71, 105]]], ["Both Th1 and Th2 responses were elicited following immunization.", [["Th1", "GENE_OR_GENE_PRODUCT", 5, 8], ["Th2", "GENE_OR_GENE_PRODUCT", 13, 16], ["immunization", "TREATMENT", 51, 63]]], ["Cytokines such as IFN-\u03b3 and IL-12, which represent the Th-1 response, were upregulated, while IL-4, which represents the Th-2 response, was downregulated.DiscussionThe Ad-MERS-S1 was able to induce production of a significant amount of IFN-\u03b3 regardless of antigen-specific stimulation.", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 18, 23], ["IL-12", "GENE_OR_GENE_PRODUCT", 28, 33], ["Th-1", "GENE_OR_GENE_PRODUCT", 55, 59], ["IL-4", "GENE_OR_GENE_PRODUCT", 94, 98], ["Th-2", "GENE_OR_GENE_PRODUCT", 121, 125], ["Ad-MERS-S1", "GENE_OR_GENE_PRODUCT", 168, 178], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 236, 241], ["antigen", "GENE_OR_GENE_PRODUCT", 256, 263], ["Cytokines", "PROTEIN", 0, 9], ["IFN", "PROTEIN", 18, 21], ["IL-12", "PROTEIN", 28, 33], ["IL-4", "PROTEIN", 94, 98], ["Ad-MERS", "PROTEIN", 168, 175], ["IFN", "PROTEIN", 236, 239], ["\u03b3", "PROTEIN", 240, 241], ["Cytokines", "TEST", 0, 9], ["IFN", "TEST", 18, 21], ["IL", "TEST", 28, 30], ["IFN", "PROBLEM", 236, 239], ["significant", "OBSERVATION_MODIFIER", 214, 225], ["amount", "OBSERVATION_MODIFIER", 226, 232]]], ["A similar increase in IL-12 was apparent in vaccinated animals in response to specific in vitro antigen stimulation.", [["IL-12", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-12", "PROTEIN", 22, 27], ["A similar increase in IL", "PROBLEM", 0, 24], ["vitro antigen stimulation", "TREATMENT", 90, 115], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["IL", "OBSERVATION_MODIFIER", 22, 24]]], ["The mRNA expression of IFN-\u03b3 was detected as early as 4 weeks after the first immunization.", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 23, 28], ["IFN", "PROTEIN", 23, 26], ["\u03b3", "PROTEIN", 27, 28], ["IFN", "TEST", 23, 26], ["the first immunization", "TREATMENT", 68, 90]]], ["In contrast, IL-4 production in cell culture showed a significant increase in control animals after antigen stimulation, while the production of this cytokine was significantly decreased in the vaccinated group.", [["cell culture", "ANATOMY", 32, 44], ["IL-4", "GENE_OR_GENE_PRODUCT", 13, 17], ["cell culture", "CELL", 32, 44], ["IL-4", "PROTEIN", 13, 17], ["cell culture", "CELL_LINE", 32, 44], ["cytokine", "PROTEIN", 150, 158], ["cell culture", "TEST", 32, 44], ["antigen stimulation", "TREATMENT", 100, 119], ["this cytokine", "PROBLEM", 145, 158], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["decreased", "OBSERVATION_MODIFIER", 177, 186]]], ["The results demonstrated neither positive nor negative impact on IL-4 expression in mice vaccinated with the Ad-MERS-S1 or mice that received only PBS.", [["IL-4", "GENE_OR_GENE_PRODUCT", 65, 69], ["mice", "ORGANISM", 84, 88], ["Ad-MERS-S1", "ORGANISM", 109, 119], ["mice", "ORGANISM", 123, 127], ["IL-4", "PROTEIN", 65, 69], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 123, 127], ["IL", "TEST", 65, 67]]], ["Interestingly, there was a significant increase in IL-4 and IFN-\u03b3 gene expression in antigen-stimulated cell culture obtained from mice vaccinated with Ad-CMV at week 6.", [["cell culture", "ANATOMY", 104, 116], ["IL-4", "GENE_OR_GENE_PRODUCT", 51, 55], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 60, 65], ["antigen", "GENE_OR_GENE_PRODUCT", 85, 92], ["cell culture", "CELL", 104, 116], ["mice", "ORGANISM", 131, 135], ["Ad", "ORGANISM", 152, 154], ["-CMV", "ORGANISM", 154, 158], ["IFN", "PROTEIN", 60, 63], ["antigen-stimulated cell culture", "CELL_LINE", 85, 116], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135], ["Ad", "SPECIES", 152, 154], ["a significant increase in IL", "PROBLEM", 25, 53], ["IFN", "TREATMENT", 60, 63], ["gene expression in antigen", "PROBLEM", 66, 92], ["stimulated cell culture", "TEST", 93, 116], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["This might be due to the ability of adenoviruses to elicit strong humoral and cellular immune responses [42,43].", [["cellular", "ANATOMY", 78, 86], ["adenoviruses", "ORGANISM", 36, 48], ["cellular", "CELL", 78, 86], ["adenoviruses", "PROBLEM", 36, 48]]], ["Therefore, it can be concluded that the presence of the S1 protein gene in the adenovirus vector genome disturbs the immune stimulation ability of the adenovirus vector to elicit IL-4 cytokine.DiscussionTwo studies have shed light on the ability of the S1 subunit, and specifically, the ability of the RBD domain, to shift the host immune response toward Th1 [14,44].", [["S1", "GENE_OR_GENE_PRODUCT", 56, 58], ["adenovirus", "ORGANISM", 79, 89], ["adenovirus", "ORGANISM", 151, 161], ["IL-4", "GENE_OR_GENE_PRODUCT", 179, 183], ["S1", "GENE_OR_GENE_PRODUCT", 253, 255], ["S1 protein gene", "DNA", 56, 71], ["adenovirus vector genome", "DNA", 79, 103], ["IL-4 cytokine", "PROTEIN", 179, 192], ["S1 subunit", "PROTEIN", 253, 263], ["RBD domain", "PROTEIN", 302, 312], ["adenovirus", "SPECIES", 151, 161], ["the S1 protein gene", "PROBLEM", 52, 71], ["the adenovirus vector genome", "TREATMENT", 75, 103], ["the adenovirus vector", "TREATMENT", 147, 168], ["Two studies", "TEST", 203, 214], ["the RBD domain", "PROBLEM", 298, 312]]], ["It was demonstrated in these two studies that IgG1, which is produced mainly during the Th2 immune response, was decreased, while IgG2a, which is produced mainly during the Th1 immune response, was upregulated following vaccination with their vaccine candidate.", [["IgG1", "GENE_OR_GENE_PRODUCT", 46, 50], ["IgG2a", "GENE_OR_GENE_PRODUCT", 130, 135], ["IgG1", "PROTEIN", 46, 50], ["IgG2a", "PROTEIN", 130, 135], ["IgG1", "TEST", 46, 50], ["vaccination", "TREATMENT", 220, 231], ["decreased", "OBSERVATION_MODIFIER", 113, 122]]], ["The truncated RBD fused with the Fc portion of human IgG was able to elicit both isotypes with a relatively higher amount of the IgG2a isotype (Th1 response) [44].", [["RBD", "GENE_OR_GENE_PRODUCT", 14, 17], ["human", "ORGANISM", 47, 52], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgG2a", "GENE_OR_GENE_PRODUCT", 129, 134], ["RBD", "PROTEIN", 14, 17], ["Fc portion", "PROTEIN", 33, 43], ["human IgG", "PROTEIN", 47, 56], ["IgG2a isotype", "PROTEIN", 129, 142], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["The truncated RBD fused", "PROBLEM", 0, 23], ["the Fc portion of human IgG", "TREATMENT", 29, 56], ["RBD fused", "OBSERVATION", 14, 23], ["relatively", "OBSERVATION_MODIFIER", 97, 107], ["higher", "OBSERVATION_MODIFIER", 108, 114], ["amount", "OBSERVATION_MODIFIER", 115, 121], ["IgG2a isotype", "OBSERVATION", 129, 142]]], ["Recombinant adenovirus vector carrying the S1 subunit or the whole S gene was also able to induce both types of the immune response.", [["adenovirus", "ORGANISM", 12, 22], ["S1", "GENE_OR_GENE_PRODUCT", 43, 45], ["S1 subunit", "PROTEIN", 43, 53], ["S gene", "DNA", 67, 73], ["adenovirus", "SPECIES", 12, 22], ["Recombinant adenovirus vector", "TREATMENT", 0, 29], ["immune response", "OBSERVATION", 116, 131]]], ["The IgG2a level was detected earlier and higher in MERS-S than MERS-S1 at week 2 post-vaccination but not after week 3 [14].", [["IgG2a", "GENE_OR_GENE_PRODUCT", 4, 9], ["MERS-S1", "CELL", 63, 70], ["IgG2a", "PROTEIN", 4, 9], ["The IgG2a level", "TEST", 0, 15], ["vaccination", "TREATMENT", 86, 97], ["higher", "OBSERVATION_MODIFIER", 41, 47]]], ["Accordingly, these findings lead to the dominance toward the Th1 cellular immunity.DiscussionSeveral in vivo and in vitro studies have revealed the ability of MERS-CoV to evade the host innate immune response through downregulating the antigen-presenting pathway and proinflammatory cytokines such as IFN-\u03b3 and IL-12 [38,45-47].DiscussionSeveral MERS-CoV proteins were previously identified as potent IFN antagonists, including the M structural protein and the ORF 4a, ORF 4b, and ORF 5 accessory proteins [46].", [["Th1 cellular", "ANATOMY", 61, 73], ["Th1 cellular", "CELL", 61, 73], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 159, 167], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 301, 306], ["IL-12", "GENE_OR_GENE_PRODUCT", 311, 316], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 346, 354], ["ORF 4a", "GENE_OR_GENE_PRODUCT", 461, 467], ["ORF 4b", "GENE_OR_GENE_PRODUCT", 469, 475], ["proinflammatory cytokines", "PROTEIN", 267, 292], ["IFN", "PROTEIN", 301, 304], ["IL", "PROTEIN", 311, 313], ["MERS-CoV proteins", "PROTEIN", 346, 363], ["IFN", "PROTEIN", 401, 404], ["M structural protein", "PROTEIN", 432, 452], ["ORF 4a", "DNA", 461, 467], ["ORF 4b", "DNA", 469, 475], ["ORF 5", "DNA", 481, 486], ["MERS-CoV", "SPECIES", 159, 167], ["vitro studies", "TEST", 116, 129], ["the antigen", "TEST", 232, 243], ["proinflammatory cytokines", "TEST", 267, 292], ["IFN", "TEST", 301, 304], ["IL", "TEST", 311, 313], ["CoV proteins", "TEST", 351, 363], ["potent IFN antagonists", "TREATMENT", 394, 416], ["the M structural protein", "TEST", 428, 452], ["the ORF 4a", "TEST", 457, 467], ["ORF 4b", "TEST", 469, 475], ["ORF 5 accessory proteins", "TEST", 481, 505]]], ["In addition, a comparison of the immune response of two MERS-infected patients [48], one of whom with a poor outcome (died) that had elevated levels of IL-17 and IL-10 which promote the Th2 immune response, while the other patient who overcame the infection had increased levels of IFN-\u03b1, IFN-\u03b3, and IL-12, which promote the Th1 immune response [48].DiscussionIn general, it is crucial to induce early and strong innate immune responses against MERS-CoV infection to save lives.", [["MERS-infected", "DISEASE", 56, 69], ["infection", "DISEASE", 248, 257], ["MERS-CoV infection", "DISEASE", 445, 463], ["patients", "ORGANISM", 70, 78], ["IL-17", "GENE_OR_GENE_PRODUCT", 152, 157], ["IL-10", "GENE_OR_GENE_PRODUCT", 162, 167], ["Th2", "GENE_OR_GENE_PRODUCT", 186, 189], ["patient", "ORGANISM", 223, 230], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 282, 287], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 289, 294], ["IL-12", "GENE_OR_GENE_PRODUCT", 300, 305], ["MERS-CoV", "ORGANISM", 445, 453], ["IL", "PROTEIN", 152, 154], ["IL", "PROTEIN", 162, 164], ["IFN", "PROTEIN", 282, 285], ["IFN", "PROTEIN", 289, 292], ["IL-12", "PROTEIN", 300, 305], ["patients", "SPECIES", 70, 78], ["patient", "SPECIES", 223, 230], ["MERS-CoV", "SPECIES", 445, 453], ["elevated levels", "PROBLEM", 133, 148], ["IL", "TEST", 152, 154], ["IL", "TEST", 162, 164], ["the infection", "PROBLEM", 244, 257], ["IFN", "TEST", 282, 285], ["IFN", "TEST", 289, 292], ["IL", "TEST", 300, 302], ["MERS", "PROBLEM", 445, 449], ["CoV infection", "PROBLEM", 450, 463], ["infection", "OBSERVATION", 248, 257]]], ["Our vaccine candidate was able to induce production of the key cytokines of activated T lymphocytes toward CD4+ Th1 cells, which is also an indication of upregulation of the antigen-presenting pathway.", [["T lymphocytes", "ANATOMY", 86, 99], ["CD4+ Th1 cells", "ANATOMY", 107, 121], ["T lymphocytes", "CELL", 86, 99], ["CD4", "GENE_OR_GENE_PRODUCT", 107, 110], ["antigen", "GENE_OR_GENE_PRODUCT", 174, 181], ["cytokines", "PROTEIN", 63, 72], ["activated T lymphocytes", "CELL_TYPE", 76, 99], ["CD4", "PROTEIN", 107, 110], ["Th1 cells", "CELL_TYPE", 112, 121], ["Our vaccine", "TREATMENT", 0, 11], ["Th1 cells", "PROBLEM", 112, 121], ["upregulation of the antigen", "PROBLEM", 154, 181], ["Th1 cells", "OBSERVATION", 112, 121]]], ["The vaccine also did not trigger the production of IL-4, which is involved in the Th2 response, which may be referred to the counter effect of the produced IFN-\u03b3 in IL-4 producing cells [41].DiscussionFinally, it is important to clarify that the in vitro antigen stimulation was done using the specific 9-mer peptide \u201cCYSSLILDY,\u201d this peptide is located at position 437-445 within the conserved region of the S glycoprotein among all identified MERS-CoV strains.", [["IL-4 producing cells", "ANATOMY", 165, 185], ["IL-4", "GENE_OR_GENE_PRODUCT", 51, 55], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 156, 161], ["IL-4", "GENE_OR_GENE_PRODUCT", 165, 169], ["cells", "CELL", 180, 185], ["CYSSLILDY", "SIMPLE_CHEMICAL", 318, 327], ["437-445", "AMINO_ACID", 366, 373], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 409, 423], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 445, 453], ["IL-4", "PROTEIN", 51, 55], ["IFN", "PROTEIN", 156, 159], ["\u03b3", "PROTEIN", 160, 161], ["IL-4 producing cells", "CELL_LINE", 165, 185], ["S glycoprotein", "PROTEIN", 409, 423], ["MERS-CoV", "SPECIES", 445, 453], ["The vaccine", "TREATMENT", 0, 11], ["IFN", "TEST", 156, 159]]], ["This was selected in a computerized simulation that showed that this sequence has the highest B cell antigenicity plot and has the ability to form the greatest number of interactions with MHC-Class I alleles [33].", [["B cell", "ANATOMY", 94, 100], ["B cell", "CELL", 94, 100], ["MHC", "PROTEIN", 188, 191], ["a computerized simulation", "TEST", 21, 46], ["this sequence", "TEST", 64, 77], ["cell antigenicity", "OBSERVATION", 96, 113], ["greatest", "OBSERVATION_MODIFIER", 151, 159]]], ["Although this epitope was not able to increase IFN-\u03b3 production level after in vitro stimulation, it resulted in a significant increase in IL-12 production and a significant decrease in IL-4 production in the vaccinated group.", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-12", "GENE_OR_GENE_PRODUCT", 139, 144], ["IL-4", "GENE_OR_GENE_PRODUCT", 186, 190], ["IFN", "PROTEIN", 47, 50], ["\u03b3", "PROTEIN", 51, 52], ["IL", "PROTEIN", 186, 188], ["IFN", "TEST", 47, 50], ["vitro stimulation", "TREATMENT", 79, 96], ["a significant increase in IL-12 production", "PROBLEM", 113, 155], ["a significant decrease in IL", "PROBLEM", 160, 188], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["significant", "OBSERVATION_MODIFIER", 162, 173], ["decrease", "OBSERVATION_MODIFIER", 174, 182]]], ["In addition, this epitope was able to increase IL-4 production after in vitro stimulation in Ad-CMV group.", [["IL-4", "GENE_OR_GENE_PRODUCT", 47, 51], ["Ad-CMV", "ORGANISM", 93, 99], ["IL-4", "PROTEIN", 47, 51], ["this epitope", "TREATMENT", 13, 25], ["vitro stimulation", "TREATMENT", 72, 89]]], ["However, these findings were not enough to prove the claim that this epitope maybe has a crucial role in MERS-CoV pathogenesis.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["MERS-CoV", "SPECIES", 105, 113], ["this epitope", "PROBLEM", 64, 76], ["CoV pathogenesis", "PROBLEM", 110, 126]]], ["Hence, further studies (such as in vivo or knockout experiments) should be conducted to address the role of this epitope in MERS-CoV pathogenesis.ConclusionOverall, the adenoviral vector encoding the S1 subunit of the MERS-CoV genome is a promising vaccine candidate against MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 275, 293], ["MERS-CoV", "ORGANISM", 124, 132], ["adenoviral", "ORGANISM", 169, 179], ["S1", "GENE_OR_GENE_PRODUCT", 200, 202], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 218, 226], ["MERS-CoV", "ORGANISM", 275, 283], ["S1 subunit", "PROTEIN", 200, 210], ["MERS-CoV genome", "DNA", 218, 233], ["MERS-CoV", "SPECIES", 124, 132], ["MERS-CoV", "SPECIES", 218, 226], ["MERS-CoV", "SPECIES", 275, 283], ["further studies", "TEST", 7, 22], ["this epitope", "PROBLEM", 108, 120], ["CoV pathogenesis", "PROBLEM", 129, 145], ["the adenoviral vector", "TREATMENT", 165, 186], ["MERS", "PROBLEM", 275, 279], ["CoV infection", "PROBLEM", 280, 293], ["CoV genome", "OBSERVATION", 223, 233], ["CoV", "OBSERVATION_MODIFIER", 280, 283], ["infection", "OBSERVATION", 284, 293]]], ["It was clearly demonstrated that this recombinant vaccine is distributed in host tissues.", [["tissues", "ANATOMY", 81, 88], ["tissues", "TISSUE", 81, 88], ["this recombinant vaccine", "TREATMENT", 33, 57], ["host tissues", "OBSERVATION", 76, 88]]], ["In addition, this construct could induce production of a specific anti-S1 IgG antibody response as well as the Th1 immune response, which was evident from the increased levels of pro-inflammatory cytokines in the vaccinated animals.Authors\u2019 ContributionsMA and MuA designed the adenovirus vaccine for the MERS-S1 vaccine.", [["adenovirus", "ORGANISM", 278, 288], ["MERS-S1", "GENE_OR_GENE_PRODUCT", 305, 312], ["S1 IgG antibody", "PROTEIN", 71, 86], ["pro-inflammatory cytokines", "PROTEIN", 179, 205], ["a specific anti-S1 IgG antibody response", "PROBLEM", 55, 95], ["the increased levels of pro-inflammatory cytokines", "PROBLEM", 155, 205], ["the adenovirus vaccine", "TREATMENT", 274, 296], ["the MERS-S1 vaccine", "TREATMENT", 301, 320], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["pro-inflammatory cytokines", "OBSERVATION", 179, 205]]], ["MA and MK designed the mice experiments.", [["MK", "CHEMICAL", 7, 9], ["mice", "ORGANISM", 23, 27], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27]]], ["MuA, MA, and MK took the different tissue samples from the mice.", [["tissue samples", "ANATOMY", 35, 49], ["MuA", "GENE_OR_GENE_PRODUCT", 0, 3], ["MA", "GENE_OR_GENE_PRODUCT", 5, 7], ["tissue samples", "TISSUE", 35, 49], ["mice", "ORGANISM", 59, 63], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63]]], ["MuA performed the molecular assays and the immunohistochemical staining.", [["MuA", "PROTEIN", 0, 3], ["the molecular assays", "TEST", 14, 34], ["the immunohistochemical staining", "TEST", 39, 71], ["immunohistochemical staining", "OBSERVATION", 43, 71]]]], "PMC7468326": [["IntroductionNitric oxide (NO) injury can lead to various neurological diseases, such as Alzheimer\u2019s disease [1] and Parkinson\u2019s disease [2, 3].", [["neurological", "ANATOMY", 57, 69], ["IntroductionNitric oxide", "CHEMICAL", 0, 24], ["NO", "CHEMICAL", 26, 28], ["neurological diseases", "DISEASE", 57, 78], ["Alzheimer\u2019s disease", "DISEASE", 88, 107], ["Parkinson\u2019s disease", "DISEASE", 116, 135], ["IntroductionNitric oxide", "CHEMICAL", 0, 24], ["NO", "CHEMICAL", 26, 28], ["IntroductionNitric oxide", "SIMPLE_CHEMICAL", 0, 24], ["NO", "SIMPLE_CHEMICAL", 26, 28], ["IntroductionNitric oxide", "TREATMENT", 0, 24], ["injury", "PROBLEM", 30, 36], ["various neurological diseases", "PROBLEM", 49, 78], ["Alzheimer\u2019s disease", "PROBLEM", 88, 107], ["Parkinson\u2019s disease", "PROBLEM", 116, 135]]], ["Sodium nitroprusside (SNP) is a donor of NO [4] and is widely used to induce NO damage in models.", [["Sodium nitroprusside", "CHEMICAL", 0, 20], ["SNP", "CHEMICAL", 22, 25], ["NO", "CHEMICAL", 41, 43], ["NO", "CHEMICAL", 77, 79], ["Sodium nitroprusside", "CHEMICAL", 0, 20], ["SNP", "CHEMICAL", 22, 25], ["NO [4]", "CHEMICAL", 41, 47], ["NO", "CHEMICAL", 77, 79], ["Sodium nitroprusside", "SIMPLE_CHEMICAL", 0, 20], ["SNP", "SIMPLE_CHEMICAL", 22, 25], ["NO [4]", "SIMPLE_CHEMICAL", 41, 47], ["NO", "SIMPLE_CHEMICAL", 77, 79], ["Sodium nitroprusside (SNP)", "TREATMENT", 0, 26], ["damage in models", "PROBLEM", 80, 96], ["NO", "UNCERTAINTY", 77, 79], ["damage", "OBSERVATION", 80, 86]]], ["Currently, SNP injury mechanisms include mitochondrial damage [5], calcium overload [6], and the promotion of apoptosis and more specifically involve the glycogen synthase kinase 3/mitogen-activated protein kinase signaling pathway [7] and reactive oxygen [8].", [["mitochondrial", "ANATOMY", 41, 54], ["SNP", "CHEMICAL", 11, 14], ["mitochondrial damage", "DISEASE", 41, 61], ["calcium", "CHEMICAL", 67, 74], ["glycogen", "CHEMICAL", 154, 162], ["oxygen", "CHEMICAL", 249, 255], ["SNP", "CHEMICAL", 11, 14], ["calcium", "CHEMICAL", 67, 74], ["oxygen", "CHEMICAL", 249, 255], ["mitochondrial", "CELLULAR_COMPONENT", 41, 54], ["calcium", "SIMPLE_CHEMICAL", 67, 74], ["glycogen synthase kinase 3", "GENE_OR_GENE_PRODUCT", 154, 180], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 181, 213], ["[7]", "SIMPLE_CHEMICAL", 232, 235], ["reactive oxygen [8]", "SIMPLE_CHEMICAL", 240, 259], ["glycogen synthase kinase 3", "PROTEIN", 154, 180], ["mitogen-activated protein kinase", "PROTEIN", 181, 213], ["SNP injury mechanisms", "PROBLEM", 11, 32], ["mitochondrial damage", "PROBLEM", 41, 61], ["calcium overload", "PROBLEM", 67, 83], ["apoptosis", "PROBLEM", 110, 119], ["the glycogen synthase kinase", "TEST", 150, 178], ["mitogen", "TEST", 181, 188], ["activated protein kinase signaling pathway", "TEST", 189, 231], ["reactive oxygen", "TREATMENT", 240, 255], ["injury", "OBSERVATION", 15, 21], ["reactive", "OBSERVATION_MODIFIER", 240, 248]]], ["However, the role of neurotransmitters of the adrenergic system in the regulation of the nervous system in vivo is unknown, and the effect of the adrenergic system in the protection against SNP injury is not clear.IntroductionThe adrenergic system plays an important role in neurological diseases, especially for mental illness, such as depression, and cerebral ischemia.", [["nervous system", "ANATOMY", 89, 103], ["neurological", "ANATOMY", 275, 287], ["cerebral", "ANATOMY", 353, 361], ["SNP", "CHEMICAL", 190, 193], ["neurological diseases", "DISEASE", 275, 296], ["illness", "DISEASE", 320, 327], ["depression", "DISEASE", 337, 347], ["cerebral ischemia", "DISEASE", 353, 370], ["SNP", "CHEMICAL", 190, 193], ["nervous system", "ANATOMICAL_SYSTEM", 89, 103], ["cerebral", "ORGAN", 353, 361], ["the adrenergic system", "TREATMENT", 142, 163], ["SNP injury", "PROBLEM", 190, 200], ["The adrenergic system", "TREATMENT", 226, 247], ["neurological diseases", "PROBLEM", 275, 296], ["mental illness", "PROBLEM", 313, 327], ["depression", "PROBLEM", 337, 347], ["cerebral ischemia", "PROBLEM", 353, 370], ["nervous system", "ANATOMY", 89, 103], ["injury", "OBSERVATION", 194, 200], ["clear", "OBSERVATION", 208, 213], ["cerebral", "ANATOMY", 353, 361], ["ischemia", "OBSERVATION", 362, 370]]], ["The depressant effects of certain antipsychotic drugs appear to be mediated by the central adrenergic system [9, 10].", [["The depressant effects", "PROBLEM", 0, 22], ["certain antipsychotic drugs", "TREATMENT", 26, 53], ["central", "ANATOMY_MODIFIER", 83, 90]]], ["One predominant biological response to acute stress is the release of norepinephrine, which activates the peripheral stress response and the hypothalamic\u2013pituitary\u2013adrenal (HPA) axis [11].", [["norepinephrine", "CHEMICAL", 70, 84], ["norepinephrine", "CHEMICAL", 70, 84], ["norepinephrine", "SIMPLE_CHEMICAL", 70, 84], ["acute stress", "PROBLEM", 39, 51], ["norepinephrine", "TREATMENT", 70, 84], ["the peripheral stress response", "PROBLEM", 102, 132], ["predominant", "OBSERVATION_MODIFIER", 4, 15], ["biological response", "OBSERVATION", 16, 35], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["stress", "OBSERVATION", 45, 51], ["peripheral", "OBSERVATION", 106, 116], ["stress response", "OBSERVATION", 117, 132]]], ["Partial \u03b21-adrenergic receptor agonists can be used for the treatment of neurocognitive disorders [12], and \u03b22-adrenergic receptor antagonists attenuate the brain damage induced by ischemia [13, 14].IntroductionRat pheochromocytoma PC12 cells are typically used as models [15] for studying neuronal degeneration disorders such as Alzheimer\u2019s disease [16] and Parkinson\u2019s disease.", [["brain", "ANATOMY", 157, 162], ["pheochromocytoma PC12 cells", "ANATOMY", 215, 242], ["neuronal", "ANATOMY", 290, 298], ["neurocognitive disorders", "DISEASE", 73, 97], ["brain damage", "DISEASE", 157, 169], ["ischemia", "DISEASE", 181, 189], ["pheochromocytoma", "DISEASE", 215, 231], ["neuronal degeneration disorders", "DISEASE", 290, 321], ["Alzheimer\u2019s disease", "DISEASE", 330, 349], ["Parkinson\u2019s disease", "DISEASE", 359, 378], ["\u03b21-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 8, 30], ["\u03b22-adrenergic receptor antagonists", "GENE_OR_GENE_PRODUCT", 108, 142], ["brain", "ORGAN", 157, 162], ["Rat pheochromocytoma PC12 cells", "CELL", 211, 242], ["neuronal", "CELL", 290, 298], ["Parkinson\u2019s disease", "CANCER", 359, 378], ["\u03b21", "PROTEIN", 8, 10], ["Rat pheochromocytoma PC12 cells", "CELL_LINE", 211, 242], ["Rat", "SPECIES", 211, 214], ["Partial \u03b21-adrenergic receptor agonists", "TREATMENT", 0, 39], ["neurocognitive disorders", "PROBLEM", 73, 97], ["\u03b22-adrenergic receptor antagonists", "TREATMENT", 108, 142], ["the brain damage", "PROBLEM", 153, 169], ["ischemia", "PROBLEM", 181, 189], ["IntroductionRat pheochromocytoma PC12 cells", "PROBLEM", 199, 242], ["neuronal degeneration disorders", "PROBLEM", 290, 321], ["Alzheimer\u2019s disease", "PROBLEM", 330, 349], ["Parkinson\u2019s disease", "PROBLEM", 359, 378], ["brain", "ANATOMY", 157, 162], ["damage", "OBSERVATION", 163, 169], ["ischemia", "OBSERVATION", 181, 189], ["PC12 cells", "OBSERVATION", 232, 242], ["degeneration", "OBSERVATION", 299, 311]]], ["They are also intensively used to investigate the reactive oxygen species (ROS) and NO synthase (NOS) [17] biochemical pathways involved in cell death and neuroprotection.", [["cell", "ANATOMY", 140, 144], ["oxygen", "CHEMICAL", 59, 65], ["ROS", "CHEMICAL", 75, 78], ["NO", "CHEMICAL", 84, 86], ["death", "DISEASE", 145, 150], ["oxygen", "CHEMICAL", 59, 65], ["NO", "CHEMICAL", 84, 86], ["reactive oxygen species", "SIMPLE_CHEMICAL", 50, 73], ["ROS", "SIMPLE_CHEMICAL", 75, 78], ["NO synthase", "GENE_OR_GENE_PRODUCT", 84, 95], ["NOS", "GENE_OR_GENE_PRODUCT", 97, 100], ["cell", "CELL", 140, 144], ["the reactive oxygen species", "PROBLEM", 46, 73], ["cell death", "PROBLEM", 140, 150], ["neuroprotection", "TREATMENT", 155, 170], ["reactive", "OBSERVATION_MODIFIER", 50, 58], ["oxygen species", "OBSERVATION", 59, 73], ["cell death", "OBSERVATION", 140, 150]]], ["Neuroblastoma SH-SY5Y cells, a cell line derived from human neuroblastomas, are also widely used in the study of the nervous system due to their cell growth and differentiation ability.", [["Neuroblastoma SH-SY5Y cells", "ANATOMY", 0, 27], ["cell line", "ANATOMY", 31, 40], ["neuroblastomas", "ANATOMY", 60, 74], ["nervous system", "ANATOMY", 117, 131], ["cell", "ANATOMY", 145, 149], ["Neuroblastoma", "DISEASE", 0, 13], ["neuroblastomas", "DISEASE", 60, 74], ["Neuroblastoma SH-SY5Y cells", "CELL", 0, 27], ["cell line", "CELL", 31, 40], ["human", "ORGANISM", 54, 59], ["neuroblastomas", "CANCER", 60, 74], ["nervous system", "ANATOMICAL_SYSTEM", 117, 131], ["cell", "CELL", 145, 149], ["Neuroblastoma SH-SY5Y cells", "CELL_LINE", 0, 27], ["cell line", "CELL_LINE", 31, 40], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["Neuroblastoma SH", "TEST", 0, 16], ["a cell line", "TREATMENT", 29, 40], ["human neuroblastomas", "PROBLEM", 54, 74], ["the study", "TEST", 100, 109], ["their cell growth", "PROBLEM", 139, 156], ["cell line", "OBSERVATION", 31, 40], ["human neuroblastomas", "OBSERVATION", 54, 74], ["nervous", "ANATOMY", 117, 124], ["cell growth", "OBSERVATION", 145, 156]]], ["Therefore, SNP-induced neurotoxicity in PC12 and SH-SY5Y cells are suitable to evaluate neuroprotective candidates.", [["PC12", "ANATOMY", 40, 44], ["SH-SY5Y cells", "ANATOMY", 49, 62], ["SNP", "CHEMICAL", 11, 14], ["neurotoxicity", "DISEASE", 23, 36], ["SNP", "CHEMICAL", 11, 14], ["PC12", "CELL", 40, 44], ["SH-SY5Y cells", "CELL", 49, 62], ["PC12", "CELL_LINE", 40, 44], ["SH-SY5Y cells", "CELL_LINE", 49, 62], ["SNP", "TEST", 11, 14], ["neurotoxicity", "PROBLEM", 23, 36], ["PC12", "TEST", 40, 44], ["SH-SY5Y cells", "TREATMENT", 49, 62]]], ["However, PC12 cells cannot produce adrenaline (AD), while SH-SY5Y cells can produce tyrosine hydroxylase, dopamine 2B2 hydroxylase, and dopamine transporters, which are characteristic of catecholaminergic neurons.IntroductionIn view of the lack of research on whether the adrenergic system is involved in NO damage, we explored the effects of different adrenergic receptor agonists and antagonists in gradient doses on cell viability.", [["PC12 cells", "ANATOMY", 9, 19], ["SH-SY5Y cells", "ANATOMY", 58, 71], ["catecholaminergic neurons", "ANATOMY", 187, 212], ["cell", "ANATOMY", 419, 423], ["adrenaline", "CHEMICAL", 35, 45], ["AD", "DISEASE", 47, 49], ["tyrosine", "CHEMICAL", 84, 92], ["dopamine", "CHEMICAL", 106, 114], ["dopamine", "CHEMICAL", 136, 144], ["NO", "CHEMICAL", 305, 307], ["adrenaline", "CHEMICAL", 35, 45], ["tyrosine", "CHEMICAL", 84, 92], ["dopamine", "CHEMICAL", 106, 114], ["dopamine", "CHEMICAL", 136, 144], ["NO", "CHEMICAL", 305, 307], ["PC12 cells", "CELL", 9, 19], ["adrenaline", "SIMPLE_CHEMICAL", 35, 45], ["SH-SY5Y cells", "CELL", 58, 71], ["tyrosine hydroxylase", "GENE_OR_GENE_PRODUCT", 84, 104], ["dopamine 2B2 hydroxylase", "GENE_OR_GENE_PRODUCT", 106, 130], ["dopamine transporters", "GENE_OR_GENE_PRODUCT", 136, 157], ["catecholaminergic neurons", "CELL", 187, 212], ["NO", "SIMPLE_CHEMICAL", 305, 307], ["cell", "CELL", 419, 423], ["PC12 cells", "CELL_LINE", 9, 19], ["SH-SY5Y cells", "CELL_LINE", 58, 71], ["tyrosine hydroxylase", "PROTEIN", 84, 104], ["dopamine 2B2 hydroxylase", "PROTEIN", 106, 130], ["catecholaminergic neurons", "CELL_TYPE", 187, 212], ["PC12 cells", "PROBLEM", 9, 19], ["adrenaline", "TEST", 35, 45], ["tyrosine hydroxylase", "TREATMENT", 84, 104], ["dopamine 2B2 hydroxylase", "TREATMENT", 106, 130], ["dopamine transporters", "TREATMENT", 136, 157], ["catecholaminergic neurons", "PROBLEM", 187, 212], ["damage", "PROBLEM", 308, 314], ["different adrenergic receptor agonists", "TREATMENT", 343, 381], ["antagonists in gradient doses", "TREATMENT", 386, 415], ["cell viability", "TREATMENT", 419, 433], ["PC12 cells", "OBSERVATION", 9, 19], ["tyrosine hydroxylase", "OBSERVATION", 84, 104], ["catecholaminergic neurons", "OBSERVATION", 187, 212], ["NO", "UNCERTAINTY", 305, 307], ["damage", "OBSERVATION", 308, 314], ["cell viability", "OBSERVATION", 419, 433]]], ["We also researched the role of the \u03b1-adrenergic receptors and \u03b2-adrenergic receptors in the neuroprotective effect of ganoderic acid A on SNP injury.Reagents ::: Materials and methodsGanoderic acid A (purity > 90%) was isolated in the Department of Natural Medicinal Chemistry, Institute of Materia Medica, Chinese Academy of Medical Sciences, and the structure is shown in Fig. 1.Reagents ::: Materials and methodsMetoprolol was purchased from Shanghai Dingkang Biomedical Materials Technology Co., Ltd.", [["ganoderic acid A", "CHEMICAL", 118, 134], ["SNP", "CHEMICAL", 138, 141], ["Ganoderic acid A", "CHEMICAL", 183, 199], ["Metoprolol", "CHEMICAL", 415, 425], ["ganoderic acid A", "CHEMICAL", 118, 134], ["SNP", "CHEMICAL", 138, 141], ["Ganoderic acid A", "CHEMICAL", 183, 199], ["Metoprolol", "CHEMICAL", 415, 425], ["\u03b1-adrenergic receptors", "GENE_OR_GENE_PRODUCT", 35, 57], ["\u03b2-adrenergic receptors", "GENE_OR_GENE_PRODUCT", 62, 84], ["ganoderic acid A", "SIMPLE_CHEMICAL", 118, 134], ["Ganoderic acid A", "SIMPLE_CHEMICAL", 183, 199], ["Metoprolol", "SIMPLE_CHEMICAL", 415, 425], ["\u03b1-adrenergic receptors", "PROTEIN", 35, 57], ["\u03b2-adrenergic receptors", "PROTEIN", 62, 84], ["the \u03b1-adrenergic receptors", "TREATMENT", 31, 57], ["\u03b2-adrenergic receptors", "TREATMENT", 62, 84], ["ganoderic acid A on SNP injury", "PROBLEM", 118, 148], ["methodsGanoderic acid A (purity", "TEST", 176, 207], ["methodsMetoprolol", "TREATMENT", 408, 425]]], ["(China). dl-Adrenalin was purchased from Shanghai Yuanye Biotechnology Co., Ltd.", [["Adrenalin", "CHEMICAL", 12, 21], ["Adrenalin", "CHEMICAL", 12, 21], ["dl-Adrenalin", "SIMPLE_CHEMICAL", 9, 21], ["dl-Adrenalin", "TREATMENT", 9, 21]]], ["Phentolamine hydrochloride, ICI 118551, SNP, and 3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA).", [["Phentolamine hydrochloride", "CHEMICAL", 0, 26], ["ICI 118551", "CHEMICAL", 28, 38], ["SNP", "CHEMICAL", 40, 43], ["3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 49, 110], ["MTT", "CHEMICAL", 112, 115], ["Phentolamine hydrochloride", "CHEMICAL", 0, 26], ["ICI 118551", "CHEMICAL", 28, 38], ["SNP", "CHEMICAL", 40, 43], ["3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 49, 110], ["MTT", "CHEMICAL", 112, 115], ["Phentolamine hydrochloride", "SIMPLE_CHEMICAL", 0, 26], ["ICI 118551", "SIMPLE_CHEMICAL", 28, 38], ["SNP", "SIMPLE_CHEMICAL", 40, 43], ["3-(4,5-dimethylthia-zol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 49, 110], ["MTT", "SIMPLE_CHEMICAL", 112, 115], ["St. Louis", "ORGANISM", 165, 174], ["Phentolamine hydrochloride", "TREATMENT", 0, 26], ["ICI", "TREATMENT", 28, 31], ["SNP", "TEST", 40, 43], ["dimethylthia-zol", "TREATMENT", 56, 72], ["diphenyltetrazolium bromide", "TREATMENT", 83, 110]]], ["Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) and horse serum (HS) were obtained from Gibco Life Technologies Inc. (Grand Island, NY, USA).", [["serum", "ANATOMY", 52, 57], ["horse", "ORGANISM", 46, 51], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["horse", "SPECIES", 46, 51], ["horse", "SPECIES", 46, 51], ["horse serum (HS", "TEST", 46, 61]]], ["Fetal bovine serum (FBS) was purchased from PAN Seratech Co. (Aidenbach, Germany).Cell culture and treatment ::: Materials and methodsBoth the SH-SY5Y and PC12 cell lines were obtained from the Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences.", [["Fetal bovine serum", "ANATOMY", 0, 18], ["FBS", "ANATOMY", 20, 23], ["Cell", "ANATOMY", 82, 86], ["SH-SY5Y", "ANATOMY", 143, 150], ["PC12 cell lines", "ANATOMY", 155, 170], ["Cell", "ANATOMY", 194, 198], ["Fetal", "ORGANISM_SUBSTANCE", 0, 5], ["bovine", "ORGANISM", 6, 12], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["FBS", "ORGANISM_SUBSTANCE", 20, 23], ["Cell", "CELL", 82, 86], ["SH-SY5Y", "CELL", 143, 150], ["PC12 cell lines", "CELL", 155, 170], ["Cell", "CELL", 194, 198], ["SH-SY5Y", "CELL_LINE", 143, 150], ["PC12 cell lines", "CELL_LINE", 155, 170], ["bovine", "SPECIES", 6, 12], ["bovine", "SPECIES", 6, 12], ["Fetal bovine serum", "TEST", 0, 18], ["FBS", "TEST", 20, 23], ["Cell culture", "TEST", 82, 94], ["methods", "TEST", 127, 134], ["PC12 cell lines", "TREATMENT", 155, 170], ["PC12 cell lines", "OBSERVATION", 155, 170]]], ["SH-SY5Y cells were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 \u03bcg/mL streptomycin at 37 \u00b0C in a 5% CO2 atmosphere incubator, and PC12 cells were cultured in DMEM supplemented with 5% FBS, 5% HS, 100 U/mL penicillin, and 100 \u03bcg/mL streptomycin.", [["SH-SY5Y cells", "ANATOMY", 0, 13], ["PC12 cells", "ANATOMY", 158, 168], ["FBS", "ANATOMY", 212, 215], ["penicillin", "CHEMICAL", 72, 82], ["streptomycin", "CHEMICAL", 98, 110], ["CO2", "CHEMICAL", 128, 131], ["FBS", "CHEMICAL", 212, 215], ["penicillin", "CHEMICAL", 233, 243], ["streptomycin", "CHEMICAL", 259, 271], ["penicillin", "CHEMICAL", 72, 82], ["streptomycin", "CHEMICAL", 98, 110], ["CO2", "CHEMICAL", 128, 131], ["penicillin", "CHEMICAL", 233, 243], ["streptomycin", "CHEMICAL", 259, 271], ["SH-SY5Y cells", "CELL", 0, 13], ["FBS", "ORGANISM_SUBSTANCE", 58, 61], ["penicillin", "SIMPLE_CHEMICAL", 72, 82], ["streptomycin", "SIMPLE_CHEMICAL", 98, 110], ["CO2", "SIMPLE_CHEMICAL", 128, 131], ["PC12 cells", "CELL", 158, 168], ["FBS", "ORGANISM_SUBSTANCE", 212, 215], ["penicillin", "SIMPLE_CHEMICAL", 233, 243], ["streptomycin", "SIMPLE_CHEMICAL", 259, 271], ["SH-SY5Y cells", "CELL_LINE", 0, 13], ["PC12 cells", "CELL_LINE", 158, 168], ["penicillin", "TREATMENT", 72, 82], ["streptomycin", "TREATMENT", 98, 110], ["a 5% CO2 atmosphere incubator", "TREATMENT", 123, 152], ["PC12 cells", "TREATMENT", 158, 168], ["penicillin", "TREATMENT", 233, 243], ["streptomycin", "TREATMENT", 259, 271]]], ["The medium was refreshed every 2 or 3 days.Cell culture and treatment ::: Materials and methodsThe cells were collected when they had grown to 80%\u201390% confluence and were then treated with different concentrations of SNP for 12, 24, and 48 h to determine the optimal damage condition.", [["Cell", "ANATOMY", 43, 47], ["cells", "ANATOMY", 99, 104], ["SNP", "CHEMICAL", 217, 220], ["SNP", "CHEMICAL", 217, 220], ["Cell", "CELL", 43, 47], ["cells", "CELL", 99, 104], ["Cell culture", "TEST", 43, 55], ["different concentrations of SNP", "TREATMENT", 189, 220], ["the optimal damage condition", "PROBLEM", 255, 283], ["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["After the SNP damage model was established, the cells were treated with SNP (500 \u03bcM) for 24 h or were preincubated with ganoderic acid A at a 10 \u03bcM concentration for 2 h before SNP exposure.", [["cells", "ANATOMY", 48, 53], ["SNP", "CHEMICAL", 10, 13], ["SNP", "CHEMICAL", 72, 75], ["ganoderic acid A", "CHEMICAL", 120, 136], ["SNP", "CHEMICAL", 177, 180], ["SNP", "CHEMICAL", 10, 13], ["SNP", "CHEMICAL", 72, 75], ["ganoderic acid A", "CHEMICAL", 120, 136], ["SNP", "CHEMICAL", 177, 180], ["cells", "CELL", 48, 53], ["ganoderic acid A", "SIMPLE_CHEMICAL", 120, 136], ["the SNP damage model", "TREATMENT", 6, 26], ["SNP", "TREATMENT", 72, 75], ["ganoderic acid A", "TREATMENT", 120, 136], ["a 10 \u03bcM concentration", "TREATMENT", 140, 161]]], ["The control group received equal-volume medium without SNP, and the model group was not preincubated with drugs.", [["SNP", "CHEMICAL", 55, 58], ["SNP", "CHEMICAL", 55, 58], ["SNP", "TREATMENT", 55, 58], ["drugs", "TREATMENT", 106, 111]]], ["Different adrenergic receptor agonists and antagonists were separately added into the 96-well plates 1 h before ganoderic acid A preincubation to research the mechanism.", [["ganoderic acid", "CHEMICAL", 112, 126], ["ganoderic acid A", "CHEMICAL", 112, 128], ["ganoderic acid A", "SIMPLE_CHEMICAL", 112, 128], ["Different adrenergic receptor agonists", "TREATMENT", 0, 38], ["antagonists", "TREATMENT", 43, 54], ["ganoderic acid A preincubation", "TREATMENT", 112, 142]]], ["Medium without SNP was added to the control group cells, and the model group received no preincubation with drugs.", [["cells", "ANATOMY", 50, 55], ["SNP", "CHEMICAL", 15, 18], ["SNP", "CHEMICAL", 15, 18], ["cells", "CELL", 50, 55], ["control group cells", "CELL_LINE", 36, 55], ["SNP", "TREATMENT", 15, 18], ["drugs", "TREATMENT", 108, 113]]], ["To properly choose suitable concentrations of adrenergic receptor agonists and antagonists, cells were treated with phentolamine, ICI 118551, metoprolol, and AD at concentrations of 0.1, 1, 3, 10, 30, and 100 \u03bcM for various intervals.", [["cells", "ANATOMY", 92, 97], ["phentolamine", "CHEMICAL", 116, 128], ["ICI 118551", "CHEMICAL", 130, 140], ["metoprolol", "CHEMICAL", 142, 152], ["AD", "CHEMICAL", 158, 160], ["phentolamine", "CHEMICAL", 116, 128], ["ICI 118551", "CHEMICAL", 130, 140], ["metoprolol", "CHEMICAL", 142, 152], ["cells", "CELL", 92, 97], ["phentolamine", "SIMPLE_CHEMICAL", 116, 128], ["ICI", "SIMPLE_CHEMICAL", 130, 133], ["118551", "SIMPLE_CHEMICAL", 134, 140], ["metoprolol", "SIMPLE_CHEMICAL", 142, 152], ["AD", "SIMPLE_CHEMICAL", 158, 160], ["adrenergic receptor agonists", "TREATMENT", 46, 74], ["antagonists", "TREATMENT", 79, 90], ["phentolamine", "TREATMENT", 116, 128], ["ICI", "TREATMENT", 130, 133], ["metoprolol", "TREATMENT", 142, 152], ["AD at concentrations", "TREATMENT", 158, 178]]], ["Then, the cell viability was determined by the MTT method.Determination of cell viability ::: Materials and methodsTo determine the cell viability, an MTT assay (0.5 g/L) was conducted in a 96-well plate (5 \u00d7 103 SH-SY5Y cells/wells and 8 \u00d7 103 PC12 cells/wells) for 4 h at 37 \u00b0C and incubated with the cells after 24 h of exposure to SNP.", [["cell", "ANATOMY", 10, 14], ["cell", "ANATOMY", 75, 79], ["cell", "ANATOMY", 132, 136], ["SH-SY5Y cells", "ANATOMY", 213, 226], ["PC12 cells", "ANATOMY", 245, 255], ["cells", "ANATOMY", 303, 308], ["SNP", "CHEMICAL", 335, 338], ["MTT", "CHEMICAL", 47, 50], ["MTT", "CHEMICAL", 151, 154], ["SNP", "CHEMICAL", 335, 338], ["cell", "CELL", 10, 14], ["cell", "CELL", 75, 79], ["cell", "CELL", 132, 136], ["SH-SY5Y cells", "CELL", 213, 226], ["PC12 cells", "CELL", 245, 255], ["cells", "CELL", 303, 308], ["SY5Y cells", "CELL_LINE", 216, 226], ["PC12 cells", "CELL_LINE", 245, 255], ["the cell viability", "TEST", 6, 24], ["the MTT method", "TEST", 43, 57], ["the cell viability", "TEST", 128, 146], ["an MTT assay", "TEST", 148, 160], ["SH-SY5Y cells/wells", "TREATMENT", 213, 232], ["PC12 cells", "TEST", 245, 255], ["SNP", "TREATMENT", 335, 338], ["cell viability", "OBSERVATION", 10, 24], ["cell viability", "OBSERVATION", 75, 89], ["cell viability", "OBSERVATION", 132, 146]]], ["The dark blue formazan crystals formed in intact cells were solubilized in dimethyl sulfoxide and detected at 570 nm using a microplate reader.", [["cells", "ANATOMY", 49, 54], ["blue formazan", "CHEMICAL", 9, 22], ["dimethyl sulfoxide", "CHEMICAL", 75, 93], ["formazan", "CHEMICAL", 14, 22], ["dimethyl sulfoxide", "CHEMICAL", 75, 93], ["blue formazan crystals", "SIMPLE_CHEMICAL", 9, 31], ["cells", "CELL", 49, 54], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 75, 93], ["intact cells", "CELL_TYPE", 42, 54], ["The dark blue formazan crystals", "TREATMENT", 0, 31], ["intact cells", "TREATMENT", 42, 54], ["dimethyl sulfoxide", "TREATMENT", 75, 93], ["a microplate reader", "TREATMENT", 123, 142], ["dark blue", "OBSERVATION", 4, 13], ["formazan crystals", "OBSERVATION", 14, 31], ["intact cells", "OBSERVATION", 42, 54]]]], "PMC7108179": [["reference plasma ::: Materials and MethodsWe obtained WHO international standard reagent [National Institute of Biological Standards and Control (NIBSC)] (16) containing 100 000.00 IU of HIV-1, subtype B, per mL(16) and a subtype reference plasma panel (NIBSC) including lyophilized human plasma samples containing HIV-1 subtypes A, B, C, D, AE, F, G, H, N, and O. Another subtype reference plasma panel obtained from the National Reference Centre for Retroviruses included aliquots of human plasma containing HIV-1 subtypes A, B, C, D (2 samples), AE, F, G, and O (2 samples).", [["plasma", "ANATOMY", 10, 16], ["plasma", "ANATOMY", 240, 246], ["plasma samples", "ANATOMY", 289, 303], ["plasma", "ANATOMY", 391, 397], ["plasma", "ANATOMY", 492, 498], ["plasma", "ORGANISM_SUBSTANCE", 10, 16], ["HIV-1", "ORGANISM", 187, 192], ["plasma", "ORGANISM_SUBSTANCE", 240, 246], ["human", "ORGANISM", 283, 288], ["plasma samples", "ORGANISM_SUBSTANCE", 289, 303], ["HIV-1 subtypes A", "ORGANISM", 315, 331], ["B", "CELL", 333, 334], ["C", "CELL", 336, 337], ["D", "SIMPLE_CHEMICAL", 339, 340], ["G, H", "SIMPLE_CHEMICAL", 349, 353], ["plasma", "ORGANISM_SUBSTANCE", 391, 397], ["Retroviruses", "ORGANISM", 452, 464], ["human", "ORGANISM", 486, 491], ["plasma", "ORGANISM_SUBSTANCE", 492, 498], ["HIV-1", "ORGANISM", 510, 515], ["B", "CELL", 528, 529], ["C", "CELL", 531, 532], ["samples", "CANCER", 568, 575], ["HIV-1", "SPECIES", 187, 192], ["human", "SPECIES", 283, 288], ["HIV-1", "SPECIES", 315, 320], ["human", "SPECIES", 486, 491], ["HIV-1", "SPECIES", 510, 515], ["HIV-1", "SPECIES", 187, 192], ["human", "SPECIES", 283, 288], ["HIV-1", "SPECIES", 315, 320], ["human", "SPECIES", 486, 491], ["HIV-1", "SPECIES", 510, 515], ["Biological Standards and Control (NIBSC)", "TREATMENT", 112, 152], ["HIV", "TEST", 187, 190], ["a subtype reference plasma panel", "TEST", 220, 252], ["NIBSC", "TEST", 254, 259], ["lyophilized human plasma samples", "TEST", 271, 303], ["HIV", "TEST", 315, 318], ["AE", "TEST", 342, 344], ["G", "TEST", 349, 350], ["plasma panel", "TEST", 391, 403], ["human plasma", "TEST", 486, 498], ["HIV", "TEST", 510, 513], ["A, B, C, D (2 samples", "TEST", 525, 546], ["AE, F, G", "TEST", 549, 557]]], ["Viral loads as determined by the Roche Amplicor system were provided with this panel.patient plasmas and commercial viral-load assays ::: Materials and MethodsHuman plasma samples from Brazil (n = 1186), South Africa (n = 130), India (n = 44), and Germany (n = 127) were obtained from ongoing ART programs.", [["plasma samples", "ANATOMY", 165, 179], ["Viral", "ORGANISM", 0, 5], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["Viral loads", "TEST", 0, 11], ["the Roche Amplicor system", "TEST", 29, 54], ["this panel", "TEST", 74, 84], ["patient plasmas", "TEST", 85, 100], ["commercial viral-load assays", "TEST", 105, 133], ["MethodsHuman plasma samples", "TEST", 152, 179], ["South Africa", "TEST", 204, 216], ["India (n", "TEST", 228, 236], ["ongoing ART programs", "TREATMENT", 285, 305]]], ["All samples were anonymized, and ethics approval was obtained.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["South African samples were collected in Cape Town and tested by the NucliSens HIV-1 QT NASBA assay (BioMerieux, formerly Organon Technika) at the University of Cape Town.", [["samples", "ANATOMY", 14, 21], ["NucliSens HIV-1", "SPECIES", 68, 83]]], ["Indian samples were collected in Chennai and tested along with the samples from Frankfurt, Germany, by the Cobas Amplicor Monitor (Ver.", [["samples", "ANATOMY", 7, 14], ["Indian samples", "TEST", 0, 14]]], ["Brazilian samples were collected in Bahia (northeastern Brazil), Espiritu Santo (eastern Brazil), or Rio Grande do Sul (southern Brazil), respectively, and tested at these places by either the BioMerieux HIV-1 QT, Roche Amplicor, or Versant HIV-1 V 3.0 bDNA assay (Bayer).", [["samples", "ANATOMY", 10, 17], ["HIV-1", "SPECIES", 241, 246], ["HIV-1", "SPECIES", 204, 209], ["HIV-1", "SPECIES", 241, 246], ["Brazilian samples", "TEST", 0, 17], ["Roche Amplicor", "TEST", 214, 228]]], ["All materials were stored at \u221220 \u00b0C after initial viral-load testing and were transferred to the Bernhard Nocht Institute, where testing with the real-time LTR assay was done.", [["LTR", "DNA", 156, 159], ["initial viral-load testing", "TEST", 42, 68], ["testing", "TEST", 129, 136], ["LTR assay", "TEST", 156, 165]]], ["LTR testing for all samples from Brazil was done by Brazilian laboratory staff during a 4-week training session at the Bernhard Nocht Institute.patient plasmas and commercial viral-load assays ::: Materials and MethodsThe following quantification ranges were provided by the manufacturers of the commercial assays: Amplicor standard protocol, 400\u2013750 000 IU/mL; Amplicor ultrasensitive protocol, 50\u201375 000 IU/mL; BioMerieux NucliSens, 80\u201310 000 000 IU/mL; Versant, 50\u2013500 000 IU/mL.oligonucleotide design ::: Materials and MethodsA nucleic acid sequence alignment was set up that contained all LTR sequences present in the Los Alamos National Laboratory database by 2002 (reproduced in Electronic File 1, which can be found in the Data Supplement accompanying the online version of this article at http://www.clinchem.org/content/vol52/issue7/).", [["LTR", "ANATOMY", 0, 3], ["samples", "ANATOMY", 20, 27], ["nucleic acid", "CHEMICAL", 532, 544], ["LTR", "CELLULAR_COMPONENT", 0, 3], ["patient", "ORGANISM", 144, 151], ["LTR", "DNA", 0, 3], ["LTR sequences", "DNA", 594, 607], ["patient", "SPECIES", 144, 151], ["LTR testing", "TEST", 0, 11], ["all samples", "TEST", 16, 27], ["patient plasmas", "TEST", 144, 159], ["commercial viral-load assays", "TEST", 164, 192], ["Methods", "TREATMENT", 211, 218], ["Amplicor standard protocol", "TREATMENT", 315, 341], ["Amplicor ultrasensitive protocol", "TREATMENT", 362, 394], ["Versant", "TREATMENT", 456, 463], ["MethodsA nucleic acid sequence alignment", "TEST", 523, 563]]], ["Three conserved domains, necessary for binding of a probe and 2 flanking primers, were identified on inspection of the alignment, as current primer design software (Primer Express; Applied Biosystems) yielded no results.", [["2 flanking primers", "DNA", 62, 80], ["a probe and 2 flanking primers", "TREATMENT", 50, 80]]], ["Two different candidate probes were defined in the middle conserved domain (region 575\u2013612).", [["middle conserved domain", "DNA", 51, 74], ["region 575\u2013612", "DNA", 76, 90], ["Two different candidate probes", "TREATMENT", 0, 30], ["middle", "ANATOMY_MODIFIER", 51, 57]]], ["In the flanking potential primer-binding sites (regions 520\u2013548 and 625\u2013653), up to 10 different variations of oligonucleotides per site were ordered and tested experimentally in each possible combination with both of the 2 candidate probes.", [["flanking potential primer-binding sites", "DNA", 7, 46], ["regions 520\u2013548 and 625\u2013653", "DNA", 48, 75], ["oligonucleotides per site", "TREATMENT", 111, 136], ["binding sites", "OBSERVATION", 33, 46]]], ["The most efficient combination of oligonucleotides showed 3 mismatched nucleotide (nt) residues in the probe-binding domain in HIV-1 subtype O (nucleotides 580, 586, and 587), which were compensated for by use of an additional 5\u2032-nuclease probe (see below).", [["nucleotide", "CHEMICAL", 71, 81], ["nucleotide", "CHEMICAL", 71, 81], ["nucleotides", "CHEMICAL", 144, 155], ["HIV-1", "ORGANISM", 127, 132], ["probe-binding domain", "PROTEIN", 103, 123], ["5\u2032", "PROTEIN", 227, 229], ["HIV-1", "SPECIES", 127, 132], ["HIV-1", "SPECIES", 127, 132], ["oligonucleotides", "TREATMENT", 34, 50], ["3 mismatched nucleotide (nt) residues", "PROBLEM", 58, 95], ["the probe-binding domain in HIV", "PROBLEM", 99, 130], ["nucleotides", "TEST", 144, 155], ["an additional 5\u2032-nuclease probe", "TREATMENT", 213, 244]]], ["Because of the high degree of conservedness at the chosen oligonucleotide binding domains, no additional mismatch compensation was necessary.lyophilized full-virus quantification calibrator ::: Materials and MethodsA storable, calibrated quantification calibrator was generated for routine use.", [["oligonucleotide binding domains", "DNA", 58, 89], ["the high degree of conservedness", "PROBLEM", 11, 43], ["additional mismatch compensation", "PROBLEM", 94, 126], ["MethodsA storable", "TREATMENT", 208, 225], ["calibrated quantification calibrator", "TREATMENT", 227, 263], ["high degree", "OBSERVATION_MODIFIER", 15, 26], ["mismatch compensation", "OBSERVATION", 105, 126]]], ["Cell-culture\u2013derived HIV-1, subtype B, strain NL4\u20133, was inoculated in fresh-frozen human plasma, diluted, and inoculated in volumes of 10 \u03bcL in 200 \u03bcL of buffer AVL.", [["Cell", "ANATOMY", 0, 4], ["plasma", "ANATOMY", 90, 96], ["NL4\u20133", "CHEMICAL", 46, 51], ["Cell", "CELL", 0, 4], ["HIV-1", "ORGANISM", 21, 26], ["subtype B", "CELL", 28, 37], ["strain NL4\u20133", "CELL", 39, 51], ["human", "ORGANISM", 84, 89], ["plasma", "ORGANISM_SUBSTANCE", 90, 96], ["HIV-1", "SPECIES", 21, 26], ["human", "SPECIES", 84, 89], ["HIV-1", "SPECIES", 21, 26], ["human", "SPECIES", 84, 89], ["Cell", "TEST", 0, 4], ["HIV", "TEST", 21, 24], ["strain NL4\u20133", "PROBLEM", 39, 51], ["volumes", "TEST", 125, 132]]], ["RNA extraction and real-time RT-PCR testing were conducted as described below.", [["RNA extraction", "TEST", 0, 14], ["real-time RT-PCR testing", "TEST", 19, 43]]], ["After an initial limiting dilution series, concentrations of 1, 2, 3, and 4 log10 above the detection limit were defined as 1, 10, 100, and 1000 PCR units (PCRU), respectively.", [["an initial limiting dilution series", "TEST", 6, 41], ["concentrations", "TEST", 43, 57]]], ["Stocks of these concentrations were generated in large volumes, divided into 10-\u03bcL aliquots, and lyophilized in vacuum glass tubes.", [["these concentrations", "TREATMENT", 10, 30], ["lyophilized in vacuum glass tubes", "TREATMENT", 97, 130], ["concentrations", "OBSERVATION_MODIFIER", 16, 30], ["large", "OBSERVATION_MODIFIER", 49, 54], ["volumes", "OBSERVATION_MODIFIER", 55, 62], ["vacuum glass tubes", "OBSERVATION", 112, 130]]], ["To calibrate the stocks, the contents of each of 4 replicate glass tubes of each concentration were completely redissolved in 200 \u03bcL of buffer AVL and extracted as described above.", [["the stocks", "TREATMENT", 13, 23], ["4 replicate glass tubes of each concentration", "TREATMENT", 49, 94], ["glass tubes", "OBSERVATION", 61, 72]]], ["In parallel, 4 replicate samples of human plasma containing 5000 IU of WHO HIV-1 international standard were treated like patient plasmas and tested by the ultrasensitive protocol.", [["samples", "ANATOMY", 25, 32], ["plasma", "ANATOMY", 42, 48], ["human", "ORGANISM", 36, 41], ["plasma", "ORGANISM_SUBSTANCE", 42, 48], ["patient", "ORGANISM", 122, 129], ["human", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 75, 80], ["patient", "SPECIES", 122, 129], ["human", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 75, 80], ["human plasma", "TREATMENT", 36, 48], ["the ultrasensitive protocol", "TEST", 152, 179]]], ["After obvious outliers were eliminated, we defined the lyophilized plasma samples as calibrators in the real-time PCR software and entered concentrations in terms of PCRU.", [["plasma samples", "ANATOMY", 67, 81], ["plasma samples", "ORGANISM_SUBSTANCE", 67, 81], ["the lyophilized plasma samples", "TREATMENT", 51, 81]]], ["The mean PCRU value obtained for the WHO standard was then used to determine a correction factor for the conversion of PCRU to WHO standard IU values.", [["The mean PCRU value", "TEST", 0, 19], ["WHO standard IU values", "TEST", 127, 149]]], ["The correction factor was readjusted for each new lot of stock preparations.", [["stock preparations", "TREATMENT", 57, 75]]], ["For up to at least 4 months, the maximum storage duration, no loss in RNA concentration was perceivable.", [["loss in RNA concentration", "PROBLEM", 62, 87]]], ["Systematic storage studies were not done because the stability of HIV-1 and other enveloped viruses in lyophilized plasma has been confirmed several times [see, for example, Refs.", [["plasma", "ANATOMY", 115, 121], ["HIV-1", "ORGANISM", 66, 71], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["HIV-1", "SPECIES", 66, 71], ["HIV-1", "SPECIES", 66, 71], ["Systematic storage studies", "TEST", 0, 26], ["HIV", "PROBLEM", 66, 69], ["other enveloped viruses in lyophilized plasma", "PROBLEM", 76, 121], ["viruses", "OBSERVATION", 92, 99]]], ["(16)(17)(18)(19)(20)].synthetic hiv-1 rna ::: Materials and MethodsThe LTR PCR fragment (see below) was ligated into a pCR 2.1 plasmid vector and cloned in Escherichia coli by means of a pCR 2.1-TOPO TA cloning reagent set (Invitrogen).", [["LTR", "ANATOMY", 71, 74], ["(16)(17)(18)(19)(20)", "SIMPLE_CHEMICAL", 0, 20], ["Escherichia coli", "ORGANISM", 156, 172], ["LTR PCR fragment", "DNA", 71, 87], ["pCR 2.1 plasmid vector", "DNA", 119, 141], ["Escherichia coli", "SPECIES", 156, 172], ["Escherichia coli", "SPECIES", 156, 172], ["The LTR PCR fragment", "PROBLEM", 67, 87], ["a pCR", "TEST", 117, 122], ["plasmid vector", "TREATMENT", 127, 141], ["Escherichia coli", "PROBLEM", 156, 172], ["a pCR", "TEST", 185, 190], ["TOPO TA cloning reagent set (Invitrogen)", "TREATMENT", 195, 235], ["Escherichia coli", "OBSERVATION", 156, 172]]], ["Plasmids were purified, sequenced, and reamplified with plasmid-specific primers (M13f-20 and M13r, from the reagent set) to lower the plasmid background in subsequent in vitro transcription.", [["plasmid", "ANATOMY", 135, 142], ["M13f-20", "GENE_OR_GENE_PRODUCT", 82, 89], ["plasmid", "DNA", 56, 63], ["M13f-20", "DNA", 82, 89], ["M13r", "DNA", 94, 98], ["Plasmids", "TREATMENT", 0, 8], ["M13f", "TEST", 82, 86]]], ["Reamplification products were transcribed into RNA with the MegaScript T7 in vitro transcription reagent set as described (Ambion) (15)(21)(22).", [["MegaScript T7", "DNA", 60, 73], ["Reamplification products", "TREATMENT", 0, 24], ["the MegaScript T7", "TREATMENT", 56, 73]]], ["After DNase I digestion, RNA transcripts were purified with Qiagen RNeasy columns and quantified spectrophotometrically.", [["DNase I", "GENE_OR_GENE_PRODUCT", 6, 13], ["DNase I", "PROTEIN", 6, 13], ["RNA transcripts", "RNA", 25, 40], ["DNase I digestion", "TREATMENT", 6, 23], ["RNA transcripts", "TREATMENT", 25, 40], ["Qiagen RNeasy columns", "TREATMENT", 60, 81]]], ["Results from RT-PCR with and without reverse transcriptase gave an RNA/DNA ratio of 106.", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["reverse transcriptase", "PROTEIN", 37, 58], ["RT-PCR", "TEST", 13, 19], ["reverse transcriptase", "PROBLEM", 37, 58], ["an RNA/DNA ratio", "TEST", 64, 80]]], ["The synthetic RNA was termed srLTRw.", [["srLTRw", "GENE_OR_GENE_PRODUCT", 29, 35], ["synthetic RNA", "RNA", 4, 17], ["srLTRw", "PROTEIN", 29, 35], ["The synthetic RNA", "TREATMENT", 0, 17]]], ["It should be noted that a much smaller RNA/DNA ratio was achieved when in vitro transcription reactions were set up according to the manufacturer\u2019s instructions, using linearized pLTRw DNA as the template for in vitro transcription instead of PCR products.internal control ::: Materials and MethodsAn alternative probe-binding site was introduced at HIV-1 nt positions 580\u2013605 (numbering according to HIV-1 strain HXB2), removing the binding site of the HIV-1\u2013specific probe at the same time.", [["DNA", "CELLULAR_COMPONENT", 43, 46], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["HIV-1 strain HXB2", "ORGANISM", 401, 418], ["pLTRw DNA", "DNA", 179, 188], ["MethodsAn alternative probe", "DNA", 291, 318], ["HIV-1 nt positions 580\u2013605", "DNA", 350, 376], ["binding site", "DNA", 434, 446], ["HIV-1\u2013specific probe", "DNA", 454, 474], ["HIV-1", "SPECIES", 401, 406], ["HIV-1", "SPECIES", 350, 355], ["HIV-1", "SPECIES", 401, 406], ["HIV-1\u2013specific", "SPECIES", 454, 468], ["a much smaller RNA/DNA ratio", "PROBLEM", 24, 52], ["vitro transcription reactions", "PROBLEM", 74, 103], ["linearized pLTRw DNA", "TREATMENT", 168, 188], ["the template", "TREATMENT", 192, 204], ["vitro transcription", "TREATMENT", 212, 231], ["PCR products", "TREATMENT", 243, 255], ["Materials", "TREATMENT", 277, 286], ["MethodsAn alternative probe-binding site", "TREATMENT", 291, 331], ["HIV", "TEST", 401, 404]]], ["According to a previously described strategy (22), 2 partial amplicons were generated by use of primer IcS (5\u2032-CAGGAGTGATGGGAAATCAAGGATGCATCATTTTTAATGGAAAA-GATTTAA-3\u2032) in combination with primer LTRAs4 (sequence below), and IcAs (5\u2032-GCATCCTTGATTTCCCATCACTCCTGGTAACACTTCACTCCAGTTCGAGCCT-3\u2032) in combination with primer LTRS3 (sequence below), respectively.", [["primer IcS", "DNA", 96, 106], ["primer LTRAs4", "DNA", 188, 201], ["IcAs", "DNA", 224, 228], ["primer LTRS3", "DNA", 310, 322], ["2 partial amplicons", "TREATMENT", 51, 70], ["primer IcS", "TREATMENT", 96, 106], ["5\u2032-CAGGAGTGATGGGAAATCAAGGATGCATCATTTTTAATGGAAAA-GATTTAA", "TREATMENT", 108, 163], ["primer LTRAs4", "TREATMENT", 188, 201], ["IcAs", "TEST", 224, 228]]], ["After extension-PCR with primers LTRS3/As4, products were TA-cloned, purified, sequenced, and transcribed as described previously(15)(21)(22).", [["LTRS3", "GENE_OR_GENE_PRODUCT", 33, 38], ["As4", "GENE_OR_GENE_PRODUCT", 39, 42], ["LTRS3", "DNA", 33, 38], ["As4", "DNA", 39, 42], ["TA", "DNA", 58, 60], ["extension-PCR", "TEST", 6, 19], ["primers LTRS3", "TEST", 25, 38]]], ["The RNA/DNA ratio, as determined by PCR and RT-PCR, was 106.", [["DNA", "CELLULAR_COMPONENT", 8, 11], ["The RNA/DNA ratio", "TEST", 0, 17], ["PCR", "TEST", 36, 39], ["RT-PCR", "TEST", 44, 50]]], ["The resulting synthetic RNA was termed srLTRic.", [["srLTRic", "GENE_OR_GENE_PRODUCT", 39, 46], ["synthetic RNA", "RNA", 14, 27], ["srLTRic", "PROTEIN", 39, 46], ["The resulting synthetic RNA", "PROBLEM", 0, 27], ["synthetic RNA", "OBSERVATION", 14, 27]]], ["With up to 160 copies of srLTRic added, a calculated 4.8 copies of HIV-1 RNA were still detectable in the same reaction in 5 of 5 parallel assays.", [["srLTRic", "GENE_OR_GENE_PRODUCT", 25, 32], ["HIV-1", "ORGANISM", 67, 72], ["srLTRic", "DNA", 25, 32], ["HIV-1 RNA", "RNA", 67, 76], ["HIV-1", "SPECIES", 67, 72], ["HIV-1", "SPECIES", 67, 72], ["srLTRic", "TREATMENT", 25, 32], ["HIV", "TEST", 67, 70]]], ["From 320 copies of internal control onward, signal strength for HIV-1 decreased.", [["HIV-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["HIV-1", "SPECIES", 64, 69], ["internal control", "TREATMENT", 19, 35], ["HIV", "TEST", 64, 67]]], ["Eighty copies of srLTRic per reaction was chosen as the working concentration, which did not interfere with the detection of 50 IU/mL HIV-1 in 24 of 24 reactions, as confirmed by testing of the WHO international standard.ultrasensitive extraction of hiv-1 rna from plasma ::: Materials and MethodsWe treated 1.2 mL of cleared plasma with centrifugation for 1 h at 21 000g in a benchtop centrifuge.", [["plasma", "ANATOMY", 265, 271], ["plasma", "ANATOMY", 326, 332], ["hiv-1 rna", "SIMPLE_CHEMICAL", 250, 259], ["plasma", "ORGANISM_SUBSTANCE", 265, 271], ["plasma", "ORGANISM_SUBSTANCE", 326, 332], ["HIV-1", "SPECIES", 134, 139], ["HIV-1", "SPECIES", 134, 139], ["ultrasensitive extraction", "TEST", 221, 246], ["hiv", "PROBLEM", 250, 253], ["MethodsWe", "TREATMENT", 290, 299], ["centrifugation", "TREATMENT", 338, 352], ["a benchtop centrifuge", "TREATMENT", 375, 396], ["hiv", "OBSERVATION", 250, 253]]], ["Supernatants were removed completely, and virus pellets were lysed directly in 200 \u03bcL of buffer AVL (Qiagen Viral RNA Mini Kit).", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["Supernatants", "TREATMENT", 0, 12], ["virus pellets", "TREATMENT", 42, 55], ["buffer AVL", "TREATMENT", 89, 99], ["Qiagen Viral RNA Mini Kit", "TREATMENT", 101, 126]]], ["To the lysed pellets we added 200 \u03bcL of ethanol (990 mL/L); after mixing, we loaded the mixture on a Qiagen viral RNA minicolumn.", [["ethanol", "CHEMICAL", 40, 47], ["ethanol", "CHEMICAL", 40, 47], ["ethanol", "SIMPLE_CHEMICAL", 40, 47], ["ethanol", "TREATMENT", 40, 47], ["a Qiagen viral RNA minicolumn", "TREATMENT", 99, 128], ["RNA minicolumn", "OBSERVATION", 114, 128]]], ["Elution was with 50 \u03bcL of buffer AVE at 80 \u00b0C. In routine testing, buffer AVL was supplemented with internal control srLTRic at 2000 copies/mL (see below) and stored for up to 5 days at room temperature.quantification of hiv-1 viral load by one-step real-time rt-pcr ::: Materials and MethodsA 50-\u03bcL reaction contained 10 \u03bcL of RNA extract, 1\u00d7 reaction buffer (Access RT-PCR reagent set; Promega), 2 mM magnesium sulfate, 200 \u03bcM each deoxynucleotide triphosphate, 600 nM primer LTR S4 (5\u2032-AAGCCTCAATAAAGCTTGCCTTGA-3\u2032; nt 520\u2013543 of HIV-1 B reference strain HXB2), 400 nM primer LTR As3 (5\u2032-GTTCGGGCGCCACTGCTAG-3\u2032; nt 629\u2013647), 50 nM probe LTRP1 (5\u2032-FAM-TCTGGTAACTAGAGATCCCTCAGACC-Black Hole Quencher 1\u20133\u2032, where FAM is 6carboxyfluorescein; nt 580\u2013605), 50 nM probe LTRP2 (5\u2032-FAM-CCTGGTGTCTAGAGATCCCTCAGACC-Black Hole Quencher 1-3\u2032 1; nt 580\u2013605), 100 nM probe YFPY (5\u2032-Yakima Yellow-ATCGTTCGTTGAGCGATTAGCAG-BlackHole Quencher 1-3\u2032; artificial binding site), 1 \u03bcL each of AMV and Tfl enzyme preparations (Promega Access reagent set), and 1 \u03bcM 6-carboxy-X-rhodamine (ROX) internal reference dye (all dyes, primers, and probes from Tib Molbiol).quantification of hiv-1 viral load by one-step real-time rt-pcr ::: Materials and MethodsThermal cycling was as follows: 48 \u00b0C for 20 min; 94 \u00b0C for 2 min; 12 cycles of 95 \u00b0C for 10 s and 62 \u00b0C for 30 s; 40 cycles of 94 \u00b0C for 10 s and 56 \u00b0C for 40 s.", [["AVL", "CHEMICAL", 74, 77], ["magnesium", "CHEMICAL", 403, 412], ["deoxynucleotide triphosphate", "CHEMICAL", 434, 462], ["6carboxyfluorescein", "CHEMICAL", 719, 738], ["6-carboxy-X-rhodamine", "CHEMICAL", 1042, 1063], ["ROX", "CHEMICAL", 1065, 1068], ["magnesium sulfate", "CHEMICAL", 403, 420], ["deoxynucleotide triphosphate", "CHEMICAL", 434, 462], ["6carboxyfluorescein", "CHEMICAL", 719, 738], ["6-carboxy-X-rhodamine", "CHEMICAL", 1042, 1063], ["ROX", "CHEMICAL", 1065, 1068], ["AVL", "SIMPLE_CHEMICAL", 74, 77], ["hiv-1", "GENE_OR_GENE_PRODUCT", 221, 226], ["rt-pcr", "SIMPLE_CHEMICAL", 260, 266], ["magnesium sulfate", "SIMPLE_CHEMICAL", 403, 420], ["deoxynucleotide triphosphate", "SIMPLE_CHEMICAL", 434, 462], ["FAM", "SIMPLE_CHEMICAL", 712, 715], ["AMV", "ORGANISM", 971, 974], ["6-carboxy-X-rhodamine", "SIMPLE_CHEMICAL", 1042, 1063], ["ROX", "SIMPLE_CHEMICAL", 1065, 1068], ["hiv-1", "GENE_OR_GENE_PRODUCT", 1160, 1165], ["rt-pcr", "SIMPLE_CHEMICAL", 1199, 1205], ["400 nM primer LTR As3", "DNA", 564, 585], ["nt 629\u2013647", "DNA", 614, 624], ["FAM is 6carboxyfluorescein; nt 580\u2013605", "DNA", 712, 750], ["BlackHole Quencher 1-3\u2032", "DNA", 907, 930], ["artificial binding site", "DNA", 932, 955], ["AMV", "DNA", 971, 974], ["HIV", "SPECIES", 532, 535], ["HIV-1", "SPECIES", 532, 537], ["routine testing", "TEST", 50, 65], ["buffer AVL", "TREATMENT", 67, 77], ["internal control srLTRic", "TREATMENT", 100, 124], ["hiv", "PROBLEM", 221, 224], ["viral load", "TEST", 227, 237], ["Materials", "TEST", 271, 280], ["MethodsA", "TEST", 285, 293], ["RNA extract", "TREATMENT", 328, 339], ["Access RT-PCR reagent set", "TREATMENT", 361, 386], ["Promega)", "TREATMENT", 388, 396], ["2 mM magnesium sulfate", "TREATMENT", 398, 420], ["deoxynucleotide triphosphate", "TREATMENT", 434, 462], ["LTR S4", "TEST", 478, 484], ["AAGCCTCAATAAAGCTTGCCTTGA", "TEST", 489, 513], ["nt", "TEST", 518, 520], ["HIV", "TEST", 532, 535], ["HXB2", "TEST", 557, 561], ["LTR As3", "TEST", 578, 585], ["GTTCGGGCGCCACTGCTAG", "TEST", 590, 609], ["nt", "TEST", 614, 616], ["nM probe LTRP1", "TEST", 630, 644], ["5\u2032-FAM-TCTGGTAACTAGAGATCCCTCAGACC", "TEST", 646, 679], ["Hole Quencher", "TEST", 686, 699], ["nt", "TEST", 740, 742], ["nM probe LTRP2", "TEST", 756, 770], ["5\u2032-FAM-CCTGGTGTCTAGAGATCCCTCAGACC", "TEST", 772, 805], ["Black Hole Quencher", "TEST", 806, 825], ["nt", "TEST", 834, 836], ["nM probe YFPY", "TEST", 851, 864], ["\u2032", "TEST", 867, 868], ["Yakima", "TEST", 869, 875], ["Yellow", "TEST", 876, 882], ["ATCGTTCGTTGAGCGATTAGCAG", "TEST", 883, 906], ["BlackHole Quencher", "TREATMENT", 907, 925], ["artificial binding site", "TREATMENT", 932, 955], ["AMV", "TREATMENT", 971, 974], ["Tfl enzyme preparations", "TREATMENT", 979, 1002], ["Promega Access reagent set", "TREATMENT", 1004, 1030], ["carboxy", "TEST", 1044, 1051], ["rhodamine (ROX", "TREATMENT", 1054, 1068], ["internal reference dye", "TREATMENT", 1070, 1092], ["all dyes, primers", "TREATMENT", 1094, 1111], ["hiv", "PROBLEM", 1160, 1163], ["viral load", "TEST", 1166, 1176], ["\u00b0C", "TEST", 1333, 1335], ["Tib", "ANATOMY", 1129, 1132]]], ["Cycling was performed in either Applied Biosystems 7700 or 7000 SDS instruments with no perceivable difference in results.", [["perceivable difference", "PROBLEM", 88, 110]]], ["Fluorescence was read out in the 56 \u00b0C step of the final segment of the cycling program.", [["Fluorescence", "TEST", 0, 12]]], ["The fluorescence at the VIC\u00ae and FAM wavelengths was analyzed separately with (ABI 7700) or without (ABI 7000) normalization with the ROX dye.", [["ROX", "CHEMICAL", 134, 137], ["FAM", "SIMPLE_CHEMICAL", 33, 36], ["ROX dye", "SIMPLE_CHEMICAL", 134, 141], ["The fluorescence", "TEST", 0, 16], ["FAM wavelengths", "TREATMENT", 33, 48], ["ABI", "TEST", 79, 82], ["ABI", "TEST", 101, 104], ["the ROX dye", "TREATMENT", 130, 141]]], ["In the ABI 7700, the baseline area was routinely defined in cycles 1 to 11.", [["the ABI", "TEST", 3, 10], ["the baseline area", "TEST", 17, 34]]], ["In the ABI 7000, the \u201cauto baseline\u201d mode was used for data analysis.", [["the ABI", "TEST", 3, 10], ["data analysis", "TEST", 55, 68]]], ["In general, calibration curves were used as automatically obtained from the operation software of the real-time RT-PCR systems.", [["calibration curves", "TEST", 12, 30]]], ["In some individual runs, manual readjustments of the threshold line had to be made according to the fluorescence noise in the negative controls.", [["manual readjustments of the threshold line", "TREATMENT", 25, 67], ["the fluorescence noise", "TEST", 96, 118], ["some", "OBSERVATION_MODIFIER", 3, 7], ["individual", "OBSERVATION_MODIFIER", 8, 18], ["runs", "OBSERVATION_MODIFIER", 19, 23], ["negative", "OBSERVATION", 126, 134]]], ["When the low\u2013copy-number reaction of the calibration curve failed, this was taken as a sign of insufficient sensitivity, and the whole run was repeated.", [["the calibration curve", "TEST", 37, 58], ["the whole run", "TEST", 125, 138]]], ["All patient data presented are for single determinations, i.e., no duplicate testing was done.quantification of hiv-1 viral load by one-step real-time rt-pcr ::: Materials and MethodsFor those reactions that did not yield FAM amplification signals, the VIC amplification signal was inspected.", [["patient", "ORGANISM", 4, 11], ["hiv-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["FAM", "SIMPLE_CHEMICAL", 222, 225], ["VIC", "GENE_OR_GENE_PRODUCT", 253, 256], ["patient", "SPECIES", 4, 11], ["single determinations", "TEST", 35, 56], ["duplicate testing", "TEST", 67, 84], ["hiv", "PROBLEM", 112, 115], ["viral load", "TEST", 118, 128], ["those reactions", "PROBLEM", 187, 202], ["the VIC amplification signal", "TEST", 249, 277], ["hiv", "OBSERVATION", 112, 115]]], ["When the signal was negative or was delayed against the mean VIC signal in the negative plasma controls by 2 or more cycles, the respective sample was considered invalid because of PCR inhibition.", [["plasma", "ANATOMY", 88, 94], ["sample", "ANATOMY", 140, 146], ["VIC", "GENE_OR_GENE_PRODUCT", 61, 64], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["the respective sample", "TEST", 125, 146], ["PCR inhibition", "PROBLEM", 181, 195]]], ["Such samples were reprocessed and retested in original concentration as well as after dilution 1:10 in plasma from an HIV-negative donor.statistical methods ::: Materials and MethodsThe Statgraphics plus (Ver.", [["samples", "ANATOMY", 5, 12], ["plasma", "ANATOMY", 103, 109], ["plasma", "ORGANISM_SUBSTANCE", 103, 109], ["HIV", "SPECIES", 118, 121], ["Such samples", "TEST", 0, 12], ["negative donor", "OBSERVATION", 122, 136]]], ["5.1) software package (Manugistics) was used for all statistical analyses described.ResultsBecause of HIV-1 variability, primer design for the real-time LTR RT-PCR was based on a comprehensive nucleic acid alignment with binding domains of maximal conservedness.", [["HIV-1", "ORGANISM", 102, 107], ["HIV-1", "SPECIES", 102, 107], ["HIV-1", "SPECIES", 102, 107], ["software package (Manugistics)", "TREATMENT", 5, 35], ["all statistical analyses", "TEST", 49, 73], ["HIV", "PROBLEM", 102, 105], ["PCR", "TEST", 160, 163], ["a comprehensive nucleic acid alignment", "PROBLEM", 177, 215], ["maximal conservedness", "PROBLEM", 240, 261], ["HIV", "OBSERVATION", 102, 105]]], ["We optimized reaction chemistry and implemented a thermal cycling protocol with a precycle element to increase the amplification stringency (23).", [["precycle element", "DNA", 82, 98], ["a thermal cycling protocol", "TREATMENT", 48, 74], ["a precycle element", "TREATMENT", 80, 98], ["the amplification stringency", "PROBLEM", 111, 139]]], ["After optimization, tests showed high sensitivity with synthetic HIV-1 RNA srLTRw, with detection of 1\u20135 copies per reaction.ResultsWe tested the quantification range with a dilution series of srLTRw.", [["HIV-1", "ORGANISM", 65, 70], ["srLTRw", "GENE_OR_GENE_PRODUCT", 193, 199], ["srLTRw", "PROTEIN", 193, 199], ["HIV-1", "SPECIES", 65, 70], ["HIV-1", "SPECIES", 65, 70], ["tests", "TEST", 20, 25], ["high sensitivity", "PROBLEM", 33, 49], ["synthetic HIV", "PROBLEM", 55, 68], ["a dilution series of srLTRw", "TREATMENT", 172, 199]]], ["Up to 4 \u00d7 109 copies of RNA per reaction, corresponding to 1.6 \u00d7 107 copies/mL of plasma sample, were quantified with a correlation coefficient between expected logarithmic copy numbers and observed threshold cycle values of \u22121.0.ResultsTo prevent PCR inhibition from interfering with accurate quantification, we designed a competitive internal control that used the same amplification primers as HIV-1 and was detected by a probe of different sequence composition and different fluorescent labeling.", [["plasma sample", "ANATOMY", 82, 95], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["HIV-1", "ORGANISM", 397, 402], ["HIV-1", "SPECIES", 397, 402], ["plasma sample", "TEST", 82, 95], ["threshold cycle values", "TEST", 199, 221], ["PCR inhibition", "PROBLEM", 248, 262], ["a competitive internal control", "TREATMENT", 322, 352], ["HIV", "PROBLEM", 397, 400], ["different sequence composition", "TREATMENT", 434, 464]]], ["The internal control was added to all reactions at the same step as the addition of lysis buffer.", [["The internal control", "TREATMENT", 0, 20], ["all reactions", "PROBLEM", 34, 47], ["lysis buffer", "TREATMENT", 84, 96], ["internal", "OBSERVATION_MODIFIER", 4, 12], ["lysis", "OBSERVATION", 84, 89]]], ["After extensive experimental evaluation, we adjusted the working concentration to 80 copies per assay, or 400 copies per RNA preparation.ResultsWe determined the assay limit of detection by diluting the WHO HIV-1 international standard in human fresh-frozen plasma to 11, 33, 100, 1000, 10 000, and 100 000 IU/mL.", [["plasma", "ANATOMY", 258, 264], ["human", "ORGANISM", 239, 244], ["plasma", "ORGANISM_SUBSTANCE", 258, 264], ["HIV-1", "SPECIES", 207, 212], ["human", "SPECIES", 239, 244], ["HIV-1", "SPECIES", 207, 212], ["human", "SPECIES", 239, 244], ["extensive experimental evaluation", "TEST", 6, 39]]], ["Plasma containing each concentration was extracted in 4 parallel ultrasensitive RNA preparations, and each of these was tested in 4 replicate RT-PCR assays, \u223c16 data points per concentration.", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["Plasma containing each concentration", "TREATMENT", 0, 36], ["4 parallel ultrasensitive RNA preparations", "TREATMENT", 54, 96], ["PCR assays", "TEST", 145, 155], ["concentration", "OBSERVATION_MODIFIER", 23, 36]]], ["No dropout in HIV-1 detection in 16 parallel reactions was observed from 100 copies/mL upward.", [["HIV-1", "ORGANISM", 14, 19], ["HIV-1", "SPECIES", 14, 19], ["HIV-1", "SPECIES", 14, 19], ["dropout in HIV", "PROBLEM", 3, 17], ["16 parallel reactions", "PROBLEM", 33, 54], ["dropout", "OBSERVATION_MODIFIER", 3, 10], ["HIV", "OBSERVATION", 14, 17]]], ["We performed Probit regression analysis to determine the projected response rates according to a dose\u2013response model (Fig. 1 ).", [["Probit regression analysis", "TEST", 13, 39]]], ["At a concentration of 31.9 IU/mL, detection probability was 95% or higher (95% confidence interval, 24.8\u201348.1 IU/mL).", [["detection probability", "TEST", 34, 55], ["interval", "TEST", 90, 98]]], ["The limit of detection was thus slightly higher than that of several commercial assays for HIV-1 viral load.ResultsWe assessed intraassay accuracy with 8 replicate results for an HIV-1 B plasma containing 1200 IU/mL tested in the same experiment.", [["plasma", "ANATOMY", 187, 193], ["HIV-1 viral", "ORGANISM", 91, 102], ["HIV-1 B", "ORGANISM", 179, 186], ["plasma", "ORGANISM_SUBSTANCE", 187, 193], ["HIV-1", "SPECIES", 91, 96], ["HIV-1", "SPECIES", 179, 184], ["HIV-1", "SPECIES", 91, 96], ["HIV-1", "SPECIES", 179, 184], ["several commercial assays", "TEST", 61, 86], ["HIV", "TEST", 91, 94], ["intraassay accuracy", "TEST", 127, 146], ["an HIV", "TEST", 176, 182]]], ["The mean viral load was 1117.5 IU/mL, with a CV of 18% and an SD of 0.09 log10.", [["The mean viral load", "TEST", 0, 19], ["a CV", "TEST", 43, 47], ["an SD", "TEST", 59, 64]]], ["To confirm that the assay accurately quantified viral loads close to the detection limit, we diluted the WHO international working reagent to 50 IU/mL and assayed it in 18 replicate tests in the same experiment.", [["the assay", "TEST", 16, 25], ["viral loads", "PROBLEM", 48, 59]]], ["The mean measured value was 51.4 IU/mL with a CV of 51% and a SD of 0.27 log10.", [["The mean measured value", "TEST", 0, 23], ["a CV", "TEST", 44, 48], ["a SD", "TEST", 60, 64]]], ["Because this deviation was compatible with clinical application, the lower limit of the quantification range was defined at 50 copies/assay.", [["this deviation", "PROBLEM", 8, 22], ["clinical application", "TREATMENT", 43, 63], ["compatible with", "UNCERTAINTY", 27, 42], ["lower limit", "OBSERVATION_MODIFIER", 69, 80]]], ["Considering the upper limit of the 7700 SDS operation software in analyzing high concentrations without a need to change analysis settings, the total quantification range was defined as 50\u201310 000 000 IU/mL.ResultsWe assessed interassay accuracy by testing 2 plasma samples to which HIV-1 B had been added at 9600 and 960 IU/mL, respectively, in 20 different experiments each.", [["plasma samples", "ANATOMY", 258, 272], ["HIV-1 B", "CHEMICAL", 282, 289], ["plasma samples", "ORGANISM_SUBSTANCE", 258, 272], ["HIV-1 B", "ORGANISM", 282, 289], ["HIV-1", "SPECIES", 282, 287], ["HIV-1", "SPECIES", 282, 287], ["analysis settings", "TEST", 121, 138], ["interassay accuracy", "TEST", 225, 244], ["testing", "TEST", 248, 255], ["plasma samples", "TEST", 258, 272], ["HIV", "TEST", 282, 285], ["upper limit", "OBSERVATION_MODIFIER", 16, 27]]], ["The mean measured quantities were 10 656 and 986 IU/mL, respectively.", [["The mean measured quantities", "TEST", 0, 28], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["The CVs were of 39% and 41%, respectively, with SDs of 0.17 and 0.23 log10.ResultsBecause our assay was intended to detect a broader spectrum of viral subtypes than gag-based assays, we assessed the efficiency with which different subtypes of HIV-1 were amplified by testing 2 different subtype reference panels containing all relevant strains of HIV-1 groups M, O, and N and 12 plasma samples from patients infected with non-B subtypes, which provided genotypes not available in the reference panels, e.g., circulating recombinant forms AE and AG and subtype J.ResultsWe expected test variation to occur preferably in the low and medium ranges of virus concentrations; we therefore diluted high-concentration reference samples in human fresh-frozen plasma to concentrations of 1000\u201310 000 copies/mL and then measured viral loads with the Roche Cobas Amplicor (Ver.", [["plasma samples", "ANATOMY", 379, 393], ["samples", "ANATOMY", 720, 727], ["plasma", "ANATOMY", 750, 756], ["gag", "GENE_OR_GENE_PRODUCT", 165, 168], ["HIV-1", "ORGANISM", 243, 248], ["HIV-1", "ORGANISM", 347, 352], ["O", "CELL", 363, 364], ["plasma samples", "ORGANISM_SUBSTANCE", 379, 393], ["patients", "ORGANISM", 399, 407], ["human", "ORGANISM", 731, 736], ["plasma", "ORGANISM_SUBSTANCE", 750, 756], ["HIV-1", "SPECIES", 243, 248], ["HIV-1", "SPECIES", 347, 352], ["patients", "SPECIES", 399, 407], ["human", "SPECIES", 731, 736], ["HIV-1", "SPECIES", 243, 248], ["HIV-1", "SPECIES", 347, 352], ["human", "SPECIES", 731, 736], ["The CVs", "TEST", 0, 7], ["SDs", "TEST", 48, 51], ["our assay", "TEST", 90, 99], ["gag", "TEST", 165, 168], ["HIV", "PROBLEM", 243, 246], ["HIV", "TEST", 347, 350], ["plasma samples", "TEST", 379, 393], ["non-B subtypes", "PROBLEM", 422, 436], ["test variation", "TEST", 581, 595], ["virus concentrations", "PROBLEM", 648, 668], ["human fresh-frozen plasma", "TREATMENT", 731, 756], ["viral subtypes", "OBSERVATION", 145, 159]]], ["1.5) and LTR assays (Fig. 2 ).ResultsNone of the samples containing HIV-1 subtypes O and N was detected by the Roche Amplicor, but all yielded viral-load results with the LTR assay.", [["LTR", "ANATOMY", 9, 12], ["samples", "ANATOMY", 49, 56], ["LTR", "ANATOMY", 171, 174], ["HIV-1", "ORGANISM", 68, 73], ["LTR", "DNA", 9, 12], ["LTR", "DNA", 171, 174], ["HIV-1", "SPECIES", 68, 73], ["HIV-1", "SPECIES", 68, 73], ["LTR assays", "TEST", 9, 19], ["the samples", "TEST", 45, 56], ["HIV", "TEST", 68, 71], ["the Roche Amplicor", "TEST", 107, 125], ["the LTR assay", "TEST", 167, 180]]], ["When we omitted the subtype N and O samples, the mean logarithmic viral loads were almost identical with both assays (3.57 and 3.60 by the Amplicor and LTR assays, respectively; difference insignificant in the t-test and Wilcoxon two-sample test).", [["O samples", "ANATOMY", 34, 43], ["O samples", "CELL", 34, 43], ["LTR", "DNA", 152, 155], ["the mean logarithmic viral loads", "TEST", 45, 77], ["the Amplicor", "TEST", 135, 147], ["LTR assays", "TEST", 152, 162], ["the t-test", "TEST", 206, 216], ["Wilcoxon two-sample test", "TEST", 221, 245]]], ["In most individual samples, the differences of viral loads were <0.5 log10 (Fig. 2 ).", [["samples", "ANATOMY", 19, 26], ["samples", "CANCER", 19, 26], ["viral loads", "TEST", 47, 58]]], ["Viral loads in individual samples contained in the reference panels differed by 0.26 log10, on average; those in individual patient samples differed by 0.37 log10, on average.", [["samples", "ANATOMY", 26, 33], ["samples", "ANATOMY", 132, 139], ["Viral", "ORGANISM", 0, 5], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["Viral loads", "TEST", 0, 11], ["individual samples", "TEST", 15, 33]]], ["In all samples, the mean difference of paired viral loads was 0.31 log10.ResultsWe next determined the quantitative correlation with other viral-load assays.", [["samples", "ANATOMY", 7, 14], ["paired viral loads", "TEST", 39, 57], ["other viral-load assays", "TEST", 133, 156]]], ["Because our assay was intended for application in resource-limited countries with high HIV-1 prevalence, evaluation included patients from such regions.", [["HIV-1", "ORGANISM", 87, 92], ["patients", "ORGANISM", 125, 133], ["HIV-1", "SPECIES", 87, 92], ["patients", "SPECIES", 125, 133], ["HIV-1", "SPECIES", 87, 92], ["our assay", "TEST", 8, 17], ["evaluation", "TEST", 105, 115]]], ["Stored samples from Germany (n = 127), Brazil (n = 1186), South Africa (n = 130), and India (n = 44) were available.", [["samples", "ANATOMY", 7, 14], ["Germany", "TEST", 20, 27], ["South Africa", "TEST", 58, 70], ["India (n", "TEST", 86, 94]]], ["All samples had been tested previously by either the Cobas Amplicor Monitor (Ver.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["1.5) RT-PCR assay from Roche, the NucliSens HIV-1 QT NASBA assay from BioMerieux, or the Versant HIV-1 bDNA assay from Bayer.", [["HIV", "SPECIES", 44, 47], ["HIV", "SPECIES", 97, 100], ["HIV-1", "SPECIES", 44, 49], ["HIV-1", "SPECIES", 97, 102], ["RT-PCR assay", "TEST", 5, 17], ["Roche", "TEST", 23, 28], ["the NucliSens HIV", "TEST", 30, 47], ["QT NASBA assay", "TEST", 50, 64], ["BioMerieux", "TEST", 70, 80]]], ["All samples were then quantified by real-time LTR RT-PCR.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["For regression analyses, those samples that had results below or above the quantification ranges of either the comparison method or the LTR assay were excluded.", [["samples", "ANATOMY", 31, 38], ["LTR", "ANATOMY", 136, 139], ["LTR", "CELLULAR_COMPONENT", 136, 139], ["LTR", "DNA", 136, 139], ["regression analyses", "TEST", 4, 23], ["those samples", "TEST", 25, 38], ["the comparison method", "TEST", 107, 128], ["the LTR assay", "TEST", 132, 145]]], ["As shown in Fig. 3 , LTR real-time RT-PCR correlated well with all of the commercial viral-load assays.", [["LTR", "DNA", 21, 24], ["RT-PCR", "TEST", 35, 41], ["the commercial viral-load assays", "TEST", 70, 102]]], ["Regression line slopes in all sample panels were in the range (SD) of 0.9 (0.13), indicating highly significant correlations (P <0.001 for all).ResultsBecause regression analysis can only compare samples in which results from both tests are within the quantification ranges of each test, respectively, it did not reflect differences in overall clinical sensitivity.", [["Regression line slopes", "PROBLEM", 0, 22], ["all sample panels", "TEST", 26, 43], ["regression analysis", "TEST", 159, 178], ["both tests", "TEST", 226, 236], ["line", "OBSERVATION_MODIFIER", 11, 15], ["slopes", "OBSERVATION_MODIFIER", 16, 22]]], ["To compare the detection rates of the LTR assay with those of commercial tests, we collected qualitative results from all available samples, as shown in Table 1 .", [["LTR", "ANATOMY", 38, 41], ["samples", "ANATOMY", 132, 139], ["LTR", "DNA", 38, 41], ["the LTR assay", "TEST", 34, 47], ["commercial tests", "TEST", 62, 78]]], ["The rate of positive results in all (n = 43) samples tested with the Roche Amplicor conventional protocol was 51.7% compared with 65% when the same samples were tested with the real-time LTR assay.", [["samples", "ANATOMY", 45, 52], ["samples", "ANATOMY", 148, 155], ["LTR", "DNA", 187, 190], ["The rate", "TEST", 0, 8], ["samples", "TEST", 45, 52], ["the Roche Amplicor conventional protocol", "TEST", 65, 105], ["the same samples", "TEST", 139, 155]]], ["The corresponding numbers (percentage positive with the comparison method/percentage positive with LTR assay) for the other methods were as follows: Roche Amplicor ultrasensitive (n = 133 samples), 81.2% vs 82.7% for the LTR assay; NucliSens QT (n = 453), 60.5% vs 65.1%; Bayer Versant (n = 43), 57.7% vs 55.4%; total (n = 1450), 59.0% vs 63.8%.", [["LTR", "ANATOMY", 221, 224], ["LTR", "DNA", 99, 102], ["LTR", "DNA", 221, 224], ["LTR assay", "TEST", 99, 108], ["the other methods", "TEST", 114, 131], ["the LTR assay", "TEST", 217, 230], ["QT", "TEST", 242, 244], ["Bayer Versant", "TEST", 272, 285], ["vs", "TEST", 336, 338], ["numbers", "OBSERVATION_MODIFIER", 18, 25]]], ["Thus, only the Bayer Versant appeared to be slightly more sensitive than the LTR real-time RT-PCR when used for testing clinical samples.ResultsWe analyzed 40 different routine quantification runs to determine the rate of inhibited reactions that occur during routine viral-load monitoring.", [["samples", "ANATOMY", 129, 136], ["LTR", "DNA", 77, 80], ["the LTR", "TEST", 73, 80], ["PCR", "TEST", 94, 97], ["testing clinical samples", "TEST", 112, 136], ["routine quantification runs", "TEST", 169, 196], ["inhibited reactions", "PROBLEM", 222, 241], ["routine viral-load monitoring", "TREATMENT", 260, 289]]], ["Of the 454 samples that did not yield an HIV-1 signal in these runs, 17 had an undetectable internal control, or 3.7% inhibited reactions (95% confidence interval, 2.32%\u20135.9%) in which a false-negative result would have been obtained had the internal control not been included.ResultsTo demonstrate the applicability of the new assay for routine monitoring of patients on ART, we selected 5 individuals in whom viral loads were determined by LTR real-time RT-PCR before and after start of therapy (Fig. 4 ).", [["samples", "ANATOMY", 11, 18], ["patients", "ORGANISM", 360, 368], ["LTR", "DNA", 442, 445], ["HIV-1", "SPECIES", 41, 46], ["patients", "SPECIES", 360, 368], ["HIV-1", "SPECIES", 41, 46], ["3.7% inhibited reactions", "PROBLEM", 113, 137], ["the new assay", "TEST", 320, 333], ["routine monitoring", "TEST", 338, 356], ["viral loads", "PROBLEM", 411, 422], ["therapy", "TREATMENT", 489, 496]]], ["Over the whole range of viral loads, no predilution of samples was necessary; all samples were well within the dynamic range of the assay.DiscussionART is now becoming an affordable option in resource-limited countries, where most HIV-1 infections occur, but without viral-load monitoring, the spread of drug-resistant virus strains has to be anticipated (12)(24).", [["samples", "ANATOMY", 55, 62], ["samples", "ANATOMY", 82, 89], ["HIV-1 infections", "DISEASE", 231, 247], ["HIV-1", "ORGANISM", 231, 236], ["HIV-1", "SPECIES", 231, 236], ["HIV-1", "SPECIES", 231, 236], ["viral loads", "TEST", 24, 35], ["predilution of samples", "PROBLEM", 40, 62], ["all samples", "TEST", 78, 89], ["1 infections", "PROBLEM", 235, 247], ["viral-load monitoring", "TEST", 267, 288], ["resistant virus strains", "PROBLEM", 309, 332], ["viral loads", "OBSERVATION", 24, 35]]], ["Unfortunately, current commercial viral-load monitoring assays were designed for use in affluent industrialized countries and are thus optimized to work best on HIV-1 subtype B(13)(14)(25)(26).DiscussionOur study results show that LTR is a highly suitable target gene for quantification of exotic HIV-1 genotypes, thereby reducing the risk of genotype bias.", [["LTR", "ANATOMY", 231, 234], ["HIV-1", "ORGANISM", 161, 166], ["LTR", "CELLULAR_COMPONENT", 231, 234], ["HIV-1", "ORGANISM", 297, 302], ["LTR", "DNA", 231, 234], ["HIV-1", "SPECIES", 161, 166], ["HIV-1", "SPECIES", 297, 302], ["HIV-1", "SPECIES", 161, 166], ["HIV-1", "SPECIES", 297, 302], ["current commercial viral-load monitoring assays", "TEST", 15, 62], ["HIV", "TEST", 161, 164], ["DiscussionOur study", "TEST", 193, 212], ["exotic HIV", "PROBLEM", 290, 300], ["genotype bias", "PROBLEM", 343, 356]]], ["We tested all important genotypes of HIV-1, and except for groups N and O, the overall results of virus quantification with different assays were highly concordant (27)(28)(29)(30).DiscussionInclusion of an inhibition control is important because inhibited tests cause false results in virus screening.", [["HIV-1", "ORGANISM", 37, 42], ["HIV-1", "SPECIES", 37, 42], ["HIV-1", "SPECIES", 37, 42], ["HIV", "TEST", 37, 40], ["virus quantification", "TEST", 98, 118], ["different assays", "TEST", 124, 140], ["an inhibition control", "TREATMENT", 204, 225], ["false results in virus screening", "PROBLEM", 269, 301]]], ["Our rate of 3.7% inhibited tests is in good concordance with the few previous studies that have addressed this issue systematically (15)(31)(32)(33)(34).", [["Our rate", "TEST", 0, 8], ["tests", "TEST", 27, 32]]], ["The accuracy of our assay was equivalent to or better than values observed in earlier studies on commercial and in-house viral-load assays(28)(35)(36)(37), and the good analytical sensitivity of our assay allowed a broad quantification range covering the range of viral loads in both treated and untreated patients.DiscussionThe major benefit of our method is cost reduction.", [["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 306, 314], ["our assay", "TEST", 16, 25], ["earlier studies", "TEST", 78, 93], ["our assay", "TEST", 195, 204], ["viral loads", "PROBLEM", 264, 275], ["cost reduction", "TREATMENT", 360, 374], ["viral loads", "OBSERVATION", 264, 275]]], ["Our test is not a Communaut\u00e9 Europ\u00e9enne-certified in vitro diagnostic method, however, and thus cannot be used for commercial diagnostic services under European Union law.DiscussionScreening of newborns is required in the context of PMTCT in developing and emerging countries; therefore, many patients require only qualitative PCR testing.", [["newborns", "ORGANISM", 194, 202], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 293, 301], ["Our test", "TEST", 0, 8], ["PMTCT", "TREATMENT", 233, 238], ["qualitative PCR testing", "TEST", 315, 338]]], ["Because most commercial PCR assays do not allow qualitative testing without unnecessary extra information, which would be less expensive, high costs are a potential barrier to PMTCT.", [["most commercial PCR assays", "TEST", 8, 34], ["qualitative testing", "TEST", 48, 67]]], ["Our assay can be used for screening of more than 90 samples per run in a purely qualitative mode because of its open format.", [["Our assay", "TEST", 0, 9], ["screening", "TEST", 26, 35]]], ["In this mode, the same reliability and sensitivity are provided as in viral-load monitoring, with the internal control to assure maximum sensitivity in each individual reaction.DiscussionIn conclusion, our method is a highly cost-efficient viral-load monitoring assay with an open format and reliable day-to-day operation.", [["viral-load monitoring", "TEST", 70, 91], ["the internal control", "TREATMENT", 98, 118], ["maximum sensitivity in each individual reaction", "PROBLEM", 129, 176]]], ["In our hands the assay has been running reliably for 3 years of routine testing.", [["routine testing", "TEST", 64, 79]]], ["The evaluation cohorts in our study may require alternative viral-load assays in the near future.", [["The evaluation", "TEST", 0, 14], ["our study", "TEST", 26, 35], ["alternative viral-load assays", "TREATMENT", 48, 77]]], ["South Africa has the largest population of HIV-infected patients in the world (38)(39) and has a nationwide public service ART program underway(40)(41), requiring urgent reduction in the cost of viralload monitoring.", [["HIV-infected", "DISEASE", 43, 55], ["HIV", "ORGANISM", 43, 46], ["patients", "ORGANISM", 56, 64], ["HIV-", "SPECIES", 43, 47], ["patients", "SPECIES", 56, 64], ["HIV", "SPECIES", 43, 46], ["HIV", "PROBLEM", 43, 46], ["urgent reduction", "TREATMENT", 163, 179], ["viralload monitoring", "TEST", 195, 215], ["largest", "OBSERVATION_MODIFIER", 21, 28], ["population", "OBSERVATION_MODIFIER", 29, 39], ["HIV", "OBSERVATION", 43, 46], ["infected", "OBSERVATION_MODIFIER", 47, 55]]], ["The situation is similar in Brazil, where the absolute number of patients is high and the government is making highly active ART universally available(42)(43).", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["similar", "OBSERVATION_MODIFIER", 17, 24], ["absolute", "OBSERVATION_MODIFIER", 46, 54], ["number", "OBSERVATION_MODIFIER", 55, 61], ["high", "OBSERVATION_MODIFIER", 77, 81]]], ["Finally, India has one of the fastest growing populations of HIV-1\u2013positive individuals, and emerging ART programs will require affordable viral-load testing(44)(45).", [["HIV-1\u2013positive", "DISEASE", 61, 75], ["HIV-1\u2013positive", "ORGANISM", 61, 75], ["HIV", "SPECIES", 61, 64], ["HIV-1\u2013positive", "SPECIES", 61, 75], ["HIV-1\u2013positive individuals", "PROBLEM", 61, 87], ["emerging ART programs", "TREATMENT", 93, 114], ["affordable viral-load testing", "TEST", 128, 157]]], ["Considering the large and increasing populations of individuals infected with HIV-1 in resource-poor settings, the potential benefit of an affordable viral-load assay is enormous.", [["HIV-1", "ORGANISM", 78, 83], ["HIV-1", "SPECIES", 78, 83], ["HIV-1", "SPECIES", 78, 83], ["HIV", "PROBLEM", 78, 81], ["an affordable viral-load assay", "TEST", 136, 166], ["large", "OBSERVATION_MODIFIER", 16, 21], ["increasing", "OBSERVATION_MODIFIER", 26, 36], ["populations", "OBSERVATION_MODIFIER", 37, 48]]], ["The need for alternative methods is obvious, and our approach might contribute to making this aim attainable.", [["alternative methods", "TREATMENT", 13, 32]]]], "e14d8123b56a1b4825bf8aa262ff4f4d0f9549b4": [["IntroductionChronic obstructive pulmonary disease (COPD) is defined as a common, preventable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation caused by exposure to noxious particles or gases.", [["pulmonary", "ANATOMY", 32, 41], ["respiratory", "ANATOMY", 152, 163], ["IntroductionChronic obstructive pulmonary disease", "DISEASE", 0, 49], ["COPD", "DISEASE", 51, 55], ["pulmonary", "ORGAN", 32, 41], ["IntroductionChronic obstructive pulmonary disease", "PROBLEM", 0, 49], ["COPD", "PROBLEM", 51, 55], ["treatable disease", "PROBLEM", 98, 115], ["persistent respiratory symptoms", "PROBLEM", 141, 172], ["airflow limitation", "PROBLEM", 177, 195], ["noxious particles", "TEST", 218, 235], ["obstructive", "OBSERVATION_MODIFIER", 20, 31], ["pulmonary", "ANATOMY", 32, 41], ["disease", "OBSERVATION", 42, 49], ["COPD", "OBSERVATION", 51, 55], ["persistent", "OBSERVATION_MODIFIER", 141, 151], ["respiratory symptoms", "OBSERVATION", 152, 172]]], ["The progressive airflow limitation is attributed to chronic inflammation leading to small airway obstruction and parenchymal Inflammation and ExacerbationAirway inflammationThe airflow limitation in COPD is associated with abnormal inflammatory response.", [["airway", "ANATOMY", 90, 96], ["parenchymal", "ANATOMY", 113, 124], ["inflammation", "DISEASE", 60, 72], ["airway obstruction", "DISEASE", 90, 108], ["Inflammation", "DISEASE", 125, 137], ["inflammation", "DISEASE", 161, 173], ["COPD", "DISEASE", 199, 203], ["airway obstruction", "PATHOLOGICAL_FORMATION", 90, 108], ["parenchymal", "MULTI-TISSUE_STRUCTURE", 113, 124], ["The progressive airflow limitation", "PROBLEM", 0, 34], ["chronic inflammation", "PROBLEM", 52, 72], ["small airway obstruction", "PROBLEM", 84, 108], ["parenchymal Inflammation", "PROBLEM", 113, 137], ["ExacerbationAirway inflammation", "PROBLEM", 142, 173], ["The airflow limitation", "PROBLEM", 173, 195], ["COPD", "PROBLEM", 199, 203], ["abnormal inflammatory response", "PROBLEM", 223, 253], ["progressive", "OBSERVATION_MODIFIER", 4, 15], ["airflow limitation", "OBSERVATION", 16, 34], ["attributed to", "UNCERTAINTY", 38, 51], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["inflammation", "OBSERVATION", 60, 72], ["small", "OBSERVATION_MODIFIER", 84, 89], ["airway", "ANATOMY", 90, 96], ["obstruction", "OBSERVATION", 97, 108], ["parenchymal", "ANATOMY_MODIFIER", 113, 124], ["Inflammation", "OBSERVATION", 125, 137], ["ExacerbationAirway", "OBSERVATION_MODIFIER", 142, 160], ["inflammation", "OBSERVATION", 161, 173], ["airflow limitation", "OBSERVATION", 177, 195], ["COPD", "OBSERVATION", 199, 203], ["associated with", "UNCERTAINTY", 207, 222], ["abnormal", "OBSERVATION_MODIFIER", 223, 231], ["inflammatory response", "OBSERVATION", 232, 253]]], ["Progression of airflow limitation is associated with the increase in accumulation of mucus exudates in the lumen and infiltration of the small airway wall by inflammatory cells 5 .", [["mucus exudates", "ANATOMY", 85, 99], ["lumen", "ANATOMY", 107, 112], ["small airway wall", "ANATOMY", 137, 154], ["inflammatory cells", "ANATOMY", 158, 176], ["mucus exudates", "TISSUE", 85, 99], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 107, 112], ["airway wall", "TISSUE", 143, 154], ["inflammatory cells", "CELL", 158, 176], ["inflammatory cells", "CELL_TYPE", 158, 176], ["airflow limitation", "PROBLEM", 15, 33], ["mucus exudates in the lumen", "PROBLEM", 85, 112], ["infiltration of the small airway wall", "PROBLEM", 117, 154], ["inflammatory cells", "PROBLEM", 158, 176], ["airflow limitation", "OBSERVATION", 15, 33], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["accumulation", "OBSERVATION_MODIFIER", 69, 81], ["mucus exudates", "OBSERVATION", 85, 99], ["lumen", "ANATOMY_MODIFIER", 107, 112], ["infiltration", "OBSERVATION", 117, 129], ["small", "OBSERVATION_MODIFIER", 137, 142], ["airway", "ANATOMY", 143, 149], ["wall", "ANATOMY_MODIFIER", 150, 154], ["inflammatory cells", "OBSERVATION", 158, 176]]], ["A variety of inflammatory cells are present in the airways of patients with COPD.", [["inflammatory cells", "ANATOMY", 13, 31], ["airways", "ANATOMY", 51, 58], ["COPD", "DISEASE", 76, 80], ["inflammatory cells", "CELL", 13, 31], ["airways", "MULTI-TISSUE_STRUCTURE", 51, 58], ["patients", "ORGANISM", 62, 70], ["inflammatory cells", "CELL_TYPE", 13, 31], ["patients", "SPECIES", 62, 70], ["inflammatory cells", "PROBLEM", 13, 31], ["COPD", "PROBLEM", 76, 80], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["inflammatory cells", "OBSERVATION", 13, 31], ["airways", "ANATOMY", 51, 58], ["COPD", "OBSERVATION", 76, 80]]], ["Neutrophils, macrophages, eosinophils, mast cells, and CD8 + lymphocytes have been shown to play important roles in the inflammatory processes in COPD [6] [7] [8] [9] .Airway inflammationNeutrophils are one of the major inflammatory cell types in COPD 5 .", [["Neutrophils", "ANATOMY", 0, 11], ["macrophages", "ANATOMY", 13, 24], ["eosinophils", "ANATOMY", 26, 37], ["mast cells", "ANATOMY", 39, 49], ["CD8 + lymphocytes", "ANATOMY", 55, 72], ["Airway", "ANATOMY", 168, 174], ["Neutrophils", "ANATOMY", 187, 198], ["cell", "ANATOMY", 233, 237], ["COPD", "DISEASE", 146, 150], ["COPD", "DISEASE", 247, 251], ["Neutrophils", "CELL", 0, 11], ["macrophages", "CELL", 13, 24], ["eosinophils", "CELL", 26, 37], ["mast cells", "CELL", 39, 49], ["CD8", "GENE_OR_GENE_PRODUCT", 55, 58], ["Airway", "MULTI-TISSUE_STRUCTURE", 168, 174], ["Neutrophils", "CELL", 187, 198], ["cell", "CELL", 233, 237], ["Neutrophils", "CELL_TYPE", 0, 11], ["macrophages", "CELL_TYPE", 13, 24], ["eosinophils", "CELL_TYPE", 26, 37], ["mast cells", "CELL_TYPE", 39, 49], ["CD8 + lymphocytes", "CELL_TYPE", 55, 72], ["Neutrophils", "CELL_TYPE", 187, 198], ["inflammatory cell types", "CELL_TYPE", 220, 243], ["Neutrophils", "TEST", 0, 11], ["macrophages", "TEST", 13, 24], ["eosinophils", "TEST", 26, 37], ["mast cells", "TEST", 39, 49], ["CD8", "TEST", 55, 58], ["lymphocytes", "PROBLEM", 61, 72], ["COPD", "PROBLEM", 146, 150], ["Airway inflammationNeutrophils", "PROBLEM", 168, 198], ["COPD 5", "PROBLEM", 247, 253], ["macrophages", "ANATOMY", 13, 24], ["mast cells", "OBSERVATION", 39, 49], ["inflammatory", "OBSERVATION_MODIFIER", 120, 132], ["COPD", "OBSERVATION", 146, 150], ["inflammation", "OBSERVATION", 175, 187], ["major", "OBSERVATION_MODIFIER", 214, 219], ["inflammatory cell types", "OBSERVATION", 220, 243], ["COPD", "OBSERVATION", 247, 251]]], ["Increased numbers of neutrophils in sputum were found to be correlated with a rapid decline in patients' forced expiratory volume in one second (FEV 1 ) in a 15-year period of observation 10 .", [["neutrophils", "ANATOMY", 21, 32], ["sputum", "ANATOMY", 36, 42], ["neutrophils", "CELL", 21, 32], ["sputum", "ORGANISM_SUBSTANCE", 36, 42], ["patients", "ORGANISM", 95, 103], ["neutrophils", "CELL_TYPE", 21, 32], ["patients", "SPECIES", 95, 103], ["Increased numbers of neutrophils in sputum", "PROBLEM", 0, 42], ["a rapid decline in patients' forced expiratory volume", "PROBLEM", 76, 129], ["numbers", "OBSERVATION_MODIFIER", 10, 17], ["neutrophils", "OBSERVATION", 21, 32], ["rapid", "OBSERVATION_MODIFIER", 78, 83], ["decline", "OBSERVATION_MODIFIER", 84, 91], ["expiratory volume", "OBSERVATION", 112, 129]]], ["In stable COPD patients, FEV 1 showed a significant inverse correlation with the number of neutrophils in induced sputum 11 and in the sub-epithelium from bronchial biopsies 12 , suggesting that neutrophilic inflammation of the airways may play an important role in the pathogenesis of COPD.Airway inflammationMacrophages can be activated by cigarette smoke to release inflammatory mediators and matrix metalloproteases (MMPs).", [["neutrophils", "ANATOMY", 91, 102], ["sputum", "ANATOMY", 114, 120], ["sub-epithelium", "ANATOMY", 135, 149], ["bronchial biopsies", "ANATOMY", 155, 173], ["neutrophilic", "ANATOMY", 195, 207], ["airways", "ANATOMY", 228, 235], ["Airway", "ANATOMY", 291, 297], ["Macrophages", "ANATOMY", 310, 321], ["COPD", "DISEASE", 10, 14], ["COPD", "DISEASE", 286, 290], ["patients", "ORGANISM", 15, 23], ["FEV 1", "GENE_OR_GENE_PRODUCT", 25, 30], ["neutrophils", "CELL", 91, 102], ["sub-epithelium", "TISSUE", 135, 149], ["airways", "MULTI-TISSUE_STRUCTURE", 228, 235], ["Airway", "MULTI-TISSUE_STRUCTURE", 291, 297], ["Macrophages", "CELL", 310, 321], ["matrix metalloproteases", "GENE_OR_GENE_PRODUCT", 396, 419], ["MMPs", "GENE_OR_GENE_PRODUCT", 421, 425], ["neutrophils", "CELL_TYPE", 91, 102], ["Macrophages", "CELL_TYPE", 310, 321], ["inflammatory mediators", "PROTEIN", 369, 391], ["matrix metalloproteases", "PROTEIN", 396, 419], ["MMPs", "PROTEIN", 421, 425], ["patients", "SPECIES", 15, 23], ["FEV 1", "TEST", 25, 30], ["neutrophils", "TEST", 91, 102], ["induced sputum", "PROBLEM", 106, 120], ["bronchial biopsies", "TEST", 155, 173], ["neutrophilic inflammation of the airways", "PROBLEM", 195, 235], ["COPD", "PROBLEM", 286, 290], ["Airway inflammationMacrophages", "PROBLEM", 291, 321], ["inflammatory mediators", "PROBLEM", 369, 391], ["matrix metalloproteases (MMPs)", "TREATMENT", 396, 426], ["stable", "OBSERVATION_MODIFIER", 3, 9], ["COPD", "OBSERVATION", 10, 14], ["neutrophils", "OBSERVATION", 91, 102], ["sputum", "OBSERVATION", 114, 120], ["sub", "ANATOMY_MODIFIER", 135, 138], ["epithelium", "ANATOMY_MODIFIER", 139, 149], ["bronchial", "ANATOMY", 155, 164], ["biopsies", "OBSERVATION", 165, 173], ["neutrophilic", "OBSERVATION_MODIFIER", 195, 207], ["inflammation", "OBSERVATION", 208, 220], ["airways", "ANATOMY", 228, 235], ["COPD", "OBSERVATION", 286, 290], ["inflammation", "OBSERVATION", 298, 310], ["inflammatory", "OBSERVATION_MODIFIER", 369, 381]]], ["The number of alveolar macrophages was correlated to the extent of emphysema formation 13 and to the severity of airway obstruction 12 .", [["alveolar macrophages", "ANATOMY", 14, 34], ["emphysema", "ANATOMY", 67, 76], ["airway", "ANATOMY", 113, 119], ["emphysema", "DISEASE", 67, 76], ["airway obstruction", "DISEASE", 113, 131], ["alveolar macrophages", "CELL", 14, 34], ["emphysema", "PATHOLOGICAL_FORMATION", 67, 76], ["alveolar macrophages", "CELL_TYPE", 14, 34], ["alveolar macrophages", "PROBLEM", 14, 34], ["emphysema formation", "PROBLEM", 67, 86], ["airway obstruction", "PROBLEM", 113, 131], ["number", "OBSERVATION_MODIFIER", 4, 10], ["alveolar macrophages", "OBSERVATION", 14, 34], ["extent", "OBSERVATION_MODIFIER", 57, 63], ["emphysema", "OBSERVATION", 67, 76], ["airway", "ANATOMY", 113, 119], ["obstruction", "OBSERVATION", 120, 131]]], ["The MMPs, Zn 2+ -dependent proteases, and Ca 2+ -dependent proteases can degrade a broad range of connective tissue proteins and are involved in remodeling damaged tissue.", [["connective tissue", "ANATOMY", 98, 115], ["tissue", "ANATOMY", 164, 170], ["Zn", "CHEMICAL", 10, 12], ["Ca", "CHEMICAL", 42, 44], ["Zn 2+", "CHEMICAL", 10, 15], ["Ca 2+", "CHEMICAL", 42, 47], ["MMPs", "GENE_OR_GENE_PRODUCT", 4, 8], ["Zn 2+", "SIMPLE_CHEMICAL", 10, 15], ["Ca 2+", "SIMPLE_CHEMICAL", 42, 47], ["connective tissue", "TISSUE", 98, 115], ["tissue", "TISSUE", 164, 170], ["MMPs", "PROTEIN", 4, 8], ["Zn 2+ -dependent proteases", "PROTEIN", 10, 36], ["Ca 2+ -dependent proteases", "PROTEIN", 42, 68], ["connective tissue proteins", "PROTEIN", 98, 124], ["The MMPs", "TEST", 0, 8], ["Zn", "TEST", 10, 12], ["dependent proteases", "PROBLEM", 17, 36], ["Ca", "TEST", 42, 44], ["dependent proteases", "PROBLEM", 49, 68], ["connective tissue proteins", "PROBLEM", 98, 124], ["remodeling damaged tissue", "PROBLEM", 145, 170], ["broad range", "OBSERVATION_MODIFIER", 83, 94], ["connective tissue proteins", "OBSERVATION", 98, 124], ["damaged tissue", "OBSERVATION", 156, 170]]], ["Increased activity of MMP-8 (collagenase) and MMP-9 (gelatinase) was detected in induced sputum from patients with COPD, and this activity was correlated to the degree of airflow limitation 14 .", [["sputum", "ANATOMY", 89, 95], ["COPD", "DISEASE", 115, 119], ["MMP-8", "GENE_OR_GENE_PRODUCT", 22, 27], ["collagenase", "GENE_OR_GENE_PRODUCT", 29, 40], ["MMP-9", "GENE_OR_GENE_PRODUCT", 46, 51], ["gelatinase", "GENE_OR_GENE_PRODUCT", 53, 63], ["patients", "ORGANISM", 101, 109], ["MMP-8", "PROTEIN", 22, 27], ["collagenase", "PROTEIN", 29, 40], ["MMP-9", "PROTEIN", 46, 51], ["gelatinase", "PROTEIN", 53, 63], ["patients", "SPECIES", 101, 109], ["MMP", "TEST", 22, 25], ["MMP", "TEST", 46, 49], ["induced sputum", "PROBLEM", 81, 95], ["COPD", "PROBLEM", 115, 119], ["airflow limitation", "PROBLEM", 171, 189], ["activity", "OBSERVATION_MODIFIER", 10, 18], ["COPD", "OBSERVATION", 115, 119], ["airflow", "OBSERVATION", 171, 178]]], ["In the animal model of knockout mice, MMP-12 deficiency can block the increase in macrophages in the lungs and the development of emphysema in response to long-term exposure to cigarette smoke 15 .", [["macrophages", "ANATOMY", 82, 93], ["lungs", "ANATOMY", 101, 106], ["emphysema", "ANATOMY", 130, 139], ["emphysema", "DISEASE", 130, 139], ["mice", "ORGANISM", 32, 36], ["MMP-12", "GENE_OR_GENE_PRODUCT", 38, 44], ["macrophages", "CELL", 82, 93], ["lungs", "ORGAN", 101, 106], ["emphysema", "PATHOLOGICAL_FORMATION", 130, 139], ["cigarette", "ORGANISM", 177, 186], ["MMP", "PROTEIN", 38, 41], ["macrophages", "CELL_TYPE", 82, 93], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["MMP-12 deficiency", "PROBLEM", 38, 55], ["the increase in macrophages in the lungs", "PROBLEM", 66, 106], ["emphysema", "PROBLEM", 130, 139], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["macrophages", "OBSERVATION", 82, 93], ["lungs", "ANATOMY", 101, 106], ["emphysema", "OBSERVATION", 130, 139], ["long-term", "OBSERVATION_MODIFIER", 155, 164]]], ["In addition, MMP-12 mediates smoke-induced inflammation by releasing tumor necrosis factor \u03b1 (TNF-\u03b1) from macrophages with subsequent endothelial activation, neutrophil influx, and proteolytic matrix breakdown caused by neutrophil-derived proteases 16 .Airway inflammationThe role of eosinophils in COPD and the mechanism of eosinophil influx into airways remain to be clarified.", [["macrophages", "ANATOMY", 106, 117], ["endothelial", "ANATOMY", 134, 145], ["neutrophil", "ANATOMY", 158, 168], ["matrix", "ANATOMY", 193, 199], ["neutrophil", "ANATOMY", 220, 230], ["Airway", "ANATOMY", 253, 259], ["eosinophils", "ANATOMY", 284, 295], ["eosinophil", "ANATOMY", 325, 335], ["airways", "ANATOMY", 348, 355], ["inflammation", "DISEASE", 43, 55], ["tumor", "DISEASE", 69, 74], ["Airway inflammation", "DISEASE", 253, 272], ["COPD", "DISEASE", 299, 303], ["MMP-12", "GENE_OR_GENE_PRODUCT", 13, 19], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 69, 92], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 94, 99], ["macrophages", "CELL", 106, 117], ["endothelial", "CELL", 134, 145], ["neutrophil", "CELL", 158, 168], ["matrix", "CELLULAR_COMPONENT", 193, 199], ["neutrophil", "CELL", 220, 230], ["Airway", "MULTI-TISSUE_STRUCTURE", 253, 259], ["eosinophils", "CELL", 284, 295], ["eosinophil", "CELL", 325, 335], ["airways", "MULTI-TISSUE_STRUCTURE", 348, 355], ["MMP-12", "PROTEIN", 13, 19], ["tumor necrosis factor \u03b1", "PROTEIN", 69, 92], ["TNF-\u03b1", "PROTEIN", 94, 99], ["macrophages", "CELL_TYPE", 106, 117], ["neutrophil", "CELL_TYPE", 220, 230], ["proteases 16", "PROTEIN", 239, 251], ["eosinophils", "CELL_TYPE", 284, 295], ["MMP", "TEST", 13, 16], ["inflammation", "PROBLEM", 43, 55], ["releasing tumor necrosis factor", "PROBLEM", 59, 90], ["TNF", "TEST", 94, 97], ["macrophages", "PROBLEM", 106, 117], ["subsequent endothelial activation", "PROBLEM", 123, 156], ["neutrophil influx", "PROBLEM", 158, 175], ["proteolytic matrix breakdown", "PROBLEM", 181, 209], ["neutrophil-derived proteases", "TREATMENT", 220, 248], ["Airway inflammation", "PROBLEM", 253, 272], ["eosinophils", "PROBLEM", 284, 295], ["COPD", "PROBLEM", 299, 303], ["eosinophil influx into airways", "PROBLEM", 325, 355], ["inflammation", "OBSERVATION", 43, 55], ["tumor necrosis", "OBSERVATION", 69, 83], ["endothelial activation", "OBSERVATION", 134, 156], ["neutrophil influx", "OBSERVATION", 158, 175], ["inflammation", "OBSERVATION", 260, 272], ["eosinophils", "OBSERVATION", 284, 295], ["COPD", "OBSERVATION", 299, 303], ["eosinophil influx", "OBSERVATION", 325, 342], ["airways", "ANATOMY", 348, 355]]], ["Hogg et al. 5 reported that eosinophils do exist in the small airways of various severity of COPD.", [["eosinophils", "ANATOMY", 28, 39], ["small airways", "ANATOMY", 56, 69], ["COPD", "DISEASE", 93, 97], ["eosinophils", "CELL", 28, 39], ["airways", "MULTI-TISSUE_STRUCTURE", 62, 69], ["eosinophils", "CELL_TYPE", 28, 39], ["eosinophils", "PROBLEM", 28, 39], ["COPD", "PROBLEM", 93, 97], ["small", "OBSERVATION_MODIFIER", 56, 61], ["airways", "ANATOMY", 62, 69], ["COPD", "OBSERVATION", 93, 97]]], ["In a prospective clinical observation, nearly one third of COPD patients had sputum eosinophilia and the number of eosinophils was significantly correlated to the level of exhaled nitric oxide 17 .", [["sputum", "ANATOMY", 77, 83], ["eosinophils", "ANATOMY", 115, 126], ["COPD", "DISEASE", 59, 63], ["sputum eosinophilia", "DISEASE", 77, 96], ["nitric oxide", "CHEMICAL", 180, 192], ["nitric oxide", "CHEMICAL", 180, 192], ["patients", "ORGANISM", 64, 72], ["eosinophils", "CELL", 115, 126], ["exhaled nitric oxide 17", "SIMPLE_CHEMICAL", 172, 195], ["eosinophils", "CELL_TYPE", 115, 126], ["patients", "SPECIES", 64, 72], ["COPD", "PROBLEM", 59, 63], ["sputum eosinophilia", "PROBLEM", 77, 96], ["eosinophils", "TEST", 115, 126], ["exhaled nitric oxide", "TREATMENT", 172, 192], ["COPD", "OBSERVATION", 59, 63], ["sputum eosinophilia", "OBSERVATION", 77, 96]]], ["The degree of eosinophilic inflammation has been related to early changes in lung function and smoking habits.", [["eosinophilic", "ANATOMY", 14, 26], ["lung", "ANATOMY", 77, 81], ["inflammation", "DISEASE", 27, 39], ["lung", "ORGAN", 77, 81], ["eosinophilic inflammation", "PROBLEM", 14, 39], ["early changes in lung function", "PROBLEM", 60, 90], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["eosinophilic inflammation", "OBSERVATION", 14, 39], ["related to", "UNCERTAINTY", 49, 59], ["early", "OBSERVATION_MODIFIER", 60, 65], ["changes", "OBSERVATION", 66, 73], ["lung", "ANATOMY", 77, 81], ["function", "OBSERVATION", 82, 90]]], ["The higher counts of eosinophils in induced sputum is associated with higher pack-years and lower peak expiratory flow 25%-75% values 18 .", [["eosinophils", "ANATOMY", 21, 32], ["sputum", "ANATOMY", 44, 50], ["eosinophils", "CELL", 21, 32], ["eosinophils", "CELL_TYPE", 21, 32], ["eosinophils in induced sputum", "PROBLEM", 21, 50], ["lower peak expiratory flow", "TEST", 92, 118], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["counts", "OBSERVATION_MODIFIER", 11, 17], ["eosinophils", "OBSERVATION", 21, 32], ["sputum", "OBSERVATION", 44, 50]]], ["In a retrospective analysis, FEV 1 reversibility was weakly correlated with the sputum eosinophil level.", [["sputum eosinophil", "ANATOMY", 80, 97], ["FEV 1", "GENE_OR_GENE_PRODUCT", 29, 34], ["a retrospective analysis", "TEST", 3, 27], ["FEV 1 reversibility", "TEST", 29, 48], ["the sputum eosinophil level", "TEST", 76, 103]]], ["Patients with FEV 1 >0.4 L and >15% increment had higher sputum eosinophil levels whereas the level did not differ when dichotomized by FEV 1 increment >0.2 L and >12% 19 .", [["sputum eosinophil", "ANATOMY", 57, 74], ["Patients", "ORGANISM", 0, 8], ["eosinophil", "CELL", 64, 74], ["Patients", "SPECIES", 0, 8], ["FEV", "TEST", 14, 17], ["higher sputum eosinophil levels", "PROBLEM", 50, 81], ["the level", "TEST", 90, 99], ["FEV", "TEST", 136, 139]]], ["The response to corticosteroids in COPD patients were better in a subset of patients presenting with more eosinophils and higher levels of eosinophil cationic protein 20 , suggesting that corticosteroids may be effective especially for patients with COPD with eosinophilic airway inflammation 21, 22 .", [["eosinophils", "ANATOMY", 106, 117], ["airway", "ANATOMY", 273, 279], ["corticosteroids", "CHEMICAL", 16, 31], ["COPD", "DISEASE", 35, 39], ["corticosteroids", "CHEMICAL", 188, 203], ["COPD", "DISEASE", 250, 254], ["eosinophilic airway inflammation", "DISEASE", 260, 292], ["corticosteroids", "CHEMICAL", 16, 31], ["corticosteroids", "CHEMICAL", 188, 203], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 76, 84], ["eosinophils", "CELL", 106, 117], ["eosinophil cationic protein 20", "GENE_OR_GENE_PRODUCT", 139, 169], ["corticosteroids", "SIMPLE_CHEMICAL", 188, 203], ["patients", "ORGANISM", 236, 244], ["eosinophils", "CELL_TYPE", 106, 117], ["eosinophil cationic protein 20", "PROTEIN", 139, 169], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 236, 244], ["corticosteroids", "TREATMENT", 16, 31], ["COPD", "PROBLEM", 35, 39], ["more eosinophils", "PROBLEM", 101, 117], ["eosinophil cationic protein", "TEST", 139, 166], ["corticosteroids", "TREATMENT", 188, 203], ["COPD", "PROBLEM", 250, 254], ["eosinophilic airway inflammation", "PROBLEM", 260, 292], ["corticosteroids", "OBSERVATION_MODIFIER", 16, 31], ["corticosteroids", "OBSERVATION", 188, 203], ["COPD", "OBSERVATION", 250, 254], ["eosinophilic airway inflammation", "OBSERVATION", 260, 292]]], ["In addition, we had reported that inhaled fluticasone (200 \u00b5g/day) can significantly suppress the numbers of eosinophils in the airways of COPD.", [["eosinophils", "ANATOMY", 109, 120], ["airways", "ANATOMY", 128, 135], ["fluticasone", "CHEMICAL", 42, 53], ["COPD", "DISEASE", 139, 143], ["fluticasone", "CHEMICAL", 42, 53], ["fluticasone", "SIMPLE_CHEMICAL", 42, 53], ["eosinophils", "CELL", 109, 120], ["airways", "MULTI-TISSUE_STRUCTURE", 128, 135], ["eosinophils", "CELL_TYPE", 109, 120], ["inhaled fluticasone", "TREATMENT", 34, 53], ["COPD", "PROBLEM", 139, 143], ["eosinophils", "OBSERVATION", 109, 120], ["airways", "ANATOMY", 128, 135], ["COPD", "OBSERVATION", 139, 143]]], ["Suppression of such eosinophilic inflammation was not associated with improvement in lung function.", [["eosinophilic", "ANATOMY", 20, 32], ["lung", "ANATOMY", 85, 89], ["inflammation", "DISEASE", 33, 45], ["eosinophilic", "PATHOLOGICAL_FORMATION", 20, 32], ["lung", "ORGAN", 85, 89], ["such eosinophilic inflammation", "PROBLEM", 15, 45], ["eosinophilic inflammation", "OBSERVATION", 20, 45], ["not associated with", "UNCERTAINTY", 50, 69], ["lung", "ANATOMY", 85, 89], ["function", "OBSERVATION", 90, 98]]], ["Brightling et al. 23 also reported that the improvement in FEV 1 is not associated with a reduction in the sputum eosinophil count in COPD with sputum eosinophilia.Airway inflammationIncreased CD8 + T lymphocytes have been shown in the central and peripheral airways and lung parenchyma in COPD 12, 13, 24, 25 .", [["sputum eosinophil", "ANATOMY", 107, 124], ["sputum", "ANATOMY", 144, 150], ["Airway", "ANATOMY", 164, 170], ["CD8 + T lymphocytes", "ANATOMY", 193, 212], ["peripheral airways", "ANATOMY", 248, 266], ["lung parenchyma", "ANATOMY", 271, 286], ["COPD", "DISEASE", 134, 138], ["sputum eosinophilia", "DISEASE", 144, 163], ["Airway inflammation", "DISEASE", 164, 183], ["COPD", "DISEASE", 290, 294], ["FEV 1", "GENE_OR_GENE_PRODUCT", 59, 64], ["eosinophil", "CELL", 114, 124], ["Airway", "MULTI-TISSUE_STRUCTURE", 164, 170], ["CD8", "GENE_OR_GENE_PRODUCT", 193, 196], ["peripheral airways", "MULTI-TISSUE_STRUCTURE", 248, 266], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 271, 286], ["CD8", "PROTEIN", 193, 196], ["T lymphocytes", "CELL_TYPE", 199, 212], ["a reduction", "PROBLEM", 88, 99], ["the sputum eosinophil count", "TEST", 103, 130], ["COPD", "PROBLEM", 134, 138], ["sputum eosinophilia", "PROBLEM", 144, 163], ["Airway inflammation", "PROBLEM", 164, 183], ["Increased CD8 + T lymphocytes", "PROBLEM", 183, 212], ["COPD", "TEST", 290, 294], ["not associated with", "UNCERTAINTY", 68, 87], ["COPD", "OBSERVATION", 134, 138], ["sputum eosinophilia", "OBSERVATION", 144, 163], ["inflammation", "OBSERVATION", 171, 183], ["CD8", "OBSERVATION", 193, 196], ["T lymphocytes", "OBSERVATION", 199, 212], ["central", "ANATOMY_MODIFIER", 236, 243], ["peripheral", "ANATOMY_MODIFIER", 248, 258], ["airways", "ANATOMY", 259, 266], ["lung", "ANATOMY", 271, 275], ["parenchyma", "ANATOMY_MODIFIER", 276, 286], ["COPD", "OBSERVATION", 290, 294]]], ["The increased number of CD8 + T lymphocytes in the subepithelium has been correlated with the severity of airflow limitation 26 .", [["CD8 + T lymphocytes", "ANATOMY", 24, 43], ["subepithelium", "ANATOMY", 51, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 24, 27], ["subepithelium", "CANCER", 51, 64], ["CD8 + T lymphocytes", "CELL_TYPE", 24, 43], ["T lymphocytes in the subepithelium", "PROBLEM", 30, 64], ["airflow limitation", "PROBLEM", 106, 124], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["CD8 + T lymphocytes", "OBSERVATION", 24, 43], ["airflow", "OBSERVATION", 106, 113]]], ["Increased cytotoxic activity of CD8 + T cells was observed in induced sputum of patients with COPD compared to those of smokers without COPD and healthy subjects.", [["CD8 + T cells", "ANATOMY", 32, 45], ["sputum", "ANATOMY", 70, 76], ["COPD", "DISEASE", 94, 98], ["COPD", "DISEASE", 136, 140], ["CD8", "GENE_OR_GENE_PRODUCT", 32, 35], ["sputum", "ORGANISM_SUBSTANCE", 70, 76], ["patients", "ORGANISM", 80, 88], ["CD8", "PROTEIN", 32, 35], ["T cells", "CELL_TYPE", 38, 45], ["patients", "SPECIES", 80, 88], ["Increased cytotoxic activity", "PROBLEM", 0, 28], ["T cells", "PROBLEM", 38, 45], ["COPD", "PROBLEM", 94, 98], ["COPD", "PROBLEM", 136, 140], ["cytotoxic", "OBSERVATION_MODIFIER", 10, 19], ["activity", "OBSERVATION_MODIFIER", 20, 28], ["sputum", "OBSERVATION", 70, 76], ["COPD", "OBSERVATION", 94, 98], ["COPD", "OBSERVATION", 136, 140]]], ["The expression of perforins, a secreted molecule that causes cytolysis, was also high 27 .", [["perforins", "GENE_OR_GENE_PRODUCT", 18, 27], ["perforins", "PROTEIN", 18, 27], ["secreted molecule", "PROTEIN", 31, 48], ["a secreted molecule", "PROBLEM", 29, 48], ["cytolysis", "PROBLEM", 61, 70], ["cytolysis", "OBSERVATION", 61, 70]]], ["However, one in vitro study demonstrated that cytolytic activity of CD8 + T cells against alveolar epithelial cells is perforin-independent and is attributed entirely by TNF-\u03b1, which is expressed on CD8 + T cells 28 .", [["CD8 + T cells", "ANATOMY", 68, 81], ["alveolar epithelial cells", "ANATOMY", 90, 115], ["CD8 + T cells", "ANATOMY", 199, 212], ["CD8", "GENE_OR_GENE_PRODUCT", 68, 71], ["alveolar epithelial cells", "CELL", 90, 115], ["perforin", "GENE_OR_GENE_PRODUCT", 119, 127], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 170, 175], ["CD8", "GENE_OR_GENE_PRODUCT", 199, 202], ["CD8 + T cells", "CELL_TYPE", 68, 81], ["alveolar epithelial cells", "CELL_TYPE", 90, 115], ["perforin", "PROTEIN", 119, 127], ["TNF", "PROTEIN", 170, 173], ["\u03b1", "PROTEIN", 174, 175], ["CD8", "PROTEIN", 199, 202], ["vitro study", "TEST", 16, 27], ["CD8", "TEST", 68, 71], ["alveolar epithelial cells", "PROBLEM", 90, 115], ["TNF", "TEST", 170, 173], ["alveolar", "ANATOMY_MODIFIER", 90, 98], ["epithelial cells", "OBSERVATION", 99, 115]]], ["However, the contribution of CD8 + T cell and the ratio of CD4 + /CD8 + cells to the pathogenesis of COPD as well as the cell recruitment to the airways are not clear.Acute exacerbationAcute exacerbation is associated with increased inflam- matory burden leading to worsening respiratory symptoms including dyspnea and sputum production.", [["CD8 + T cell", "ANATOMY", 29, 41], ["CD4 + /CD8 + cells", "ANATOMY", 59, 77], ["cell", "ANATOMY", 121, 125], ["airways", "ANATOMY", 145, 152], ["respiratory", "ANATOMY", 276, 287], ["sputum", "ANATOMY", 319, 325], ["COPD", "DISEASE", 101, 105], ["respiratory symptoms", "DISEASE", 276, 296], ["dyspnea", "DISEASE", 307, 314], ["CD8", "GENE_OR_GENE_PRODUCT", 29, 32], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 66, 69], ["cell", "CELL", 121, 125], ["airways", "MULTI-TISSUE_STRUCTURE", 145, 152], ["sputum", "ORGANISM_SUBSTANCE", 319, 325], ["CD8", "PROTEIN", 29, 32], ["CD4 + /CD8 + cells", "CELL_TYPE", 59, 77], ["CD8", "TEST", 29, 32], ["T cell", "PROBLEM", 35, 41], ["the ratio", "TEST", 46, 55], ["CD4", "TEST", 59, 62], ["CD8 + cells", "PROBLEM", 66, 77], ["COPD", "PROBLEM", 101, 105], ["the cell recruitment", "TREATMENT", 117, 137], ["Acute exacerbation", "PROBLEM", 167, 185], ["Acute exacerbation", "PROBLEM", 185, 203], ["increased inflam- matory burden", "PROBLEM", 223, 254], ["worsening respiratory symptoms", "PROBLEM", 266, 296], ["dyspnea", "PROBLEM", 307, 314], ["sputum production", "PROBLEM", 319, 336], ["T cell", "OBSERVATION", 35, 41], ["COPD", "OBSERVATION", 101, 105], ["cell recruitment", "OBSERVATION", 121, 137], ["airways", "ANATOMY", 145, 152], ["not", "UNCERTAINTY", 157, 160], ["clear", "OBSERVATION", 161, 166], ["exacerbation", "OBSERVATION", 173, 185], ["exacerbation", "OBSERVATION", 191, 203], ["increased", "OBSERVATION_MODIFIER", 223, 232], ["inflam", "OBSERVATION", 233, 239], ["worsening", "OBSERVATION_MODIFIER", 266, 275], ["respiratory symptoms", "OBSERVATION", 276, 296], ["dyspnea", "OBSERVATION", 307, 314], ["sputum", "OBSERVATION", 319, 325]]], ["In the ECLIPSE study, the exacerbation rates were 0.85, 1.34, and 2.0 (number/ yr/patient) for patients with Global Initiative for Obstructive Lung Disease (GOLD) stages 2, 3, and 4, respectively, during the first year of follow-up 4 .", [["Lung", "ANATOMY", 143, 147], ["Obstructive Lung Disease", "DISEASE", 131, 155], ["patient", "ORGANISM", 82, 89], ["patients", "ORGANISM", 95, 103], ["Lung", "ORGAN", 143, 147], ["patient", "SPECIES", 82, 89], ["patients", "SPECIES", 95, 103], ["the ECLIPSE study", "TEST", 3, 20], ["the exacerbation rates", "TEST", 22, 44], ["Obstructive Lung Disease", "PROBLEM", 131, 155], ["Obstructive", "OBSERVATION_MODIFIER", 131, 142], ["Lung", "ANATOMY", 143, 147], ["Disease", "OBSERVATION", 148, 155]]], ["The exacerbation rates were significantly associated with post-bronchodilator FEV 1 , impairment in health status, history of reflux or heartburn, white blood cell count, and prior history of exacerbation.", [["white blood cell", "ANATOMY", 147, 163], ["reflux", "DISEASE", 126, 132], ["heartburn", "DISEASE", 136, 145], ["FEV 1", "GENE_OR_GENE_PRODUCT", 78, 83], ["blood cell", "CELL", 153, 163], ["The exacerbation rates", "PROBLEM", 0, 22], ["post-bronchodilator FEV", "PROBLEM", 58, 81], ["impairment in health status", "PROBLEM", 86, 113], ["reflux", "PROBLEM", 126, 132], ["heartburn", "PROBLEM", 136, 145], ["white blood cell count", "TEST", 147, 169], ["exacerbation", "PROBLEM", 192, 204], ["exacerbation", "OBSERVATION", 4, 16], ["reflux", "OBSERVATION", 126, 132], ["exacerbation", "OBSERVATION", 192, 204]]], ["In addition, acute exacerbation of COPD had been found to be an independent factor of mortality, suggesting more exacerbations with higher mortality 29 .", [["COPD", "DISEASE", 35, 39], ["acute exacerbation", "PROBLEM", 13, 31], ["COPD", "PROBLEM", 35, 39], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["exacerbation", "OBSERVATION", 19, 31], ["COPD", "OBSERVATION", 35, 39]]], ["In a subgroup analysis in the Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) study, 39% and 36% of patients with or without inhaled corticosteroid treatment had no exacerbation in the first year of follow-up.", [["Lung", "ANATOMY", 62, 66], ["Obstructive Lung Disease", "DISEASE", 50, 74], ["Lung", "ORGAN", 62, 66], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["a subgroup analysis", "TEST", 3, 22], ["the Inhaled Steroids", "TREATMENT", 26, 46], ["Obstructive Lung Disease", "PROBLEM", 50, 74], ["study", "TEST", 94, 99], ["inhaled corticosteroid treatment", "TREATMENT", 141, 173], ["exacerbation", "PROBLEM", 181, 193], ["Obstructive", "OBSERVATION_MODIFIER", 50, 61], ["Lung", "ANATOMY", 62, 66], ["Disease", "OBSERVATION", 67, 74]]], ["During the three-year study period, 22% and 23% of patients respectively had no exacerbations 30 .", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["exacerbations", "PROBLEM", 80, 93], ["no", "UNCERTAINTY", 77, 79], ["exacerbations", "OBSERVATION", 80, 93]]], ["In a retrospective observational study, 85.5%, 80.4%, 60.6%, and 48.1% of COPD patients with GOLD classification group A, B, C, and D had no acute exacerbation in the previous year before enrollment 31 .What Is the Breach of Stability of AirwayInflammation?Bacterial and viral infectionIn a prospective observational study, 55% and 29% of COPD patients had bacteria or virus-associated exacerbations, respectively 32 .", [["COPD", "DISEASE", 74, 78], ["COPD", "DISEASE", 339, 343], ["exacerbations", "DISEASE", 386, 399], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 344, 352], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 344, 352], ["a retrospective observational study", "TEST", 3, 38], ["COPD", "PROBLEM", 74, 78], ["GOLD classification group A, B, C", "PROBLEM", 93, 126], ["acute exacerbation", "PROBLEM", 141, 159], ["AirwayInflammation", "PROBLEM", 238, 256], ["Bacterial and viral infectionIn", "PROBLEM", 257, 288], ["a prospective observational study", "TEST", 289, 322], ["COPD", "PROBLEM", 339, 343], ["bacteria", "PROBLEM", 357, 365], ["virus", "PROBLEM", 369, 374], ["associated exacerbations", "PROBLEM", 375, 399], ["no", "UNCERTAINTY", 138, 140], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["exacerbation", "OBSERVATION", 147, 159], ["AirwayInflammation", "OBSERVATION", 238, 256], ["viral infectionIn", "OBSERVATION", 271, 288]]], ["The most common causes of bacteria-associated exacerbations were Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae 33 .", [["Haemophilus influenzae", "DISEASE", 65, 87], ["Moraxella catarrhalis", "DISEASE", 89, 110], ["Haemophilus influenzae", "ORGANISM", 65, 87], ["Moraxella catarrhalis", "ORGANISM", 89, 110], ["Streptococcus pneumoniae 33", "ORGANISM", 116, 143], ["Haemophilus influenzae", "SPECIES", 65, 87], ["Moraxella catarrhalis", "SPECIES", 89, 110], ["Streptococcus pneumoniae", "SPECIES", 116, 140], ["Haemophilus influenzae", "SPECIES", 65, 87], ["Moraxella catarrhalis", "SPECIES", 89, 110], ["Streptococcus pneumoniae", "SPECIES", 116, 140], ["bacteria", "PROBLEM", 26, 34], ["associated exacerbations", "PROBLEM", 35, 59], ["Haemophilus influenzae", "PROBLEM", 65, 87], ["Moraxella catarrhalis", "PROBLEM", 89, 110], ["Streptococcus pneumoniae", "PROBLEM", 116, 140], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["bacteria", "OBSERVATION", 26, 34], ["Moraxella catarrhalis", "OBSERVATION", 89, 110], ["Streptococcus pneumoniae", "OBSERVATION", 116, 140]]], ["The major viruses associated with COPD exacerbations were rhinovirus (common cold), coronavirus, influenza, and parainfluenza 34 .", [["COPD", "DISEASE", 34, 38], ["rhinovirus (common cold), coronavirus", "DISEASE", 58, 95], ["influenza", "DISEASE", 97, 106], ["parainfluenza", "DISEASE", 112, 125], ["rhinovirus", "ORGANISM", 58, 68], ["coronavirus", "ORGANISM", 84, 95], ["parainfluenza 34", "ORGANISM", 112, 128], ["coronavirus", "SPECIES", 84, 95], ["parainfluenza", "SPECIES", 112, 125], ["The major viruses", "PROBLEM", 0, 17], ["COPD exacerbations", "PROBLEM", 34, 52], ["rhinovirus", "PROBLEM", 58, 68], ["common cold)", "PROBLEM", 70, 82], ["coronavirus", "PROBLEM", 84, 95], ["influenza", "PROBLEM", 97, 106], ["parainfluenza", "PROBLEM", 112, 125], ["major", "OBSERVATION_MODIFIER", 4, 9], ["viruses", "OBSERVATION", 10, 17], ["COPD", "OBSERVATION", 34, 38], ["rhinovirus", "OBSERVATION", 58, 68]]], ["Papi et al. 35 reported that patients with infectious exacerbation (bacteria, virus, or coinfection) may have longer hospitalization and greater impairment of lung function compared to those noninfectious exacerbations.", [["lung", "ANATOMY", 159, 163], ["infectious exacerbation", "DISEASE", 43, 66], ["coinfection", "DISEASE", 88, 99], ["impairment of lung function", "DISEASE", 145, 172], ["patients", "ORGANISM", 29, 37], ["lung", "ORGAN", 159, 163], ["patients", "SPECIES", 29, 37], ["infectious exacerbation", "PROBLEM", 43, 66], ["bacteria", "PROBLEM", 68, 76], ["virus", "PROBLEM", 78, 83], ["coinfection", "PROBLEM", 88, 99], ["greater impairment of lung function", "PROBLEM", 137, 172], ["those noninfectious exacerbations", "PROBLEM", 185, 218], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["greater", "OBSERVATION_MODIFIER", 137, 144], ["impairment", "OBSERVATION_MODIFIER", 145, 155], ["lung", "ANATOMY", 159, 163], ["noninfectious", "OBSERVATION_MODIFIER", 191, 204]]], ["Sputum neutrophilia were observed in all exacerbations and was associated with disease severity.", [["Sputum", "ANATOMY", 0, 6], ["neutrophilia", "DISEASE", 7, 19], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["Sputum neutrophilia", "PROBLEM", 0, 19], ["all exacerbations", "PROBLEM", 37, 54], ["disease severity", "PROBLEM", 79, 95], ["neutrophilia", "OBSERVATION", 7, 19], ["all", "OBSERVATION_MODIFIER", 37, 40], ["exacerbations", "OBSERVATION", 41, 54], ["associated with", "UNCERTAINTY", 63, 78], ["disease", "OBSERVATION", 79, 86]]], ["Sputum eosinophilia was observed during virus-associated exacerbations 35 .Bacterial and viral infectionNormally, the lower airways are sterile.", [["Sputum", "ANATOMY", 0, 6], ["lower airways", "ANATOMY", 118, 131], ["eosinophilia", "DISEASE", 7, 19], ["airways", "MULTI-TISSUE_STRUCTURE", 124, 131], ["Sputum eosinophilia", "PROBLEM", 0, 19], ["exacerbations", "PROBLEM", 57, 70], ["Bacterial and viral infectionNormally", "PROBLEM", 75, 112], ["eosinophilia", "OBSERVATION", 7, 19], ["viral infectionNormally", "OBSERVATION", 89, 112], ["lower", "ANATOMY_MODIFIER", 118, 123], ["airways", "ANATOMY", 124, 131], ["sterile", "OBSERVATION", 136, 143]]], ["Bacterial components such as flagella, lipoproteins, and lipopolysaccharides may initiate inflammatory reactions by releasing a variety of pro-inflammatory mediators and recruiting inflammatory cells 36 .", [["flagella", "ANATOMY", 29, 37], ["inflammatory cells", "ANATOMY", 181, 199], ["flagella", "CELLULAR_COMPONENT", 29, 37], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 57, 76], ["inflammatory cells", "CELL", 181, 199], ["flagella", "PROTEIN", 29, 37], ["lipoproteins", "PROTEIN", 39, 51], ["pro-inflammatory mediators", "PROTEIN", 139, 165], ["inflammatory cells", "CELL_TYPE", 181, 199], ["Bacterial components", "PROBLEM", 0, 20], ["flagella, lipoproteins", "TREATMENT", 29, 51], ["lipopolysaccharides", "TREATMENT", 57, 76], ["inflammatory reactions", "PROBLEM", 90, 112], ["pro-inflammatory mediators", "TREATMENT", 139, 165], ["recruiting inflammatory cells", "PROBLEM", 170, 199], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102], ["inflammatory cells", "OBSERVATION", 181, 199]]], ["For example, protein A from staphylococci can recognize TNF-\u03b1 receptors in airway epithelium and induce production of IL-8, which is an important chemokine for neutrophils 37 .", [["airway epithelium", "ANATOMY", 75, 92], ["neutrophils", "ANATOMY", 160, 171], ["protein A", "GENE_OR_GENE_PRODUCT", 13, 22], ["staphylococci", "CANCER", 28, 41], ["TNF-\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 56, 71], ["airway epithelium", "TISSUE", 75, 92], ["IL-8", "GENE_OR_GENE_PRODUCT", 118, 122], ["neutrophils", "CELL", 160, 171], ["protein A", "PROTEIN", 13, 22], ["TNF-\u03b1 receptors", "PROTEIN", 56, 71], ["IL-8", "PROTEIN", 118, 122], ["chemokine", "PROTEIN", 146, 155], ["staphylococci", "PROBLEM", 28, 41], ["TNF", "TEST", 56, 59], ["airway epithelium", "PROBLEM", 75, 92], ["IL", "TEST", 118, 120], ["neutrophils", "TEST", 160, 171], ["airway epithelium", "ANATOMY", 75, 92]]], ["Pseudomonas aeruginosa flagella can activate airway epithelial cells to produce IL-8 through toll-like receptors 2 and 5 38 .", [["flagella", "ANATOMY", 23, 31], ["airway epithelial cells", "ANATOMY", 45, 68], ["Pseudomonas aeruginosa", "ORGANISM", 0, 22], ["airway epithelial cells", "CELL", 45, 68], ["IL-8", "GENE_OR_GENE_PRODUCT", 80, 84], ["toll-like receptors 2", "GENE_OR_GENE_PRODUCT", 93, 114], ["airway epithelial cells", "CELL_TYPE", 45, 68], ["IL-8", "PROTEIN", 80, 84], ["toll-like receptors 2 and 5 38", "PROTEIN", 93, 123], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["Pseudomonas aeruginosa flagella", "PROBLEM", 0, 31], ["airway epithelial cells", "PROBLEM", 45, 68], ["IL", "TEST", 80, 82], ["airway epithelial cells", "OBSERVATION", 45, 68]]], ["In stable COPD patients, sputum neutrophils and IL-8 levels were higher than those in healthy subjects, which suggested ongoing neutrophilic inflammation in the airways 11 .Bacterial and viral infectionSputum IL-8 levels were reported to be correlated with total bacterial count, and bacterial load in the airways was associated with increased exacerbation frequency 39 .", [["sputum neutrophils", "ANATOMY", 25, 43], ["neutrophilic", "ANATOMY", 128, 140], ["airways", "ANATOMY", 161, 168], ["airways", "ANATOMY", 306, 313], ["COPD", "DISEASE", 10, 14], ["inflammation", "DISEASE", 141, 153], ["patients", "ORGANISM", 15, 23], ["sputum neutrophils", "CELL", 25, 43], ["IL-8", "GENE_OR_GENE_PRODUCT", 48, 52], ["airways", "MULTI-TISSUE_STRUCTURE", 161, 168], ["IL-8", "GENE_OR_GENE_PRODUCT", 209, 213], ["airways", "MULTI-TISSUE_STRUCTURE", 306, 313], ["sputum neutrophils", "CELL_TYPE", 25, 43], ["IL", "PROTEIN", 48, 50], ["patients", "SPECIES", 15, 23], ["sputum neutrophils", "TEST", 25, 43], ["IL-8 levels", "TEST", 48, 59], ["ongoing neutrophilic inflammation in the airways", "PROBLEM", 120, 168], ["Bacterial and viral infectionSputum IL", "PROBLEM", 173, 211], ["total bacterial count", "TEST", 257, 278], ["bacterial load in the airways", "PROBLEM", 284, 313], ["increased exacerbation frequency", "PROBLEM", 334, 366], ["stable", "OBSERVATION_MODIFIER", 3, 9], ["COPD", "OBSERVATION", 10, 14], ["neutrophilic", "OBSERVATION_MODIFIER", 128, 140], ["inflammation", "OBSERVATION", 141, 153], ["airways", "ANATOMY", 161, 168], ["viral infectionSputum", "OBSERVATION", 187, 208], ["bacterial count", "OBSERVATION", 263, 278], ["bacterial load", "OBSERVATION", 284, 298], ["airways", "ANATOMY", 306, 313], ["increased", "OBSERVATION_MODIFIER", 334, 343], ["exacerbation", "OBSERVATION", 344, 356]]], ["Rhinovirus infection can increase the production of IL-8, IL-6, and granulocyte-macrophage colony-stimulating factor (GM-CSF) from airway epithelial cells; IL-8 production was associated with viral replication 40 .", [["airway epithelial cells", "ANATOMY", 131, 154], ["infection", "DISEASE", 11, 20], ["IL-8", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-6", "GENE_OR_GENE_PRODUCT", 58, 62], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 68, 116], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 118, 124], ["airway epithelial cells", "CELL", 131, 154], ["IL-8", "GENE_OR_GENE_PRODUCT", 156, 160], ["IL-8", "PROTEIN", 52, 56], ["IL-6", "PROTEIN", 58, 62], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 68, 116], ["GM", "PROTEIN", 118, 120], ["CSF", "PROTEIN", 121, 124], ["airway epithelial cells", "CELL_TYPE", 131, 154], ["IL-8", "PROTEIN", 156, 160], ["Rhinovirus", "SPECIES", 0, 10], ["Rhinovirus infection", "PROBLEM", 0, 20], ["the production of IL", "TEST", 34, 54], ["IL", "TEST", 58, 60], ["granulocyte", "TEST", 68, 79], ["macrophage colony", "TEST", 80, 97], ["stimulating factor", "PROBLEM", 98, 116], ["GM-CSF", "TEST", 118, 124], ["airway epithelial cells", "PROBLEM", 131, 154], ["IL", "TEST", 156, 158], ["viral replication", "TREATMENT", 192, 209], ["infection", "OBSERVATION", 11, 20], ["granulocyte", "ANATOMY", 68, 79], ["macrophage colony", "OBSERVATION", 80, 97], ["airway", "ANATOMY", 131, 137], ["epithelial cells", "OBSERVATION", 138, 154]]], ["In a study in mice, influenza virus infection resulted in influx of neutrophils, monocytes, lymphocytes, and eosinophils as well as various chemokines and cytokines 3 to 10 days after infection 41 .Air pollution and temperatureIncreased concentration of outdoor pollutants such as NO 2 , O 3 , SO 2 , particulate matter 2.5 (PM 2.5 ), and particulate matter 10 (PM 10 ) were associated with increased respiratory symptoms, acute exacerbations, and hospital admissions in COPD patients 42 .", [["neutrophils", "ANATOMY", 68, 79], ["monocytes", "ANATOMY", 81, 90], ["lymphocytes", "ANATOMY", 92, 103], ["eosinophils", "ANATOMY", 109, 120], ["respiratory", "ANATOMY", 401, 412], ["influenza virus infection", "DISEASE", 20, 45], ["infection", "DISEASE", 184, 193], ["NO", "CHEMICAL", 281, 283], ["O 3 , SO 2 , particulate matter 2.5", "CHEMICAL", 288, 323], ["respiratory symptoms", "DISEASE", 401, 421], ["COPD", "DISEASE", 471, 475], ["NO 2", "CHEMICAL", 281, 285], ["O 3", "CHEMICAL", 288, 291], ["SO 2", "CHEMICAL", 294, 298], ["mice", "ORGANISM", 14, 18], ["influenza virus", "ORGANISM", 20, 35], ["neutrophils", "CELL", 68, 79], ["monocytes", "CELL", 81, 90], ["lymphocytes", "CELL", 92, 103], ["eosinophils", "CELL", 109, 120], ["NO 2", "SIMPLE_CHEMICAL", 281, 285], ["O 3", "SIMPLE_CHEMICAL", 288, 291], ["SO 2", "SIMPLE_CHEMICAL", 294, 298], ["patients", "ORGANISM", 476, 484], ["neutrophils", "CELL_TYPE", 68, 79], ["monocytes", "CELL_TYPE", 81, 90], ["lymphocytes", "CELL_TYPE", 92, 103], ["eosinophils", "CELL_TYPE", 109, 120], ["chemokines", "PROTEIN", 140, 150], ["cytokines", "PROTEIN", 155, 164], ["mice", "SPECIES", 14, 18], ["influenza virus", "SPECIES", 20, 35], ["patients", "SPECIES", 476, 484], ["mice", "SPECIES", 14, 18], ["influenza virus", "SPECIES", 20, 35], ["a study", "TEST", 3, 10], ["influenza virus infection", "PROBLEM", 20, 45], ["influx of neutrophils", "TEST", 58, 79], ["monocytes", "TEST", 81, 90], ["lymphocytes", "TEST", 92, 103], ["eosinophils", "TEST", 109, 120], ["various chemokines and cytokines", "TREATMENT", 132, 164], ["infection", "PROBLEM", 184, 193], ["Air pollution", "PROBLEM", 198, 211], ["Increased concentration of outdoor pollutants", "PROBLEM", 227, 272], ["increased respiratory symptoms", "PROBLEM", 391, 421], ["acute exacerbations", "PROBLEM", 423, 442], ["lymphocytes", "ANATOMY", 92, 103], ["temperature", "OBSERVATION_MODIFIER", 216, 227], ["concentration", "OBSERVATION_MODIFIER", 237, 250], ["outdoor pollutants", "OBSERVATION", 254, 272], ["increased", "OBSERVATION_MODIFIER", 391, 400], ["respiratory symptoms", "OBSERVATION", 401, 421], ["acute", "OBSERVATION_MODIFIER", 423, 428], ["exacerbations", "OBSERVATION", 429, 442]]], ["Inhalation of high concentration of NO 2 may correlate to acute epithelial damage 43 .", [["epithelial", "ANATOMY", 64, 74], ["NO", "CHEMICAL", 36, 38], ["acute epithelial damage", "DISEASE", 58, 81], ["NO 2", "CHEMICAL", 36, 40], ["NO 2", "GENE_OR_GENE_PRODUCT", 36, 40], ["epithelial", "TISSUE", 64, 74], ["acute epithelial damage", "PROBLEM", 58, 81], ["high concentration", "OBSERVATION_MODIFIER", 14, 32], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["epithelial damage", "OBSERVATION", 64, 81]]], ["Cultured human bronchial epithelial cells exposed to NO 2 could increase the expression of IL-1\u03b2, IL-8, GM-CSF, and TNF-\u03b1 44 .", [["bronchial epithelial cells", "ANATOMY", 15, 41], ["NO", "CHEMICAL", 53, 55], ["NO 2", "CHEMICAL", 53, 57], ["human", "ORGANISM", 9, 14], ["bronchial epithelial cells", "CELL", 15, 41], ["NO 2", "GENE_OR_GENE_PRODUCT", 53, 57], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 91, 96], ["IL-8", "GENE_OR_GENE_PRODUCT", 98, 102], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 104, 110], ["TNF-\u03b1 44", "GENE_OR_GENE_PRODUCT", 116, 124], ["human bronchial epithelial cells", "CELL_TYPE", 9, 41], ["GM", "PROTEIN", 104, 106], ["CSF", "PROTEIN", 107, 110], ["TNF", "PROTEIN", 116, 119], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["Cultured human bronchial epithelial cells", "TEST", 0, 41], ["IL", "TEST", 91, 93], ["IL", "TEST", 98, 100], ["CSF", "TEST", 107, 110], ["TNF", "TEST", 116, 119], ["bronchial", "ANATOMY", 15, 24], ["epithelial cells", "OBSERVATION", 25, 41]]], ["SO 2 can lead to airway edema, inflammation, and fibrosis in an animal model after 3-25 days' exposure to different levels of SO 2 45 .", [["airway", "ANATOMY", 17, 23], ["airway edema", "DISEASE", 17, 29], ["inflammation", "DISEASE", 31, 43], ["fibrosis", "DISEASE", 49, 57], ["SO 2", "CHEMICAL", 0, 4], ["SO 2", "GENE_OR_GENE_PRODUCT", 0, 4], ["airway edema", "PATHOLOGICAL_FORMATION", 17, 29], ["airway edema", "PROBLEM", 17, 29], ["inflammation", "PROBLEM", 31, 43], ["fibrosis", "PROBLEM", 49, 57], ["airway", "ANATOMY", 17, 23], ["edema", "OBSERVATION", 24, 29], ["inflammation", "OBSERVATION", 31, 43], ["fibrosis", "OBSERVATION", 49, 57]]], ["O 3 and PM 10 have been reported to increase the incidence of hospital admission for pneumonia and acute exacerbation of COPD in a meta-analysis based on city-specific regression models 46 .", [["pneumonia", "DISEASE", 85, 94], ["COPD", "DISEASE", 121, 125], ["O 3", "CHEMICAL", 0, 3], ["O 3", "GENE_OR_GENE_PRODUCT", 0, 3], ["pneumonia", "PROBLEM", 85, 94], ["acute exacerbation", "PROBLEM", 99, 117], ["COPD", "PROBLEM", 121, 125], ["pneumonia", "OBSERVATION", 85, 94], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["exacerbation", "OBSERVATION", 105, 117], ["COPD", "OBSERVATION", 121, 125]]], ["Short-term PM 2.5 exposure was associated with an increased risk of about 0.9% for COPD hospitalization 47 .", [["COPD", "DISEASE", 83, 87], ["an increased risk", "PROBLEM", 47, 64], ["COPD hospitalization", "PROBLEM", 83, 103], ["increased", "OBSERVATION_MODIFIER", 50, 59]]], ["In an epidemiologic study, for every 10 \u00b5g/m 3 increase in O 3 , NO 2 , and SO 2 concentrations, the risks of hospitalization for COPD increase to about 0.58%, 0.38%, and 0.44%, respectively 48 .", [["NO", "CHEMICAL", 65, 67], ["COPD", "DISEASE", 130, 134], ["O 3", "CHEMICAL", 59, 62], ["NO 2", "CHEMICAL", 65, 69], ["SO 2", "CHEMICAL", 76, 80], ["O 3", "GENE_OR_GENE_PRODUCT", 59, 62], ["NO 2", "SIMPLE_CHEMICAL", 65, 69], ["SO 2", "GENE_OR_GENE_PRODUCT", 76, 80], ["an epidemiologic study", "TEST", 3, 25], ["COPD increase", "PROBLEM", 130, 143], ["COPD", "OBSERVATION", 130, 134]]], ["Seasonal variations and temperature may affect the incidence of acute exacerbation of COPD.", [["COPD", "DISEASE", 86, 90], ["Seasonal variations", "PROBLEM", 0, 19], ["acute exacerbation", "PROBLEM", 64, 82], ["COPD", "PROBLEM", 86, 90], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["exacerbation", "OBSERVATION", 70, 82], ["COPD", "OBSERVATION", 86, 90]]], ["Tseng et al. 49 reported that a 1\u00b0C decrease in air temperature was associated with a 0.8% increase in the exacerbation rate on event-days.", [["C decrease in air temperature", "PROBLEM", 34, 63], ["a 0.8% increase", "PROBLEM", 84, 99], ["the exacerbation rate", "PROBLEM", 103, 124], ["decrease", "OBSERVATION_MODIFIER", 36, 44], ["air temperature", "OBSERVATION", 48, 63], ["increase", "OBSERVATION_MODIFIER", 91, 99]]], ["The cold temperature was reported to be linked to bronchoconstriction 50 and FEV 1 decrease 51 especially for COPD patients.Gastroesophageal refluxateThe gastroesophageal refluxate contains gastric acids, bile, and pepsin.", [["Gastroesophageal", "ANATOMY", 124, 140], ["gastroesophageal", "ANATOMY", 154, 170], ["gastric", "ANATOMY", 190, 197], ["bile", "ANATOMY", 205, 209], ["COPD", "DISEASE", 110, 114], ["Gastroesophageal refluxate", "DISEASE", 124, 150], ["patients", "ORGANISM", 115, 123], ["Gastroesophageal", "ORGAN", 124, 140], ["gastroesophageal", "ORGAN", 154, 170], ["gastric acids", "SIMPLE_CHEMICAL", 190, 203], ["bile", "SIMPLE_CHEMICAL", 205, 209], ["pepsin", "GENE_OR_GENE_PRODUCT", 215, 221], ["patients", "SPECIES", 115, 123], ["The cold temperature", "TEST", 0, 20], ["bronchoconstriction", "TEST", 50, 69], ["FEV", "TEST", 77, 80], ["COPD patients", "PROBLEM", 110, 123], ["Gastroesophageal refluxate", "PROBLEM", 124, 150], ["The gastroesophageal refluxate", "TREATMENT", 150, 180], ["gastric acids", "TREATMENT", 190, 203], ["pepsin", "TREATMENT", 215, 221], ["refluxate", "OBSERVATION", 141, 150], ["gastroesophageal", "ANATOMY", 154, 170], ["gastric", "ANATOMY", 190, 197], ["acids", "OBSERVATION_MODIFIER", 198, 203], ["bile", "ANATOMY", 205, 209]]], ["Gastroesophageal reflux (GER) is a major cause of subacute and chronic cough.", [["Gastroesophageal", "ANATOMY", 0, 16], ["Gastroesophageal reflux", "DISEASE", 0, 23], ["GER", "DISEASE", 25, 28], ["cough", "DISEASE", 71, 76], ["Gastroesophageal", "ORGAN", 0, 16], ["Gastroesophageal reflux (GER", "PROBLEM", 0, 28], ["subacute and chronic cough", "PROBLEM", 50, 76], ["reflux", "OBSERVATION", 17, 23], ["subacute", "OBSERVATION_MODIFIER", 50, 58], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["cough", "OBSERVATION", 71, 76]]], ["In a questionnaire-based prospective survey, the prevalence of GER disease (GERD) was 26.7% among stable COPD patients, and severe GERD symptoms were associated with more frequent exacerbations of COPD and hospitalization with crude relative risks of 3.42 and 3.66, respectively 51 .", [["GER disease", "DISEASE", 63, 74], ["GERD", "DISEASE", 76, 80], ["COPD", "DISEASE", 105, 109], ["GERD", "DISEASE", 131, 135], ["COPD", "DISEASE", 197, 201], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["GER disease", "PROBLEM", 63, 74], ["GERD", "PROBLEM", 76, 80], ["severe GERD symptoms", "PROBLEM", 124, 144], ["COPD", "PROBLEM", 197, 201], ["GER disease", "OBSERVATION", 63, 74], ["stable", "OBSERVATION_MODIFIER", 98, 104], ["COPD", "OBSERVATION", 105, 109], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["GERD", "OBSERVATION", 131, 135], ["COPD", "OBSERVATION", 197, 201]]], ["Casanova et al. 52 reported that severe COPD patients had high prevalence of GERD (62%) confirmed by esophageal 24-hour pH monitoring but 58% of them did not have any reflux symptoms.", [["esophageal", "ANATOMY", 101, 111], ["COPD", "DISEASE", 40, 44], ["GERD", "DISEASE", 77, 81], ["reflux symptoms", "DISEASE", 167, 182], ["patients", "ORGANISM", 45, 53], ["esophageal", "ORGAN", 101, 111], ["patients", "SPECIES", 45, 53], ["severe COPD", "PROBLEM", 33, 44], ["GERD", "PROBLEM", 77, 81], ["pH monitoring", "TEST", 120, 133], ["any reflux symptoms", "PROBLEM", 163, 182], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["COPD", "OBSERVATION", 40, 44], ["esophageal", "ANATOMY", 101, 111], ["reflux", "OBSERVATION", 167, 173]]], ["In addition, the annual rate of exacerbations of COPD was twice as high in patients with GER symptoms compared to those without GER Tuberc Respir Dis 2017;80:325-335Gastroesophageal refluxatewww.e-trd.org symptoms (3.2/yr vs. 1.6/yr, p=0.02) 53 .", [["exacerbations", "DISEASE", 32, 45], ["COPD", "DISEASE", 49, 53], ["GER symptoms", "DISEASE", 89, 101], ["Gastroesophageal refluxatewww.e-trd.org symptoms", "DISEASE", 165, 213], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["exacerbations", "PROBLEM", 32, 45], ["COPD", "PROBLEM", 49, 53], ["GER symptoms", "PROBLEM", 89, 101], ["GER", "PROBLEM", 128, 131], ["Gastroesophageal refluxatewww.e-trd.org symptoms", "PROBLEM", 165, 213], ["COPD", "OBSERVATION", 49, 53], ["Gastroesophageal", "ANATOMY", 165, 181]]], ["In our previous study, the amount of total bile acids in induced sputum was significantly higher in patients with GER and asthma-associated GER symptoms compared to that of healthy control subjects (p<0.005).", [["sputum", "ANATOMY", 65, 71], ["bile acids", "CHEMICAL", 43, 53], ["GER", "DISEASE", 114, 117], ["GER symptoms", "DISEASE", 140, 152], ["bile acids", "CHEMICAL", 43, 53], ["bile acids", "SIMPLE_CHEMICAL", 43, 53], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["our previous study", "TEST", 3, 21], ["total bile acids", "TREATMENT", 37, 53], ["induced sputum", "PROBLEM", 57, 71], ["GER", "PROBLEM", 114, 117], ["asthma-associated GER symptoms", "PROBLEM", 122, 152], ["amount", "OBSERVATION_MODIFIER", 27, 33], ["total", "OBSERVATION_MODIFIER", 37, 42], ["bile acids", "OBSERVATION", 43, 53], ["sputum", "OBSERVATION", 65, 71], ["higher", "OBSERVATION_MODIFIER", 90, 96]]], ["Bile acid significantly induced transforming growth factor \u03b21 (TGF-\u03b21) production from airway epithelial cells, which in turn enhanced fibroblast proliferation 54 and altered alveolar epithelial permeability, which may contribute to the pathogenesis of lung injury 55 .", [["airway epithelial cells", "ANATOMY", 87, 110], ["fibroblast", "ANATOMY", 135, 145], ["alveolar epithelial", "ANATOMY", 175, 194], ["lung", "ANATOMY", 253, 257], ["Bile acid", "CHEMICAL", 0, 9], ["lung injury", "DISEASE", 253, 264], ["Bile acid", "CHEMICAL", 0, 9], ["Bile acid", "SIMPLE_CHEMICAL", 0, 9], ["transforming growth factor \u03b21", "GENE_OR_GENE_PRODUCT", 32, 61], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 63, 69], ["airway epithelial cells", "CELL", 87, 110], ["fibroblast", "CELL", 135, 145], ["alveolar epithelial", "TISSUE", 175, 194], ["lung", "ORGAN", 253, 257], ["TGF-\u03b21", "PROTEIN", 63, 69], ["airway epithelial cells", "CELL_TYPE", 87, 110], ["Bile acid", "TEST", 0, 9], ["transforming growth factor", "PROBLEM", 32, 58], ["TGF", "TEST", 63, 66], ["airway epithelial cells", "PROBLEM", 87, 110], ["fibroblast proliferation", "TEST", 135, 159], ["altered alveolar epithelial permeability", "PROBLEM", 167, 207], ["lung injury", "PROBLEM", 253, 264], ["acid significantly", "OBSERVATION_MODIFIER", 5, 23], ["growth", "OBSERVATION_MODIFIER", 45, 51], ["airway", "ANATOMY", 87, 93], ["epithelial cells", "OBSERVATION", 94, 110], ["turn", "OBSERVATION_MODIFIER", 121, 125], ["enhanced", "OBSERVATION_MODIFIER", 126, 134], ["fibroblast proliferation", "OBSERVATION", 135, 159], ["altered", "OBSERVATION_MODIFIER", 167, 174], ["alveolar", "ANATOMY_MODIFIER", 175, 183], ["epithelial permeability", "OBSERVATION", 184, 207], ["may contribute to", "UNCERTAINTY", 215, 232], ["lung", "ANATOMY", 253, 257], ["injury", "OBSERVATION", 258, 264]]], ["Airway epithelium exposed to bile acids could induce fibrosis via production of connective tissue growth factor (CCN2).", [["Airway epithelium", "ANATOMY", 0, 17], ["bile", "ANATOMY", 29, 33], ["bile acids", "CHEMICAL", 29, 39], ["fibrosis", "DISEASE", 53, 61], ["bile acids", "CHEMICAL", 29, 39], ["Airway epithelium", "TISSUE", 0, 17], ["bile acids", "SIMPLE_CHEMICAL", 29, 39], ["connective tissue growth factor", "GENE_OR_GENE_PRODUCT", 80, 111], ["CCN2", "GENE_OR_GENE_PRODUCT", 113, 117], ["connective tissue growth factor", "PROTEIN", 80, 111], ["CCN2", "PROTEIN", 113, 117], ["Airway epithelium", "PROBLEM", 0, 17], ["bile acids", "PROBLEM", 29, 39], ["fibrosis", "PROBLEM", 53, 61], ["connective tissue growth factor", "PROBLEM", 80, 111], ["bile", "ANATOMY", 29, 33], ["fibrosis", "OBSERVATION", 53, 61], ["connective tissue", "OBSERVATION_MODIFIER", 80, 97]]], ["CCN2 is essential for TGF-\u03b21induced fibrogenesis and functions as a downstream mediator of TGF-\u03b21 action on fibroblasts 56 .", [["fibroblasts", "ANATOMY", 108, 119], ["CCN2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 22, 27], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 91, 97], ["fibroblasts 56", "CELL", 108, 122], ["CCN2", "PROTEIN", 0, 4], ["TGF", "PROTEIN", 22, 25], ["\u03b2", "PROTEIN", 26, 27], ["TGF-\u03b21", "PROTEIN", 91, 97], ["TGF", "TEST", 22, 25], ["1induced fibrogenesis", "PROBLEM", 27, 48], ["TGF", "TEST", 91, 94], ["fibrogenesis", "OBSERVATION", 36, 48]]], ["The major bile acid, chenodeoxycholic acid, stimulated alveolar epithelial cells to increase IL-8 production through p38 and c-Jun N-terminal kinase activation.", [["alveolar epithelial cells", "ANATOMY", 55, 80], ["bile acid", "CHEMICAL", 10, 19], ["chenodeoxycholic acid", "CHEMICAL", 21, 42], ["bile acid", "CHEMICAL", 10, 19], ["chenodeoxycholic acid", "CHEMICAL", 21, 42], ["N", "CHEMICAL", 131, 132], ["bile acid", "SIMPLE_CHEMICAL", 10, 19], ["chenodeoxycholic acid", "SIMPLE_CHEMICAL", 21, 42], ["alveolar epithelial cells", "CELL", 55, 80], ["IL-8", "GENE_OR_GENE_PRODUCT", 93, 97], ["p38", "GENE_OR_GENE_PRODUCT", 117, 120], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 125, 148], ["alveolar epithelial cells", "CELL_TYPE", 55, 80], ["IL-8", "PROTEIN", 93, 97], ["p38", "PROTEIN", 117, 120], ["Jun N-terminal kinase", "PROTEIN", 127, 148], ["The major bile acid", "TEST", 0, 19], ["chenodeoxycholic acid", "TEST", 21, 42], ["stimulated alveolar epithelial cells", "PROBLEM", 44, 80], ["IL", "TEST", 93, 95], ["p38", "TEST", 117, 120], ["c", "TEST", 125, 126], ["terminal kinase activation", "PROBLEM", 133, 159], ["bile acid", "ANATOMY", 10, 19], ["alveolar epithelial cells", "OBSERVATION", 55, 80], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["IL", "OBSERVATION_MODIFIER", 93, 95], ["terminal kinase activation", "OBSERVATION", 133, 159]]], ["This may enhance neutrophilic inflammation in chronic airway disorders 57 .", [["neutrophilic", "ANATOMY", 17, 29], ["airway", "ANATOMY", 54, 60], ["inflammation", "DISEASE", 30, 42], ["chronic airway disorders", "DISEASE", 46, 70], ["airway", "ORGAN", 54, 60], ["neutrophilic inflammation", "PROBLEM", 17, 42], ["chronic airway disorders", "PROBLEM", 46, 70], ["neutrophilic", "OBSERVATION_MODIFIER", 17, 29], ["inflammation", "OBSERVATION", 30, 42], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["airway", "ANATOMY", 54, 60]]], ["How to intervene and attenuate GER-related inflammation and fibrogenesis in chronic airway disorders is worth further investigation.Bronchiectasis and bacterial colonizationThe prevalence of bronchiectasis in COPD varies according to COPD severity.", [["airway", "ANATOMY", 84, 90], ["GER", "DISEASE", 31, 34], ["inflammation", "DISEASE", 43, 55], ["fibrogenesis", "DISEASE", 60, 72], ["airway disorders", "DISEASE", 84, 100], ["Bronchiectasis", "DISEASE", 132, 146], ["bronchiectasis", "DISEASE", 191, 205], ["COPD", "DISEASE", 209, 213], ["COPD", "DISEASE", 234, 238], ["airway", "MULTI-TISSUE_STRUCTURE", 84, 90], ["attenuate GER", "PROBLEM", 21, 34], ["inflammation", "PROBLEM", 43, 55], ["fibrogenesis in chronic airway disorders", "PROBLEM", 60, 100], ["further investigation", "TEST", 110, 131], ["Bronchiectasis", "PROBLEM", 132, 146], ["bacterial colonization", "PROBLEM", 151, 173], ["bronchiectasis", "PROBLEM", 191, 205], ["COPD varies", "PROBLEM", 209, 220], ["COPD severity", "PROBLEM", 234, 247], ["inflammation", "OBSERVATION", 43, 55], ["fibrogenesis", "OBSERVATION", 60, 72], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["airway", "ANATOMY", 84, 90], ["bacterial colonization", "OBSERVATION", 151, 173], ["bronchiectasis", "OBSERVATION", 191, 205], ["COPD", "OBSERVATION", 209, 213], ["COPD", "OBSERVATION", 234, 238]]], ["In a prospective observational study, 50% of moderate to severe COPD patients had significant detectable bronchiectasis on high-resolution computed tomography scanning.", [["COPD", "DISEASE", 64, 68], ["bronchiectasis", "DISEASE", 105, 119], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["a prospective observational study", "TEST", 3, 36], ["moderate to severe COPD", "PROBLEM", 45, 68], ["significant detectable bronchiectasis", "PROBLEM", 82, 119], ["computed tomography scanning", "TEST", 139, 167], ["moderate", "OBSERVATION_MODIFIER", 45, 53], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["COPD", "OBSERVATION", 64, 68], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["detectable", "OBSERVATION_MODIFIER", 94, 104], ["bronchiectasis", "OBSERVATION", 105, 119]]], ["Lower lobe bronchiectasis was associated with bacterial colonization quantified by sputum sampling 58 .", [["Lower lobe", "ANATOMY", 0, 10], ["sputum", "ANATOMY", 83, 89], ["Lower lobe bronchiectasis", "DISEASE", 0, 25], ["Lower lobe", "MULTI-TISSUE_STRUCTURE", 0, 10], ["Lower lobe bronchiectasis", "PROBLEM", 0, 25], ["bacterial colonization", "PROBLEM", 46, 68], ["sputum sampling", "TEST", 83, 98], ["lobe", "ANATOMY", 6, 10], ["bronchiectasis", "OBSERVATION", 11, 25], ["associated with", "UNCERTAINTY", 30, 45], ["bacterial colonization", "OBSERVATION", 46, 68], ["sputum", "OBSERVATION", 83, 89]]], ["Martinez-Garcia et al. 59 reported that the prevalence of bronchiectasis in moderate and severe COPD patients was 34.7% and 72.5%, respectively.", [["bronchiectasis", "DISEASE", 58, 72], ["COPD", "DISEASE", 96, 100], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["bronchiectasis in moderate and severe COPD", "PROBLEM", 58, 100], ["bronchiectasis", "OBSERVATION", 58, 72], ["moderate", "OBSERVATION_MODIFIER", 76, 84], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["COPD", "OBSERVATION", 96, 100]]], ["Patients with bronchiectasis had more chronic expectoration, more exacerbation indices, more severe airflow obstruction, and greater positive cultures of potentially pathogenic microorganism.", [["bronchiectasis", "DISEASE", 14, 28], ["expectoration", "DISEASE", 46, 59], ["airflow obstruction", "DISEASE", 100, 119], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["bronchiectasis", "PROBLEM", 14, 28], ["more chronic expectoration", "PROBLEM", 33, 59], ["more exacerbation indices", "PROBLEM", 61, 86], ["more severe airflow obstruction", "PROBLEM", 88, 119], ["greater positive cultures", "PROBLEM", 125, 150], ["pathogenic microorganism", "PROBLEM", 166, 190], ["bronchiectasis", "OBSERVATION", 14, 28], ["more", "OBSERVATION_MODIFIER", 33, 37], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["expectoration", "OBSERVATION", 46, 59], ["exacerbation", "OBSERVATION_MODIFIER", 66, 78], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["airflow", "OBSERVATION_MODIFIER", 100, 107], ["obstruction", "OBSERVATION", 108, 119], ["greater", "OBSERVATION_MODIFIER", 125, 132], ["pathogenic microorganism", "OBSERVATION", 166, 190]]], ["Haemophilus influenzae and Pseudomonas aeruginosa were the most common microorganisms isolated from sputum 59 .", [["sputum", "ANATOMY", 100, 106], ["Haemophilus influenzae", "DISEASE", 0, 22], ["Haemophilus influenzae", "ORGANISM", 0, 22], ["Pseudomonas aeruginosa", "ORGANISM", 27, 49], ["Haemophilus influenzae", "SPECIES", 0, 22], ["Pseudomonas aeruginosa", "SPECIES", 27, 49], ["Haemophilus influenzae", "SPECIES", 0, 22], ["Pseudomonas aeruginosa", "SPECIES", 27, 49], ["Haemophilus influenzae", "PROBLEM", 0, 22], ["Pseudomonas aeruginosa", "PROBLEM", 27, 49], ["sputum", "TEST", 100, 106]]], ["In addition, moderate-to-severe COPD patients with bronchiectasis was associated with increased all-cause mortality (37.4%) compared to COPD patients without bronchiectasis (9.3%) 60 .Asthma and eosinophilic inflammationEosinophilic airway inflammation is a characteristic feature of atopic asthma and exists in a subgroup of COPD.", [["airway", "ANATOMY", 233, 239], ["COPD", "DISEASE", 32, 36], ["bronchiectasis", "DISEASE", 51, 65], ["COPD", "DISEASE", 136, 140], ["bronchiectasis", "DISEASE", 158, 172], ["Asthma", "DISEASE", 184, 190], ["airway inflammation", "DISEASE", 233, 252], ["atopic asthma", "DISEASE", 284, 297], ["COPD", "DISEASE", 326, 330], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 141, 149], ["airway", "MULTI-TISSUE_STRUCTURE", 233, 239], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 141, 149], ["moderate-to-severe COPD", "PROBLEM", 13, 36], ["bronchiectasis", "PROBLEM", 51, 65], ["bronchiectasis", "PROBLEM", 158, 172], ["Asthma", "PROBLEM", 184, 190], ["eosinophilic inflammation", "PROBLEM", 195, 220], ["Eosinophilic airway inflammation", "PROBLEM", 220, 252], ["atopic asthma", "PROBLEM", 284, 297], ["COPD", "PROBLEM", 326, 330], ["moderate", "OBSERVATION_MODIFIER", 13, 21], ["-to-severe", "OBSERVATION_MODIFIER", 21, 31], ["COPD", "OBSERVATION", 32, 36], ["bronchiectasis", "OBSERVATION", 51, 65], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["COPD", "OBSERVATION", 136, 140], ["without", "UNCERTAINTY", 150, 157], ["bronchiectasis", "OBSERVATION", 158, 172], ["eosinophilic", "OBSERVATION_MODIFIER", 195, 207], ["inflammation", "OBSERVATION_MODIFIER", 208, 220], ["Eosinophilic airway inflammation", "OBSERVATION", 220, 252], ["atopic", "OBSERVATION_MODIFIER", 284, 290], ["asthma", "OBSERVATION", 291, 297], ["COPD", "OBSERVATION", 326, 330]]], ["Bafadhel et al. 32 reported that 28% of cases of acute exacerbation of COPD were associated with sputum eosinophilia.", [["sputum", "ANATOMY", 97, 103], ["COPD", "DISEASE", 71, 75], ["sputum eosinophilia", "DISEASE", 97, 116], ["acute exacerbation", "PROBLEM", 49, 67], ["COPD", "PROBLEM", 71, 75], ["sputum eosinophilia", "PROBLEM", 97, 116], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["exacerbation", "OBSERVATION", 55, 67], ["COPD", "OBSERVATION", 71, 75], ["sputum eosinophilia", "OBSERVATION", 97, 116]]], ["In our previous study, 32% of na\u00efve COPD patients had sputum eosinophilia and tended to have higher serum IgE levels and positive allergen tests 17 .", [["sputum", "ANATOMY", 54, 60], ["serum", "ANATOMY", 100, 105], ["COPD", "DISEASE", 36, 40], ["sputum eosinophilia", "DISEASE", 54, 73], ["patients", "ORGANISM", 41, 49], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["IgE", "GENE_OR_GENE_PRODUCT", 106, 109], ["IgE", "PROTEIN", 106, 109], ["patients", "SPECIES", 41, 49], ["our previous study", "TEST", 3, 21], ["na\u00efve COPD", "PROBLEM", 30, 40], ["sputum eosinophilia", "PROBLEM", 54, 73], ["higher serum IgE levels", "TEST", 93, 116], ["positive allergen tests", "TEST", 121, 144], ["COPD", "OBSERVATION", 36, 40], ["sputum eosinophilia", "OBSERVATION", 54, 73]]], ["Patients with asthma-COPD overlap syndrome may present with more respiratory symptoms, worse lung function, and increased risk of exacerbation and hospitalization (prevalence ratio, 2.11 and 4.11, respectively) compared to patients with COPD alone 61 .", [["respiratory", "ANATOMY", 65, 76], ["lung", "ANATOMY", 93, 97], ["asthma-COPD overlap syndrome", "DISEASE", 14, 42], ["COPD", "DISEASE", 237, 241], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 93, 97], ["patients", "ORGANISM", 223, 231], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 223, 231], ["asthma-COPD overlap syndrome", "PROBLEM", 14, 42], ["more respiratory symptoms", "PROBLEM", 60, 85], ["worse lung function", "PROBLEM", 87, 106], ["exacerbation", "PROBLEM", 130, 142], ["prevalence ratio", "TEST", 164, 180], ["COPD alone", "PROBLEM", 237, 247], ["overlap syndrome", "OBSERVATION", 26, 42], ["lung", "ANATOMY", 93, 97], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["exacerbation", "OBSERVATION", 130, 142], ["COPD", "OBSERVATION", 237, 241]]], ["Hardin et al. 62 reported that patients with asthma and COPD overlap syndrome (ACOS) were more likely to experience frequent exacerbations (odds ratio, 3.55) and have had a severe exacerbation in the past years.", [["asthma", "DISEASE", 45, 51], ["COPD overlap syndrome", "DISEASE", 56, 77], ["ACOS", "DISEASE", 79, 83], ["exacerbations", "DISEASE", 125, 138], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["asthma", "PROBLEM", 45, 51], ["COPD overlap syndrome", "PROBLEM", 56, 77], ["frequent exacerbations", "PROBLEM", 116, 138], ["a severe exacerbation", "PROBLEM", 171, 192], ["asthma", "OBSERVATION", 45, 51], ["COPD", "OBSERVATION", 56, 60], ["more likely", "UNCERTAINTY", 90, 101], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["exacerbation", "OBSERVATION", 180, 192]]], ["In a prospective randomized study, a reduction in eosinophilic airway inflammation was associated with a reduction in severe exacerbation of COPD 63 .", [["eosinophilic airway", "ANATOMY", 50, 69], ["airway inflammation", "DISEASE", 63, 82], ["COPD", "DISEASE", 141, 145], ["airway", "MULTI-TISSUE_STRUCTURE", 63, 69], ["a prospective randomized study", "TEST", 3, 33], ["eosinophilic airway inflammation", "PROBLEM", 50, 82], ["severe exacerbation of COPD", "PROBLEM", 118, 145], ["reduction", "OBSERVATION_MODIFIER", 37, 46], ["eosinophilic airway inflammation", "OBSERVATION", 50, 82], ["reduction", "OBSERVATION_MODIFIER", 105, 114], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["exacerbation", "OBSERVATION", 125, 137], ["COPD", "OBSERVATION", 141, 145]]], ["Sputum eosinophilia and high blood eosinophil counts are associated with increased responsiveness to steroids in COPD patients 22, 23, 64, 65 .", [["Sputum", "ANATOMY", 0, 6], ["blood eosinophil", "ANATOMY", 29, 45], ["eosinophilia", "DISEASE", 7, 19], ["steroids", "CHEMICAL", 101, 109], ["COPD", "DISEASE", 113, 117], ["steroids", "CHEMICAL", 101, 109], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["eosinophil", "CELL", 35, 45], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["Sputum eosinophilia", "PROBLEM", 0, 19], ["high blood eosinophil counts", "PROBLEM", 24, 52], ["increased responsiveness", "PROBLEM", 73, 97], ["steroids", "TREATMENT", 101, 109], ["eosinophilia", "OBSERVATION", 7, 19], ["high", "OBSERVATION_MODIFIER", 24, 28], ["blood eosinophil counts", "OBSERVATION", 29, 52], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["responsiveness", "OBSERVATION_MODIFIER", 83, 97]]], ["Accordingly, the detection of eosinophilic inflammation is a crucial step to make a precise treatment in COPD patients.Obstructive sleep apneaIn an epidemiologic study for COPD, the risk of obstructive sleep apnea (OSA) assessed by questionnaire was 29.5% among COPD patients 66 .", [["eosinophilic", "ANATOMY", 30, 42], ["inflammation", "DISEASE", 43, 55], ["COPD", "DISEASE", 105, 109], ["Obstructive sleep apneaIn", "DISEASE", 119, 144], ["COPD", "DISEASE", 172, 176], ["obstructive sleep apnea", "DISEASE", 190, 213], ["OSA", "DISEASE", 215, 218], ["COPD", "DISEASE", 262, 266], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 267, 275], ["eosinophilic inflammation", "PROBLEM", 30, 55], ["a precise treatment in COPD patients", "TREATMENT", 82, 118], ["Obstructive sleep apneaIn", "PROBLEM", 119, 144], ["an epidemiologic study", "TEST", 145, 167], ["COPD", "PROBLEM", 172, 176], ["obstructive sleep apnea", "PROBLEM", 190, 213], ["OSA", "PROBLEM", 215, 218], ["eosinophilic inflammation", "OBSERVATION", 30, 55], ["COPD", "OBSERVATION", 172, 176], ["obstructive", "OBSERVATION_MODIFIER", 190, 201], ["sleep apnea", "OBSERVATION", 202, 213]]], ["The prevalence was reported to be 65.9% for moderate to severe COPD confirmed by polysomnography 67 .", [["COPD", "DISEASE", 63, 67], ["moderate to severe COPD", "PROBLEM", 44, 67], ["polysomnography", "TEST", 81, 96], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["COPD", "OBSERVATION", 63, 67]]], ["Marin et al. 68 showed that COPD patients with OSA overlap syndrome without continuous positive airway pressure (CPAP) treatment had higher mortality rates and were more likely to have a severe COPD exacerbation leading to hospitalization (relative risk, 1.70; 95% confidence interval [CI], 1.21-2.38) compared to patients with COPD alone.", [["airway", "ANATOMY", 96, 102], ["COPD", "DISEASE", 28, 32], ["OSA overlap syndrome", "DISEASE", 47, 67], ["COPD", "DISEASE", 194, 198], ["COPD", "DISEASE", 328, 332], ["patients", "ORGANISM", 33, 41], ["airway", "MULTI-TISSUE_STRUCTURE", 96, 102], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 314, 322], ["COPD", "PROBLEM", 28, 32], ["OSA overlap syndrome", "PROBLEM", 47, 67], ["continuous positive airway pressure", "TREATMENT", 76, 111], ["CPAP", "TREATMENT", 113, 117], ["treatment", "TREATMENT", 119, 128], ["higher mortality rates", "PROBLEM", 133, 155], ["a severe COPD exacerbation", "PROBLEM", 185, 211], ["CI", "TEST", 286, 288], ["COPD", "PROBLEM", 328, 332], ["COPD", "OBSERVATION", 28, 32], ["OSA", "OBSERVATION", 47, 50], ["airway pressure", "OBSERVATION", 96, 111], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["COPD", "OBSERVATION", 194, 198], ["COPD", "OBSERVATION", 328, 332]]], ["OSA exacerbated airway inflammation by increasing neutrophil proportion and levels of IL-8 and TNF-\u03b1 in bronchoalveolar lavage fluid samples from moderate to severe COPD patients.", [["airway", "ANATOMY", 16, 22], ["neutrophil", "ANATOMY", 50, 60], ["bronchoalveolar lavage fluid samples", "ANATOMY", 104, 140], ["OSA", "DISEASE", 0, 3], ["airway inflammation", "DISEASE", 16, 35], ["COPD", "DISEASE", 165, 169], ["airway", "MULTI-TISSUE_STRUCTURE", 16, 22], ["neutrophil", "CELL", 50, 60], ["IL-8", "GENE_OR_GENE_PRODUCT", 86, 90], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 95, 100], ["bronchoalveolar lavage fluid samples", "ORGANISM_SUBSTANCE", 104, 140], ["patients", "ORGANISM", 170, 178], ["IL-8", "PROTEIN", 86, 90], ["TNF", "PROTEIN", 95, 98], ["patients", "SPECIES", 170, 178], ["OSA exacerbated airway inflammation", "PROBLEM", 0, 35], ["increasing neutrophil proportion", "PROBLEM", 39, 71], ["IL", "TEST", 86, 88], ["TNF", "TEST", 95, 98], ["bronchoalveolar lavage fluid samples", "TEST", 104, 140], ["moderate to severe COPD patients", "PROBLEM", 146, 178], ["airway", "ANATOMY", 16, 22], ["inflammation", "OBSERVATION", 23, 35], ["increasing", "OBSERVATION_MODIFIER", 39, 49], ["neutrophil proportion", "OBSERVATION", 50, 71], ["bronchoalveolar lavage", "OBSERVATION", 104, 126], ["moderate", "OBSERVATION_MODIFIER", 146, 154], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["COPD", "OBSERVATION", 165, 169]]], ["The augmentation of inflammation can be curbed by treatment with CPAP 69 .", [["inflammation", "DISEASE", 20, 32], ["CPAP", "CHEMICAL", 65, 69], ["inflammation", "PROBLEM", 20, 32], ["CPAP", "TREATMENT", 65, 69], ["augmentation", "OBSERVATION_MODIFIER", 4, 16], ["inflammation", "OBSERVATION", 20, 32]]], ["The mechanisms of how OSA exacerbates airway inflammation in COPD remain to be elucidated.Obstructive sleep apneaThe significant predictors or factors that are associated with increased risk of acute exacerbation in COPD is summarized in Table 1 .Airway inflammationLong-acting bronchodilators such as long-acting muscarinic antagonist (LAMA) and long acting \u03b2 2 -adrenergic receptor agonist (LABA) are the major pharmacological drugs for COPD to improve airflow limitation, respiratory symptoms, and quality of life as well as reduce exacerbations 70, 71 .", [["airway", "ANATOMY", 38, 44], ["Airway", "ANATOMY", 247, 253], ["respiratory", "ANATOMY", 475, 486], ["OSA", "DISEASE", 22, 25], ["airway inflammation", "DISEASE", 38, 57], ["COPD", "DISEASE", 61, 65], ["Obstructive sleep apnea", "DISEASE", 90, 113], ["COPD", "DISEASE", 216, 220], ["LAMA", "CHEMICAL", 337, 341], ["LABA", "CHEMICAL", 393, 397], ["COPD", "DISEASE", 439, 443], ["respiratory symptoms", "DISEASE", 475, 495], ["airway", "MULTI-TISSUE_STRUCTURE", 38, 44], ["Airway", "MULTI-TISSUE_STRUCTURE", 247, 253], ["long-acting muscarinic antagonist", "SIMPLE_CHEMICAL", 302, 335], ["LAMA", "SIMPLE_CHEMICAL", 337, 341], ["long acting \u03b2 2 -adrenergic receptor agonist", "GENE_OR_GENE_PRODUCT", 347, 391], ["LABA", "SIMPLE_CHEMICAL", 393, 397], ["how OSA", "PROBLEM", 18, 25], ["airway inflammation", "PROBLEM", 38, 57], ["COPD", "PROBLEM", 61, 65], ["Obstructive sleep apnea", "PROBLEM", 90, 113], ["acute exacerbation", "PROBLEM", 194, 212], ["COPD", "PROBLEM", 216, 220], ["Airway inflammationLong-acting bronchodilators", "TREATMENT", 247, 293], ["long-acting muscarinic antagonist (LAMA)", "TREATMENT", 302, 342], ["long acting \u03b2 2 -adrenergic receptor agonist (LABA", "TREATMENT", 347, 397], ["the major pharmacological drugs", "TREATMENT", 403, 434], ["COPD", "PROBLEM", 439, 443], ["airflow limitation", "PROBLEM", 455, 473], ["respiratory symptoms", "PROBLEM", 475, 495], ["exacerbations", "PROBLEM", 535, 548], ["OSA", "OBSERVATION", 22, 25], ["airway", "ANATOMY", 38, 44], ["inflammation", "OBSERVATION", 45, 57], ["COPD", "OBSERVATION", 61, 65], ["sleep apnea", "OBSERVATION", 102, 113], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["exacerbation", "OBSERVATION", 200, 212], ["COPD", "OBSERVATION", 216, 220]]], ["The mechanisms of long-acting bronchodilators in reducing exacerbation either by improving hyperinflation or targeting inflammation remain controversial.", [["inflammation", "DISEASE", 119, 131], ["long-acting bronchodilators", "TREATMENT", 18, 45], ["reducing exacerbation", "PROBLEM", 49, 70], ["improving hyperinflation", "PROBLEM", 81, 105], ["targeting inflammation", "PROBLEM", 109, 131], ["long", "OBSERVATION_MODIFIER", 18, 22], ["improving", "OBSERVATION_MODIFIER", 81, 90], ["hyperinflation", "OBSERVATION", 91, 105], ["inflammation", "OBSERVATION", 119, 131]]], ["The combination of LABA and corticosteroids can reduce the numbers of macrophages 72 , neutrophils 73 , and CD8 + T lymphocytes 72, 73 in bronchial biopsy tissue and in induced sputum from patients with COPD.", [["macrophages", "ANATOMY", 70, 81], ["neutrophils", "ANATOMY", 87, 98], ["CD8 + T lymphocytes", "ANATOMY", 108, 127], ["bronchial biopsy tissue", "ANATOMY", 138, 161], ["sputum", "ANATOMY", 177, 183], ["LABA", "CHEMICAL", 19, 23], ["corticosteroids", "CHEMICAL", 28, 43], ["COPD", "DISEASE", 203, 207], ["LABA", "CHEMICAL", 19, 23], ["corticosteroids", "CHEMICAL", 28, 43], ["LABA", "SIMPLE_CHEMICAL", 19, 23], ["corticosteroids", "SIMPLE_CHEMICAL", 28, 43], ["macrophages", "CELL", 70, 81], ["neutrophils", "CELL", 87, 98], ["CD8", "GENE_OR_GENE_PRODUCT", 108, 111], ["bronchial biopsy tissue", "TISSUE", 138, 161], ["sputum", "ORGANISM_SUBSTANCE", 177, 183], ["patients", "ORGANISM", 189, 197], ["CD8", "PROTEIN", 108, 111], ["patients", "SPECIES", 189, 197], ["LABA", "TREATMENT", 19, 23], ["corticosteroids", "TREATMENT", 28, 43], ["macrophages", "TEST", 70, 81], ["neutrophils", "TEST", 87, 98], ["CD8", "TEST", 108, 111], ["T lymphocytes", "TEST", 114, 127], ["bronchial biopsy tissue", "TEST", 138, 161], ["induced sputum", "PROBLEM", 169, 183], ["COPD", "PROBLEM", 203, 207], ["LABA", "OBSERVATION", 19, 23], ["bronchial", "ANATOMY", 138, 147], ["biopsy tissue", "OBSERVATION", 148, 161], ["sputum", "OBSERVATION", 177, 183], ["COPD", "OBSERVATION", 203, 207]]], ["We had reported that the combination of inhaled salmeterol and fluticasone caused a significant reduction in IL-8 and MMP-9 in induced sputum from COPD patients compared to levels in those who received treatment with tiotropium alone 74 .", [["sputum", "ANATOMY", 135, 141], ["salmeterol", "CHEMICAL", 48, 58], ["fluticasone", "CHEMICAL", 63, 74], ["COPD", "DISEASE", 147, 151], ["tiotropium", "CHEMICAL", 217, 227], ["salmeterol", "CHEMICAL", 48, 58], ["fluticasone", "CHEMICAL", 63, 74], ["tiotropium", "CHEMICAL", 217, 227], ["salmeterol", "SIMPLE_CHEMICAL", 48, 58], ["fluticasone", "SIMPLE_CHEMICAL", 63, 74], ["IL-8", "GENE_OR_GENE_PRODUCT", 109, 113], ["MMP-9", "GENE_OR_GENE_PRODUCT", 118, 123], ["sputum", "ORGANISM_SUBSTANCE", 135, 141], ["patients", "ORGANISM", 152, 160], ["tiotropium", "SIMPLE_CHEMICAL", 217, 227], ["IL-8", "PROTEIN", 109, 113], ["MMP-9", "PROTEIN", 118, 123], ["patients", "SPECIES", 152, 160], ["inhaled salmeterol", "TREATMENT", 40, 58], ["fluticasone", "TREATMENT", 63, 74], ["a significant reduction in IL", "PROBLEM", 82, 111], ["MMP", "TEST", 118, 121], ["induced sputum", "PROBLEM", 127, 141], ["COPD patients", "PROBLEM", 147, 160], ["treatment", "TREATMENT", 202, 211], ["tiotropium", "TREATMENT", 217, 227], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["reduction", "OBSERVATION_MODIFIER", 96, 105], ["COPD", "OBSERVATION", 147, 151]]], ["Tiotropium can www.e-trd.org inhibit airway inflammation and remodeling 75 and attenuate neutrophilic inflammation as well as associated mediators LTB 4 , IL-6, monocyte chemoattractant protein-1, macrophage inflammatory protein (MIP)-1, MIP-2, and TNF-\u03b1 in the animal model 76 .", [["airway", "ANATOMY", 37, 43], ["neutrophilic", "ANATOMY", 89, 101], ["Tiotropium", "CHEMICAL", 0, 10], ["inflammation", "DISEASE", 44, 56], ["inflammation", "DISEASE", 102, 114], ["Tiotropium", "CHEMICAL", 0, 10], ["Tiotropium", "SIMPLE_CHEMICAL", 0, 10], ["org", "SIMPLE_CHEMICAL", 25, 28], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["LTB 4", "GENE_OR_GENE_PRODUCT", 147, 152], ["IL-6", "GENE_OR_GENE_PRODUCT", 155, 159], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 161, 195], ["macrophage inflammatory protein (MIP)-1", "GENE_OR_GENE_PRODUCT", 197, 236], ["MIP-2", "GENE_OR_GENE_PRODUCT", 238, 243], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 249, 254], ["LTB 4", "PROTEIN", 147, 152], ["IL-6", "PROTEIN", 155, 159], ["monocyte chemoattractant protein-1", "PROTEIN", 161, 195], ["macrophage inflammatory protein (MIP)-1", "PROTEIN", 197, 236], ["MIP", "PROTEIN", 238, 241], ["TNF", "PROTEIN", 249, 252], ["Tiotropium", "TREATMENT", 0, 10], ["trd", "PROBLEM", 21, 24], ["org inhibit airway inflammation", "PROBLEM", 25, 56], ["neutrophilic inflammation", "PROBLEM", 89, 114], ["mediators LTB", "TEST", 137, 150], ["IL", "TEST", 155, 157], ["monocyte chemoattractant protein", "TEST", 161, 193], ["macrophage inflammatory protein", "TEST", 197, 228], ["MIP", "TEST", 230, 233], ["MIP", "TEST", 238, 241], ["TNF", "TEST", 249, 252], ["airway", "ANATOMY", 37, 43], ["inflammation", "OBSERVATION", 44, 56], ["neutrophilic", "OBSERVATION_MODIFIER", 89, 101], ["inflammation", "OBSERVATION", 102, 114]]], ["In clinical studies, the odds ratio for tiotropium in reducing exacerbations compared to placebo was 0.74 (95% CI, 0.66-0.83) and hospitalizations 0.69 (95% CI, 0.55-0.87) 77 .", [["tiotropium", "CHEMICAL", 40, 50], ["exacerbations", "DISEASE", 63, 76], ["tiotropium", "CHEMICAL", 40, 50], ["tiotropium", "SIMPLE_CHEMICAL", 40, 50], ["clinical studies", "TEST", 3, 19], ["tiotropium", "TREATMENT", 40, 50], ["reducing exacerbations", "PROBLEM", 54, 76], ["placebo", "TEST", 89, 96], ["CI", "TEST", 111, 113], ["hospitalizations", "TEST", 130, 146], ["CI", "TEST", 157, 159]]], ["Indacaterol and formoterol can suppress neutrophilassociated mediators such as reactive oxygen species, LTB 4 , and elastase in a dose-dependent manner 78 .", [["Indacaterol", "CHEMICAL", 0, 11], ["formoterol", "CHEMICAL", 16, 26], ["oxygen", "CHEMICAL", 88, 94], ["Indacaterol", "CHEMICAL", 0, 11], ["formoterol", "CHEMICAL", 16, 26], ["oxygen", "CHEMICAL", 88, 94], ["Indacaterol", "SIMPLE_CHEMICAL", 0, 11], ["formoterol", "SIMPLE_CHEMICAL", 16, 26], ["reactive oxygen species", "SIMPLE_CHEMICAL", 79, 102], ["LTB 4", "GENE_OR_GENE_PRODUCT", 104, 109], ["elastase", "GENE_OR_GENE_PRODUCT", 116, 124], ["neutrophilassociated mediators", "PROTEIN", 40, 70], ["LTB 4", "PROTEIN", 104, 109], ["elastase", "PROTEIN", 116, 124], ["Indacaterol", "TREATMENT", 0, 11], ["formoterol", "TREATMENT", 16, 26], ["neutrophilassociated mediators", "PROBLEM", 40, 70], ["reactive oxygen species", "PROBLEM", 79, 102], ["LTB", "TEST", 104, 107], ["elastase", "TREATMENT", 116, 124], ["reactive", "OBSERVATION_MODIFIER", 79, 87], ["oxygen species", "OBSERVATION", 88, 102]]], ["In a prospective, randomized, blinded, and double-dummy study, it was found that tiotropium was superior to indacaterol in terms of annualized exacerbation rate (0.61 vs. 0.79) for severe COPD 79 .", [["tiotropium", "CHEMICAL", 81, 91], ["indacaterol", "CHEMICAL", 108, 119], ["COPD", "DISEASE", 188, 192], ["tiotropium", "CHEMICAL", 81, 91], ["indacaterol", "CHEMICAL", 108, 119], ["tiotropium", "SIMPLE_CHEMICAL", 81, 91], ["indacaterol", "SIMPLE_CHEMICAL", 108, 119], ["double-dummy study", "TEST", 43, 61], ["tiotropium", "TREATMENT", 81, 91], ["indacaterol", "TREATMENT", 108, 119], ["annualized exacerbation rate", "PROBLEM", 132, 160], ["severe COPD", "PROBLEM", 181, 192], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["COPD", "OBSERVATION", 188, 192]]], ["A combination of indacaterol and glycopyrronium significantly reduced the annual rate of moderate to severe exacerbations versus glycopyrronium alone by 12%, suggesting that the combination of indacaterol/glycopyrronium was superior in preventing moderate to severe exacerbations compared to glycopyrronium alone 80 .", [["indacaterol", "CHEMICAL", 17, 28], ["glycopyrronium", "CHEMICAL", 33, 47], ["exacerbations", "DISEASE", 108, 121], ["glycopyrronium", "CHEMICAL", 129, 143], ["indacaterol", "CHEMICAL", 193, 204], ["glycopyrronium", "CHEMICAL", 205, 219], ["exacerbations", "DISEASE", 266, 279], ["glycopyrronium", "CHEMICAL", 292, 306], ["indacaterol", "CHEMICAL", 17, 28], ["glycopyrronium", "CHEMICAL", 33, 47], ["glycopyrronium", "CHEMICAL", 129, 143], ["indacaterol", "CHEMICAL", 193, 204], ["glycopyrronium", "CHEMICAL", 205, 219], ["glycopyrronium", "CHEMICAL", 292, 306], ["indacaterol", "SIMPLE_CHEMICAL", 17, 28], ["glycopyrronium", "SIMPLE_CHEMICAL", 33, 47], ["glycopyrronium", "SIMPLE_CHEMICAL", 129, 143], ["indacaterol", "SIMPLE_CHEMICAL", 193, 204], ["glycopyrronium", "SIMPLE_CHEMICAL", 205, 219], ["glycopyrronium", "SIMPLE_CHEMICAL", 292, 306], ["indacaterol", "TREATMENT", 17, 28], ["glycopyrronium", "TREATMENT", 33, 47], ["moderate to severe exacerbations", "PROBLEM", 89, 121], ["glycopyrronium", "TREATMENT", 129, 143], ["indacaterol/glycopyrronium", "TREATMENT", 193, 219], ["moderate to severe exacerbations", "PROBLEM", 247, 279], ["glycopyrronium", "TREATMENT", 292, 306], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["exacerbations", "OBSERVATION", 108, 121], ["moderate", "OBSERVATION_MODIFIER", 247, 255], ["severe", "OBSERVATION_MODIFIER", 259, 265], ["exacerbations", "OBSERVATION", 266, 279]]], ["Roflumilast, a]' phosphodiesterase-4 (PDE 4 ) inhibitor, has been reported to significantly reduce moderate to severe exacerbations by 17% compared to placebo for severe COPD patients with chronic bronchitis and frequent exacerbation phenotype 81 .", [["Roflumilast", "CHEMICAL", 0, 11], ["phosphodiesterase-4 (PDE 4 ) inhibitor", "CHEMICAL", 17, 55], ["exacerbations", "DISEASE", 118, 131], ["COPD", "DISEASE", 170, 174], ["chronic bronchitis", "DISEASE", 189, 207], ["Roflumilast", "CHEMICAL", 0, 11], ["Roflumilast", "SIMPLE_CHEMICAL", 0, 11], ["phosphodiesterase-4", "GENE_OR_GENE_PRODUCT", 17, 36], ["PDE 4", "GENE_OR_GENE_PRODUCT", 38, 43], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["Roflumilast", "TREATMENT", 0, 11], ["a]' phosphodiesterase-4 (PDE 4 ) inhibitor", "TREATMENT", 13, 55], ["moderate to severe exacerbations", "PROBLEM", 99, 131], ["placebo", "TREATMENT", 151, 158], ["severe COPD", "PROBLEM", 163, 174], ["chronic bronchitis", "PROBLEM", 189, 207], ["frequent exacerbation phenotype", "PROBLEM", 212, 243], ["moderate", "OBSERVATION_MODIFIER", 99, 107], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["exacerbations", "OBSERVATION", 118, 131], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["COPD", "OBSERVATION", 170, 174], ["chronic", "OBSERVATION_MODIFIER", 189, 196], ["bronchitis", "OBSERVATION", 197, 207]]], ["PDE 4 inhibitors were associated with a reduced likelihood of COPD exacerbation with odds ratio 0.77 (95% CI, 0.71-0.83) in a pooled analysis 82 .", [["COPD", "DISEASE", 62, 66], ["PDE 4", "GENE_OR_GENE_PRODUCT", 0, 5], ["PDE 4 inhibitors", "TREATMENT", 0, 16], ["COPD exacerbation", "PROBLEM", 62, 79], ["odds ratio", "TEST", 85, 95], ["CI", "TEST", 106, 108], ["a pooled analysis", "TEST", 124, 141], ["reduced", "OBSERVATION_MODIFIER", 40, 47], ["COPD", "OBSERVATION", 62, 66]]], ["Choosing the optimal LABA, LAMA, dual bronchodilator, PDE 4 inhibitor, inhaled corticosteroids, or specific combination of different drugs for COPD patients with various severity and phenotype is challenging in our clinical practice.Bacterial and viral infectionsPneumococcal and influenza vaccinations have been recommended for patients with COPD as a preventive strategy 1 .", [["LABA", "CHEMICAL", 21, 25], ["LAMA", "CHEMICAL", 27, 31], ["COPD", "DISEASE", 143, 147], ["Bacterial and viral infections", "DISEASE", 233, 263], ["COPD", "DISEASE", 343, 347], ["LABA", "SIMPLE_CHEMICAL", 21, 25], ["LAMA", "SIMPLE_CHEMICAL", 27, 31], ["PDE 4", "GENE_OR_GENE_PRODUCT", 54, 59], ["patients", "ORGANISM", 148, 156], ["patients", "ORGANISM", 329, 337], ["patients", "SPECIES", 148, 156], ["patients", "SPECIES", 329, 337], ["the optimal LABA", "TREATMENT", 9, 25], ["LAMA", "TREATMENT", 27, 31], ["dual bronchodilator", "TREATMENT", 33, 52], ["PDE 4 inhibitor", "TREATMENT", 54, 69], ["inhaled corticosteroids", "TREATMENT", 71, 94], ["different drugs", "TREATMENT", 123, 138], ["COPD", "PROBLEM", 143, 147], ["various severity", "PROBLEM", 162, 178], ["Bacterial and viral infections", "PROBLEM", 233, 263], ["Pneumococcal and influenza vaccinations", "TREATMENT", 263, 302], ["COPD", "PROBLEM", 343, 347], ["a preventive strategy", "TREATMENT", 351, 372], ["LAMA", "ANATOMY", 27, 31], ["viral", "OBSERVATION_MODIFIER", 247, 252], ["infections", "OBSERVATION", 253, 263]]], ["A recent meta-analysis showed that pneumococcal vaccination can provide significant protection against community-acquired pneumonia (CAP) and reduce the likelihood of a COPD exacerbation 83 .", [["pneumonia", "DISEASE", 122, 131], ["CAP", "DISEASE", 133, 136], ["COPD", "DISEASE", 169, 173], ["pneumococcal", "ORGANISM", 35, 47], ["pneumococcal", "SPECIES", 35, 47], ["A recent meta-analysis", "TEST", 0, 22], ["pneumococcal vaccination", "TREATMENT", 35, 59], ["community-acquired pneumonia", "PROBLEM", 103, 131], ["a COPD exacerbation", "PROBLEM", 167, 186], ["pneumococcal", "OBSERVATION", 35, 47], ["pneumonia", "OBSERVATION", 122, 131], ["COPD", "OBSERVATION", 169, 173]]], ["By contrast, Sehatzadeh 84 reported that the time to the first episode of CAP due to pneumococcus or of unknown etiology was not significantly different between the vaccine and control groups.", [["CAP", "DISEASE", 74, 77], ["pneumococcus", "DISEASE", 85, 97], ["CAP", "PROBLEM", 74, 77], ["pneumococcus", "PROBLEM", 85, 97], ["the vaccine", "TREATMENT", 161, 172], ["pneumococcus", "OBSERVATION", 85, 97]]], ["For influenza vaccination, it was found that the vaccine group had fewer episodes of influenza-related acute respiratory illnesses in all severities (mild, moderate, and severe) of COPD, fewer hospitalizations, and fewer requirements for mechanical ventilation 84 .1) Air pollutionIt is necessary to promote and conduct research on ambient air pollution as a COPD risk factor.", [["respiratory", "ANATOMY", 109, 120], ["influenza", "DISEASE", 4, 13], ["influenza", "DISEASE", 85, 94], ["respiratory illnesses", "DISEASE", 109, 130], ["COPD", "DISEASE", 181, 185], ["COPD", "DISEASE", 359, 363], ["influenza vaccination", "TREATMENT", 4, 25], ["influenza", "PROBLEM", 85, 94], ["acute respiratory illnesses in all severities (mild, moderate, and severe) of COPD", "PROBLEM", 103, 185], ["mechanical ventilation", "TREATMENT", 238, 260], ["Air pollution", "PROBLEM", 268, 281], ["ambient air pollution", "TREATMENT", 332, 353], ["a COPD risk factor", "PROBLEM", 357, 375], ["influenza", "OBSERVATION", 85, 94], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory illnesses", "OBSERVATION", 109, 130], ["mild", "OBSERVATION_MODIFIER", 150, 154], ["moderate", "OBSERVATION_MODIFIER", 156, 164], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["COPD", "OBSERVATION", 181, 185], ["Air pollution", "OBSERVATION", 268, 281]]], ["It is necessary to form a partnership with government institutions such as the Environmental Protection Agency (EPA) and academic institutions to investigate the detrimental effect of environmental exposure and occupational hazards as well as to apply prevention strategy and patient education.", [["patient", "ORGANISM", 276, 283], ["patient", "SPECIES", 276, 283], ["academic institutions", "TREATMENT", 121, 142], ["occupational hazards", "TREATMENT", 211, 231], ["prevention strategy", "TREATMENT", 252, 271]]], ["The U.S. EPA has recommended that time and intensity of outdoor activity should be regulated by air quality index since 2009.", [["EPA", "CHEMICAL", 9, 12]]], ["The N95 respirator was reported to be able to provide excellent protection against airborne particles 85 .Gastroesophageal refluxateAspiration of gastroesophageal refluxate can trigger exacerbation of COPD and enhance airway inflammation and fibrosis as we discussed earlier.", [["Gastroesophageal", "ANATOMY", 106, 122], ["gastroesophageal", "ANATOMY", 146, 162], ["airway", "ANATOMY", 218, 224], ["refluxate", "CHEMICAL", 163, 172], ["COPD", "DISEASE", 201, 205], ["airway inflammation", "DISEASE", 218, 237], ["fibrosis", "DISEASE", 242, 250], ["Gastroesophageal", "ORGAN", 106, 122], ["gastroesophageal", "ORGAN", 146, 162], ["airway", "MULTI-TISSUE_STRUCTURE", 218, 224], ["The N95 respirator", "TREATMENT", 0, 18], ["Gastroesophageal refluxateAspiration", "TREATMENT", 106, 142], ["gastroesophageal refluxate", "TREATMENT", 146, 172], ["exacerbation", "PROBLEM", 185, 197], ["COPD", "PROBLEM", 201, 205], ["enhance airway inflammation", "PROBLEM", 210, 237], ["fibrosis", "PROBLEM", 242, 250], ["gastroesophageal refluxate", "OBSERVATION", 146, 172], ["COPD", "OBSERVATION", 201, 205], ["airway", "ANATOMY", 218, 224], ["inflammation", "OBSERVATION", 225, 237], ["fibrosis", "OBSERVATION", 242, 250]]], ["Among COPD patients with GERD, those who did not use acid inhibitory treatment regularly had a significantly increased risk of COPD exacerbation with a hazard ratio (HR) of 2.7 as compared to those who were treated regularly with an HR of 1.2 86 .", [["COPD", "DISEASE", 6, 10], ["GERD", "DISEASE", 25, 29], ["COPD", "DISEASE", 127, 131], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["GERD", "PROBLEM", 25, 29], ["acid inhibitory treatment", "TREATMENT", 53, 78], ["COPD exacerbation", "PROBLEM", 127, 144], ["a hazard ratio", "TEST", 150, 164], ["HR", "TEST", 166, 168], ["an HR", "TEST", 230, 235], ["COPD", "OBSERVATION", 6, 10], ["GERD", "OBSERVATION", 25, 29], ["COPD", "OBSERVATION", 127, 131]]], ["In moderate to severe asthma patients with GERD and nocturnal respiratory symptoms, taking proton pump inhibitors significantly improved morning and evening peak expiratory flow over those taking palcebo 87 .", [["respiratory", "ANATOMY", 62, 73], ["asthma", "DISEASE", 22, 28], ["GERD", "DISEASE", 43, 47], ["nocturnal respiratory symptoms", "DISEASE", 52, 82], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["moderate to severe asthma", "PROBLEM", 3, 28], ["GERD", "PROBLEM", 43, 47], ["nocturnal respiratory symptoms", "PROBLEM", 52, 82], ["proton pump inhibitors", "TREATMENT", 91, 113], ["peak expiratory flow", "TEST", 157, 177], ["moderate", "OBSERVATION_MODIFIER", 3, 11], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["asthma", "OBSERVATION", 22, 28], ["GERD", "OBSERVATION", 43, 47], ["respiratory symptoms", "OBSERVATION", 62, 82]]], ["The ability to identify COPD patients who are at risk for GERD or GER-related chronic cough is essential to COPD management.", [["COPD", "DISEASE", 24, 28], ["GERD", "DISEASE", 58, 62], ["GER", "DISEASE", 66, 69], ["cough", "DISEASE", 86, 91], ["COPD", "DISEASE", 108, 112], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["COPD", "PROBLEM", 24, 28], ["GERD", "PROBLEM", 58, 62], ["GER", "PROBLEM", 66, 69], ["chronic cough", "PROBLEM", 78, 91], ["COPD management", "TREATMENT", 108, 123], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["cough", "OBSERVATION", 86, 91]]], ["It is worth conducting randomized trials to investigate the efficacy of anti-acid and anti-reflux therapy on COPD patients with GERD and whether these treatments can decrease respiratory symptoms, improve lung function, and quality of life as well as reduce exacerbation.Bronchiectasis and bacterial colonizationIn a prospective study, the incidence of bacterial colonization in bronchiectasis was as high as 64%.", [["respiratory", "ANATOMY", 175, 186], ["lung", "ANATOMY", 205, 209], ["anti-acid", "CHEMICAL", 72, 81], ["COPD", "DISEASE", 109, 113], ["GERD", "DISEASE", 128, 132], ["respiratory symptoms", "DISEASE", 175, 195], ["Bronchiectasis", "DISEASE", 271, 285], ["bronchiectasis", "DISEASE", 379, 393], ["anti-acid", "SIMPLE_CHEMICAL", 72, 81], ["patients", "ORGANISM", 114, 122], ["lung", "ORGAN", 205, 209], ["patients", "SPECIES", 114, 122], ["anti-acid", "TREATMENT", 72, 81], ["anti-reflux therapy", "TREATMENT", 86, 105], ["COPD patients", "TREATMENT", 109, 122], ["GERD", "PROBLEM", 128, 132], ["these treatments", "TREATMENT", 145, 161], ["respiratory symptoms", "PROBLEM", 175, 195], ["exacerbation", "PROBLEM", 258, 270], ["Bronchiectasis", "PROBLEM", 271, 285], ["bacterial colonization", "PROBLEM", 290, 312], ["a prospective study", "TEST", 315, 334], ["bacterial colonization", "PROBLEM", 353, 375], ["bronchiectasis", "PROBLEM", 379, 393], ["lung", "ANATOMY", 205, 209], ["bacterial colonization", "OBSERVATION", 290, 312], ["bacterial", "OBSERVATION_MODIFIER", 353, 362], ["colonization", "OBSERVATION", 363, 375], ["bronchiectasis", "OBSERVATION", 379, 393], ["high", "OBSERVATION_MODIFIER", 401, 405]]], ["The risk factors included diagnosis of bronchiectasis before the age of 14 years (odds ratio [OR], 3.92), FEV 1 <80% predicted (OR, 3.91) and presence of varicose or cystic bronchiectasis (OR, 4.8) 88 .", [["varicose", "ANATOMY", 154, 162], ["cystic", "ANATOMY", 166, 172], ["bronchiectasis", "DISEASE", 39, 53], ["bronchiectasis", "DISEASE", 173, 187], ["varicose", "MULTI-TISSUE_STRUCTURE", 154, 162], ["bronchiectasis", "PROBLEM", 39, 53], ["FEV", "TEST", 106, 109], ["varicose or cystic bronchiectasis", "PROBLEM", 154, 187], ["bronchiectasis", "OBSERVATION", 39, 53], ["varicose", "OBSERVATION", 154, 162], ["cystic", "OBSERVATION_MODIFIER", 166, 172], ["bronchiectasis", "OBSERVATION", 173, 187]]], ["Bacterial infection can cause airway inflammation, which can subsequently result in exacerbation.", [["airway", "ANATOMY", 30, 36], ["infection", "DISEASE", 10, 19], ["airway inflammation", "DISEASE", 30, 49], ["airway", "MULTI-TISSUE_STRUCTURE", 30, 36], ["Bacterial infection", "PROBLEM", 0, 19], ["airway inflammation", "PROBLEM", 30, 49], ["exacerbation", "PROBLEM", 84, 96], ["infection", "OBSERVATION", 10, 19], ["airway", "ANATOMY", 30, 36], ["inflammation", "OBSERVATION", 37, 49], ["exacerbation", "OBSERVATION", 84, 96]]], ["COPD patients with bronchiectasis have more respiratory symptoms, more exac-erbations, and worse prognosis.", [["respiratory", "ANATOMY", 44, 55], ["COPD", "DISEASE", 0, 4], ["bronchiectasis", "DISEASE", 19, 33], ["respiratory symptoms", "DISEASE", 44, 64], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["COPD", "PROBLEM", 0, 4], ["bronchiectasis", "PROBLEM", 19, 33], ["more respiratory symptoms", "PROBLEM", 39, 64], ["bronchiectasis", "OBSERVATION", 19, 33]]], ["Azithromycin 250 mg taken daily for 1 year, decreased the frequency of exacerbations (HR, 0.73; p<0.001) and improved the quality of life among COPD patients 89 .", [["Azithromycin", "CHEMICAL", 0, 12], ["exacerbations", "DISEASE", 71, 84], ["COPD", "DISEASE", 144, 148], ["Azithromycin", "CHEMICAL", 0, 12], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Azithromycin", "TREATMENT", 0, 12], ["exacerbations", "PROBLEM", 71, 84], ["HR", "TEST", 86, 88], ["COPD patients", "PROBLEM", 144, 157]]], ["The clinical efficacy on hospitalization, urgent care visit, and intubation was similar between both groups and the adverse reaction (hearing impairment) was more common in the azithromycin group.", [["hearing impairment", "DISEASE", 134, 152], ["azithromycin", "CHEMICAL", 177, 189], ["azithromycin", "CHEMICAL", 177, 189], ["azithromycin", "SIMPLE_CHEMICAL", 177, 189], ["intubation", "TREATMENT", 65, 75], ["the adverse reaction", "PROBLEM", 112, 132], ["hearing impairment", "PROBLEM", 134, 152], ["the azithromycin group", "TREATMENT", 173, 195]]], ["Uzun et al. 90 reported that azithromycin 500 mg taken 3 times a week for 12 months resulted in a significant reduction in the exacerbation rate versus placebo (HR, 0.58; p=0.001) among COPD patients who had 3 or more exacerbations in the previous year.", [["azithromycin", "CHEMICAL", 29, 41], ["COPD", "DISEASE", 186, 190], ["azithromycin", "CHEMICAL", 29, 41], ["azithromycin", "SIMPLE_CHEMICAL", 29, 41], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["azithromycin", "TREATMENT", 29, 41], ["a significant reduction", "PROBLEM", 96, 119], ["the exacerbation rate", "PROBLEM", 123, 144], ["placebo", "TREATMENT", 152, 159], ["HR", "TEST", 161, 163], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["reduction", "OBSERVATION_MODIFIER", 110, 119]]], ["A small study demonstrated that inhaled tobramycin reduced the inflammatory impact of Pseudomonas aeruginosa in a multiresistant Pseudomonas-colonized patient with severe COPD after 2-week treatment.", [["tobramycin", "CHEMICAL", 40, 50], ["Pseudomonas aeruginosa", "DISEASE", 86, 108], ["COPD", "DISEASE", 171, 175], ["tobramycin", "CHEMICAL", 40, 50], ["tobramycin", "SIMPLE_CHEMICAL", 40, 50], ["Pseudomonas aeruginosa", "ORGANISM", 86, 108], ["patient", "ORGANISM", 151, 158], ["Pseudomonas aeruginosa", "SPECIES", 86, 108], ["patient", "SPECIES", 151, 158], ["Pseudomonas aeruginosa", "SPECIES", 86, 108], ["A small study", "TEST", 0, 13], ["inhaled tobramycin", "TREATMENT", 32, 50], ["Pseudomonas aeruginosa", "PROBLEM", 86, 108], ["a multiresistant Pseudomonas", "PROBLEM", 112, 140], ["severe COPD", "PROBLEM", 164, 175], ["2-week treatment", "TREATMENT", 182, 198], ["small", "OBSERVATION_MODIFIER", 2, 7], ["inflammatory", "OBSERVATION_MODIFIER", 63, 75], ["Pseudomonas aeruginosa", "OBSERVATION", 86, 108], ["multiresistant Pseudomonas", "OBSERVATION", 114, 140], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["COPD", "OBSERVATION", 171, 175]]], ["A 42% reduction in exacerbation rate was observed in the 6-month follow-up 91 .", [["A 42% reduction", "TREATMENT", 0, 15], ["exacerbation rate", "PROBLEM", 19, 36], ["reduction", "OBSERVATION_MODIFIER", 6, 15], ["exacerbation", "OBSERVATION", 19, 31]]], ["The ability to select patients, choose appropriate antibiotics, decide the duration of treatment are the major concerns for treatment strategy for frequent exacerbations of COPD with bacterial colonization.Asthma and eosinophilic inflammationWhether eosinophilic inflammation in COPD is attributable to ACOS or is a specific phenotype of COPD is still controversial.", [["eosinophilic", "ANATOMY", 217, 229], ["eosinophilic", "ANATOMY", 250, 262], ["COPD", "DISEASE", 173, 177], ["Asthma", "DISEASE", 206, 212], ["eosinophilic inflammation", "DISEASE", 217, 242], ["inflammation", "DISEASE", 263, 275], ["COPD", "DISEASE", 279, 283], ["ACOS", "DISEASE", 303, 307], ["COPD", "DISEASE", 338, 342], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["appropriate antibiotics", "TREATMENT", 39, 62], ["treatment", "TREATMENT", 87, 96], ["treatment strategy", "TREATMENT", 124, 142], ["frequent exacerbations", "PROBLEM", 147, 169], ["COPD", "PROBLEM", 173, 177], ["bacterial colonization", "PROBLEM", 183, 205], ["Asthma", "PROBLEM", 206, 212], ["eosinophilic inflammation", "PROBLEM", 217, 242], ["eosinophilic inflammation", "PROBLEM", 250, 275], ["COPD", "PROBLEM", 279, 283], ["ACOS", "PROBLEM", 303, 307], ["a specific phenotype of COPD", "PROBLEM", 314, 342], ["COPD", "OBSERVATION", 173, 177], ["bacterial colonization", "OBSERVATION", 183, 205], ["eosinophilic inflammation", "OBSERVATION", 217, 242], ["eosinophilic", "OBSERVATION_MODIFIER", 250, 262], ["inflammation", "OBSERVATION", 263, 275], ["COPD", "OBSERVATION", 279, 283], ["ACOS", "OBSERVATION", 303, 307], ["COPD", "OBSERVATION", 338, 342]]], ["However, the response of eosinophilic inflammation to treatment would be more important than the delineation of the differences between these two terms.", [["eosinophilic", "ANATOMY", 25, 37], ["inflammation", "DISEASE", 38, 50], ["eosinophilic inflammation", "PROBLEM", 25, 50], ["treatment", "TREATMENT", 54, 63], ["eosinophilic", "OBSERVATION_MODIFIER", 25, 37], ["inflammation", "OBSERVATION", 38, 50]]], ["Early detection of characteristic features of asthma or eosinophilic airway inflammation in COPD patients is necessary before starting treatment.", [["airway", "ANATOMY", 69, 75], ["asthma", "DISEASE", 46, 52], ["airway inflammation", "DISEASE", 69, 88], ["COPD", "DISEASE", 92, 96], ["airway", "MULTI-TISSUE_STRUCTURE", 69, 75], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["asthma", "PROBLEM", 46, 52], ["eosinophilic airway inflammation", "PROBLEM", 56, 88], ["COPD patients", "PROBLEM", 92, 105], ["treatment", "TREATMENT", 135, 144], ["asthma", "OBSERVATION", 46, 52], ["eosinophilic", "OBSERVATION_MODIFIER", 56, 68], ["airway", "ANATOMY", 69, 75], ["inflammation", "OBSERVATION", 76, 88], ["COPD", "OBSERVATION", 92, 96]]], ["Zanini et al. 92 reported that COPD patients with bronchial hyper-responsiveness (BHR) had higher sputum eosinophils than those without BHR.", [["sputum eosinophils", "ANATOMY", 98, 116], ["COPD", "DISEASE", 31, 35], ["patients", "ORGANISM", 36, 44], ["sputum eosinophils", "CELL_TYPE", 98, 116], ["patients", "SPECIES", 36, 44], ["COPD", "PROBLEM", 31, 35], ["bronchial hyper-responsiveness", "PROBLEM", 50, 80], ["BHR", "PROBLEM", 82, 85], ["higher sputum eosinophils", "PROBLEM", 91, 116], ["BHR", "PROBLEM", 136, 139], ["COPD", "OBSERVATION", 31, 35], ["bronchial", "ANATOMY", 50, 59]]], ["The change in FEV 1 was positively correlated with sputum eosinophils while patients had bronchial reversibility 19, 92 .", [["sputum eosinophils", "ANATOMY", 51, 69], ["bronchial", "ANATOMY", 89, 98], ["FEV 1", "GENE_OR_GENE_PRODUCT", 14, 19], ["patients", "ORGANISM", 76, 84], ["FEV 1", "PROTEIN", 14, 19], ["sputum eosinophils", "CELL_TYPE", 51, 69], ["patients", "SPECIES", 76, 84], ["The change in FEV 1", "TEST", 0, 19], ["sputum eosinophils", "TEST", 51, 69], ["bronchial reversibility", "TEST", 89, 112], ["bronchial", "ANATOMY", 89, 98]]], ["The prevalence of elevated serum IgE had been reported to be 47.3% in COPD patients 93 .", [["serum", "ANATOMY", 27, 32], ["COPD", "DISEASE", 70, 74], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["IgE", "GENE_OR_GENE_PRODUCT", 33, 36], ["patients", "ORGANISM", 75, 83], ["IgE", "PROTEIN", 33, 36], ["patients", "SPECIES", 75, 83], ["elevated serum IgE", "PROBLEM", 18, 36], ["elevated", "OBSERVATION_MODIFIER", 18, 26]]], ["Serum IgE levels were associated with COPD severity 94 and sputum eosinophilia 17 .", [["Serum", "ANATOMY", 0, 5], ["COPD", "DISEASE", 38, 42], ["eosinophilia", "DISEASE", 66, 78], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IgE", "GENE_OR_GENE_PRODUCT", 6, 9], ["IgE", "PROTEIN", 6, 9], ["Serum IgE levels", "TEST", 0, 16], ["COPD severity", "PROBLEM", 38, 51], ["sputum eosinophilia", "TEST", 59, 78]]], ["The levels of eosinophils in sputum samples were significantly correlated with exhaled nitric oxide level (eNO) 17 .", [["eosinophils", "ANATOMY", 14, 25], ["sputum samples", "ANATOMY", 29, 43], ["nitric oxide", "CHEMICAL", 87, 99], ["nitric oxide", "CHEMICAL", 87, 99], ["eNO) 17", "CHEMICAL", 107, 114], ["eosinophils", "CELL", 14, 25], ["sputum samples", "ORGANISM_SUBSTANCE", 29, 43], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 79, 99], ["eosinophils", "CELL_TYPE", 14, 25], ["The levels of eosinophils in sputum samples", "TEST", 0, 43], ["exhaled nitric oxide level", "TREATMENT", 79, 105], ["eosinophils", "OBSERVATION", 14, 25]]], ["The eNO, blood eosinophils, and antigenspecific IgE were significantly higher in ACOS than in COPD alone according to a cross-sectional study in Japan 95 .", [["blood eosinophils", "ANATOMY", 9, 26], ["COPD", "DISEASE", 94, 98], ["eNO", "GENE_OR_GENE_PRODUCT", 4, 7], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["eosinophils", "CELL", 15, 26], ["IgE", "GENE_OR_GENE_PRODUCT", 48, 51], ["eNO", "PROTEIN", 4, 7], ["blood eosinophils", "CELL_TYPE", 9, 26], ["antigenspecific IgE", "PROTEIN", 32, 51], ["The eNO, blood eosinophils", "TEST", 0, 26], ["antigenspecific IgE", "TEST", 32, 51], ["COPD", "PROBLEM", 94, 98], ["blood eosinophils", "OBSERVATION", 9, 26], ["higher", "OBSERVATION_MODIFIER", 71, 77], ["COPD", "OBSERVATION", 94, 98]]], ["Blood eosinophils were proposed to be a surrogate marker for airway eosinophilia in stable COPD 96 and a marker of response to inhaled corticosteroids 97 .", [["Blood eosinophils", "ANATOMY", 0, 17], ["airway", "ANATOMY", 61, 67], ["airway eosinophilia", "DISEASE", 61, 80], ["COPD", "DISEASE", 91, 95], ["corticosteroids", "CHEMICAL", 135, 150], ["corticosteroids", "CHEMICAL", 135, 150], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["eosinophils", "CELL", 6, 17], ["Blood eosinophils", "CELL_TYPE", 0, 17], ["Blood eosinophils", "TEST", 0, 17], ["a surrogate marker", "TEST", 38, 56], ["airway eosinophilia", "PROBLEM", 61, 80], ["stable COPD", "PROBLEM", 84, 95], ["inhaled corticosteroids", "TREATMENT", 127, 150], ["eosinophils", "OBSERVATION", 6, 17], ["airway", "ANATOMY", 61, 67], ["eosinophilia", "OBSERVATION", 68, 80], ["stable", "OBSERVATION_MODIFIER", 84, 90], ["COPD", "OBSERVATION", 91, 95]]], ["COPD patients with blood eosinophils \u22652% treated with inhaled corticosteroid/LABA had significantly fewer exacerbations than those treated with LAMA (relative risk [RR], 0.75; p=0.006, INSPIRE study) or placebo (RR, 0.63; p<0.001) 98 .", [["blood eosinophils", "ANATOMY", 19, 36], ["COPD", "DISEASE", 0, 4], ["LABA", "CHEMICAL", 77, 81], ["patients", "ORGANISM", 5, 13], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["eosinophils", "CELL", 25, 36], ["blood eosinophils", "CELL_TYPE", 19, 36], ["patients", "SPECIES", 5, 13], ["COPD", "PROBLEM", 0, 4], ["blood eosinophils", "PROBLEM", 19, 36], ["inhaled corticosteroid", "TREATMENT", 54, 76], ["LABA", "TREATMENT", 77, 81], ["significantly fewer exacerbations", "PROBLEM", 86, 119], ["RR", "TEST", 165, 167], ["INSPIRE study", "TEST", 185, 198], ["placebo", "TREATMENT", 203, 210], ["RR", "TEST", 212, 214], ["blood eosinophils", "OBSERVATION", 19, 36], ["fewer", "OBSERVATION_MODIFIER", 100, 105], ["exacerbations", "OBSERVATION", 106, 119]]], ["It is warranted to conduct a prospective study to determine which marker is better in predicting corticosteroid response in COPD with eosinophilic airway inflammation. www.e-trd.orgObstructive sleep apneaCPAP is considered to be the standard treatment for OSA patients.", [["airway", "ANATOMY", 147, 153], ["COPD", "DISEASE", 124, 128], ["airway inflammation", "DISEASE", 147, 166], ["OSA", "DISEASE", 256, 259], ["corticosteroid", "SIMPLE_CHEMICAL", 97, 111], ["airway", "MULTI-TISSUE_STRUCTURE", 147, 153], ["patients", "ORGANISM", 260, 268], ["patients", "SPECIES", 260, 268], ["a prospective study", "TEST", 27, 46], ["COPD", "PROBLEM", 124, 128], ["eosinophilic airway inflammation", "PROBLEM", 134, 166], ["OSA", "PROBLEM", 256, 259], ["COPD", "OBSERVATION", 124, 128], ["eosinophilic airway inflammation", "OBSERVATION", 134, 166]]], ["The benefit of CPAP treatment on reducing airway inflammation in COPD is barely discussed.", [["airway", "ANATOMY", 42, 48], ["airway inflammation", "DISEASE", 42, 61], ["COPD", "DISEASE", 65, 69], ["CPAP", "CHEMICAL", 15, 19], ["CPAP", "SIMPLE_CHEMICAL", 15, 19], ["airway", "MULTI-TISSUE_STRUCTURE", 42, 48], ["CPAP treatment", "TREATMENT", 15, 29], ["reducing airway inflammation", "PROBLEM", 33, 61], ["COPD", "PROBLEM", 65, 69], ["airway", "ANATOMY", 42, 48], ["inflammation", "OBSERVATION", 49, 61], ["COPD", "OBSERVATION", 65, 69]]], ["CPAP may reduce oxidative stress by decreasing plasma malondialdehyde in OSA 99 and significantly reduce urinary norepinephrine levels and blood pressure in patients with severe OSA 100 .", [["plasma", "ANATOMY", 47, 53], ["urinary", "ANATOMY", 105, 112], ["blood", "ANATOMY", 139, 144], ["malondialdehyde", "CHEMICAL", 54, 69], ["OSA", "DISEASE", 73, 76], ["norepinephrine", "CHEMICAL", 113, 127], ["OSA", "DISEASE", 178, 181], ["CPAP", "CHEMICAL", 0, 4], ["malondialdehyde", "CHEMICAL", 54, 69], ["norepinephrine", "CHEMICAL", 113, 127], ["CPAP", "SIMPLE_CHEMICAL", 0, 4], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["malondialdehyde", "SIMPLE_CHEMICAL", 54, 69], ["urinary", "ORGANISM_SUBSTANCE", 105, 112], ["norepinephrine", "SIMPLE_CHEMICAL", 113, 127], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["CPAP", "TREATMENT", 0, 4], ["oxidative stress", "PROBLEM", 16, 32], ["decreasing plasma malondialdehyde in OSA", "PROBLEM", 36, 76], ["urinary norepinephrine levels", "TEST", 105, 134], ["blood pressure", "TEST", 139, 153], ["severe OSA", "PROBLEM", 171, 181], ["urinary norepinephrine", "ANATOMY", 105, 127], ["pressure", "OBSERVATION_MODIFIER", 145, 153], ["severe", "OBSERVATION_MODIFIER", 171, 177], ["OSA", "OBSERVATION", 178, 181]]], ["Briefly, OSA may exacerbate airway inflammation in COPD and CPAP is the optimal choice to reverse the inflammatory process so far.ConclusionThough airway inflammation in COPD varies based on severity, there is still a gap between inflammation and exacerbation.", [["airway", "ANATOMY", 28, 34], ["airway", "ANATOMY", 147, 153], ["OSA", "DISEASE", 9, 12], ["airway inflammation", "DISEASE", 28, 47], ["COPD", "DISEASE", 51, 55], ["airway inflammation", "DISEASE", 147, 166], ["COPD", "DISEASE", 170, 174], ["inflammation", "DISEASE", 230, 242], ["airway", "MULTI-TISSUE_STRUCTURE", 28, 34], ["airway", "MULTI-TISSUE_STRUCTURE", 147, 153], ["OSA", "PROBLEM", 9, 12], ["airway inflammation", "PROBLEM", 28, 47], ["COPD", "PROBLEM", 51, 55], ["CPAP", "TREATMENT", 60, 64], ["the inflammatory process", "PROBLEM", 98, 122], ["airway inflammation", "PROBLEM", 147, 166], ["COPD", "PROBLEM", 170, 174], ["severity", "PROBLEM", 191, 199], ["a gap between inflammation", "PROBLEM", 216, 242], ["exacerbation", "PROBLEM", 247, 259], ["OSA", "OBSERVATION", 9, 12], ["may exacerbate", "UNCERTAINTY", 13, 27], ["airway", "ANATOMY", 28, 34], ["inflammation", "OBSERVATION", 35, 47], ["COPD", "OBSERVATION", 51, 55], ["inflammatory", "OBSERVATION", 102, 114], ["airway", "ANATOMY", 147, 153], ["inflammation", "OBSERVATION", 154, 166], ["COPD", "OBSERVATION", 170, 174], ["inflammation", "OBSERVATION", 230, 242], ["exacerbation", "OBSERVATION", 247, 259]]], ["Bacterial or viral infection, air pollution, GERD, bronchiectasis with bacterial colonization, and eosinophils may breach the airway stability and lead to overwhelming inflammation and acute exacerbation.", [["eosinophils", "ANATOMY", 99, 110], ["airway", "ANATOMY", 126, 132], ["viral infection", "DISEASE", 13, 28], ["GERD", "DISEASE", 45, 49], ["bronchiectasis", "DISEASE", 51, 65], ["inflammation", "DISEASE", 168, 180], ["eosinophils", "CELL", 99, 110], ["airway", "MULTI-TISSUE_STRUCTURE", 126, 132], ["eosinophils", "CELL_TYPE", 99, 110], ["Bacterial or viral infection", "PROBLEM", 0, 28], ["air pollution", "PROBLEM", 30, 43], ["GERD", "PROBLEM", 45, 49], ["bronchiectasis", "PROBLEM", 51, 65], ["bacterial colonization", "PROBLEM", 71, 93], ["eosinophils", "PROBLEM", 99, 110], ["the airway stability", "PROBLEM", 122, 142], ["overwhelming inflammation", "PROBLEM", 155, 180], ["acute exacerbation", "PROBLEM", 185, 203], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28], ["air pollution", "OBSERVATION", 30, 43], ["GERD", "OBSERVATION", 45, 49], ["bronchiectasis", "OBSERVATION", 51, 65], ["bacterial colonization", "OBSERVATION", 71, 93], ["eosinophils", "OBSERVATION", 99, 110], ["airway", "ANATOMY", 126, 132], ["overwhelming", "OBSERVATION_MODIFIER", 155, 167], ["inflammation", "OBSERVATION", 168, 180], ["acute", "OBSERVATION_MODIFIER", 185, 190], ["exacerbation", "OBSERVATION", 191, 203]]], ["The application of antiinflammatory agents and vaccines, prevention strategies for air pollution, early detection of GERD, reduction of bacterial load in bronchiectasis, and measurement of biomarkers that can predict response to corticosteroids are becoming the therapeutic goals to minimize the risks of acute exacerbation.", [["GERD", "DISEASE", 117, 121], ["bronchiectasis", "DISEASE", 154, 168], ["corticosteroids", "CHEMICAL", 229, 244], ["antiinflammatory agents", "TREATMENT", 19, 42], ["vaccines", "TREATMENT", 47, 55], ["prevention strategies", "TREATMENT", 57, 78], ["air pollution", "PROBLEM", 83, 96], ["GERD", "PROBLEM", 117, 121], ["bacterial load", "PROBLEM", 136, 150], ["bronchiectasis", "PROBLEM", 154, 168], ["measurement of biomarkers", "TEST", 174, 199], ["corticosteroids", "TREATMENT", 229, 244], ["acute exacerbation", "PROBLEM", 305, 323], ["GERD", "OBSERVATION", 117, 121], ["bacterial load", "OBSERVATION", 136, 150], ["bronchiectasis", "OBSERVATION", 154, 168], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["exacerbation", "OBSERVATION", 311, 323]]], ["We still need more evidence and clinical studies to achieve these endpoints and improve health-related quality of life among COPD patients.Conflicts of InterestNo potential conflict of interest relevant to this article was reported.", [["COPD", "DISEASE", 125, 129], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["clinical studies", "TEST", 32, 48], ["COPD patients", "PROBLEM", 125, 138]]]], "PMC7279646": [["IntroductionTotal knee arthroplasty (TKA) procedures impose a high-cost burden on health services worldwide.1 In Australia, over 63 000 knee arthroplasty procedures were performed in 2017, costing approximately $A20 000 per procedure.2 3 Incidence of TKA is projected to rise 276% from 2013 to 2030, with projected costs to increase by $A521 million over the same time period,4 so optimising health outcomes following TKA is important to ensure that costs are restrained and TKA procedures remain high value.IntroductionPreoperative medical, surgical and sociodemographic factors influence postoperative TKA outcomes, but recent evidence suggests that preoperative psychological distress independently predicts longer hospital length of stay, higher pain levels and higher dissatisfaction at 6 months following TKA.5\u20137 However, few clinicians assess or treat psychological health before TKA, despite up to 42% of preoperative patients reporting psychological distress.8IntroductionPreoperative interventions to improve outcomes after TKA have mixed effects.9 10 Most of these interventions are standardised exercise and/or education and delivered by physiotherapists, with no psychological interventions used.", [["knee", "ANATOMY", 18, 22], ["knee", "ANATOMY", 136, 140], ["psychological distress", "DISEASE", 665, 687], ["pain", "DISEASE", 750, 754], ["psychological distress", "DISEASE", 945, 967], ["patients", "ORGANISM", 926, 934], ["patients", "SPECIES", 926, 934], ["IntroductionTotal knee arthroplasty", "TREATMENT", 0, 35], ["TKA) procedures", "TREATMENT", 37, 52], ["knee arthroplasty procedures", "TREATMENT", 136, 164], ["procedure", "TREATMENT", 224, 233], ["TKA", "TREATMENT", 251, 254], ["TKA", "TREATMENT", 418, 421], ["TKA procedures", "TREATMENT", 475, 489], ["postoperative TKA outcomes", "TREATMENT", 590, 616], ["preoperative psychological distress", "PROBLEM", 652, 687], ["higher pain levels", "PROBLEM", 743, 761], ["higher dissatisfaction", "PROBLEM", 766, 788], ["TKA", "TREATMENT", 811, 814], ["TKA", "TREATMENT", 887, 890], ["psychological distress", "PROBLEM", 945, 967], ["Preoperative interventions", "TREATMENT", 981, 1007], ["TKA", "TREATMENT", 1034, 1037], ["mixed effects", "PROBLEM", 1043, 1056], ["these interventions", "TREATMENT", 1070, 1089], ["psychological interventions", "TREATMENT", 1176, 1203], ["knee", "ANATOMY", 18, 22], ["arthroplasty", "OBSERVATION", 23, 35], ["knee", "ANATOMY", 136, 140], ["arthroplasty", "OBSERVATION", 141, 153], ["TKA", "OBSERVATION", 251, 254]]], ["Only two pilot studies have used robust psychological interventions before TKA, with promising results.11 12 These studies added mental health professionals to existing orthopaedic teams to provide psychological interventions, but this is difficult to implement equitably for health services worldwide, given the high volume of patients who may benefit.", [["patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 328, 336], ["two pilot studies", "TEST", 5, 22], ["robust psychological interventions", "TREATMENT", 33, 67], ["TKA", "TREATMENT", 75, 78], ["psychological interventions", "TREATMENT", 198, 225]]], ["Equipping professionals already embedded in orthopaedic teams, such as physiotherapists, to provide psychologically-informed preoperative intervention may be a feasible and effective alternative.", [["preoperative intervention", "TREATMENT", 125, 150]]], ["Psychologically-informed physiotherapy is a growing area of clinical practice and research in the management of chronic musculoskeletal pain and osteoarthritis,13 14 which has been well received by patients and physiotherapists.15IntroductionWe have developed a physiotherapist-delivered, psychologically-informed intervention based on Acceptance and Commitment Therapy (ACT).", [["musculoskeletal", "ANATOMY", 120, 135], ["musculoskeletal pain", "DISEASE", 120, 140], ["osteoarthritis", "DISEASE", 145, 159], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["clinical practice", "TREATMENT", 60, 77], ["chronic musculoskeletal pain", "PROBLEM", 112, 140], ["osteoarthritis", "PROBLEM", 145, 159], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["musculoskeletal", "ANATOMY", 120, 135], ["pain", "OBSERVATION", 136, 140], ["osteoarthritis", "OBSERVATION", 145, 159]]], ["ACT is more effective than traditional cognitive\u2013behavioural therapy for older people experiencing chronic pain16 and is focused on developing psychological flexibility to promote values-based behaviour change.", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["traditional cognitive\u2013behavioural therapy", "TREATMENT", 27, 68], ["chronic pain16", "PROBLEM", 99, 113], ["more effective", "OBSERVATION_MODIFIER", 7, 21], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["pain16", "OBSERVATION", 107, 113]]], ["Psychological flexibility is a transdiagnostic concept, and lack of psychological flexibility is associated with functional impairment in people experiencing chronic pain.17 This is achieved by improving the key domains of openness, awareness and engagement.", [["functional impairment", "DISEASE", 113, 134], ["chronic pain", "DISEASE", 158, 170], ["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["psychological flexibility", "PROBLEM", 68, 93], ["functional impairment", "PROBLEM", 113, 134], ["chronic pain", "PROBLEM", 158, 170], ["chronic", "OBSERVATION_MODIFIER", 158, 165], ["pain", "OBSERVATION", 166, 170]]], ["Our intervention, named KOMPACT (Knee Osteoarthritis Management with Physiotherapy informed by Acceptance and Commitment Therapy), is focused on the engagement domain, with identification of core values, and subsequent emotionally relevant behavioural goal setting as explicit inclusions from an ACT perspective.", [["Osteoarthritis", "DISEASE", 38, 52], ["Our intervention", "TREATMENT", 0, 16], ["KOMPACT (Knee Osteoarthritis Management", "TREATMENT", 24, 63], ["core values", "TEST", 191, 202], ["Knee", "ANATOMY", 33, 37], ["Osteoarthritis", "OBSERVATION", 38, 52]]], ["This domain intersects well with physiotherapy clinical practice, evidence-based guidelines for knee osteoarthritis management18 19 and evidence that physiotherapists can successfully implement ACT with people experiencing chronic pain.20 21 The domains of openness and awareness will be more implicit to ensure that KOMPACT is feasible and relevant for physiotherapists and tesheir clients.", [["knee", "ANATOMY", 96, 100], ["osteoarthritis", "DISEASE", 101, 115], ["chronic pain", "DISEASE", 223, 235], ["knee", "ORGANISM_SUBDIVISION", 96, 100], ["people", "ORGANISM", 203, 209], ["people", "SPECIES", 203, 209], ["physiotherapy clinical practice", "TREATMENT", 33, 64], ["knee osteoarthritis", "PROBLEM", 96, 115], ["chronic pain", "PROBLEM", 223, 235], ["knee", "ANATOMY", 96, 100], ["osteoarthritis", "OBSERVATION", 101, 115], ["chronic", "OBSERVATION_MODIFIER", 223, 230], ["pain", "OBSERVATION", 231, 235]]], ["ACT also specifies an equal, respectful and empathetic therapeutic stance with a mandate not to challenge beliefs but to accept them.22 A strong therapeutic stance is important as it is associated with perceived improvement in chronic musculoskeletal pain.23 24IntroductionThis pilot study is testing the KOMPACT intervention in people awaiting TKA.", [["musculoskeletal", "ANATOMY", 235, 250], ["chronic musculoskeletal pain", "DISEASE", 227, 255], ["people", "ORGANISM", 329, 335], ["people", "SPECIES", 329, 335], ["chronic musculoskeletal pain", "PROBLEM", 227, 255], ["This pilot study", "TEST", 273, 289], ["the KOMPACT intervention", "TREATMENT", 301, 325], ["TKA", "TREATMENT", 345, 348], ["chronic", "OBSERVATION_MODIFIER", 227, 234], ["musculoskeletal", "ANATOMY", 235, 250], ["pain", "OBSERVATION", 251, 255], ["TKA", "OBSERVATION", 345, 348]]], ["The primary aim of this pilot study is to evaluate the safety, acceptability and feasibility of the KOMPACT approach among patients awaiting TKA according to success criteria determined a priori.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["this pilot study", "TEST", 19, 35], ["the KOMPACT approach", "TREATMENT", 96, 116], ["TKA", "TREATMENT", 141, 144]]], ["This approach consists of four physiotherapy sessions over 2 months before and after TKA in a public hospital setting, including psychologically-informed goal setting, lower limb strength training and physical activity coaching, in addition to usual care.", [["lower limb", "ANATOMY", 168, 178], ["limb", "ORGANISM_SUBDIVISION", 174, 178], ["four physiotherapy sessions", "TREATMENT", 26, 53], ["TKA", "TREATMENT", 85, 88], ["lower limb strength training", "TREATMENT", 168, 196], ["physical activity coaching", "TREATMENT", 201, 227], ["lower limb", "ANATOMY", 168, 178]]], ["The secondary aim is to collect outcome data on effect size and variation for a range of variables (health service, psychological health, patient-reported outcomes, quality of life and physical performance measures) that will inform the design and sample size for a future randomised controlled trial (RCT).Design ::: Methods and analysisThis is a mixed-methods, parallel-group, pilot RCT with recruitment at two hospital sites in Sydney, Australia.", [["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["outcome data", "TEST", 32, 44], ["physical performance measures", "TREATMENT", 185, 214], ["a future randomised controlled trial (RCT)", "TREATMENT", 264, 306], ["Methods and analysis", "TEST", 318, 338], ["pilot RCT", "TREATMENT", 379, 388], ["size", "OBSERVATION_MODIFIER", 55, 59], ["mixed", "OBSERVATION_MODIFIER", 348, 353], ["recruitment", "OBSERVATION_MODIFIER", 394, 405]]], ["Participants will be randomised into one of two groups: usual care or KOMPACT plus usual care.Sample size estimation ::: Methods and analysisWe aim to recruit 51 participants, which is adequate to enable randomisation with stratification for sex, site and psychological state.", [["KOMPACT", "CHEMICAL", 70, 77], ["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 162, 174], ["KOMPACT", "TREATMENT", 70, 77], ["Sample size estimation", "TEST", 94, 116], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["Stratification will ensure sufficient qualitative data regarding KOMPACT acceptability and no significant differences between groups due to three factors: anticipated 70% female participants2; current local procedures that determine hospital site (those with higher anaesthetic risk are operated on at one site only), and anticipation of a 30% psychological distress rate.5 Considering most physiotherapy interventions have a small effect size of 0.2 and a two-sided significance of p=0.05, our sample size met recommendations by Whitehead and colleagues for external pilot randomised trials.25 This sample size was also considered feasible for research conducted within a health service and is consistent with available time and funding for recruitment.Participants ::: Methods and analysisWe will recruit 51 sequential participants who are awaiting primary unilateral TKA, drawn from two hospital sites that performed a combined total of approximately 400 arthroplasty procedures in 2018 (Blacktown Hospital and Mount Druitt Hospital).Participants ::: Methods and analysisPotential participants will be considered eligible for inclusion in this study if they are:Participants ::: Methods and analysisPotential participants will be excluded from the study if they:Participants ::: Methods and analysisPeople who are interested and eligible for the study but have insufficient English language skills to engage with KOMPACT will be referred to a government-funded telephone coaching service available in different languages (Get Healthy https://www.gethealthynsw.com.au) to support lifestyle-related behavioural goal setting.Recruitment method and screening procedures ::: Methods and analysisPotential participants awaiting TKA will be scheduled by administration staff to attend the usual care preadmission class approximately 2 months before surgery as per usual clinical care.", [["People", "ORGANISM", 1302, 1308], ["Participants", "SPECIES", 754, 766], ["participants", "SPECIES", 821, 833], ["Participants", "SPECIES", 1037, 1049], ["participants", "SPECIES", 1084, 1096], ["Participants", "SPECIES", 1165, 1177], ["participants", "SPECIES", 1212, 1224], ["Participants", "SPECIES", 1265, 1277], ["People", "SPECIES", 1302, 1308], ["participants", "SPECIES", 1703, 1715], ["KOMPACT acceptability", "TEST", 65, 86], ["significant differences between groups", "PROBLEM", 94, 132], ["current local procedures", "TREATMENT", 193, 217], ["higher anaesthetic risk", "TREATMENT", 259, 282], ["a 30% psychological distress rate", "PROBLEM", 338, 371], ["most physiotherapy interventions", "TREATMENT", 386, 418], ["a small effect size", "PROBLEM", 424, 443], ["external pilot randomised trials", "TREATMENT", 559, 591], ["This sample size", "TEST", 595, 611], ["recruitment", "PROBLEM", 742, 753], ["primary unilateral TKA", "TREATMENT", 851, 873], ["this study", "TEST", 1142, 1152], ["the study", "TEST", 1247, 1256], ["Methods and analysis", "TEST", 1282, 1302], ["the study", "TEST", 1345, 1354], ["TKA", "TREATMENT", 1725, 1728], ["surgery", "TREATMENT", 1845, 1852], ["small", "OBSERVATION_MODIFIER", 426, 431], ["effect", "OBSERVATION_MODIFIER", 432, 438], ["size", "OBSERVATION_MODIFIER", 439, 443], ["size", "OBSERVATION_MODIFIER", 607, 611], ["consistent with", "UNCERTAINTY", 695, 710], ["arthroplasty", "OBSERVATION", 958, 970]]], ["On attendance, all potentially eligible participants will be provided with information regarding study participation by a study investigator, given the opportunity to ask questions and, if agreeable, will be invited to consent to screening for the study.", [["participants", "SPECIES", 40, 52], ["the study", "TEST", 244, 253]]], ["If the participant remains eligible after screening, then they will be asked to provide written informed consent.", [["participant", "SPECIES", 7, 18], ["screening", "TEST", 42, 51]]], ["Once consented, and prior to treatment allocation, baseline measures will be collected by an allied health student or staff member trained by the lead author in the requisite standardised assessment procedures, who is blinded to allocation.", [["treatment allocation", "TREATMENT", 29, 49]]], ["Recruitment will commence February 2020 and will be completed by December 2020, however, this may be delayed due to the COVID-19 pandemic.Randomisation ::: Methods and analysisParticipants will be randomised in a 1:2 allocation to either usual care (n=17) or the KOMPACT treatment group (n=34).Randomisation ::: Methods and analysisOnce consent and baseline assessments are complete, participants will be randomised to either the usual care group or KOMPACT treatment group.", [["KOMPACT", "CHEMICAL", 450, 457], ["participants", "SPECIES", 384, 396], ["the COVID", "TEST", 116, 125], ["pandemic", "PROBLEM", 129, 137], ["the KOMPACT treatment group", "TREATMENT", 259, 286], ["baseline assessments", "TEST", 349, 369], ["KOMPACT treatment group", "TREATMENT", 450, 473]]], ["An offsite investigator will be contacted when a random allocation of participants is required.", [["participants", "SPECIES", 70, 82]]], ["Randomisation will be stratified for three binary variables: sex, hospital site and psychological health (if the score in any domain of the Depression, Anxiety and Stress Score-21 (DASS-21) above validated \u2018normal\u2019 threshold, participant classified as \u2018distressed\u2019;27 note the DASS-21 is valid in older people with chronic disease28).", [["Depression", "DISEASE", 140, 150], ["Anxiety", "DISEASE", 152, 159], ["chronic disease28", "DISEASE", 315, 332], ["people", "ORGANISM", 303, 309], ["participant", "SPECIES", 226, 237], ["people", "SPECIES", 303, 309], ["Randomisation", "TREATMENT", 0, 13], ["the score", "PROBLEM", 109, 118], ["the Depression", "PROBLEM", 136, 150], ["Anxiety", "PROBLEM", 152, 159], ["Stress Score", "TEST", 164, 176], ["chronic disease28", "PROBLEM", 315, 332]]], ["Unequal randomisation favouring the KOMPACT treatment group will generate more quantitative and qualitative data regarding this intervention and allow for any learning effects from the treating physiotherapist using KOMPACT.Usual care ::: Intervention ::: Methods and analysisThe usual care group (and accompanying support people) will attend a 1-hour education class at the physiotherapy department at 2 months before surgery.", [["people", "ORGANISM", 323, 329], ["people", "SPECIES", 323, 329], ["Unequal randomisation", "PROBLEM", 0, 21], ["the KOMPACT treatment group", "TREATMENT", 32, 59], ["qualitative data", "TEST", 96, 112], ["this intervention", "TREATMENT", 123, 140], ["KOMPACT", "TREATMENT", 216, 223], ["Methods and analysis", "TEST", 256, 276], ["surgery", "TREATMENT", 419, 426]]], ["This class and the supporting education manual will describe the usual clinical pathway for TKA at these sites, the role of health professionals involved with TKA care, address expectations of recovery, demonstrate two exercises to address knee range of motion, outline follow-up plans after discharge from hospital and encourage independent goal setting for return to usual activities.", [["knee", "ANATOMY", 240, 244], ["TKA", "TREATMENT", 92, 95], ["TKA care", "TREATMENT", 159, 167], ["knee", "ANATOMY", 240, 244]]], ["They will receive usual postoperative physiotherapy on the ward at least once daily to improve mobility and knee range of motion.KOMPACT treatment group ::: Intervention ::: Methods and analysisThe treatment group will receive four one-to-one KOMPACT sessions with the KOMPACT physiotherapist (2 hours 20 min total duration), in addition to usual care.", [["knee", "ANATOMY", 108, 112], ["knee", "ORGANISM_SUBDIVISION", 108, 112], ["usual postoperative physiotherapy", "TREATMENT", 18, 51], ["Methods and analysis", "TEST", 174, 194], ["the KOMPACT physiotherapist", "TREATMENT", 265, 292], ["knee", "ANATOMY", 108, 112]]], ["The fourth appointment will occur during the inpatient stay in the orthopaedic ward after TKA.", [["TKA", "TREATMENT", 90, 93]]], ["This dosage parallels Godfrey and colleagues\u2019 intervention of physiotherapy informed by ACT for chronic low back pain.20Box 1 describes the KOMPACT intervention at each session in detail, and table 1 provides some examples of how ACT is applied in KOMPACT.", [["low back pain", "DISEASE", 104, 117], ["physiotherapy", "TREATMENT", 62, 75], ["chronic low back pain", "PROBLEM", 96, 117], ["the KOMPACT intervention", "TREATMENT", 136, 160], ["back", "ANATOMY", 108, 112], ["pain", "OBSERVATION", 113, 117]]], ["The therapeutic stance adopted by KOMPACT will be integrated into the application of psychological skills and exercise-based interventions.KOMPACT treatment group ::: Intervention ::: Methods and analysisThe use of behaviour change techniques in physiotherapy is a growing area of research, as many physiotherapy interventions depend on patients independently implementing prescribed strategies outside of the supervised clinic.", [["patients", "ORGANISM", 337, 345], ["patients", "SPECIES", 337, 345], ["psychological skills", "TREATMENT", 85, 105], ["exercise-based interventions", "TREATMENT", 110, 138], ["Methods and analysis", "TEST", 184, 204], ["behaviour change techniques", "TREATMENT", 215, 242], ["physiotherapy", "TREATMENT", 246, 259], ["many physiotherapy interventions", "TREATMENT", 294, 326]]], ["The Behaviour Change Taxonomy (BCT)29 itemises behaviour change techniques used to standardise identification and reporting of techniques used, for health professionals within and outside the psychological sciences.", [["Taxonomy (BCT)", "TREATMENT", 21, 35], ["behaviour change techniques", "TREATMENT", 47, 74], ["standardise identification", "TEST", 83, 109]]], ["Both usual care and KOMPACT interventions were mapped to the BCT (online supplementary appendix 1) by the lead author, with independent checking by two authors (EG, SD).", [["KOMPACT interventions", "TREATMENT", 20, 41], ["the BCT", "TEST", 57, 64]]], ["The lead author undertook online training in BCT mapping as prescribed by the authors of the BCT.Therapist training ::: Methods and analysisThe single physiotherapist delivering KOMPACT treatment will undergo a 16-hour online course \u2018ACT for Beginners\u2019,30 with an additional 1 day of trial-specific KOMPACT training conducted by a clinical psychologist and an experienced physiotherapist familiar with psychologically-informed physiotherapy and KOMPACT, complemented by a therapist training manual.", [["BCT mapping", "TREATMENT", 45, 56], ["the BCT", "TEST", 89, 96], ["Methods and analysis", "TEST", 120, 140], ["KOMPACT treatment", "TREATMENT", 178, 195], ["specific KOMPACT training", "TREATMENT", 290, 315]]], ["The KOMPACT physiotherapist has over 10 years\u2019 experience in orthopaedic and musculoskeletal physiotherapy and is familiar with the ACT therapeutic stance.", [["musculoskeletal physiotherapy", "TREATMENT", 77, 106], ["musculoskeletal", "ANATOMY", 77, 92]]], ["The KOMPACT physiotherapist will participate in monthly reflective supervision from a clinical psychologist (SV) in person or via video-conferencing to improve KOMPACT intervention fidelity and ensure psychological safety for the KOMPACT physiotherapist.Intervention fidelity ::: Methods and analysisIntervention fidelity will be assessed with an a priori checklist tailored to KOMPACT, assessing adherence and competence in key components (online supplementary appendix 2).", [["person", "SPECIES", 116, 122], ["KOMPACT intervention fidelity", "TREATMENT", 160, 189], ["the KOMPACT physiotherapist", "TREATMENT", 226, 253], ["an a priori checklist", "TEST", 344, 365], ["KOMPACT", "TEST", 378, 385]]], ["All treatment sessions will be audio-recorded and the supervising clinical psychologist will listen to at least a 10% sample for supervision and fidelity purposes.", [["All treatment sessions", "TREATMENT", 0, 22]]], ["The nature of the study renders both therapist and participant blinding impossible.", [["the study", "TEST", 14, 23]]], ["Usual care will be standardised with the provision of presentation slides, notes and manuals, and the KOMPACT physiotherapist will not provide usual care for any participants.", [["participants", "SPECIES", 162, 174]]], ["Usual care fidelity will not be formally assessed as participants not enrolled in the study will also be present and unable to give consent.Primary outcomes ::: Methods and analysisAll outcomes will be assessed by an assessor blinded to treatment group allocation.", [["participants", "SPECIES", 53, 65], ["the study", "TEST", 82, 91], ["analysis", "TEST", 173, 181], ["treatment group allocation", "TREATMENT", 237, 263]]], ["The primary outcomes for this pilot RCT are safety, acceptability and feasibility.", [["this pilot RCT", "TREATMENT", 25, 39]]], ["Safety will be assessed using DASS-21 data after preoperative KOMPACT treatment, postoperative length of stay, and complications.", [["preoperative KOMPACT treatment", "TREATMENT", 49, 79], ["complications", "PROBLEM", 115, 128]]], ["Acceptability will be determined using treatment credibility scores developed by Borkovec and Nau tailored for KOMPACT,31 in addition to qualitative data.", [["treatment credibility scores", "TEST", 39, 67], ["KOMPACT", "TEST", 111, 118], ["qualitative data", "TEST", 137, 153]]], ["Feasibility will be determined using recruitment and retention rates, recruitment time, attendance rates and intervention fidelity.", [["recruitment and retention rates", "TREATMENT", 37, 68], ["intervention fidelity", "TREATMENT", 109, 130]]], ["Specific criteria for success are stated in the online supplementary appendix 3.Physical performance measures ::: Secondary outcomes ::: Methods and analysisA summary of outcome measures and the time of collection is provided in table 2.Data analysis ::: Methods and analysisAn independent biostatistician assisted in developing the data analysis plan and randomisation methods and will be involved in data analysis.", [["outcome measures", "TREATMENT", 170, 186], ["Data analysis", "TEST", 237, 250], ["the data analysis", "TEST", 329, 346], ["data analysis", "TEST", 402, 415]]], ["Quantitative data will be described with measures of central tendency and variation appropriate to their distribution, allowing estimation of effect size, sample size and selection of outcome measures for a future fully powered trial.", [["Quantitative data", "TEST", 0, 17], ["central tendency", "PROBLEM", 53, 69], ["outcome measures", "TREATMENT", 184, 200], ["central tendency", "OBSERVATION", 53, 69], ["size", "OBSERVATION_MODIFIER", 149, 153], ["size", "OBSERVATION_MODIFIER", 162, 166]]], ["Qualitative data will be acquired by purposive sampling and one-to-one, semistructured interviewing of \u226510 participants in the treatment group.", [["participants", "SPECIES", 107, 119], ["Qualitative data", "TEST", 0, 16], ["the treatment group", "TREATMENT", 123, 142]]], ["Purposive sampling will occur considering sociodemographic variables, level of psychological distress and KOMPACT completion.", [["Purposive sampling", "TEST", 0, 18], ["psychological distress", "PROBLEM", 79, 101], ["KOMPACT completion", "TREATMENT", 106, 124]]], ["Informal checking during the interview process will occur, and after transcription of interviews verbatim, the thematic analysis will be performed, with two researchers involved in developing a framework within which the data will be interpreted, and major themes described.43 Formal member checking will not occur to minimise patient burden during the acute recovery from TKA and to avoid confounding by postoperative experiences.", [["patient", "ORGANISM", 327, 334], ["patient", "SPECIES", 327, 334], ["the thematic analysis", "TEST", 107, 128], ["TKA", "TREATMENT", 373, 376]]], ["Our mixed-methods approach will be a triangulation approach, as qualitative data will inform and enrich the interpretation of the quantitative data and inform a future efficacy trial of KOMPACT.Data analysis ::: Methods and analysisQuantitative data will be checked on collection to ensure completeness, with prompts for completion if required.", [["a triangulation approach", "TREATMENT", 35, 59], ["the quantitative data", "TEST", 126, 147], ["KOMPACT", "TREATMENT", 186, 193], ["Data analysis", "TEST", 194, 207], ["analysisQuantitative data", "TEST", 224, 249]]], ["Data will be checked for correctness during data analysis, and if required, missing values will be carried forward from previous assessments.", [["data analysis", "TEST", 44, 57], ["previous assessments", "TEST", 120, 140]]], ["Imputation will not occur from preoperative to postoperative variables.Patient and public involvement ::: Methods and analysisNo patients or members of the general public were involved in the design of this study.", [["patients", "ORGANISM", 129, 137], ["Patient", "SPECIES", 71, 78], ["patients", "SPECIES", 129, 137], ["Imputation", "TREATMENT", 0, 10], ["Methods and analysis", "TEST", 106, 126], ["this study", "TEST", 202, 212]]], ["However, qualitative study data will allow the research team to incorporate participant feedback for any future studies using KOMPACT.Data protection, storage and dissemination ::: Ethics and disseminationAll data will be collected electronically and deidentified.", [["qualitative study data", "TEST", 9, 31], ["any future studies", "TEST", 101, 119], ["KOMPACT", "TREATMENT", 126, 133]]], ["Data will be extracted from the participant\u2019s electronic medical record and stored in a secure, password-protected file on the secure computer network owned by the health service.", [["computer network", "MULTI-TISSUE_STRUCTURE", 134, 150], ["participant", "SPECIES", 32, 43]]], ["Patient-reported outcomes data will be collected and managed securely using Research Electronic Data Capture hosted at the University of Sydney.47 Researchers external to the clinical setting will only be able to access de-identified data, and data will be aggregated and anonymised during analysis and publication to render individual patient identification impossible.", [["patient", "ORGANISM", 336, 343], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 336, 343], ["de-identified data", "TEST", 220, 238], ["analysis", "TEST", 290, 298]]], ["Access to deidentified, individual participant data after the completion of the study will be considered on a case-by-case basis in consultation with local researchers and the local human ethics committee.", [["human", "ORGANISM", 182, 187], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["the study", "TEST", 76, 85]]]], "6538a7befb7665b542e6fd66363665912fad02f9": [["IntroductionThe genetic code uses 61 nucleotide triplets (codons) to encode 20 amino acids and three to terminate translation [1] .", [["nucleotide", "CHEMICAL", 37, 47], ["amino acids", "CHEMICAL", 79, 90], ["nucleotide", "CHEMICAL", 37, 47], ["amino acids", "CHEMICAL", 79, 90], ["amino acids", "AMINO_ACID", 79, 90], ["nucleotide triplets (codons)", "TREATMENT", 37, 65], ["encode 20 amino acids", "TREATMENT", 69, 90]]], ["So the genetic code is necessarily redundant which are more than amino acids.", [["amino acids", "CHEMICAL", 65, 76], ["amino acids", "CHEMICAL", 65, 76], ["amino acids", "AMINO_ACID", 65, 76], ["amino acids", "TREATMENT", 65, 76]]], ["Each amino acid is encoded by between one (Met and Trp) and six (Arg, Leu and Ser) synonymous codons [2] .", [["amino acid", "CHEMICAL", 5, 15], ["amino acid", "CHEMICAL", 5, 15], ["Met", "CHEMICAL", 43, 46], ["Trp", "CHEMICAL", 51, 54], ["Arg", "CHEMICAL", 65, 68], ["Leu", "CHEMICAL", 70, 73], ["Ser", "CHEMICAL", 78, 81], ["amino acid", "AMINO_ACID", 5, 15], ["Met", "GENE_OR_GENE_PRODUCT", 43, 46], ["Trp", "GENE_OR_GENE_PRODUCT", 51, 54], ["Arg", "AMINO_ACID", 65, 68], ["Leu", "AMINO_ACID", 70, 73], ["Ser", "AMINO_ACID", 78, 81], ["Each amino acid", "TEST", 0, 15], ["Arg", "TEST", 65, 68], ["Leu", "TEST", 70, 73]]], ["Different codons that encode the same amino acid are known as synonymous codons.", [["amino acid", "CHEMICAL", 38, 48], ["amino acid", "CHEMICAL", 38, 48], ["amino acid", "AMINO_ACID", 38, 48], ["Different codons", "PROBLEM", 0, 16], ["synonymous codons", "PROBLEM", 62, 79], ["synonymous codons", "OBSERVATION", 62, 79]]], ["Changes in the DNA sequence of a protein between two synonymous codons are often assumed to have no effect and are thus called synonymous changes or even silent changes [2] .", [["DNA", "CELLULAR_COMPONENT", 15, 18], ["the DNA sequence", "TEST", 11, 27], ["a protein between two synonymous codons", "PROBLEM", 31, 70], ["synonymous changes", "PROBLEM", 127, 145], ["synonymous codons", "OBSERVATION", 53, 70]]], ["In a wide variety of organisms such as bacteria, fungi, and insects (Sharp et al. 1992) , codons within synonymous groups are used with different frequencies [3] [4] [5] [6] the phenomenon called codon usage bias.IntroductionThere is continuing speculation regarding the reasons what have made these differences in codon preferences [7] . the most commonly accepted hypothesis for the unequal usage of synonymous codons stated that it was the result of mutational biases and natural selection acting at the level of translation.", [["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 158, 173], ["organisms", "PROBLEM", 21, 30], ["bacteria", "PROBLEM", 39, 47], ["fungi", "PROBLEM", 49, 54], ["codons within synonymous groups", "TREATMENT", 90, 121], ["synonymous codons", "PROBLEM", 402, 419], ["mutational biases", "PROBLEM", 453, 470], ["synonymous codons", "OBSERVATION", 402, 419]]], ["However, several other causes have also been reported, such as GC compositions, gene length, gene expression level, gene translation initiation signal, protein amino acid composition, protein structure, mutation frequency and patterns, and tRNA abundance [8] [9] [10] [11] [12] .", [["amino acid", "CHEMICAL", 160, 170], ["amino acid", "CHEMICAL", 160, 170], ["amino acid", "AMINO_ACID", 160, 170], ["[8] [9] [10] [11] [12]", "SIMPLE_CHEMICAL", 255, 277], ["gene length, gene expression level", "PROBLEM", 80, 114], ["gene translation initiation signal", "TEST", 116, 150], ["protein amino acid composition", "TEST", 152, 182], ["protein structure", "TEST", 184, 201], ["mutation frequency", "TEST", 203, 221], ["tRNA abundance", "TEST", 240, 254]]], ["In some other researches, it was also found that codon usage was related to gene function [13, 14] and cellular location of gene products [15] [16] [17] .", [["cellular", "ANATOMY", 103, 111], ["cellular", "CELL", 103, 111], ["codon usage", "TREATMENT", 49, 60], ["gene function", "TEST", 76, 89]]], ["Whatever the reasons for codon bias, it has become increasingly clear that codon biases can have profound impacts on the expression of heterologous proteins.IntroductionIn this study, characterization of codon usage bias on interferon alpha gene without signal peptide of the giant panda had been evaluated.", [["interferon alpha", "GENE_OR_GENE_PRODUCT", 224, 240], ["panda", "ORGANISM", 282, 287], ["heterologous proteins", "PROTEIN", 135, 156], ["interferon alpha gene", "DNA", 224, 245], ["codon bias", "PROBLEM", 25, 35], ["codon biases", "PROBLEM", 75, 87], ["heterologous proteins", "PROBLEM", 135, 156], ["this study", "TEST", 172, 182], ["codon usage bias", "TREATMENT", 204, 220], ["interferon alpha gene", "TREATMENT", 224, 245], ["giant panda", "OBSERVATION", 276, 287]]], ["Giant panda is a much loved animal all over the world and is considered a symbol of China.", [["Giant panda", "SPECIES", 0, 11], ["panda", "OBSERVATION", 6, 11]]], ["However, it is also one of the world's most endangered species.", [["endangered species", "OBSERVATION", 44, 62]]], ["In addition, giant pandas are considered to be particularly vulnerable to infectious disease and parasites [18] .", [["giant pandas", "ANATOMY", 13, 25], ["infectious disease and parasites", "DISEASE", 74, 106], ["giant pandas", "PROBLEM", 13, 25], ["infectious disease", "PROBLEM", 74, 92], ["parasites", "PROBLEM", 97, 106], ["giant pandas", "OBSERVATION", 13, 25], ["infectious", "OBSERVATION", 74, 84]]], ["Therefore, analysis and study on cytokine genes of the giant panda are important to facilitate the use of these cytokines in the immunotherapy of infectious diseases of the giant panda [19] .IntroductionThe interferons are a group of natural antiviral substances first discovered in 1957 [20] .", [["giant panda", "ANATOMY", 55, 66], ["infectious diseases", "DISEASE", 146, 165], ["panda", "ORGANISM", 61, 66], ["cytokine genes", "DNA", 33, 47], ["cytokines", "PROTEIN", 112, 121], ["interferons", "PROTEIN", 207, 218], ["analysis", "TEST", 11, 19], ["study", "TEST", 24, 29], ["cytokine genes", "TREATMENT", 33, 47], ["the giant panda", "TREATMENT", 51, 66], ["these cytokines", "TREATMENT", 106, 121], ["infectious diseases", "PROBLEM", 146, 165], ["natural antiviral substances", "TREATMENT", 234, 262], ["giant", "OBSERVATION_MODIFIER", 173, 178]]], ["Many studies have performed on the function of IFN-a.", [["IFN", "GENE_OR_GENE_PRODUCT", 47, 50], ["IFN", "PROTEIN", 47, 50], ["Many studies", "TEST", 0, 12]]], ["It influences many biological processes including broad spectrum antiviral effects, inhibition of tumor cell proliferation and enhancement of immune functions.", [["tumor cell", "ANATOMY", 98, 108], ["tumor", "DISEASE", 98, 103], ["tumor cell", "CELL", 98, 108], ["broad spectrum antiviral effects", "TREATMENT", 50, 82], ["tumor cell proliferation", "PROBLEM", 98, 122], ["enhancement of immune functions", "PROBLEM", 127, 158], ["broad spectrum", "OBSERVATION_MODIFIER", 50, 64], ["antiviral effects", "OBSERVATION", 65, 82], ["tumor cell proliferation", "OBSERVATION", 98, 122], ["enhancement", "OBSERVATION_MODIFIER", 127, 138], ["immune functions", "OBSERVATION", 142, 158]]], ["And it is considered to be a potential agents for therapy of neoplastic diseases and cancers [21] .IntroductionSo far, research on the giant panda genome is still rare. only a few genes with immunity function have been cloned.", [["neoplastic", "ANATOMY", 61, 71], ["cancers", "ANATOMY", 85, 92], ["neoplastic diseases", "DISEASE", 61, 80], ["cancers", "DISEASE", 85, 92], ["neoplastic diseases", "CANCER", 61, 80], ["cancers", "CANCER", 85, 92], ["panda", "ORGANISM", 141, 146], ["giant panda genome", "DNA", 135, 153], ["giant panda", "SPECIES", 135, 146], ["therapy", "TREATMENT", 50, 57], ["neoplastic diseases", "PROBLEM", 61, 80], ["cancers", "PROBLEM", 85, 92], ["neoplastic", "OBSERVATION", 61, 71], ["few", "OBSERVATION_MODIFIER", 176, 179]]], ["Recently, the interferon alpha gene of giant panda had been cloned in our laboratory called GpIFN-a.", [["interferon alpha", "GENE_OR_GENE_PRODUCT", 14, 30], ["panda", "ORGANISM", 45, 50], ["GpIFN", "GENE_OR_GENE_PRODUCT", 92, 97], ["interferon alpha gene", "DNA", 14, 35], ["GpIFN", "DNA", 92, 97], ["giant panda", "PROBLEM", 39, 50], ["giant panda", "OBSERVATION", 39, 50]]], ["Here, we first time analyzed the codon usage data of GpIFN-a and those of other 15 species' IFN-a.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 53, 58], ["GpIFN", "PROTEIN", 53, 58], ["IFN", "PROTEIN", 92, 95], ["GpIFN", "TEST", 53, 58]]], ["Moreover, the codon usage bias in the GpIFN-a gene was also compared with Escherichia coli, yeast, and Homo sapiens.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 38, 43], ["Escherichia coli", "ORGANISM", 74, 90], ["Homo sapiens", "ORGANISM", 103, 115], ["GpIFN", "DNA", 38, 43], ["Escherichia coli", "SPECIES", 74, 90], ["yeast", "SPECIES", 92, 97], ["Homo sapiens", "SPECIES", 103, 115], ["Escherichia coli", "SPECIES", 74, 90], ["yeast", "SPECIES", 92, 97], ["Homo sapiens", "SPECIES", 103, 115], ["the codon usage bias", "PROBLEM", 10, 30], ["Escherichia coli", "PROBLEM", 74, 90], ["yeast", "PROBLEM", 92, 97], ["Homo sapiens", "PROBLEM", 103, 115], ["Escherichia coli", "OBSERVATION", 74, 90], ["Homo sapiens", "OBSERVATION", 103, 115]]], ["In this research, codon usage data of GpIFN-a and the comparison results might give some clues to the features of GpIFN-a gene and some evolutionary information of IFN-a gene.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 38, 43], ["GpIFN", "GENE_OR_GENE_PRODUCT", 114, 119], ["IFN", "GENE_OR_GENE_PRODUCT", 164, 167], ["GpIFN", "DNA", 38, 43], ["GpIFN", "DNA", 114, 119], ["IFN-a gene", "DNA", 164, 174], ["GpIFN", "TEST", 38, 43]]], ["And also provide insights into the expression and possible function of GpIFN-a.Sequence DataThe mature sequence of GpIFN-a which cloned in our laboratory had been submitted to GenBank and the accession number is HQ378189.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 71, 76], ["GpIFN", "GENE_OR_GENE_PRODUCT", 115, 120], ["GpIFN", "PROTEIN", 71, 76], ["GpIFN", "PROTEIN", 115, 120], ["Sequence Data", "TEST", 79, 92]]], ["The overall IFN-\u03b1 reference sequences were download from NCBI (http://www.ncb i.nlm.nih.gov/).", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 12, 17], ["IFN-\u03b1 reference sequences", "DNA", 12, 37]]], ["The informations such as GenBank accession No., Natural host and Length of the IFN-\u03b1 gene of overall 16 reference sequence are shown in Table 1 .Analysis on Codon Usage in GpIFN-a Genes and 15 Reference SequencesCodon bias was calculated according to methods described elsewhere.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 79, 84], ["IFN-\u03b1 gene", "DNA", 79, 89], ["16 reference sequence", "DNA", 101, 122], ["GpIFN", "DNA", 172, 177], ["the IFN", "TREATMENT", 75, 82], ["Analysis", "TEST", 145, 153], ["Codon Usage", "TREATMENT", 157, 168], ["Reference SequencesCodon bias", "TEST", 193, 222]]], ["Relative synonymous codon usage (RSCU) is the observed frequency of a codon divided by the frequency expected if all synonyms for that amino acid were used equally.", [["amino acid", "CHEMICAL", 135, 145], ["amino acid", "CHEMICAL", 135, 145], ["amino acid", "AMINO_ACID", 135, 145], ["a codon", "TREATMENT", 68, 75], ["all synonyms", "TREATMENT", 113, 125], ["amino acid", "TREATMENT", 135, 145], ["synonymous codon", "OBSERVATION", 9, 25]]], ["It is independent of amino acid composition and is thus useful for comparing different sets of genes [22] .", [["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "AMINO_ACID", 21, 31], ["amino acid composition", "TREATMENT", 21, 43]]], ["The effective number of codons (ENC) is a measure analogous to the effective number of alleles.", [["ENC", "DNA", 32, 35], ["alleles", "DNA", 87, 94], ["codons (ENC)", "TREATMENT", 24, 36], ["effective", "OBSERVATION_MODIFIER", 4, 13]]], ["Based on simulation studies, ENC appears to be low sensitive to gene length [23] .", [["ENC", "DNA", 29, 32], ["simulation studies", "TEST", 9, 27]]], ["The ENC value of the IFN-a gene of each reference was computed with the EMBOSS CHIPS online service program.", [["IFN", "GENE_OR_GENE_PRODUCT", 21, 24], ["ENC", "DNA", 4, 7], ["IFN", "PROTEIN", 21, 24]]], ["The degree of synonymous-codon usage bias was also measured by the codon adaptation index (CAI) which estimates the extent of bias toward codons that are known to be favored in highly expressed genes. which was calculated with the EMBOSS CAI program [24] .", [["synonymous-codon usage bias", "PROBLEM", 14, 41], ["bias toward codons", "PROBLEM", 126, 144], ["the EMBOSS CAI program", "TREATMENT", 227, 249], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["synonymous-", "OBSERVATION", 14, 25], ["codon usage", "OBSERVATION", 25, 36]]], ["The peculiarity in codon usage frequency ,the G+C content of the gene sequences and the G+C content at the synonymous third position of codons (GC3S) were also calculated with the EMBOSS CUSP program [25] .Phylogenetic Analysis of the GpIFN-a GeneThe mature nucleotide sequences of the GpIFN-a gene and 15 reference IFN-a were translated into amino acid sequences by using DNASTAR software.Then, multiple sequence alignment and phylogenetic analysis by the bootstrap option were performed by using ClustalW and TREEVIEW software.Comparison of Codon Preferences of GpIFN-a Gene with Those of E. coli, Yeast, Adenovirus, and HumanA comparison analysis was performed between the GpIFN-a\uff0cEscherichia coli, yeast, and Homo sapiens.", [["amino acid", "CHEMICAL", 343, 353], ["nucleotide", "CHEMICAL", 258, 268], ["amino acid", "CHEMICAL", 343, 353], ["G+C", "GENE_OR_GENE_PRODUCT", 46, 49], ["G+C", "GENE_OR_GENE_PRODUCT", 88, 91], ["GpIFN", "GENE_OR_GENE_PRODUCT", 235, 240], ["GpIFN", "GENE_OR_GENE_PRODUCT", 286, 291], ["IFN", "GENE_OR_GENE_PRODUCT", 316, 319], ["amino acid", "AMINO_ACID", 343, 353], ["E. coli", "ORGANISM", 591, 598], ["Adenovirus", "ORGANISM", 607, 617], ["GpIFN-a\uff0cEscherichia coli", "ORGANISM", 676, 700], ["Homo sapiens", "ORGANISM", 713, 725], ["GC3S", "DNA", 144, 148], ["GpIFN", "DNA", 235, 240], ["Gene", "DNA", 243, 247], ["mature nucleotide sequences", "DNA", 251, 278], ["GpIFN", "DNA", 286, 291], ["IFN", "PROTEIN", 316, 319], ["GpIFN", "DNA", 564, 569], ["E. coli", "SPECIES", 591, 598], ["Yeast", "SPECIES", 600, 605], ["a\uff0cEscherichia coli", "SPECIES", 682, 700], ["yeast", "SPECIES", 702, 707], ["Homo sapiens", "SPECIES", 713, 725], ["E. coli", "SPECIES", 591, 598], ["Yeast", "SPECIES", 600, 605], ["Adenovirus", "SPECIES", 607, 617], ["a\uff0cEscherichia coli", "SPECIES", 682, 700], ["yeast", "SPECIES", 702, 707], ["Homo sapiens", "SPECIES", 713, 725], ["the G+C content", "TEST", 42, 57], ["the gene sequences", "TEST", 61, 79], ["the G+C content", "TEST", 84, 99], ["the EMBOSS CUSP program", "TREATMENT", 176, 199], ["Phylogenetic Analysis", "TEST", 206, 227], ["the GpIFN", "TEST", 231, 240], ["amino acid sequences", "TEST", 343, 363], ["multiple sequence alignment", "TEST", 396, 423], ["phylogenetic analysis", "TEST", 428, 449], ["the bootstrap option", "TREATMENT", 453, 473], ["GpIFN", "TEST", 564, 569], ["E. coli", "PROBLEM", 591, 598], ["Yeast", "PROBLEM", 600, 605], ["Adenovirus", "PROBLEM", 607, 617], ["HumanA comparison analysis", "TEST", 623, 649], ["a\uff0cEscherichia coli", "PROBLEM", 682, 700], ["yeast", "PROBLEM", 702, 707], ["Homo sapiens", "PROBLEM", 713, 725], ["a\uff0cEscherichia coli", "ANATOMY", 682, 700], ["Homo sapiens", "OBSERVATION", 713, 725]]], ["The database of the codon usage in E. coli, yeast, and Homo sapiens was available at (http://www.kazusa.or. jp/ codon/).Characterization of Synonymous Codon Usage in the IFN-a Gene of Giant PandaWhile the relative synonymous codon usage values (RSCU) and the related measures indicate the overall GpIFN-a codon bias, it is also important to look more closely at the patterns of codon bias.", [["E. coli", "ORGANISM", 35, 42], ["Homo sapiens", "ORGANISM", 55, 67], ["jp", "GENE_OR_GENE_PRODUCT", 108, 110], ["IFN", "GENE_OR_GENE_PRODUCT", 170, 173], ["GpIFN", "GENE_OR_GENE_PRODUCT", 297, 302], ["jp", "PROTEIN", 108, 110], ["IFN", "PROTEIN", 170, 173], ["GpIFN", "DNA", 297, 302], ["E. coli", "SPECIES", 35, 42], ["yeast", "SPECIES", 44, 49], ["Homo sapiens", "SPECIES", 55, 67], ["E. coli", "SPECIES", 35, 42], ["yeast", "SPECIES", 44, 49], ["Homo sapiens", "SPECIES", 55, 67], ["E. coli", "PROBLEM", 35, 42], ["yeast", "PROBLEM", 44, 49], ["Homo sapiens", "PROBLEM", 55, 67], ["jp/ codon", "TREATMENT", 108, 117], ["Synonymous Codon Usage", "TREATMENT", 140, 162], ["coli", "ANATOMY", 38, 42], ["Synonymous Codon", "OBSERVATION", 140, 156], ["synonymous codon", "OBSERVATION", 214, 230], ["codon bias", "OBSERVATION", 378, 388]]], ["Table 2 shows the details of the codon usage patterns and codon usage data of giant panda IFN-\u03b1 gene (excluding Met, Trp, and the termination codons).", [["Trp", "CHEMICAL", 117, 120], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 90, 95], ["Met", "GENE_OR_GENE_PRODUCT", 112, 115], ["Trp", "GENE_OR_GENE_PRODUCT", 117, 120], ["giant panda IFN-\u03b1 gene", "DNA", 78, 100], ["Met, Trp, and the termination codons", "DNA", 112, 148], ["the codon usage", "TREATMENT", 29, 44], ["Trp", "TEST", 117, 120]]], ["A high level of diversity in codon usage bias existed for coding the Ala, Leu and Ser amino acids(emphasized with underline).", [["amino acids", "CHEMICAL", 86, 97], ["Ala", "CHEMICAL", 69, 72], ["Leu", "CHEMICAL", 74, 77], ["Ser", "CHEMICAL", 82, 85], ["amino acids", "CHEMICAL", 86, 97], ["Ala", "AMINO_ACID", 69, 72], ["Leu", "AMINO_ACID", 74, 77], ["Ser", "AMINO_ACID", 82, 85], ["amino acids", "AMINO_ACID", 86, 97], ["Leu and Ser amino acids", "TREATMENT", 74, 97], ["high", "OBSERVATION_MODIFIER", 2, 6]]], ["From the table 2 we can see that the frequencies of codons usage in coding the same amino acids are different.", [["amino acids", "CHEMICAL", 84, 95], ["amino acids", "CHEMICAL", 84, 95], ["amino acids", "AMINO_ACID", 84, 95], ["codons usage", "TREATMENT", 52, 64]]], ["There are 26 codons, such as CTG(Leu), AGG (Arg), ATC(Ile), CCC(Pro), TGG(Trp), TAC(Tyr) and so on, were more frequently used.", [["TAC", "CHEMICAL", 80, 83], ["Leu", "CHEMICAL", 33, 36], ["Arg", "CHEMICAL", 44, 47], ["Ile", "CHEMICAL", 54, 57], ["Pro", "CHEMICAL", 64, 67], ["Trp", "CHEMICAL", 74, 77], ["TAC", "CHEMICAL", 80, 83], ["Tyr", "CHEMICAL", 84, 87], ["AGG", "SIMPLE_CHEMICAL", 39, 42], ["Arg", "AMINO_ACID", 44, 47], ["ATC", "SIMPLE_CHEMICAL", 50, 53], ["TGG", "SIMPLE_CHEMICAL", 70, 73], ["Trp", "AMINO_ACID", 74, 77], ["TAC", "SIMPLE_CHEMICAL", 80, 83], ["26 codons", "PROBLEM", 10, 19], ["CTG", "TEST", 29, 32], ["AGG", "TEST", 39, 42], ["ATC", "TEST", 50, 53], ["TGG", "TEST", 70, 73], ["Trp", "TEST", 74, 77], ["26 codons", "OBSERVATION_MODIFIER", 10, 19]]], ["Among the preferred codons nineteen synonymous codons strong bias toward C-ended and nine toward G-ended at the third codon position.", [["G-ended", "GENE_OR_GENE_PRODUCT", 97, 104], ["third codon position", "DNA", 112, 132], ["synonymous codons", "TREATMENT", 36, 53]]], ["It is evident that codon usage bias in the mature polypeptide is strong bias towards the synonymous codons with G and C in the wobble.Codon Usage Analysis of the IFN-a Gene of Grint Panda and Reference SpeciesThe value of CAI, ENC and GC and GC3S content analysis of grint panda IFN-\u03b1 and other kinds of IFN-\u03b1 genes were obtained by EMBOSS.", [["IFN", "GENE_OR_GENE_PRODUCT", 162, 165], ["panda", "ORGANISM", 273, 278], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 279, 284], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 304, 309], ["IFN", "PROTEIN", 162, 165], ["CAI", "DNA", 222, 225], ["ENC", "DNA", 227, 230], ["grint panda IFN-\u03b1 and other kinds of IFN-\u03b1 genes", "DNA", 267, 315], ["grint panda", "SPECIES", 267, 278], ["the IFN", "TREATMENT", 158, 165], ["CAI", "TEST", 222, 225], ["ENC", "TEST", 227, 230], ["GC", "TEST", 235, 237], ["GC3S content analysis", "TEST", 242, 263], ["panda IFN", "TEST", 273, 282], ["IFN", "TEST", 304, 307], ["strong", "OBSERVATION_MODIFIER", 65, 71], ["synonymous codons", "OBSERVATION", 89, 106], ["wobble", "ANATOMY_MODIFIER", 127, 133]]], ["The results are shown in Table 3 It has been reported that a plot of ENC against GC 3S can be effectively used to explore the heterogeneity of codon usage among genes [23] .", [["ENC", "DNA", 69, 72], ["GC 3S", "TREATMENT", 81, 86]]], ["Figure 1 shows the distribution plot of the ENC and GC3S values for the IFN-\u03b1 gene in the reference species.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["ENC", "DNA", 44, 47], ["GC3S", "DNA", 52, 56], ["IFN-\u03b1 gene", "DNA", 72, 82], ["the ENC", "TEST", 40, 47], ["GC3S values", "TEST", 52, 63], ["the IFN", "TEST", 68, 75]]], ["The solid line represented the curve if codon usage was only determined by GC content on the third codon position [26] .", [["solid line", "ANATOMY", 4, 14], ["solid line", "CELL", 4, 14], ["The solid line", "TREATMENT", 0, 14], ["codon usage", "TREATMENT", 40, 51], ["solid line", "OBSERVATION", 4, 14]]], ["It is evident that there is only a small number of genes lying on the expect plot curve, most of the plot lay near to the solid line of this distribution (shown in Figure.Phylogenetic Analysis on the IFN-a Gene of Grint Panda and Reference SpeciesA phylogenetic tree based on the amino acid sequences of the IFN-a gene of the 16 reference species was shown in Fig. 2 .", [["amino acid", "CHEMICAL", 280, 290], ["amino acid", "CHEMICAL", 280, 290], ["amino acid", "AMINO_ACID", 280, 290], ["IFN", "GENE_OR_GENE_PRODUCT", 308, 311], ["IFN-a Gene of Grint Panda", "DNA", 200, 225], ["Reference SpeciesA phylogenetic tree", "DNA", 230, 266], ["IFN-a gene", "DNA", 308, 318], ["plot curve", "TEST", 77, 87], ["Phylogenetic Analysis", "TEST", 171, 192], ["the IFN", "TEST", 196, 203], ["the amino acid sequences", "TEST", 276, 300], ["small", "OBSERVATION_MODIFIER", 35, 40], ["number", "OBSERVATION_MODIFIER", 41, 47], ["solid line", "OBSERVATION", 122, 132]]], ["It shows that there are mainly two branches for the IFN-a family.", [["IFN", "GENE_OR_GENE_PRODUCT", 52, 55], ["IFN", "PROTEIN", 52, 55], ["mainly", "OBSERVATION_MODIFIER", 24, 30], ["two", "OBSERVATION_MODIFIER", 31, 34], ["branches", "OBSERVATION_MODIFIER", 35, 43]]], ["GpIFN-a has been clustered in the mammal branch.", [["GpIFN", "CHEMICAL", 0, 5], ["GpIFN", "GENE_OR_GENE_PRODUCT", 0, 5], ["mammal branch", "MULTI-TISSUE_STRUCTURE", 34, 47], ["GpIFN", "PROTEIN", 0, 5], ["mammal", "ANATOMY_MODIFIER", 34, 40], ["branch", "ANATOMY_MODIFIER", 41, 47]]], ["And we can also see that the grint panda and mustela putorius furo clustered in a monophyletic clade, and have a closer relationship with canis famililiaris and vulpes vulpes.", [["canis famililiaris", "DISEASE", 138, 156], ["grint panda", "ORGANISM", 29, 40], ["mustela putorius furo", "ORGANISM", 45, 66], ["canis famililiaris", "ORGANISM", 138, 156], ["vulpes vulpes", "ORGANISM", 161, 174], ["mustela putorius", "SPECIES", 45, 61], ["canis famililiaris", "SPECIES", 138, 156], ["grint panda", "SPECIES", 29, 40], ["canis famililiaris", "SPECIES", 138, 156], ["the grint panda", "PROBLEM", 25, 40], ["mustela putorius furo", "TREATMENT", 45, 66], ["vulpes vulpes", "OBSERVATION", 161, 174]]], ["Multiple sequence alignment of the amino acid sequences testify to the conclusion that grint panda is evolutionarily closer to the animal mentioned above.", [["amino acid", "CHEMICAL", 35, 45], ["amino acid", "CHEMICAL", 35, 45], ["amino acid", "AMINO_ACID", 35, 45], ["grint panda", "ORGANISM", 87, 98], ["grint panda", "SPECIES", 87, 98], ["the amino acid sequences", "TEST", 31, 55]]], ["The figure also shows that the IFN-a gene of grint panda is alienated to those whose natural host is avian on the evolution relationship.", [["IFN", "GENE_OR_GENE_PRODUCT", 31, 34], ["grint panda", "ORGANISM", 45, 56], ["IFN", "PROTEIN", 31, 34], ["grint panda", "SPECIES", 45, 56]]], ["(Table 1) , and constructed by CLUSTAL-W and TREEVIEW softwareComparison of Codon Usage between GpIFN-a and E. coli, Yeast and H. SapiensThe codon usage bias in genes remains at a certain level across species.", [["E. coli", "ORGANISM", 108, 115], ["H. Sapiens", "ORGANISM", 127, 137], ["E. coli", "SPECIES", 108, 115], ["Yeast", "SPECIES", 117, 122], ["E. coli", "SPECIES", 108, 115], ["Codon Usage", "TREATMENT", 76, 87], ["GpIFN", "TEST", 96, 101], ["E. coli", "PROBLEM", 108, 115], ["Yeast", "PROBLEM", 117, 122], ["The codon usage bias", "TREATMENT", 137, 157], ["Sapiens", "OBSERVATION", 130, 137], ["species", "OBSERVATION", 201, 208]]], ["We compared GpIFN-a gene with those of E.coli, yeast and H. sapiens to see which will be the suitable host for the optimal expression of GpIFN-a gene.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 12, 17], ["E.coli", "GENE_OR_GENE_PRODUCT", 39, 45], ["H. sapiens", "ORGANISM", 57, 67], ["GpIFN", "GENE_OR_GENE_PRODUCT", 137, 142], ["GpIFN", "PROTEIN", 12, 17], ["GpIFN", "PROTEIN", 137, 142], ["yeast", "SPECIES", 47, 52], ["H. sapiens", "SPECIES", 57, 67], ["E.coli", "SPECIES", 39, 45], ["yeast", "SPECIES", 47, 52], ["H. sapiens", "SPECIES", 57, 67], ["E.coli", "PROBLEM", 39, 45], ["yeast", "PROBLEM", 47, 52], ["H. sapiens", "PROBLEM", 57, 67], ["E.coli", "OBSERVATION", 39, 45]]], ["Contrastive analysis showed that there are 40 codons showing distinct usage differences between GpIFN-a and E.coli, 38 codons between GpIFN-a and yeast, but only 30 between GpIFN-a and H. sapiens, suggesting that codon usage of GpIFN-a genes more closely resembles that of H. sapiens genes.DiscussionCodon bias refers to the nonrandom usage of synonymous codons for encoding amino acids in organisms.", [["amino acids", "CHEMICAL", 375, 386], ["amino acids", "CHEMICAL", 375, 386], ["GpIFN-a", "GENE_OR_GENE_PRODUCT", 96, 103], ["E.coli", "GENE_OR_GENE_PRODUCT", 108, 114], ["GpIFN", "GENE_OR_GENE_PRODUCT", 134, 139], ["GpIFN", "GENE_OR_GENE_PRODUCT", 173, 178], ["H. sapiens", "ORGANISM", 185, 195], ["GpIFN", "GENE_OR_GENE_PRODUCT", 228, 233], ["H. sapiens", "ORGANISM", 273, 283], ["amino acids", "AMINO_ACID", 375, 386], ["GpIFN-a and E.coli, 38 codons", "DNA", 96, 125], ["GpIFN", "DNA", 134, 139], ["GpIFN", "DNA", 228, 233], ["H. sapiens genes", "DNA", 273, 289], ["yeast", "SPECIES", 146, 151], ["H. sapiens", "SPECIES", 185, 195], ["H. sapiens", "SPECIES", 273, 283], ["yeast", "SPECIES", 146, 151], ["H. sapiens", "SPECIES", 185, 195], ["H. sapiens", "SPECIES", 273, 283], ["Contrastive analysis", "TEST", 0, 20], ["40 codons", "PROBLEM", 43, 52], ["GpIFN", "TEST", 96, 101], ["E.coli", "PROBLEM", 108, 114], ["GpIFN", "TEST", 134, 139], ["H. sapiens", "PROBLEM", 185, 195], ["GpIFN", "PROBLEM", 228, 233], ["H. sapiens genes", "PROBLEM", 273, 289], ["synonymous codons", "TREATMENT", 344, 361], ["encoding amino acids in organisms", "PROBLEM", 366, 399], ["E.coli", "ANATOMY", 108, 114]]], ["As it is related to the carrier molecular of genetic information(DNA) and functional molecular (protein) of life, this phenomenon implicates important biological sense [27] .", [["DNA", "CELLULAR_COMPONENT", 65, 68], ["this phenomenon", "PROBLEM", 114, 129]]], ["Extensive studies had shown that synonymous codon usage in various organisms.", [["Extensive studies", "TEST", 0, 17], ["synonymous codon usage", "PROBLEM", 33, 55], ["various organisms", "PROBLEM", 59, 76], ["synonymous codon", "OBSERVATION", 33, 49]]], ["Although the codon usage pattern among different species is a complex phenomenon, it plays an important role in illuminating the underlying mechanisms of codon usage patterns in order to understand the evolution of the species.", [["a complex phenomenon", "PROBLEM", 60, 80], ["the species", "PROBLEM", 215, 226], ["different", "OBSERVATION_MODIFIER", 39, 48], ["species", "OBSERVATION_MODIFIER", 49, 56], ["complex", "OBSERVATION_MODIFIER", 62, 69], ["phenomenon", "OBSERVATION", 70, 80]]], ["Signal peptides consist of short stretches of amino acids which, after protein delivery to the correct subcellular compartment, are frequently removed by specialized signal peptidases [28] .", [["subcellular compartment", "ANATOMY", 103, 126], ["amino acids", "CHEMICAL", 46, 57], ["amino acids", "CHEMICAL", 46, 57], ["amino acids", "AMINO_ACID", 46, 57], ["signal peptidases", "PROTEIN", 166, 183], ["Signal peptides", "TEST", 0, 15], ["short stretches of amino acids", "PROBLEM", 27, 57], ["protein delivery", "TREATMENT", 71, 87], ["amino acids", "OBSERVATION", 46, 57], ["subcellular compartment", "ANATOMY", 103, 126]]], ["Only after removal of the signal peptide sequence, the precursor protein may be allowed to entry into the secretory pathway and become a normal function of the mature protein [29] .", [["precursor protein", "PROTEIN", 55, 72], ["removal", "TREATMENT", 11, 18], ["the signal peptide sequence", "TEST", 22, 49], ["the precursor protein", "TEST", 51, 72], ["normal", "OBSERVATION", 137, 143]]], ["We intend to express the GpIFN-a gene in prokaryotic expression system and test its antiviral effects in future.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 25, 30], ["GpIFN", "PROTEIN", 25, 30]]], ["In order to keep the higher biological activity, we cloned the gene fragment coding for mature protein of GpIFN-a.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 106, 111], ["mature protein", "PROTEIN", 88, 102], ["GpIFN", "PROTEIN", 106, 111]]], ["In this study, we analyzed the codon usage data of GpIFN-a without signal peptide and those of other 15 species of IFN-a, Additionally, we investigated the correlation of codon usage between GpIFN-a gene with Escherichia coli, yeast, and Homo sapiens to find the suitable expression system.", [["GpIFN", "GENE_OR_GENE_PRODUCT", 51, 56], ["IFN", "GENE_OR_GENE_PRODUCT", 115, 118], ["GpIFN", "GENE_OR_GENE_PRODUCT", 191, 196], ["Escherichia coli", "ORGANISM", 209, 225], ["Homo sapiens", "ORGANISM", 238, 250], ["GpIFN", "PROTEIN", 51, 56], ["IFN", "PROTEIN", 115, 118], ["GpIFN-a gene", "DNA", 191, 203], ["Escherichia coli", "SPECIES", 209, 225], ["yeast", "SPECIES", 227, 232], ["Homo sapiens", "SPECIES", 238, 250], ["Escherichia coli", "SPECIES", 209, 225], ["yeast", "SPECIES", 227, 232], ["Homo sapiens", "SPECIES", 238, 250], ["this study", "TEST", 3, 13], ["GpIFN", "TEST", 51, 56], ["signal peptide", "PROBLEM", 67, 81], ["IFN", "TEST", 115, 118], ["codon usage", "PROBLEM", 171, 182], ["GpIFN", "TEST", 191, 196], ["Escherichia coli", "PROBLEM", 209, 225], ["yeast", "PROBLEM", 227, 232], ["Homo sapiens", "PROBLEM", 238, 250], ["Escherichia coli", "OBSERVATION", 209, 225]]], ["RSCU, CAI, ENC values, GC and GC3s content of the IFN-\u03b1 gene were predicted by using the EMBOSS CUSP program and CHIPS program.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 50, 55], ["ENC", "DNA", 11, 14], ["IFN-\u03b1 gene", "DNA", 50, 60], ["CAI", "TEST", 6, 9], ["ENC values", "TEST", 11, 21], ["GC", "TEST", 23, 25], ["CHIPS program", "TREATMENT", 113, 126]]], ["RSCU with direct assessment codon usage bias of different codons in each gene sample.", [["direct assessment", "TEST", 10, 27], ["different codons", "PROBLEM", 48, 64]]], ["When its value greater than 1.0 indicated that the corresponding codon was used more frequently than expected.", [["the corresponding codon", "PROBLEM", 47, 70], ["codon", "OBSERVATION", 65, 70]]], ["Table 2 showed that there were 26 preferred codons\uff0cmost of them were strong bias towards the synonymous codons with G and C in the wobble, coincides with high G+C content at the third codon position (the mean value was 76.85%).", [["G+C", "SIMPLE_CHEMICAL", 159, 162], ["third codon position", "DNA", 178, 198], ["G and C in the wobble", "PROBLEM", 116, 137], ["high G+C content", "PROBLEM", 154, 170], ["the mean value", "TEST", 200, 214], ["synonymous codons", "OBSERVATION", 93, 110]]], ["CAI was used as a measure to predict the level of gene expression.The value was between 0 and 1 [30] , a higher value means a stronger codon usage bias and a higher expression level. the CAI values for IFN-\u03b1 genes were slight variation among different species and with a mean value of 0.808, so we concluded IFN-\u03b1 gene was likely to be moderately expressed in giant panda genome.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 202, 207], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 308, 313], ["panda", "ORGANISM", 366, 371], ["CAI", "DNA", 0, 3], ["CAI", "DNA", 187, 190], ["IFN-\u03b1 genes", "DNA", 202, 213], ["IFN-\u03b1 gene", "DNA", 308, 318], ["giant panda genome", "DNA", 360, 378], ["giant panda", "SPECIES", 360, 371], ["The value", "TEST", 66, 75], ["a higher expression level", "PROBLEM", 156, 181], ["the CAI values", "TEST", 183, 197], ["IFN", "TEST", 202, 205], ["slight variation among different species", "PROBLEM", 219, 259], ["a mean value", "TEST", 269, 281], ["IFN", "TEST", 308, 311], ["slight", "OBSERVATION_MODIFIER", 219, 225], ["variation", "OBSERVATION_MODIFIER", 226, 235], ["giant panda genome", "OBSERVATION", 360, 378]]], ["The ENC is a measure analogous to the effective number of alleles.", [["ENC", "DNA", 4, 7], ["alleles", "DNA", 58, 65]]], ["It ranges from 20, where only one codon is used for each amino acid to 61 if all codons are used equally [31] .", [["amino acid", "CHEMICAL", 57, 67], ["amino acid", "CHEMICAL", 57, 67], ["amino acid", "AMINO_ACID", 57, 67], ["each amino acid", "TEST", 52, 67], ["all codons", "TEST", 77, 87]]], ["In general, if the ENC value of a gene is 35 or less, that gene is thought to possess strong codon bias [32] .", [["ENC", "DNA", 19, 22], ["the ENC value", "TEST", 15, 28]]], ["Analyzing the ENC values of all the IFN-\u03b1 genes, the results showed the ENC values of mammal's IFN-\u03b1 genes(mean value of 45.26) were higher than birds' IFN-\u03b1 gene(mean value of 30.20) , So the codon usage bias was slightly low in mammal but strong in bird.DiscussionThe ENC-plot (ENC plotted against GC ) is used as part of a general strategy to investigate patterns of synonymous codon usage.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 36, 41], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 95, 100], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 152, 157], ["ENC", "DNA", 14, 17], ["IFN-\u03b1 genes", "DNA", 36, 47], ["ENC", "DNA", 72, 75], ["mammal's IFN-\u03b1 genes", "DNA", 86, 106], ["IFN-\u03b1 gene", "DNA", 152, 162], ["ENC", "DNA", 270, 273], ["ENC", "DNA", 280, 283], ["Analyzing the ENC values", "TEST", 0, 24], ["all the IFN", "TEST", 28, 39], ["the ENC values", "TEST", 68, 82], ["mammal's IFN", "TEST", 86, 98], ["mean value", "TEST", 107, 117], ["IFN", "TEST", 152, 155], ["mean value", "TEST", 163, 173], ["slightly low in mammal", "PROBLEM", 214, 236], ["GC )", "TREATMENT", 300, 304], ["a general strategy", "TREATMENT", 324, 342], ["synonymous codon usage", "TREATMENT", 370, 392], ["slightly", "OBSERVATION_MODIFIER", 214, 222], ["low", "OBSERVATION_MODIFIER", 223, 226], ["synonymous codon", "OBSERVATION", 370, 386]]], ["In fig.1 , the solid line represents the curve if codon usage is only determined by GC content on the third codon position [33] , There is only a small number of genes lying on the expect plot curve, most of the plot lay near to the solid line.", [["solid line", "ANATOMY", 15, 25], ["solid line", "CELL", 15, 25], ["solid line", "CELL", 233, 243], ["the solid line", "TREATMENT", 11, 25], ["codon usage", "TREATMENT", 50, 61], ["plot curve", "TEST", 188, 198], ["solid line", "OBSERVATION", 15, 25], ["small", "OBSERVATION_MODIFIER", 146, 151], ["number", "OBSERVATION_MODIFIER", 152, 158], ["solid line", "OBSERVATION", 233, 243]]], ["In principle, proprietary proportion of points lay near to the solid line on this distribution.", [["solid line", "OBSERVATION", 63, 73]]], ["It suggested that mutational bias was the main factor determining the codon usage variation among these IFN-\u03b1 genes.DiscussionComparative analysis of IFN-\u03b1 genes in giant panda and the reference species indicated that synonymous codon usage in mammal's IFN-\u03b1 genes are phylogenetically conserved.", [["giant panda", "ANATOMY", 165, 176], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 150, 155], ["giant panda", "CELL", 165, 176], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 253, 258], ["IFN-\u03b1 genes", "DNA", 104, 115], ["IFN-\u03b1 genes", "DNA", 150, 161], ["mammal's IFN-\u03b1 genes", "DNA", 244, 264], ["mutational bias", "PROBLEM", 18, 33], ["DiscussionComparative analysis", "TEST", 116, 146], ["IFN", "PROBLEM", 150, 153], ["giant panda", "PROBLEM", 165, 176], ["synonymous codon usage", "PROBLEM", 218, 240], ["mutational bias", "OBSERVATION", 18, 33], ["synonymous codon", "OBSERVATION", 218, 234]]], ["Data in table 3 show that the IFN-\u03b1 genes of mammal have similar CAI, ENC value and GC content.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 30, 35], ["IFN-\u03b1 genes", "DNA", 30, 41], ["CAI", "DNA", 65, 68], ["ENC", "DNA", 70, 73], ["Data in table", "TEST", 0, 13], ["the IFN", "TEST", 26, 33], ["similar CAI", "PROBLEM", 57, 68]]], ["But a slight difference with birds'.", [["slight", "OBSERVATION_MODIFIER", 6, 12], ["difference", "OBSERVATION", 13, 23]]], ["Therefore we can conclude species with near homology relationship on evolution share the near codon usage frequency and preference index or the similar index.", [["preference index", "TEST", 120, 136]]], ["The phylogenetic tree analysis based on the IFN-\u03b1 genes testify to the conclusion.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 44, 49], ["IFN-\u03b1 genes", "DNA", 44, 55], ["The phylogenetic tree analysis", "TEST", 0, 30], ["the IFN", "TEST", 40, 47], ["phylogenetic tree", "OBSERVATION", 4, 21]]], ["So species has a centain influence to the preference of codon usage.DiscussionThe expression of functional proteins in heterologous hosts is a cornerstone of modern biotechnology.", [["functional proteins", "PROTEIN", 96, 115], ["codon usage", "TREATMENT", 56, 67]]], ["In order to find the suitable host for the optimal expression of GpIFN-\u03b1 genes. we compared it with those of E. coli, yeast, and H. sapiens.", [["GpIFN-\u03b1", "GENE_OR_GENE_PRODUCT", 65, 72], ["E. coli", "ORGANISM", 109, 116], ["H. sapiens", "ORGANISM", 129, 139], ["GpIFN", "PROTEIN", 65, 70], ["\u03b1 genes", "DNA", 71, 78], ["E. coli", "SPECIES", 109, 116], ["yeast", "SPECIES", 118, 123], ["H. sapiens", "SPECIES", 129, 139], ["E. coli", "SPECIES", 109, 116], ["yeast", "SPECIES", 118, 123], ["H. sapiens", "SPECIES", 129, 139], ["E. coli", "PROBLEM", 109, 116], ["yeast", "PROBLEM", 118, 123], ["H. sapiens", "PROBLEM", 129, 139], ["H. sapiens", "OBSERVATION", 129, 139]]], ["The ratio higher than 2 or lower than 0.050 indicated the codon usage preference differed (shown in table 4.).", [["The ratio", "TEST", 0, 9], ["ratio", "OBSERVATION_MODIFIER", 4, 9], ["higher", "OBSERVATION_MODIFIER", 10, 16]]], ["The rusults revealed that Homo sapiens may more efficiently to express the GpIFN-\u03b1 genes.", [["Homo sapiens", "ORGANISM", 26, 38], ["GpIFN-\u03b1", "GENE_OR_GENE_PRODUCT", 75, 82], ["GpIFN", "PROTEIN", 75, 80], ["\u03b1 genes", "DNA", 81, 88], ["Homo sapiens", "SPECIES", 26, 38], ["Homo sapiens", "SPECIES", 26, 38], ["Homo sapiens", "PROBLEM", 26, 38], ["Homo sapiens", "OBSERVATION", 26, 38]]], ["If we want to express this gene in prokaryotic expression system, maybe some strategies should be taken in the target gene so that they more closely reflect the codon usage of the host.DiscussionIn summary, codon usage patterns and the phylogenetic results we proposed here were useful to understand the characteres of GpIFN-\u03b1 gene and a better understanding of both the evolutionary history of these genes.", [["GpIFN-\u03b1", "GENE_OR_GENE_PRODUCT", 319, 326], ["target gene", "DNA", 111, 122], ["GpIFN-\u03b1 gene", "DNA", 319, 331]]], ["And also might help in increasing the efficiency of gene delivery/expression systems.", [["gene delivery/expression systems", "TREATMENT", 52, 84]]]], "PMC7382711": [["In certain parts of the world, the toll on healthcare workers has been immense, and practicing outside one's traditional scope and comfort zone has become the rule rather than the exception.", [["comfort zone", "TREATMENT", 131, 143]]], ["For Radiology as a discipline, the stress of COVID-19 may be comparatively small when measured against the frontline physicians and nurses in the Emergency Department and Intensive Care Unit.", [["COVID", "TEST", 45, 50]]], ["In fact, recent prior work has demonstrated significant declines in imaging volumes due to a combination of cancelation of elective procedures and outpatient diagnostic services, public policy and patient fear [1,2].", [["patient", "ORGANISM", 197, 204], ["patient", "SPECIES", 197, 204], ["significant declines", "PROBLEM", 44, 64], ["imaging volumes", "TEST", 68, 83], ["elective procedures", "TREATMENT", 123, 142], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["declines", "OBSERVATION_MODIFIER", 56, 64]]], ["Imaging does however play a vital role in the initial diagnosis and follow up of suspected COVID-19 cases in the acute care setting, and as such, radiologists are an integral part of the healthcare delivery team [3,4].", [["COVID", "DISEASE", 91, 96], ["Imaging", "TEST", 0, 7]]], ["It is incumbent upon all disciplines to learn and grow from the challenges encountered during this crisis.", [["this crisis", "PROBLEM", 94, 105]]]], "PMC7114227": [["IntroductionMany viruses with a single-stranded, positive-sense RNA genome regulate their genome expression by synthesizing large precursor polypeptides (or polyproteins) that are subsequently subjected to limited proteolysis to produce functional viral proteins (for reviews, see Dougherty and Semler, 1993, Gorbalenya and Snijder, 1996, Krausslich and Wimmer, 1988, Spall et al., 1997).", [["positive-sense RNA genome", "DNA", 49, 74], ["precursor polypeptides", "PROTEIN", 130, 152], ["polyproteins", "PROTEIN", 157, 169], ["viral proteins", "PROTEIN", 248, 262], ["IntroductionMany viruses", "PROBLEM", 0, 24], ["a single-stranded, positive-sense RNA genome", "PROBLEM", 30, 74], ["synthesizing large precursor polypeptides", "PROBLEM", 111, 152], ["polyproteins", "PROBLEM", 157, 169], ["limited proteolysis", "PROBLEM", 206, 225], ["viruses", "OBSERVATION", 17, 24], ["large", "OBSERVATION_MODIFIER", 124, 129], ["precursor polypeptides", "OBSERVATION", 130, 152]]], ["RNA virus polyproteins that include replicative proteins are often processed autocatalytically, although in some virus groups cellular proteinases are also involved.", [["cellular", "ANATOMY", 126, 134], ["cellular proteinases", "GENE_OR_GENE_PRODUCT", 126, 146], ["replicative proteins", "PROTEIN", 36, 56], ["cellular proteinases", "PROTEIN", 126, 146], ["RNA virus polyproteins", "PROBLEM", 0, 22], ["replicative proteins", "TREATMENT", 36, 56], ["some virus groups cellular proteinases", "PROBLEM", 108, 146], ["virus polyproteins", "OBSERVATION", 4, 22], ["replicative proteins", "OBSERVATION", 36, 56]]], ["In this manner, the expression of the non-structural proteins (or \u201creplicase\u201d complex) can be regulated in time and space, e.g. to produce alternative cleavage products or stable processing intermediates with unique functions (de Groot et al., 1990, Jore et al., 1988, Lemm et al., 1994, Ypma-Wong et al., 1988).IntroductionViruses in the order Nidovirales, which unifies the enveloped, positive-stranded Arteriviridae, Coronaviridae, and Roniviridae (Snijder et al., 2005, Spaan et al., 2005), have a similar polycistronic genome organization, share a conserved array of homologous replicase domains, and use common transcriptional and (post)-translational strategies to regulate their genome expression.", [["replicase\u201d complex", "GENE_OR_GENE_PRODUCT", 67, 85], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 345, 356], ["non-structural proteins", "PROTEIN", 38, 61], ["\u201creplicase\u201d complex", "PROTEIN", 66, 85], ["cleavage products", "PROTEIN", 151, 168], ["homologous replicase domains", "DNA", 572, 600], ["the non-structural proteins", "PROBLEM", 34, 61], ["alternative cleavage products", "TREATMENT", 139, 168], ["IntroductionViruses", "TREATMENT", 312, 331], ["Nidovirales", "TREATMENT", 345, 356], ["stranded Arteriviridae", "TREATMENT", 396, 418], ["Coronaviridae", "TREATMENT", 420, 433], ["Roniviridae", "TREATMENT", 439, 450], ["translational strategies", "TREATMENT", 644, 668], ["polycistronic genome", "OBSERVATION", 510, 530]]], ["Among these strategies, one of the most crucial is the proteolytic maturation of the replicase polyproteins pp1a and pp1ab that are translated from the incoming genome (den Boon et al., 1991, Ziebuhr et al., 2000).IntroductionEquine arteritis virus (EAV) is the prototype of the arterivirus family and has a genome of approximately 12.7 kb, of which the 5\u2032-proximal three quarters contain the replicase gene.", [["Equine arteritis", "DISEASE", 226, 242], ["pp1a", "GENE_OR_GENE_PRODUCT", 108, 112], ["pp1ab", "GENE_OR_GENE_PRODUCT", 117, 122], ["Equine arteritis virus", "ORGANISM", 226, 248], ["EAV", "ORGANISM", 250, 253], ["arterivirus", "CANCER", 279, 290], ["replicase polyproteins", "PROTEIN", 85, 107], ["pp1a", "PROTEIN", 108, 112], ["pp1ab", "PROTEIN", 117, 122], ["5\u2032", "DNA", 354, 356], ["replicase gene", "DNA", 393, 407], ["Equine arteritis virus", "SPECIES", 226, 248], ["Equine arteritis virus", "SPECIES", 226, 248], ["EAV", "SPECIES", 250, 253], ["IntroductionEquine arteritis virus", "PROBLEM", 214, 248], ["arteritis", "OBSERVATION", 233, 242], ["proximal", "ANATOMY_MODIFIER", 357, 365], ["replicase gene", "OBSERVATION", 393, 407]]], ["The 3\u2032-proximal region of the genome includes seven open reading frames encoding the viral structural proteins, which are expressed from a nested set of subgenomic mRNAs (de Vries et al., 1990, Snijder and Meulenberg, 2001).", [["3\u2032-proximal region", "DNA", 4, 22], ["open reading frames", "DNA", 52, 71], ["viral structural proteins", "PROTEIN", 85, 110], ["subgenomic mRNAs", "RNA", 153, 169], ["the viral structural proteins", "PROBLEM", 81, 110], ["proximal", "ANATOMY_MODIFIER", 7, 15], ["region", "ANATOMY_MODIFIER", 16, 22], ["genome", "OBSERVATION", 30, 36], ["viral structural proteins", "OBSERVATION", 85, 110], ["subgenomic mRNAs", "OBSERVATION", 153, 169]]], ["Replicase gene expression ultimately yields (at least) 12 non-structural proteins (Fig. 1A; Snijder et al., 1994, van Dinten et al., 1996, Wassenaar et al., 1997), which are produced from two primary genome translation products, the large polyproteins pp1a (1728 amino acids) and pp1ab (3175 amino acids), with the latter being expressed following a ribosomal frameshifting event (den Boon et al., 1991).", [["ribosomal", "ANATOMY", 350, 359], ["amino acids", "CHEMICAL", 263, 274], ["amino acids", "CHEMICAL", 292, 303], ["amino acids", "CHEMICAL", 263, 274], ["amino acids", "CHEMICAL", 292, 303], ["Replicase", "GENE_OR_GENE_PRODUCT", 0, 9], ["pp1a", "GENE_OR_GENE_PRODUCT", 252, 256], ["amino acids", "AMINO_ACID", 263, 274], ["pp1ab", "AMINO_ACID", 280, 285], ["amino acids", "AMINO_ACID", 292, 303], ["non-structural proteins", "PROTEIN", 58, 81], ["primary genome translation products", "PROTEIN", 192, 227], ["large polyproteins", "PROTEIN", 233, 251], ["pp1a", "PROTEIN", 252, 256], ["1728 amino acids", "PROTEIN", 258, 274], ["pp1ab", "PROTEIN", 280, 285], ["the large polyproteins pp1a", "TREATMENT", 229, 256], ["amino acids", "TEST", 263, 274], ["pp1ab (3175 amino acids", "TREATMENT", 280, 303], ["a ribosomal frameshifting event", "PROBLEM", 348, 379], ["large", "OBSERVATION_MODIFIER", 233, 238], ["ribosomal frameshifting", "OBSERVATION", 350, 373]]], ["The replicase subunits are released from the polyproteins by three virus-encoded proteinases (Fig. 1), of which the one located in nsp4 is responsible for the processing of the polypeptides that remain after nsp1 and nsp2 have been autocatalytically released from pp1a and pp1ab (Snijder et al., 1992, Snijder et al., 1994, Snijder et al., 1995, Snijder et al., 1996, van Dinten et al., 1999, Wassenaar et al., 1997).", [["Fig. 1", "GENE_OR_GENE_PRODUCT", 94, 100], ["nsp4", "GENE_OR_GENE_PRODUCT", 131, 135], ["nsp1", "GENE_OR_GENE_PRODUCT", 208, 212], ["nsp2", "GENE_OR_GENE_PRODUCT", 217, 221], ["pp1a", "GENE_OR_GENE_PRODUCT", 264, 268], ["pp1ab", "GENE_OR_GENE_PRODUCT", 273, 278], ["replicase subunits", "PROTEIN", 4, 22], ["virus-encoded proteinases", "PROTEIN", 67, 92], ["Fig. 1", "PROTEIN", 94, 100], ["nsp4", "PROTEIN", 131, 135], ["nsp1", "PROTEIN", 208, 212], ["nsp2", "PROTEIN", 217, 221], ["pp1a", "PROTEIN", 264, 268], ["pp1ab", "PROTEIN", 273, 278], ["The replicase subunits", "TREATMENT", 0, 22], ["the polyproteins", "PROBLEM", 41, 57], ["nsp4", "PROBLEM", 131, 135], ["the polypeptides", "TREATMENT", 173, 189], ["nsp1", "PROBLEM", 208, 212], ["nsp2", "PROBLEM", 217, 221], ["replicase subunits", "OBSERVATION", 4, 22], ["nsp4", "OBSERVATION", 131, 135]]], ["Since nsp4 controls the production of the viral RNA-dependent RNA polymerase and RNA helicase, it has been termed the EAV \u201cmain proteinase\u201d (Gorbalenya et al., 1991, Ziebuhr et al., 2000).IntroductionThe arterivirus nsp4 main proteinase belongs to the 3C-like serine proteinases, a distinct group of viral chymotrypsin-like proteolytic enzymes (Barrette-Ng et al., 2002, Snijder et al., 1996, Ziebuhr et al., 2000).", [["serine", "CHEMICAL", 260, 266], ["nsp4", "GENE_OR_GENE_PRODUCT", 6, 10], ["3C", "GENE_OR_GENE_PRODUCT", 252, 254], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 306, 318], ["nsp4", "PROTEIN", 6, 10], ["viral RNA", "RNA", 42, 51], ["RNA polymerase", "PROTEIN", 62, 76], ["RNA helicase", "PROTEIN", 81, 93], ["arterivirus nsp4 main proteinase", "PROTEIN", 204, 236], ["3C-like serine proteinases", "PROTEIN", 252, 278], ["viral chymotrypsin-like proteolytic enzymes", "PROTEIN", 300, 343], ["the viral RNA-dependent RNA polymerase and RNA helicase", "PROBLEM", 38, 93], ["the 3C", "TEST", 248, 254], ["serine proteinases", "PROBLEM", 260, 278], ["viral chymotrypsin", "PROBLEM", 300, 318], ["proteolytic enzymes", "TEST", 324, 343], ["viral RNA", "OBSERVATION", 42, 51], ["viral chymotrypsin", "OBSERVATION", 300, 318]]], ["The arterivirus proteinase combines the catalytic triad His/Asp/Ser of canonical chymotrypsin-like proteinases with the substrate specificity of the 3C-like cysteine proteinases, a subgroup of chymotrypsin-like enzymes named after the picornavirus 3C proteinases.", [["His", "CHEMICAL", 56, 59], ["Asp", "CHEMICAL", 60, 63], ["Ser", "CHEMICAL", 64, 67], ["cysteine", "CHEMICAL", 157, 165], ["arterivirus proteinase", "GENE_OR_GENE_PRODUCT", 4, 26], ["Asp", "AMINO_ACID", 60, 63], ["Ser", "AMINO_ACID", 64, 67], ["chymotrypsin-like proteinases", "GENE_OR_GENE_PRODUCT", 81, 110], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 193, 205], ["arterivirus proteinase", "PROTEIN", 4, 26], ["catalytic triad His/Asp/Ser of canonical chymotrypsin-like proteinases", "PROTEIN", 40, 110], ["3C-like cysteine proteinases", "PROTEIN", 149, 177], ["chymotrypsin-like enzymes", "PROTEIN", 193, 218], ["picornavirus 3C proteinases", "PROTEIN", 235, 262], ["The arterivirus proteinase", "TEST", 0, 26], ["Asp", "TEST", 60, 63], ["canonical chymotrypsin-like proteinases", "PROBLEM", 71, 110], ["the 3C-like cysteine proteinases", "PROBLEM", 145, 177], ["chymotrypsin", "TEST", 193, 205], ["enzymes", "TEST", 211, 218], ["the picornavirus 3C proteinases", "TREATMENT", 231, 262]]], ["In the cleaved, 204-residue EAV nsp4 (which equals Gly-1065 to Glu-1268 of the EAV replicase polyproteins) the catalytic triad is formed by His-39, Asp-65, and Ser-120.", [["Gly-1065", "CHEMICAL", 51, 59], ["Glu-1268", "CHEMICAL", 63, 71], ["Gly", "CHEMICAL", 51, 54], ["Glu", "CHEMICAL", 63, 66], ["His", "CHEMICAL", 140, 143], ["Asp", "CHEMICAL", 148, 151], ["Ser", "CHEMICAL", 160, 163], ["nsp4", "GENE_OR_GENE_PRODUCT", 32, 36], ["Gly-1065", "AMINO_ACID", 51, 59], ["Glu-1268", "AMINO_ACID", 63, 71], ["Asp-65", "AMINO_ACID", 148, 154], ["Ser-120", "AMINO_ACID", 160, 167], ["EAV replicase polyproteins", "PROTEIN", 79, 105], ["catalytic triad", "PROTEIN", 111, 126], ["residue EAV nsp4", "TEST", 20, 36], ["Gly", "TEST", 51, 54], ["Glu", "TEST", 63, 66], ["the EAV replicase polyproteins", "TREATMENT", 75, 105], ["the catalytic triad", "TEST", 107, 126], ["His", "TEST", 140, 143], ["Asp", "TEST", 148, 151], ["Ser", "TEST", 160, 163]]], ["Cleavage sites recognized by the nsp4 proteinase carry a Glu at the P 1 position (Gln in one case) and a small amino acid (Gly, Ser, Ala) at the P 1\u2032 position (using the cleavage site nomenclature of Schechter and Berger, 1967).", [["Glu", "CHEMICAL", 57, 60], ["Gln", "CHEMICAL", 82, 85], ["amino acid", "CHEMICAL", 111, 121], ["Glu", "CHEMICAL", 57, 60], ["Gln", "CHEMICAL", 82, 85], ["amino acid", "CHEMICAL", 111, 121], ["Gly", "CHEMICAL", 123, 126], ["Ser", "CHEMICAL", 128, 131], ["Ala", "CHEMICAL", 133, 136], ["nsp4 proteinase", "GENE_OR_GENE_PRODUCT", 33, 48], ["Glu", "AMINO_ACID", 57, 60], ["Gln", "AMINO_ACID", 82, 85], ["amino acid", "AMINO_ACID", 111, 121], ["Gly", "AMINO_ACID", 123, 126], ["Ser, Ala", "AMINO_ACID", 128, 136], ["nsp4 proteinase", "PROTEIN", 33, 48], ["P 1 position", "DNA", 68, 80], ["P 1\u2032 position", "DNA", 145, 158], ["Cleavage sites", "PROBLEM", 0, 14], ["a small amino acid (Gly, Ser, Ala)", "TREATMENT", 103, 137], ["small", "OBSERVATION_MODIFIER", 105, 110], ["amino acid", "OBSERVATION", 111, 121]]], ["Furthermore, nsp4 possesses a unique C-terminal domain (CTD) extension of unknown function, which is not found in most other chymotrypsin-like proteinases and might be involved in modulation of nsp4 activity (Barrette-Ng et al., 2002).IntroductionArterivirus replication depends on the regulation of replicase gene expression in time and space, in which nsp4 plays a key role.", [["nsp4", "CHEMICAL", 13, 17], ["C", "CHEMICAL", 37, 38], ["nsp4", "GENE_OR_GENE_PRODUCT", 13, 17], ["chymotrypsin-like proteinases", "GENE_OR_GENE_PRODUCT", 125, 154], ["nsp4", "GENE_OR_GENE_PRODUCT", 194, 198], ["Arterivirus", "GENE_OR_GENE_PRODUCT", 247, 258], ["nsp4", "GENE_OR_GENE_PRODUCT", 354, 358], ["nsp4", "PROTEIN", 13, 17], ["C-terminal domain", "PROTEIN", 37, 54], ["CTD", "PROTEIN", 56, 59], ["chymotrypsin-like proteinases", "PROTEIN", 125, 154], ["nsp4", "PROTEIN", 194, 198], ["replicase gene", "DNA", 300, 314], ["nsp4", "PROTEIN", 354, 358], ["nsp4", "PROBLEM", 13, 17], ["a unique C-terminal domain (CTD) extension", "PROBLEM", 28, 70], ["nsp4 activity", "PROBLEM", 194, 207], ["IntroductionArterivirus replication", "TREATMENT", 235, 270], ["unknown function", "OBSERVATION", 74, 90], ["nsp4 activity", "OBSERVATION", 194, 207]]], ["Notably, an elegant (presumably) regulatory mechanism connected to nsp4-driven proteolysis was documented in the form of the differential processing of the nsp4\u20138 part of the EAV replicase polyproteins (Fig. 1B; Wassenaar et al., 1997).", [["nsp4", "GENE_OR_GENE_PRODUCT", 67, 71], ["nsp4\u20138", "GENE_OR_GENE_PRODUCT", 156, 162], ["nsp4", "PROTEIN", 67, 71], ["nsp4\u20138 part", "PROTEIN", 156, 167], ["EAV replicase polyproteins", "PROTEIN", 175, 201], ["EAV", "SPECIES", 175, 178], ["an elegant (presumably) regulatory mechanism", "PROBLEM", 9, 53], ["nsp4-driven proteolysis", "PROBLEM", 67, 90], ["the EAV replicase polyproteins", "PROBLEM", 171, 201], ["EAV", "OBSERVATION", 175, 178], ["replicase polyproteins", "OBSERVATION", 179, 201]]], ["Together, the two pathways yield a variety of products, whose role in the viral life cycle remains to be studied in detail.IntroductionThe biochemical characterization of the arterivirus main proteinase requires the large-scale expression and purification of an active form of the enzyme.", [["arterivirus main proteinase", "PROTEIN", 175, 202], ["enzyme", "PROTEIN", 281, 287], ["the viral life cycle", "TREATMENT", 70, 90], ["The biochemical characterization", "TEST", 135, 167], ["the large-scale expression", "TREATMENT", 212, 238], ["the enzyme", "TEST", 277, 287], ["variety", "OBSERVATION_MODIFIER", 35, 42], ["large", "OBSERVATION_MODIFIER", 216, 221], ["active", "OBSERVATION", 262, 268]]], ["In this paper, we describe the production of active, recombinant EAV nsp4 from Escherichia coli (E. coli), allowing the design of an in vitro cleavage assay, which was used to characterize the properties of nsp4 and its interaction with substrates.", [["EAV", "ORGANISM", 65, 68], ["nsp4", "GENE_OR_GENE_PRODUCT", 69, 73], ["Escherichia coli", "ORGANISM", 79, 95], ["E. coli", "ORGANISM", 97, 104], ["nsp4", "GENE_OR_GENE_PRODUCT", 207, 211], ["recombinant EAV nsp4", "PROTEIN", 53, 73], ["nsp4", "PROTEIN", 207, 211], ["Escherichia coli", "SPECIES", 79, 95], ["E. coli", "SPECIES", 97, 104], ["EAV", "SPECIES", 65, 68], ["Escherichia coli", "SPECIES", 79, 95], ["E. coli", "SPECIES", 97, 104], ["active, recombinant EAV nsp4", "PROBLEM", 45, 73], ["Escherichia coli", "PROBLEM", 79, 95], ["E. coli", "PROBLEM", 97, 104], ["an in vitro cleavage assay", "TEST", 130, 156], ["nsp4", "PROBLEM", 207, 211], ["active", "OBSERVATION_MODIFIER", 45, 51], ["Escherichia coli", "OBSERVATION", 79, 95], ["nsp4", "OBSERVATION", 207, 211]]], ["The expression system also formed the basis for structural studies, which led to the elucidation of the three-dimensional structure of EAV nsp4 by X-ray crystallography (Barrette-Ng et al., 2002).", [["EAV", "ORGANISM", 135, 138], ["nsp4", "GENE_OR_GENE_PRODUCT", 139, 143], ["EAV nsp4", "PROTEIN", 135, 143], ["EAV", "SPECIES", 135, 138], ["structural studies", "TEST", 48, 66], ["EAV nsp4", "PROBLEM", 135, 143], ["X-ray crystallography", "TEST", 147, 168], ["EAV nsp4", "OBSERVATION", 135, 143]]], ["Together, these studies are a major step towards dissecting the structure\u2013function relationships of this key arterivirus enzyme and the future design of inhibitor drugs.Expression and purification of EAV MBP-nsp4 ::: Expression plasmid construction ::: Materials and methods", [["arterivirus enzyme", "GENE_OR_GENE_PRODUCT", 109, 127], ["EAV", "ORGANISM", 200, 203], ["MBP", "GENE_OR_GENE_PRODUCT", 204, 207], ["arterivirus enzyme", "PROTEIN", 109, 127], ["MBP", "PROTEIN", 204, 207], ["nsp4", "PROTEIN", 208, 212], ["EAV", "SPECIES", 200, 203], ["these studies", "TEST", 10, 23], ["inhibitor drugs", "TREATMENT", 153, 168], ["EAV MBP", "TEST", 200, 207]]]], "1644c892d1e205a05aac952e6e7d071ac9daa376": [["Rhinitis has not been as extensively studied as its counterparts, eczema and asthma, in very young children.", [["Rhinitis", "DISEASE", 0, 8], ["eczema", "DISEASE", 66, 72], ["asthma", "DISEASE", 77, 83], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["Rhinitis", "PROBLEM", 0, 8], ["eczema", "PROBLEM", 66, 72], ["asthma", "PROBLEM", 77, 83], ["eczema", "OBSERVATION", 66, 72], ["asthma", "OBSERVATION", 77, 83]]], ["This may stem from the notion that allergic rhinitis is one of the later manifestations of the atopic march and therefore not significant in early life (2, 3) .", [["allergic rhinitis", "DISEASE", 35, 52], ["atopic march", "DISEASE", 95, 107], ["allergic rhinitis", "PROBLEM", 35, 52], ["allergic", "OBSERVATION_MODIFIER", 35, 43], ["rhinitis", "OBSERVATION", 44, 52], ["atopic march", "OBSERVATION", 95, 107], ["significant", "OBSERVATION_MODIFIER", 126, 137]]], ["A cross-sectional survey of Singaporean toddlers in 2005 showed that rhinitis had a cumulative prevalence of as high as 42.7% in the first 2 yr of life (4) .", [["rhinitis", "DISEASE", 69, 77], ["rhinitis", "PROBLEM", 69, 77], ["rhinitis", "OBSERVATION", 69, 77]]], ["This suggests that, contrary to the allergic march model which described rhinitis to occur later in life, allergic and non-allergic rhinitis might, in at least a subset of atopic individuals, have their onset as early as infancy.", [["allergic", "DISEASE", 36, 44], ["rhinitis", "DISEASE", 73, 81], ["allergic", "DISEASE", 106, 114], ["non-allergic rhinitis", "DISEASE", 119, 140], ["the allergic march model", "PROBLEM", 32, 56], ["rhinitis", "PROBLEM", 73, 81], ["allergic", "PROBLEM", 106, 114], ["non-allergic rhinitis", "PROBLEM", 119, 140], ["rhinitis", "OBSERVATION", 73, 81], ["non-allergic rhinitis", "OBSERVATION", 119, 140]]]], "799fa15be695fcb9df49cc4227e261accd1170fb": [["S1.", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S1", "PROTEIN", 0, 2]]], ["Wind driven cross ventilationThe market was simplified as a long tunnel, and the mean wind driven ventilation rate Q (m 3 /s) induced by two opening on the windward and leeward facades was calculated as 1S1.", [["1S1", "PROTEIN", 203, 206], ["cross ventilation", "TREATMENT", 12, 29], ["a long tunnel", "TREATMENT", 58, 71]]], ["Wind driven cross ventilationwhere C Dw and C Dl are respectively the discharge coefficients of windward and leeward facades, A w and A l (m 2 ) are the opening area on the windward and leeward facades, Uref (m/s) is the reference wind speed, Cp w and Cp l are the pressure coefficients.S1.", [["C Dl", "GENE_OR_GENE_PRODUCT", 44, 48], ["S1", "GENE_OR_GENE_PRODUCT", 287, 289], ["C Dl", "PROTEIN", 44, 48], ["S1", "PROTEIN", 287, 289], ["Cp", "PROBLEM", 243, 245], ["Cp", "PROBLEM", 252, 254], ["the pressure coefficients", "TEST", 261, 286]]], ["Wind driven cross ventilationIn this study, the opening areas are the same on both facades, and it is also assumed that the discharge coefficients are the same.", [["cross ventilation", "TREATMENT", 12, 29], ["this study", "TEST", 32, 42], ["the opening areas", "PROBLEM", 44, 61], ["opening", "OBSERVATION_MODIFIER", 48, 55], ["areas", "OBSERVATION_MODIFIER", 56, 61]]], ["The ventilation rate becomes:S1.", [["S1", "ANATOMY", 29, 31]]], ["Wind driven cross ventilationwhere C D and A are respectively the discharge coefficients and opening areas on both facades.", [["C D", "SIMPLE_CHEMICAL", 35, 38], ["the discharge coefficients", "PROBLEM", 62, 88], ["opening areas", "PROBLEM", 93, 106]]], ["Here the discharge coefficient is assumed to be 0.60, which is the typical value for sharp-edged openings 2 .", [["sharp-edged openings", "PROBLEM", 85, 105]]], ["The mean air flow speed inside the market is then calculated asS1.", [["S1", "PROTEIN", 63, 65], ["The mean air flow speed", "TEST", 0, 23], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["air flow", "OBSERVATION", 9, 17]]], ["The ambient wind velocity U ref was calculated by the Gral model, which had already considered the sheltering effects from the surrounding buildings.", [["The ambient wind velocity U ref", "TEST", 0, 31]]], ["As a result, the unsheltered pressure coefficients were utilized to estimate the wind driven ventilation rate inside the market.", [["the unsheltered pressure coefficients", "TREATMENT", 13, 50]]], ["The pressure coefficients (Cp) were adopted from various datasets 3 as a function of the wind attack angle as shown in Figure S1 .", [["Cp", "DNA", 27, 29], ["The pressure coefficients", "TEST", 0, 25], ["Cp", "PROBLEM", 27, 29], ["pressure", "OBSERVATION_MODIFIER", 4, 12], ["coefficients", "OBSERVATION_MODIFIER", 13, 25], ["Figure S1", "OBSERVATION", 119, 128]]], ["It was assumed that the pressure coefficient followed normal distribution in this study, with the averaged value as the mean.", [["the pressure coefficient", "TEST", 20, 44], ["this study", "TEST", 77, 87], ["pressure", "OBSERVATION_MODIFIER", 24, 32], ["coefficient", "OBSERVATION_MODIFIER", 33, 44], ["distribution", "OBSERVATION_MODIFIER", 61, 73]]], ["The standard deviation of the distribution was estimated as a quarter of the width of the data spread, namely the shade area.", [["standard", "OBSERVATION_MODIFIER", 4, 12], ["deviation", "OBSERVATION", 13, 22], ["distribution", "OBSERVATION_MODIFIER", 30, 42], ["shade", "OBSERVATION_MODIFIER", 114, 119]]], ["The distribution of the parameter was included in the Monte Carlo S3 simulations.", [["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["Figure S1 Range and average value of the pressure coefficients from various datasets 3 as a function of the wind attack angleS2.", [["Figure S1 Range", "TEST", 0, 15], ["average value", "TEST", 20, 33], ["the pressure coefficients", "TEST", 37, 62], ["various datasets", "TEST", 68, 84]]], ["Estimation of the friction velocity inside the marketThe Reynolds number for the flow inside the market was calculated following the method for rectangular ductS2.", [["duct", "ANATOMY", 156, 160], ["duct", "MULTI-TISSUE_STRUCTURE", 156, 160], ["the friction velocity", "TEST", 14, 35], ["rectangular ductS2", "PROBLEM", 144, 162], ["friction velocity", "OBSERVATION", 18, 35], ["market", "OBSERVATION_MODIFIER", 47, 53], ["Reynolds", "OBSERVATION_MODIFIER", 57, 65], ["number", "OBSERVATION_MODIFIER", 66, 72], ["flow", "OBSERVATION", 81, 85], ["ductS2", "ANATOMY", 156, 162]]], ["Estimation of the friction velocity inside the marketwhere u is the flow velocity, d h is the hydraulic diameter, and \u03bd is the kinematic viscosity of air.S2.", [["S2", "GENE_OR_GENE_PRODUCT", 154, 156], ["S2", "PROTEIN", 154, 156], ["the friction velocity", "TEST", 14, 35], ["the flow velocity", "TEST", 64, 81], ["friction velocity", "OBSERVATION", 18, 35], ["flow velocity", "OBSERVATION", 68, 81], ["hydraulic", "OBSERVATION_MODIFIER", 94, 103], ["diameter", "OBSERVATION_MODIFIER", 104, 112], ["kinematic", "OBSERVATION_MODIFIER", 127, 136], ["viscosity", "OBSERVATION_MODIFIER", 137, 146], ["air", "OBSERVATION", 150, 153]]], ["Estimation of the friction velocity inside the marketThe skin friction coefficient was estimated by Prandtl's one-seventh-power law For the deposition velocity on the vertical surface:S2.", [["skin", "ANATOMY", 57, 61], ["surface", "ANATOMY", 176, 183], ["skin", "ORGAN", 57, 61], ["the friction velocity", "TEST", 14, 35], ["The skin friction coefficient", "PROBLEM", 53, 82], ["the deposition velocity", "TEST", 136, 159], ["friction velocity", "OBSERVATION", 18, 35], ["market", "OBSERVATION_MODIFIER", 47, 53], ["skin", "ANATOMY", 57, 61], ["friction coefficient", "OBSERVATION", 62, 82], ["deposition", "OBSERVATION_MODIFIER", 140, 150], ["velocity", "OBSERVATION_MODIFIER", 151, 159], ["vertical", "OBSERVATION_MODIFIER", 167, 175], ["surface", "OBSERVATION_MODIFIER", 176, 183], ["S2", "ANATOMY", 184, 186]]], ["Estimation of the friction velocity inside the marketFor the upward-facing horizontal surface:S2.", [["surface", "ANATOMY", 86, 93], ["S2", "PROTEIN", 94, 96], ["the friction velocity", "TEST", 14, 35], ["friction velocity", "OBSERVATION", 18, 35], ["upward", "OBSERVATION_MODIFIER", 61, 67], ["S2", "ANATOMY", 94, 96]]], ["Estimation of the friction velocity inside the marketFor the downward-facing horizontal surface:S2.", [["surface", "ANATOMY", 88, 95], ["S2", "PROTEIN", 96, 98], ["the friction velocity", "TEST", 14, 35], ["friction velocity", "OBSERVATION", 18, 35], ["downward", "OBSERVATION_MODIFIER", 61, 69], ["S2", "ANATOMY", 96, 98]]], ["Estimation of the friction velocity inside the marketwhere I is the integral (S12)S2.", [["marketwhere I", "PROTEIN", 47, 60], ["integral (S12)S2", "PROTEIN", 68, 84], ["the friction velocity", "TEST", 14, 35], ["friction velocity", "OBSERVATION", 18, 35]]], ["Estimation of the friction velocity inside the marketwhere d p is the particle diameter.", [["the friction velocity", "TEST", 14, 35], ["friction velocity", "OBSERVATION", 18, 35], ["particle", "OBSERVATION_MODIFIER", 70, 78], ["diameter", "OBSERVATION_MODIFIER", 79, 87]]], ["Schmidt number (Sc) isS2.", [["S2", "ANATOMY", 22, 24]]], ["Estimation of the friction velocity inside the marketwhere D is the Brownian diffusivity of the particle, which is estimated asS2.", [["S2", "PROTEIN", 127, 129], ["the friction velocity", "TEST", 14, 35], ["the Brownian diffusivity of the particle", "PROBLEM", 64, 104], ["friction velocity", "OBSERVATION", 18, 35], ["Brownian diffusivity", "OBSERVATION", 68, 88], ["particle", "OBSERVATION_MODIFIER", 96, 104], ["S2", "OBSERVATION_MODIFIER", 127, 129]]], ["Estimation of the friction velocity inside the marketwhere k is the Boltzmann constant (1.38\u00d710 -23 J/K), C c is the Cunningham correction factor, which is estimated as (S18) 2 1S2.", [["C c", "GENE_OR_GENE_PRODUCT", 106, 109], ["Cunningham correction factor", "PROTEIN", 117, 145], ["the friction velocity", "TEST", 14, 35], ["the Boltzmann constant", "TEST", 64, 86], ["friction velocity", "OBSERVATION", 18, 35]]], ["Estimation of the friction velocity inside the market1.257 0.4 exp 1.1 2S2.", [["the friction velocity", "TEST", 14, 35], ["friction velocity", "OBSERVATION", 18, 35]]], ["Estimation of the friction velocity inside the marketwhere \u03bb is the mean free path of air.S2.", [["S2", "GENE_OR_GENE_PRODUCT", 90, 92], ["S2", "PROTEIN", 90, 92], ["the friction velocity", "TEST", 14, 35], ["friction velocity", "OBSERVATION", 18, 35], ["mean", "OBSERVATION_MODIFIER", 68, 72], ["free path", "OBSERVATION", 73, 82], ["air", "OBSERVATION", 86, 89]]], ["Estimation of the friction velocity inside the marketA zone model was developed to estimate the virus concentration and deposition inside Street No. 7 of the market using the above viral shedding and biologic decay data.", [["the friction velocity", "TEST", 14, 35], ["A zone model", "TEST", 53, 65], ["the virus concentration", "PROBLEM", 92, 115], ["the above viral shedding", "TREATMENT", 171, 195], ["friction velocity", "OBSERVATION", 18, 35], ["zone", "OBSERVATION_MODIFIER", 55, 59], ["virus concentration", "OBSERVATION", 96, 115]]], ["The zone model assumed that the virus concentration was homogeneous inside the target area due to the mixing by human movements.S2.", [["human", "ORGANISM", 112, 117], ["S2", "GENE_OR_GENE_PRODUCT", 128, 130], ["S2", "PROTEIN", 128, 130], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["the virus concentration", "PROBLEM", 28, 51], ["virus", "OBSERVATION", 32, 37], ["homogeneous", "OBSERVATION_MODIFIER", 56, 67], ["mixing", "OBSERVATION", 102, 108]]], ["Estimation of the friction velocity inside the market(S19) is the decay rate of the virus (s -1 ), \u03c3 is the viral generation rate (PFU s -1 ).", [["\u03c3", "GENE_OR_GENE_PRODUCT", 99, 100], ["the friction velocity", "TEST", 14, 35], ["the viral generation rate", "TEST", 104, 129], ["PFU s", "TEST", 131, 136], ["friction velocity", "OBSERVATION", 18, 35]]], ["In this study, the duration of each scenario was one hour.", [["this study", "TEST", 3, 13]]], ["We assumed that the generation of virus within one hour remained constant.", [["the generation of virus", "PROBLEM", 16, 39], ["constant", "OBSERVATION_MODIFIER", 65, 73]]], ["Lung depositionThe deposition fraction f dep was calculated using deposition model for pathogenic bioaerosols 5 .", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung deposition", "PROBLEM", 0, 15], ["The deposition fraction f dep", "PROBLEM", 15, 44], ["deposition model", "TREATMENT", 66, 82], ["pathogenic bioaerosols", "PROBLEM", 87, 109], ["deposition", "OBSERVATION", 5, 15], ["deposition", "OBSERVATION_MODIFIER", 19, 29], ["fraction", "OBSERVATION_MODIFIER", 30, 38]]], ["S6 Figure S2 Deposition fraction of particles inside the respiratory tract.", [["respiratory tract", "ANATOMY", 57, 74], ["respiratory tract", "ORGANISM_SUBDIVISION", 57, 74], ["S6", "PROTEIN", 0, 2], ["S2", "OBSERVATION_MODIFIER", 10, 12], ["Deposition fraction", "OBSERVATION", 13, 32], ["particles", "OBSERVATION_MODIFIER", 36, 45], ["respiratory tract", "ANATOMY", 57, 74]]], ["ET 1 : Anterior nasal; ET 2 : Naso-Oropharynx/Larynx; BB: Bronchi; bb: Bronchioles; Al: Alveolar Interstitial.", [["nasal", "ANATOMY", 16, 21], ["ET 1", "GENE_OR_GENE_PRODUCT", 0, 4], ["nasal", "ORGAN", 16, 21], ["Naso", "TEST", 30, 34], ["Anterior", "ANATOMY_MODIFIER", 7, 15], ["nasal", "ANATOMY", 16, 21], ["Oropharynx", "ANATOMY", 35, 45], ["Larynx", "ANATOMY", 46, 52], ["Bronchi", "ANATOMY", 58, 65], ["Bronchioles", "ANATOMY", 71, 82], ["Alveolar", "ANATOMY_MODIFIER", 88, 96], ["Interstitial", "ANATOMY_MODIFIER", 97, 109]]]]}